/*! For license information please see main.11573d7d.js.LICENSE.txt */
!function(){var e={76:function(e,t,n){"use strict";n.d(t,{Z:function(){return oe}});var r=function(){function e(e){var t=this;this._insertTag=function(e){var n;n=0===t.tags.length?t.insertionPoint?t.insertionPoint.nextSibling:t.prepend?t.container.firstChild:t.before:t.tags[t.tags.length-1].nextSibling,t.container.insertBefore(e,n),t.tags.push(e)},this.isSpeedy=void 0===e.speedy||e.speedy,this.tags=[],this.ctr=0,this.nonce=e.nonce,this.key=e.key,this.container=e.container,this.prepend=e.prepend,this.insertionPoint=e.insertionPoint,this.before=null}var t=e.prototype;return t.hydrate=function(e){e.forEach(this._insertTag)},t.insert=function(e){this.ctr%(this.isSpeedy?65e3:1)===0&&this._insertTag(function(e){var t=document.createElement("style");return t.setAttribute("data-emotion",e.key),void 0!==e.nonce&&t.setAttribute("nonce",e.nonce),t.appendChild(document.createTextNode("")),t.setAttribute("data-s",""),t}(this));var t=this.tags[this.tags.length-1];if(this.isSpeedy){var n=function(e){if(e.sheet)return e.sheet;for(var t=0;t<document.styleSheets.length;t++)if(document.styleSheets[t].ownerNode===e)return document.styleSheets[t]}(t);try{n.insertRule(e,n.cssRules.length)}catch(r){0}}else t.appendChild(document.createTextNode(e));this.ctr++},t.flush=function(){this.tags.forEach((function(e){return e.parentNode&&e.parentNode.removeChild(e)})),this.tags=[],this.ctr=0},e}(),o=Math.abs,a=String.fromCharCode,i=Object.assign;function s(e){return e.trim()}function l(e,t,n){return e.replace(t,n)}function c(e,t){return e.indexOf(t)}function u(e,t){return 0|e.charCodeAt(t)}function d(e,t,n){return e.slice(t,n)}function f(e){return e.length}function p(e){return e.length}function m(e,t){return t.push(e),e}var h=1,v=1,b=0,y=0,g=0,_="";function w(e,t,n,r,o,a,i){return{value:e,root:t,parent:n,type:r,props:o,children:a,line:h,column:v,length:i,return:""}}function T(e,t){return i(w("",null,null,"",null,null,0),e,{length:-e.length},t)}function S(){return g=y>0?u(_,--y):0,v--,10===g&&(v=1,h--),g}function P(){return g=y<b?u(_,y++):0,v++,10===g&&(v=1,h++),g}function k(){return u(_,y)}function x(){return y}function C(e,t){return d(_,e,t)}function A(e){switch(e){case 0:case 9:case 10:case 13:case 32:return 5;case 33:case 43:case 44:case 47:case 62:case 64:case 126:case 59:case 123:case 125:return 4;case 58:return 3;case 34:case 39:case 40:case 91:return 2;case 41:case 93:return 1}return 0}function M(e){return h=v=1,b=f(_=e),y=0,[]}function F(e){return _="",e}function E(e){return s(C(y-1,O(91===e?e+2:40===e?e+1:e)))}function R(e){for(;(g=k())&&g<33;)P();return A(e)>2||A(g)>3?"":" "}function N(e,t){for(;--t&&P()&&!(g<48||g>102||g>57&&g<65||g>70&&g<97););return C(e,x()+(t<6&&32==k()&&32==P()))}function O(e){for(;P();)switch(g){case e:return y;case 34:case 39:34!==e&&39!==e&&O(g);break;case 40:41===e&&O(e);break;case 92:P()}return y}function V(e,t){for(;P()&&e+g!==57&&(e+g!==84||47!==k()););return"/*"+C(t,y-1)+"*"+a(47===e?e:P())}function L(e){for(;!A(k());)P();return C(e,y)}var D="-ms-",z="-moz-",I="-webkit-",H="comm",j="rule",Z="decl",B="@keyframes";function G(e,t){for(var n="",r=p(e),o=0;o<r;o++)n+=t(e[o],o,e,t)||"";return n}function W(e,t,n,r){switch(e.type){case"@import":case Z:return e.return=e.return||e.value;case H:return"";case B:return e.return=e.value+"{"+G(e.children,r)+"}";case j:e.value=e.props.join(",")}return f(n=G(e.children,r))?e.return=e.value+"{"+n+"}":""}function U(e,t){switch(function(e,t){return(((t<<2^u(e,0))<<2^u(e,1))<<2^u(e,2))<<2^u(e,3)}(e,t)){case 5103:return I+"print-"+e+e;case 5737:case 4201:case 3177:case 3433:case 1641:case 4457:case 2921:case 5572:case 6356:case 5844:case 3191:case 6645:case 3005:case 6391:case 5879:case 5623:case 6135:case 4599:case 4855:case 4215:case 6389:case 5109:case 5365:case 5621:case 3829:return I+e+e;case 5349:case 4246:case 4810:case 6968:case 2756:return I+e+z+e+D+e+e;case 6828:case 4268:return I+e+D+e+e;case 6165:return I+e+D+"flex-"+e+e;case 5187:return I+e+l(e,/(\w+).+(:[^]+)/,"-webkit-box-$1$2-ms-flex-$1$2")+e;case 5443:return I+e+D+"flex-item-"+l(e,/flex-|-self/,"")+e;case 4675:return I+e+D+"flex-line-pack"+l(e,/align-content|flex-|-self/,"")+e;case 5548:return I+e+D+l(e,"shrink","negative")+e;case 5292:return I+e+D+l(e,"basis","preferred-size")+e;case 6060:return I+"box-"+l(e,"-grow","")+I+e+D+l(e,"grow","positive")+e;case 4554:return I+l(e,/([^-])(transform)/g,"$1-webkit-$2")+e;case 6187:return l(l(l(e,/(zoom-|grab)/,I+"$1"),/(image-set)/,I+"$1"),e,"")+e;case 5495:case 3959:return l(e,/(image-set\([^]*)/,I+"$1$`$1");case 4968:return l(l(e,/(.+:)(flex-)?(.*)/,"-webkit-box-pack:$3-ms-flex-pack:$3"),/s.+-b[^;]+/,"justify")+I+e+e;case 4095:case 3583:case 4068:case 2532:return l(e,/(.+)-inline(.+)/,I+"$1$2")+e;case 8116:case 7059:case 5753:case 5535:case 5445:case 5701:case 4933:case 4677:case 5533:case 5789:case 5021:case 4765:if(f(e)-1-t>6)switch(u(e,t+1)){case 109:if(45!==u(e,t+4))break;case 102:return l(e,/(.+:)(.+)-([^]+)/,"$1-webkit-$2-$3$1"+z+(108==u(e,t+3)?"$3":"$2-$3"))+e;case 115:return~c(e,"stretch")?U(l(e,"stretch","fill-available"),t)+e:e}break;case 4949:if(115!==u(e,t+1))break;case 6444:switch(u(e,f(e)-3-(~c(e,"!important")&&10))){case 107:return l(e,":",":"+I)+e;case 101:return l(e,/(.+:)([^;!]+)(;|!.+)?/,"$1"+I+(45===u(e,14)?"inline-":"")+"box$3$1"+I+"$2$3$1"+D+"$2box$3")+e}break;case 5936:switch(u(e,t+11)){case 114:return I+e+D+l(e,/[svh]\w+-[tblr]{2}/,"tb")+e;case 108:return I+e+D+l(e,/[svh]\w+-[tblr]{2}/,"tb-rl")+e;case 45:return I+e+D+l(e,/[svh]\w+-[tblr]{2}/,"lr")+e}return I+e+D+e+e}return e}function q(e){return F($("",null,null,null,[""],e=M(e),0,[0],e))}function $(e,t,n,r,o,i,s,u,d){for(var p=0,h=0,v=s,b=0,y=0,g=0,_=1,w=1,T=1,C=0,A="",M=o,F=i,O=r,D=A;w;)switch(g=C,C=P()){case 40:if(108!=g&&58==D.charCodeAt(v-1)){-1!=c(D+=l(E(C),"&","&\f"),"&\f")&&(T=-1);break}case 34:case 39:case 91:D+=E(C);break;case 9:case 10:case 13:case 32:D+=R(g);break;case 92:D+=N(x()-1,7);continue;case 47:switch(k()){case 42:case 47:m(K(V(P(),x()),t,n),d);break;default:D+="/"}break;case 123*_:u[p++]=f(D)*T;case 125*_:case 59:case 0:switch(C){case 0:case 125:w=0;case 59+h:y>0&&f(D)-v&&m(y>32?Q(D+";",r,n,v-1):Q(l(D," ","")+";",r,n,v-2),d);break;case 59:D+=";";default:if(m(O=J(D,t,n,p,h,o,u,A,M=[],F=[],v),i),123===C)if(0===h)$(D,t,O,O,M,i,v,u,F);else switch(b){case 100:case 109:case 115:$(e,O,O,r&&m(J(e,O,O,0,0,o,u,A,o,M=[],v),F),o,F,v,u,r?M:F);break;default:$(D,O,O,O,[""],F,0,u,F)}}p=h=y=0,_=T=1,A=D="",v=s;break;case 58:v=1+f(D),y=g;default:if(_<1)if(123==C)--_;else if(125==C&&0==_++&&125==S())continue;switch(D+=a(C),C*_){case 38:T=h>0?1:(D+="\f",-1);break;case 44:u[p++]=(f(D)-1)*T,T=1;break;case 64:45===k()&&(D+=E(P())),b=k(),h=v=f(A=D+=L(x())),C++;break;case 45:45===g&&2==f(D)&&(_=0)}}return i}function J(e,t,n,r,a,i,c,u,f,m,h){for(var v=a-1,b=0===a?i:[""],y=p(b),g=0,_=0,T=0;g<r;++g)for(var S=0,P=d(e,v+1,v=o(_=c[g])),k=e;S<y;++S)(k=s(_>0?b[S]+" "+P:l(P,/&\f/g,b[S])))&&(f[T++]=k);return w(e,t,n,0===a?j:u,f,m,h)}function K(e,t,n){return w(e,t,n,H,a(g),d(e,2,-2),0)}function Q(e,t,n,r){return w(e,t,n,Z,d(e,0,r),d(e,r+1,-1),r)}var Y=function(e,t,n){for(var r=0,o=0;r=o,o=k(),38===r&&12===o&&(t[n]=1),!A(o);)P();return C(e,y)},X=function(e,t){return F(function(e,t){var n=-1,r=44;do{switch(A(r)){case 0:38===r&&12===k()&&(t[n]=1),e[n]+=Y(y-1,t,n);break;case 2:e[n]+=E(r);break;case 4:if(44===r){e[++n]=58===k()?"&\f":"",t[n]=e[n].length;break}default:e[n]+=a(r)}}while(r=P());return e}(M(e),t))},ee=new WeakMap,te=function(e){if("rule"===e.type&&e.parent&&!(e.length<1)){for(var t=e.value,n=e.parent,r=e.column===n.column&&e.line===n.line;"rule"!==n.type;)if(!(n=n.parent))return;if((1!==e.props.length||58===t.charCodeAt(0)||ee.get(n))&&!r){ee.set(e,!0);for(var o=[],a=X(t,o),i=n.props,s=0,l=0;s<a.length;s++)for(var c=0;c<i.length;c++,l++)e.props[l]=o[s]?a[s].replace(/&\f/g,i[c]):i[c]+" "+a[s]}}},ne=function(e){if("decl"===e.type){var t=e.value;108===t.charCodeAt(0)&&98===t.charCodeAt(2)&&(e.return="",e.value="")}},re=[function(e,t,n,r){if(e.length>-1&&!e.return)switch(e.type){case Z:e.return=U(e.value,e.length);break;case B:return G([T(e,{value:l(e.value,"@","@"+I)})],r);case j:if(e.length)return function(e,t){return e.map(t).join("")}(e.props,(function(t){switch(function(e,t){return(e=t.exec(e))?e[0]:e}(t,/(::plac\w+|:read-\w+)/)){case":read-only":case":read-write":return G([T(e,{props:[l(t,/:(read-\w+)/,":-moz-$1")]})],r);case"::placeholder":return G([T(e,{props:[l(t,/:(plac\w+)/,":-webkit-input-$1")]}),T(e,{props:[l(t,/:(plac\w+)/,":-moz-$1")]}),T(e,{props:[l(t,/:(plac\w+)/,D+"input-$1")]})],r)}return""}))}}],oe=function(e){var t=e.key;if("css"===t){var n=document.querySelectorAll("style[data-emotion]:not([data-s])");Array.prototype.forEach.call(n,(function(e){-1!==e.getAttribute("data-emotion").indexOf(" ")&&(document.head.appendChild(e),e.setAttribute("data-s",""))}))}var o=e.stylisPlugins||re;var a,i,s={},l=[];a=e.container||document.head,Array.prototype.forEach.call(document.querySelectorAll('style[data-emotion^="'+t+' "]'),(function(e){for(var t=e.getAttribute("data-emotion").split(" "),n=1;n<t.length;n++)s[t[n]]=!0;l.push(e)}));var c,u,d=[W,(u=function(e){c.insert(e)},function(e){e.root||(e=e.return)&&u(e)})],f=function(e){var t=p(e);return function(n,r,o,a){for(var i="",s=0;s<t;s++)i+=e[s](n,r,o,a)||"";return i}}([te,ne].concat(o,d));i=function(e,t,n,r){c=n,G(q(e?e+"{"+t.styles+"}":t.styles),f),r&&(m.inserted[t.name]=!0)};var m={key:t,sheet:new r({key:t,container:a,nonce:e.nonce,speedy:e.speedy,prepend:e.prepend,insertionPoint:e.insertionPoint}),nonce:e.nonce,inserted:s,registered:{},insert:i};return m.sheet.hydrate(l),m}},9797:function(e,t){"use strict";t.Z=function(e){var t=Object.create(null);return function(n){return void 0===t[n]&&(t[n]=e(n)),t[n]}}},9886:function(e,t,n){"use strict";n.d(t,{T:function(){return s},w:function(){return i}});var r=n(2791),o=n(76),a=(n(9140),n(2561),(0,r.createContext)("undefined"!==typeof HTMLElement?(0,o.Z)({key:"css"}):null));a.Provider;var i=function(e){return(0,r.forwardRef)((function(t,n){var o=(0,r.useContext)(a);return e(t,o,n)}))},s=(0,r.createContext)({})},9140:function(e,t,n){"use strict";n.d(t,{O:function(){return h}});var r=function(e){for(var t,n=0,r=0,o=e.length;o>=4;++r,o-=4)t=1540483477*(65535&(t=255&e.charCodeAt(r)|(255&e.charCodeAt(++r))<<8|(255&e.charCodeAt(++r))<<16|(255&e.charCodeAt(++r))<<24))+(59797*(t>>>16)<<16),n=1540483477*(65535&(t^=t>>>24))+(59797*(t>>>16)<<16)^1540483477*(65535&n)+(59797*(n>>>16)<<16);switch(o){case 3:n^=(255&e.charCodeAt(r+2))<<16;case 2:n^=(255&e.charCodeAt(r+1))<<8;case 1:n=1540483477*(65535&(n^=255&e.charCodeAt(r)))+(59797*(n>>>16)<<16)}return(((n=1540483477*(65535&(n^=n>>>13))+(59797*(n>>>16)<<16))^n>>>15)>>>0).toString(36)},o={animationIterationCount:1,borderImageOutset:1,borderImageSlice:1,borderImageWidth:1,boxFlex:1,boxFlexGroup:1,boxOrdinalGroup:1,columnCount:1,columns:1,flex:1,flexGrow:1,flexPositive:1,flexShrink:1,flexNegative:1,flexOrder:1,gridRow:1,gridRowEnd:1,gridRowSpan:1,gridRowStart:1,gridColumn:1,gridColumnEnd:1,gridColumnSpan:1,gridColumnStart:1,msGridRow:1,msGridRowSpan:1,msGridColumn:1,msGridColumnSpan:1,fontWeight:1,lineHeight:1,opacity:1,order:1,orphans:1,tabSize:1,widows:1,zIndex:1,zoom:1,WebkitLineClamp:1,fillOpacity:1,floodOpacity:1,stopOpacity:1,strokeDasharray:1,strokeDashoffset:1,strokeMiterlimit:1,strokeOpacity:1,strokeWidth:1},a=n(9797),i=/[A-Z]|^ms/g,s=/_EMO_([^_]+?)_([^]*?)_EMO_/g,l=function(e){return 45===e.charCodeAt(1)},c=function(e){return null!=e&&"boolean"!==typeof e},u=(0,a.Z)((function(e){return l(e)?e:e.replace(i,"-$&").toLowerCase()})),d=function(e,t){switch(e){case"animation":case"animationName":if("string"===typeof t)return t.replace(s,(function(e,t,n){return p={name:t,styles:n,next:p},t}))}return 1===o[e]||l(e)||"number"!==typeof t||0===t?t:t+"px"};function f(e,t,n){if(null==n)return"";if(void 0!==n.__emotion_styles)return n;switch(typeof n){case"boolean":return"";case"object":if(1===n.anim)return p={name:n.name,styles:n.styles,next:p},n.name;if(void 0!==n.styles){var r=n.next;if(void 0!==r)for(;void 0!==r;)p={name:r.name,styles:r.styles,next:p},r=r.next;return n.styles+";"}return function(e,t,n){var r="";if(Array.isArray(n))for(var o=0;o<n.length;o++)r+=f(e,t,n[o])+";";else for(var a in n){var i=n[a];if("object"!==typeof i)null!=t&&void 0!==t[i]?r+=a+"{"+t[i]+"}":c(i)&&(r+=u(a)+":"+d(a,i)+";");else if(!Array.isArray(i)||"string"!==typeof i[0]||null!=t&&void 0!==t[i[0]]){var s=f(e,t,i);switch(a){case"animation":case"animationName":r+=u(a)+":"+s+";";break;default:r+=a+"{"+s+"}"}}else for(var l=0;l<i.length;l++)c(i[l])&&(r+=u(a)+":"+d(a,i[l])+";")}return r}(e,t,n);case"function":if(void 0!==e){var o=p,a=n(e);return p=o,f(e,t,a)}}if(null==t)return n;var i=t[n];return void 0!==i?i:n}var p,m=/label:\s*([^\s;\n{]+)\s*(;|$)/g;var h=function(e,t,n){if(1===e.length&&"object"===typeof e[0]&&null!==e[0]&&void 0!==e[0].styles)return e[0];var o=!0,a="";p=void 0;var i=e[0];null==i||void 0===i.raw?(o=!1,a+=f(n,t,i)):a+=i[0];for(var s=1;s<e.length;s++)a+=f(n,t,e[s]),o&&(a+=i[s]);m.lastIndex=0;for(var l,c="";null!==(l=m.exec(a));)c+="-"+l[1];return{name:r(a)+c,styles:a,next:p}}},2561:function(e,t,n){"use strict";var r;n.d(t,{L:function(){return i},j:function(){return s}});var o=n(2791),a=!!(r||(r=n.t(o,2))).useInsertionEffect&&(r||(r=n.t(o,2))).useInsertionEffect,i=a||function(e){return e()},s=a||o.useLayoutEffect},5438:function(e,t,n){"use strict";n.d(t,{My:function(){return a},fp:function(){return r},hC:function(){return o}});function r(e,t,n){var r="";return n.split(" ").forEach((function(n){void 0!==e[n]?t.push(e[n]+";"):r+=n+" "})),r}var o=function(e,t,n){var r=e.key+"-"+t.name;!1===n&&void 0===e.registered[r]&&(e.registered[r]=t.styles)},a=function(e,t,n){o(e,t,n);var r=e.key+"-"+t.name;if(void 0===e.inserted[t.name]){var a=t;do{e.insert(t===a?"."+r:"",a,e.sheet,!0);a=a.next}while(void 0!==a)}}},2156:function(e,t,n){"use strict";var r=n(4836);t.Z=void 0;var o=r(n(5649)),a=n(184),i=(0,o.default)((0,a.jsx)("path",{d:"M15.41 7.41 14 6l-6 6 6 6 1.41-1.41L10.83 12z"}),"NavigateBefore");t.Z=i},5129:function(e,t,n){"use strict";var r=n(4836);t.Z=void 0;var o=r(n(5649)),a=n(184),i=(0,o.default)((0,a.jsx)("path",{d:"M10 6 8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z"}),"NavigateNext");t.Z=i},5649:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0}),Object.defineProperty(t,"default",{enumerable:!0,get:function(){return r.createSvgIcon}});var r=n(3111)},4360:function(e,t,n){"use strict";n.d(t,{Z:function(){return I}});var r=n(7462),o=n(3366),a=n(6189),i=n(2466),s=n(5080),l=n(4942);function c(e,t){var n;return(0,r.Z)({toolbar:(n={minHeight:56},(0,l.Z)(n,e.up("xs"),{"@media (orientation: landscape)":{minHeight:48}}),(0,l.Z)(n,e.up("sm"),{minHeight:64}),n)},t)}var u=n(2065),d={black:"#000",white:"#fff"},f={50:"#fafafa",100:"#f5f5f5",200:"#eeeeee",300:"#e0e0e0",400:"#bdbdbd",500:"#9e9e9e",600:"#757575",700:"#616161",800:"#424242",900:"#212121",A100:"#f5f5f5",A200:"#eeeeee",A400:"#bdbdbd",A700:"#616161"},p={50:"#f3e5f5",100:"#e1bee7",200:"#ce93d8",300:"#ba68c8",400:"#ab47bc",500:"#9c27b0",600:"#8e24aa",700:"#7b1fa2",800:"#6a1b9a",900:"#4a148c",A100:"#ea80fc",A200:"#e040fb",A400:"#d500f9",A700:"#aa00ff"},m={50:"#ffebee",100:"#ffcdd2",200:"#ef9a9a",300:"#e57373",400:"#ef5350",500:"#f44336",600:"#e53935",700:"#d32f2f",800:"#c62828",900:"#b71c1c",A100:"#ff8a80",A200:"#ff5252",A400:"#ff1744",A700:"#d50000"},h={50:"#fff3e0",100:"#ffe0b2",200:"#ffcc80",300:"#ffb74d",400:"#ffa726",500:"#ff9800",600:"#fb8c00",700:"#f57c00",800:"#ef6c00",900:"#e65100",A100:"#ffd180",A200:"#ffab40",A400:"#ff9100",A700:"#ff6d00"},v={50:"#e3f2fd",100:"#bbdefb",200:"#90caf9",300:"#64b5f6",400:"#42a5f5",500:"#2196f3",600:"#1e88e5",700:"#1976d2",800:"#1565c0",900:"#0d47a1",A100:"#82b1ff",A200:"#448aff",A400:"#2979ff",A700:"#2962ff"},b={50:"#e1f5fe",100:"#b3e5fc",200:"#81d4fa",300:"#4fc3f7",400:"#29b6f6",500:"#03a9f4",600:"#039be5",700:"#0288d1",800:"#0277bd",900:"#01579b",A100:"#80d8ff",A200:"#40c4ff",A400:"#00b0ff",A700:"#0091ea"},y={50:"#e8f5e9",100:"#c8e6c9",200:"#a5d6a7",300:"#81c784",400:"#66bb6a",500:"#4caf50",600:"#43a047",700:"#388e3c",800:"#2e7d32",900:"#1b5e20",A100:"#b9f6ca",A200:"#69f0ae",A400:"#00e676",A700:"#00c853"},g=["mode","contrastThreshold","tonalOffset"],_={text:{primary:"rgba(0, 0, 0, 0.87)",secondary:"rgba(0, 0, 0, 0.6)",disabled:"rgba(0, 0, 0, 0.38)"},divider:"rgba(0, 0, 0, 0.12)",background:{paper:d.white,default:d.white},action:{active:"rgba(0, 0, 0, 0.54)",hover:"rgba(0, 0, 0, 0.04)",hoverOpacity:.04,selected:"rgba(0, 0, 0, 0.08)",selectedOpacity:.08,disabled:"rgba(0, 0, 0, 0.26)",disabledBackground:"rgba(0, 0, 0, 0.12)",disabledOpacity:.38,focus:"rgba(0, 0, 0, 0.12)",focusOpacity:.12,activatedOpacity:.12}},w={text:{primary:d.white,secondary:"rgba(255, 255, 255, 0.7)",disabled:"rgba(255, 255, 255, 0.5)",icon:"rgba(255, 255, 255, 0.5)"},divider:"rgba(255, 255, 255, 0.12)",background:{paper:"#121212",default:"#121212"},action:{active:d.white,hover:"rgba(255, 255, 255, 0.08)",hoverOpacity:.08,selected:"rgba(255, 255, 255, 0.16)",selectedOpacity:.16,disabled:"rgba(255, 255, 255, 0.3)",disabledBackground:"rgba(255, 255, 255, 0.12)",disabledOpacity:.38,focus:"rgba(255, 255, 255, 0.12)",focusOpacity:.12,activatedOpacity:.24}};function T(e,t,n,r){var o=r.light||r,a=r.dark||1.5*r;e[t]||(e.hasOwnProperty(n)?e[t]=e[n]:"light"===t?e.light=(0,u.$n)(e.main,o):"dark"===t&&(e.dark=(0,u._j)(e.main,a)))}function S(e){var t=e.mode,n=void 0===t?"light":t,s=e.contrastThreshold,l=void 0===s?3:s,c=e.tonalOffset,S=void 0===c?.2:c,P=(0,o.Z)(e,g),k=e.primary||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:v[200],light:v[50],dark:v[400]}:{main:v[700],light:v[400],dark:v[800]}}(n),x=e.secondary||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:p[200],light:p[50],dark:p[400]}:{main:p[500],light:p[300],dark:p[700]}}(n),C=e.error||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:m[500],light:m[300],dark:m[700]}:{main:m[700],light:m[400],dark:m[800]}}(n),A=e.info||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:b[400],light:b[300],dark:b[700]}:{main:b[700],light:b[500],dark:b[900]}}(n),M=e.success||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:y[400],light:y[300],dark:y[700]}:{main:y[800],light:y[500],dark:y[900]}}(n),F=e.warning||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:h[400],light:h[300],dark:h[700]}:{main:"#ed6c02",light:h[500],dark:h[900]}}(n);function E(e){return(0,u.mi)(e,w.text.primary)>=l?w.text.primary:_.text.primary}var R=function(e){var t=e.color,n=e.name,o=e.mainShade,i=void 0===o?500:o,s=e.lightShade,l=void 0===s?300:s,c=e.darkShade,u=void 0===c?700:c;if(!(t=(0,r.Z)({},t)).main&&t[i]&&(t.main=t[i]),!t.hasOwnProperty("main"))throw new Error((0,a.Z)(11,n?" (".concat(n,")"):"",i));if("string"!==typeof t.main)throw new Error((0,a.Z)(12,n?" (".concat(n,")"):"",JSON.stringify(t.main)));return T(t,"light",l,S),T(t,"dark",u,S),t.contrastText||(t.contrastText=E(t.main)),t},N={dark:w,light:_};return(0,i.Z)((0,r.Z)({common:(0,r.Z)({},d),mode:n,primary:R({color:k,name:"primary"}),secondary:R({color:x,name:"secondary",mainShade:"A400",lightShade:"A200",darkShade:"A700"}),error:R({color:C,name:"error"}),warning:R({color:F,name:"warning"}),info:R({color:A,name:"info"}),success:R({color:M,name:"success"}),grey:f,contrastThreshold:l,getContrastText:E,augmentColor:R,tonalOffset:S},N[n]),P)}var P=["fontFamily","fontSize","fontWeightLight","fontWeightRegular","fontWeightMedium","fontWeightBold","htmlFontSize","allVariants","pxToRem"];var k={textTransform:"uppercase"},x='"Roboto", "Helvetica", "Arial", sans-serif';function C(e,t){var n="function"===typeof t?t(e):t,a=n.fontFamily,s=void 0===a?x:a,l=n.fontSize,c=void 0===l?14:l,u=n.fontWeightLight,d=void 0===u?300:u,f=n.fontWeightRegular,p=void 0===f?400:f,m=n.fontWeightMedium,h=void 0===m?500:m,v=n.fontWeightBold,b=void 0===v?700:v,y=n.htmlFontSize,g=void 0===y?16:y,_=n.allVariants,w=n.pxToRem,T=(0,o.Z)(n,P);var S=c/14,C=w||function(e){return"".concat(e/g*S,"rem")},A=function(e,t,n,o,a){return(0,r.Z)({fontFamily:s,fontWeight:e,fontSize:C(t),lineHeight:n},s===x?{letterSpacing:"".concat((i=o/t,Math.round(1e5*i)/1e5),"em")}:{},a,_);var i},M={h1:A(d,96,1.167,-1.5),h2:A(d,60,1.2,-.5),h3:A(p,48,1.167,0),h4:A(p,34,1.235,.25),h5:A(p,24,1.334,0),h6:A(h,20,1.6,.15),subtitle1:A(p,16,1.75,.15),subtitle2:A(h,14,1.57,.1),body1:A(p,16,1.5,.15),body2:A(p,14,1.43,.15),button:A(h,14,1.75,.4,k),caption:A(p,12,1.66,.4),overline:A(p,12,2.66,1,k)};return(0,i.Z)((0,r.Z)({htmlFontSize:g,pxToRem:C,fontFamily:s,fontSize:c,fontWeightLight:d,fontWeightRegular:p,fontWeightMedium:h,fontWeightBold:b},M),T,{clone:!1})}function A(){return["".concat(arguments.length<=0?void 0:arguments[0],"px ").concat(arguments.length<=1?void 0:arguments[1],"px ").concat(arguments.length<=2?void 0:arguments[2],"px ").concat(arguments.length<=3?void 0:arguments[3],"px rgba(0,0,0,").concat(.2,")"),"".concat(arguments.length<=4?void 0:arguments[4],"px ").concat(arguments.length<=5?void 0:arguments[5],"px ").concat(arguments.length<=6?void 0:arguments[6],"px ").concat(arguments.length<=7?void 0:arguments[7],"px rgba(0,0,0,").concat(.14,")"),"".concat(arguments.length<=8?void 0:arguments[8],"px ").concat(arguments.length<=9?void 0:arguments[9],"px ").concat(arguments.length<=10?void 0:arguments[10],"px ").concat(arguments.length<=11?void 0:arguments[11],"px rgba(0,0,0,").concat(.12,")")].join(",")}var M=["none",A(0,2,1,-1,0,1,1,0,0,1,3,0),A(0,3,1,-2,0,2,2,0,0,1,5,0),A(0,3,3,-2,0,3,4,0,0,1,8,0),A(0,2,4,-1,0,4,5,0,0,1,10,0),A(0,3,5,-1,0,5,8,0,0,1,14,0),A(0,3,5,-1,0,6,10,0,0,1,18,0),A(0,4,5,-2,0,7,10,1,0,2,16,1),A(0,5,5,-3,0,8,10,1,0,3,14,2),A(0,5,6,-3,0,9,12,1,0,3,16,2),A(0,6,6,-3,0,10,14,1,0,4,18,3),A(0,6,7,-4,0,11,15,1,0,4,20,3),A(0,7,8,-4,0,12,17,2,0,5,22,4),A(0,7,8,-4,0,13,19,2,0,5,24,4),A(0,7,9,-4,0,14,21,2,0,5,26,4),A(0,8,9,-5,0,15,22,2,0,6,28,5),A(0,8,10,-5,0,16,24,2,0,6,30,5),A(0,8,11,-5,0,17,26,2,0,6,32,5),A(0,9,11,-5,0,18,28,2,0,7,34,6),A(0,9,12,-6,0,19,29,2,0,7,36,6),A(0,10,13,-6,0,20,31,3,0,8,38,7),A(0,10,13,-6,0,21,33,3,0,8,40,7),A(0,10,14,-6,0,22,35,3,0,8,42,7),A(0,11,14,-7,0,23,36,3,0,9,44,8),A(0,11,15,-7,0,24,38,3,0,9,46,8)],F=["duration","easing","delay"],E={easeInOut:"cubic-bezier(0.4, 0, 0.2, 1)",easeOut:"cubic-bezier(0.0, 0, 0.2, 1)",easeIn:"cubic-bezier(0.4, 0, 1, 1)",sharp:"cubic-bezier(0.4, 0, 0.6, 1)"},R={shortest:150,shorter:200,short:250,standard:300,complex:375,enteringScreen:225,leavingScreen:195};function N(e){return"".concat(Math.round(e),"ms")}function O(e){if(!e)return 0;var t=e/36;return Math.round(10*(4+15*Math.pow(t,.25)+t/5))}function V(e){var t=(0,r.Z)({},E,e.easing),n=(0,r.Z)({},R,e.duration);return(0,r.Z)({getAutoHeightDuration:O,create:function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:["all"],r=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},a=r.duration,i=void 0===a?n.standard:a,s=r.easing,l=void 0===s?t.easeInOut:s,c=r.delay,u=void 0===c?0:c;(0,o.Z)(r,F);return(Array.isArray(e)?e:[e]).map((function(e){return"".concat(e," ").concat("string"===typeof i?i:N(i)," ").concat(l," ").concat("string"===typeof u?u:N(u))})).join(",")}},e,{easing:t,duration:n})}var L={mobileStepper:1e3,fab:1050,speedDial:1050,appBar:1100,drawer:1200,modal:1300,snackbar:1400,tooltip:1500},D=["breakpoints","mixins","spacing","palette","transitions","typography","shape"];function z(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=e.mixins,n=void 0===t?{}:t,l=e.palette,u=void 0===l?{}:l,d=e.transitions,f=void 0===d?{}:d,p=e.typography,m=void 0===p?{}:p,h=(0,o.Z)(e,D);if(e.vars)throw new Error((0,a.Z)(18));var v=S(u),b=(0,s.Z)(e),y=(0,i.Z)(b,{mixins:c(b.breakpoints,n),palette:v,shadows:M.slice(),typography:C(v,m),transitions:V(f),zIndex:(0,r.Z)({},L)});y=(0,i.Z)(y,h);for(var g=arguments.length,_=new Array(g>1?g-1:0),w=1;w<g;w++)_[w-1]=arguments[w];return y=_.reduce((function(e,t){return(0,i.Z)(e,t)}),y)}var I=z},4205:function(e,t,n){"use strict";var r=(0,n(4360).Z)();t.Z=r},277:function(e,t,n){"use strict";var r=n(4046),o=n(4205),a=(0,r.ZP)({defaultTheme:o.Z,rootShouldForwardProp:function(e){return(0,r.x9)(e)&&"classes"!==e}});t.ZP=a},5513:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(8691),o=n(4205);function a(e){var t=e.props,n=e.name;return(0,r.Z)({props:t,name:n,defaultTheme:o.Z})}},9853:function(e,t,n){"use strict";var r=n(7312);t.Z=r.Z},3111:function(e,t,n){"use strict";n.r(t),n.d(t,{capitalize:function(){return o.Z},createChainedFunction:function(){return a},createSvgIcon:function(){return w},debounce:function(){return T},deprecatedPropType:function(){return S},isMuiElement:function(){return P},ownerDocument:function(){return x},ownerWindow:function(){return C},requirePropFactory:function(){return A},setRef:function(){return M},unstable_ClassNameGenerator:function(){return H},unstable_useEnhancedEffect:function(){return F},unstable_useId:function(){return O},unsupportedProp:function(){return V},useControlled:function(){return L},useEventCallback:function(){return D.Z},useForkRef:function(){return z.Z},useIsFocusVisible:function(){return I.Z}});var r=n(5902),o=n(9853);var a=function(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];return t.reduce((function(e,t){return null==t?e:function(){for(var n=arguments.length,r=new Array(n),o=0;o<n;o++)r[o]=arguments[o];e.apply(this,r),t.apply(this,r)}}),(function(){}))},i=n(7462),s=n(2791),l=n.t(s,2),c=n(3366),u=n(8182),d=n(4419),f=n(5513),p=n(277),m=n(1217);function h(e){return(0,m.Z)("MuiSvgIcon",e)}(0,n(5878).Z)("MuiSvgIcon",["root","colorPrimary","colorSecondary","colorAction","colorError","colorDisabled","fontSizeInherit","fontSizeSmall","fontSizeMedium","fontSizeLarge"]);var v=n(184),b=["children","className","color","component","fontSize","htmlColor","inheritViewBox","titleAccess","viewBox"],y=(0,p.ZP)("svg",{name:"MuiSvgIcon",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,"inherit"!==n.color&&t["color".concat((0,o.Z)(n.color))],t["fontSize".concat((0,o.Z)(n.fontSize))]]}})((function(e){var t,n,r,o,a,i,s,l,c,u,d,f,p,m,h,v,b,y=e.theme,g=e.ownerState;return{userSelect:"none",width:"1em",height:"1em",display:"inline-block",fill:"currentColor",flexShrink:0,transition:null==(t=y.transitions)||null==(n=t.create)?void 0:n.call(t,"fill",{duration:null==(r=y.transitions)||null==(o=r.duration)?void 0:o.shorter}),fontSize:{inherit:"inherit",small:(null==(a=y.typography)||null==(i=a.pxToRem)?void 0:i.call(a,20))||"1.25rem",medium:(null==(s=y.typography)||null==(l=s.pxToRem)?void 0:l.call(s,24))||"1.5rem",large:(null==(c=y.typography)||null==(u=c.pxToRem)?void 0:u.call(c,35))||"2.1875rem"}[g.fontSize],color:null!=(d=null==(f=(y.vars||y).palette)||null==(p=f[g.color])?void 0:p.main)?d:{action:null==(m=(y.vars||y).palette)||null==(h=m.action)?void 0:h.active,disabled:null==(v=(y.vars||y).palette)||null==(b=v.action)?void 0:b.disabled,inherit:void 0}[g.color]}})),g=s.forwardRef((function(e,t){var n=(0,f.Z)({props:e,name:"MuiSvgIcon"}),r=n.children,a=n.className,s=n.color,l=void 0===s?"inherit":s,p=n.component,m=void 0===p?"svg":p,g=n.fontSize,_=void 0===g?"medium":g,w=n.htmlColor,T=n.inheritViewBox,S=void 0!==T&&T,P=n.titleAccess,k=n.viewBox,x=void 0===k?"0 0 24 24":k,C=(0,c.Z)(n,b),A=(0,i.Z)({},n,{color:l,component:m,fontSize:_,instanceFontSize:e.fontSize,inheritViewBox:S,viewBox:x}),M={};S||(M.viewBox=x);var F=function(e){var t=e.color,n=e.fontSize,r=e.classes,a={root:["root","inherit"!==t&&"color".concat((0,o.Z)(t)),"fontSize".concat((0,o.Z)(n))]};return(0,d.Z)(a,h,r)}(A);return(0,v.jsxs)(y,(0,i.Z)({as:m,className:(0,u.Z)(F.root,a),focusable:"false",color:w,"aria-hidden":!P||void 0,role:P?"img":void 0,ref:t},M,C,{ownerState:A,children:[r,P?(0,v.jsx)("title",{children:P}):null]}))}));g.muiName="SvgIcon";var _=g;function w(e,t){var n=function(n,r){return(0,v.jsx)(_,(0,i.Z)({"data-testid":"".concat(t,"Icon"),ref:r},n,{children:e}))};return n.muiName=_.muiName,s.memo(s.forwardRef(n))}var T=function(e){var t,n=arguments.length>1&&void 0!==arguments[1]?arguments[1]:166;function r(){for(var r=this,o=arguments.length,a=new Array(o),i=0;i<o;i++)a[i]=arguments[i];var s=function(){e.apply(r,a)};clearTimeout(t),t=setTimeout(s,n)}return r.clear=function(){clearTimeout(t)},r};var S=function(e,t){return function(){return null}};var P=function(e,t){return s.isValidElement(e)&&-1!==t.indexOf(e.type.muiName)};function k(e){return e&&e.ownerDocument||document}var x=k;var C=function(e){return k(e).defaultView||window};var A=function(e,t){return function(){return null}},M=n(2971).Z,F=n(5721).Z,E=n(885),R=0;var N=l.useId;var O=function(e){if(void 0!==N){var t=N();return null!=e?e:t}return function(e){var t=s.useState(e),n=(0,E.Z)(t,2),r=n[0],o=n[1],a=e||r;return s.useEffect((function(){null==r&&o("mui-".concat(R+=1))}),[r]),a}(e)};var V=function(e,t,n,r,o){return null};var L=function(e){var t=e.controlled,n=e.default,r=(e.name,e.state,s.useRef(void 0!==t).current),o=s.useState(n),a=(0,E.Z)(o,2),i=a[0],l=a[1];return[r?t:i,s.useCallback((function(e){r||l(e)}),[])]},D=n(6702),z=n(792),I=n(2763),H={configure:function(e){console.warn(["MUI: `ClassNameGenerator` import from `@mui/material/utils` is outdated and might cause unexpected issues.","","You should use `import { unstable_ClassNameGenerator } from '@mui/material/className'` instead","","The detail of the issue: https://github.com/mui/material-ui/issues/30011#issuecomment-1024993401","","The updated documentation: https://mui.com/guides/classname-generator/"].join("\n")),r.Z.configure(e)}}},6702:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(2791),o=n(5721);var a=function(e){var t=r.useRef(e);return(0,o.Z)((function(){t.current=e})),r.useCallback((function(){return t.current.apply(void 0,arguments)}),[])}},792:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(2791),o=n(2971);var a=function(e,t){return r.useMemo((function(){return null==e&&null==t?null:function(n){(0,o.Z)(e,n),(0,o.Z)(t,n)}}),[e,t])}},2763:function(e,t,n){"use strict";n.d(t,{Z:function(){return f}});var r,o=n(2791),a=!0,i=!1,s={text:!0,search:!0,url:!0,tel:!0,email:!0,password:!0,number:!0,date:!0,month:!0,week:!0,time:!0,datetime:!0,"datetime-local":!0};function l(e){e.metaKey||e.altKey||e.ctrlKey||(a=!0)}function c(){a=!1}function u(){"hidden"===this.visibilityState&&i&&(a=!0)}function d(e){var t=e.target;try{return t.matches(":focus-visible")}catch(n){}return a||function(e){var t=e.type,n=e.tagName;return!("INPUT"!==n||!s[t]||e.readOnly)||"TEXTAREA"===n&&!e.readOnly||!!e.isContentEditable}(t)}var f=function(){var e=o.useCallback((function(e){var t;null!=e&&((t=e.ownerDocument).addEventListener("keydown",l,!0),t.addEventListener("mousedown",c,!0),t.addEventListener("pointerdown",c,!0),t.addEventListener("touchstart",c,!0),t.addEventListener("visibilitychange",u,!0))}),[]),t=o.useRef(!1);return{isFocusVisibleRef:t,onFocus:function(e){return!!d(e)&&(t.current=!0,!0)},onBlur:function(){return!!t.current&&(i=!0,window.clearTimeout(r),r=window.setTimeout((function(){i=!1}),100),t.current=!1,!0)},ref:e}}},2421:function(e,t,n){"use strict";n.d(t,{ZP:function(){return _},Co:function(){return w}});var r=n(2791),o=n(7462),a=n(9797),i=/^((children|dangerouslySetInnerHTML|key|ref|autoFocus|defaultValue|defaultChecked|innerHTML|suppressContentEditableWarning|suppressHydrationWarning|valueLink|abbr|accept|acceptCharset|accessKey|action|allow|allowUserMedia|allowPaymentRequest|allowFullScreen|allowTransparency|alt|async|autoComplete|autoPlay|capture|cellPadding|cellSpacing|challenge|charSet|checked|cite|classID|className|cols|colSpan|content|contentEditable|contextMenu|controls|controlsList|coords|crossOrigin|data|dateTime|decoding|default|defer|dir|disabled|disablePictureInPicture|download|draggable|encType|enterKeyHint|form|formAction|formEncType|formMethod|formNoValidate|formTarget|frameBorder|headers|height|hidden|high|href|hrefLang|htmlFor|httpEquiv|id|inputMode|integrity|is|keyParams|keyType|kind|label|lang|list|loading|loop|low|marginHeight|marginWidth|max|maxLength|media|mediaGroup|method|min|minLength|multiple|muted|name|nonce|noValidate|open|optimum|pattern|placeholder|playsInline|poster|preload|profile|radioGroup|readOnly|referrerPolicy|rel|required|reversed|role|rows|rowSpan|sandbox|scope|scoped|scrolling|seamless|selected|shape|size|sizes|slot|span|spellCheck|src|srcDoc|srcLang|srcSet|start|step|style|summary|tabIndex|target|title|translate|type|useMap|value|width|wmode|wrap|about|datatype|inlist|prefix|property|resource|typeof|vocab|autoCapitalize|autoCorrect|autoSave|color|incremental|fallback|inert|itemProp|itemScope|itemType|itemID|itemRef|on|option|results|security|unselectable|accentHeight|accumulate|additive|alignmentBaseline|allowReorder|alphabetic|amplitude|arabicForm|ascent|attributeName|attributeType|autoReverse|azimuth|baseFrequency|baselineShift|baseProfile|bbox|begin|bias|by|calcMode|capHeight|clip|clipPathUnits|clipPath|clipRule|colorInterpolation|colorInterpolationFilters|colorProfile|colorRendering|contentScriptType|contentStyleType|cursor|cx|cy|d|decelerate|descent|diffuseConstant|direction|display|divisor|dominantBaseline|dur|dx|dy|edgeMode|elevation|enableBackground|end|exponent|externalResourcesRequired|fill|fillOpacity|fillRule|filter|filterRes|filterUnits|floodColor|floodOpacity|focusable|fontFamily|fontSize|fontSizeAdjust|fontStretch|fontStyle|fontVariant|fontWeight|format|from|fr|fx|fy|g1|g2|glyphName|glyphOrientationHorizontal|glyphOrientationVertical|glyphRef|gradientTransform|gradientUnits|hanging|horizAdvX|horizOriginX|ideographic|imageRendering|in|in2|intercept|k|k1|k2|k3|k4|kernelMatrix|kernelUnitLength|kerning|keyPoints|keySplines|keyTimes|lengthAdjust|letterSpacing|lightingColor|limitingConeAngle|local|markerEnd|markerMid|markerStart|markerHeight|markerUnits|markerWidth|mask|maskContentUnits|maskUnits|mathematical|mode|numOctaves|offset|opacity|operator|order|orient|orientation|origin|overflow|overlinePosition|overlineThickness|panose1|paintOrder|pathLength|patternContentUnits|patternTransform|patternUnits|pointerEvents|points|pointsAtX|pointsAtY|pointsAtZ|preserveAlpha|preserveAspectRatio|primitiveUnits|r|radius|refX|refY|renderingIntent|repeatCount|repeatDur|requiredExtensions|requiredFeatures|restart|result|rotate|rx|ry|scale|seed|shapeRendering|slope|spacing|specularConstant|specularExponent|speed|spreadMethod|startOffset|stdDeviation|stemh|stemv|stitchTiles|stopColor|stopOpacity|strikethroughPosition|strikethroughThickness|string|stroke|strokeDasharray|strokeDashoffset|strokeLinecap|strokeLinejoin|strokeMiterlimit|strokeOpacity|strokeWidth|surfaceScale|systemLanguage|tableValues|targetX|targetY|textAnchor|textDecoration|textRendering|textLength|to|transform|u1|u2|underlinePosition|underlineThickness|unicode|unicodeBidi|unicodeRange|unitsPerEm|vAlphabetic|vHanging|vIdeographic|vMathematical|values|vectorEffect|version|vertAdvY|vertOriginX|vertOriginY|viewBox|viewTarget|visibility|widths|wordSpacing|writingMode|x|xHeight|x1|x2|xChannelSelector|xlinkActuate|xlinkArcrole|xlinkHref|xlinkRole|xlinkShow|xlinkTitle|xlinkType|xmlBase|xmlns|xmlnsXlink|xmlLang|xmlSpace|y|y1|y2|yChannelSelector|z|zoomAndPan|for|class|autofocus)|(([Dd][Aa][Tt][Aa]|[Aa][Rr][Ii][Aa]|x)-.*))$/,s=(0,a.Z)((function(e){return i.test(e)||111===e.charCodeAt(0)&&110===e.charCodeAt(1)&&e.charCodeAt(2)<91})),l=n(9886),c=n(5438),u=n(9140),d=n(2561),f=s,p=function(e){return"theme"!==e},m=function(e){return"string"===typeof e&&e.charCodeAt(0)>96?f:p},h=function(e,t,n){var r;if(t){var o=t.shouldForwardProp;r=e.__emotion_forwardProp&&o?function(t){return e.__emotion_forwardProp(t)&&o(t)}:o}return"function"!==typeof r&&n&&(r=e.__emotion_forwardProp),r},v=function(e){var t=e.cache,n=e.serialized,r=e.isStringTag;(0,c.hC)(t,n,r);(0,d.L)((function(){return(0,c.My)(t,n,r)}));return null},b=function e(t,n){var a,i,s=t.__emotion_real===t,d=s&&t.__emotion_base||t;void 0!==n&&(a=n.label,i=n.target);var f=h(t,n,s),p=f||m(d),b=!p("as");return function(){var y=arguments,g=s&&void 0!==t.__emotion_styles?t.__emotion_styles.slice(0):[];if(void 0!==a&&g.push("label:"+a+";"),null==y[0]||void 0===y[0].raw)g.push.apply(g,y);else{0,g.push(y[0][0]);for(var _=y.length,w=1;w<_;w++)g.push(y[w],y[0][w])}var T=(0,l.w)((function(e,t,n){var o=b&&e.as||d,a="",s=[],h=e;if(null==e.theme){for(var y in h={},e)h[y]=e[y];h.theme=(0,r.useContext)(l.T)}"string"===typeof e.className?a=(0,c.fp)(t.registered,s,e.className):null!=e.className&&(a=e.className+" ");var _=(0,u.O)(g.concat(s),t.registered,h);a+=t.key+"-"+_.name,void 0!==i&&(a+=" "+i);var w=b&&void 0===f?m(o):p,T={};for(var S in e)b&&"as"===S||w(S)&&(T[S]=e[S]);return T.className=a,T.ref=n,(0,r.createElement)(r.Fragment,null,(0,r.createElement)(v,{cache:t,serialized:_,isStringTag:"string"===typeof o}),(0,r.createElement)(o,T))}));return T.displayName=void 0!==a?a:"Styled("+("string"===typeof d?d:d.displayName||d.name||"Component")+")",T.defaultProps=t.defaultProps,T.__emotion_real=T,T.__emotion_base=d,T.__emotion_styles=g,T.__emotion_forwardProp=f,Object.defineProperty(T,"toString",{value:function(){return"."+i}}),T.withComponent=function(t,r){return e(t,(0,o.Z)({},n,r,{shouldForwardProp:h(T,r,!0)})).apply(void 0,g)},T}},y=b.bind();["a","abbr","address","area","article","aside","audio","b","base","bdi","bdo","big","blockquote","body","br","button","canvas","caption","cite","code","col","colgroup","data","datalist","dd","del","details","dfn","dialog","div","dl","dt","em","embed","fieldset","figcaption","figure","footer","form","h1","h2","h3","h4","h5","h6","head","header","hgroup","hr","html","i","iframe","img","input","ins","kbd","keygen","label","legend","li","link","main","map","mark","marquee","menu","menuitem","meta","meter","nav","noscript","object","ol","optgroup","option","output","p","param","picture","pre","progress","q","rp","rt","ruby","s","samp","script","section","select","small","source","span","strong","style","sub","summary","sup","table","tbody","td","textarea","tfoot","th","thead","time","title","tr","track","u","ul","var","video","wbr","circle","clipPath","defs","ellipse","foreignObject","g","image","line","linearGradient","mask","path","pattern","polygon","polyline","radialGradient","rect","stop","svg","text","tspan"].forEach((function(e){y[e]=y(e)}));var g=y;function _(e,t){return g(e,t)}var w=function(e,t){Array.isArray(e.__emotion_styles)&&(e.__emotion_styles=t(e.__emotion_styles))}},1184:function(e,t,n){"use strict";n.d(t,{L7:function(){return l},P$:function(){return u},VO:function(){return o},W8:function(){return s},dt:function(){return c},k9:function(){return i}});var r=n(2466),o={xs:0,sm:600,md:900,lg:1200,xl:1536},a={keys:["xs","sm","md","lg","xl"],up:function(e){return"@media (min-width:".concat(o[e],"px)")}};function i(e,t,n){var r=e.theme||{};if(Array.isArray(t)){var i=r.breakpoints||a;return t.reduce((function(e,r,o){return e[i.up(i.keys[o])]=n(t[o]),e}),{})}if("object"===typeof t){var s=r.breakpoints||a;return Object.keys(t).reduce((function(e,r){if(-1!==Object.keys(s.values||o).indexOf(r)){e[s.up(r)]=n(t[r],r)}else{var a=r;e[a]=t[a]}return e}),{})}return n(t)}function s(){var e,t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},n=null==(e=t.keys)?void 0:e.reduce((function(e,n){return e[t.up(n)]={},e}),{});return n||{}}function l(e,t){return e.reduce((function(e,t){var n=e[t];return(!n||0===Object.keys(n).length)&&delete e[t],e}),t)}function c(e){for(var t=s(e),n=arguments.length,o=new Array(n>1?n-1:0),a=1;a<n;a++)o[a-1]=arguments[a];var i=[t].concat(o).reduce((function(e,t){return(0,r.Z)(e,t)}),{});return l(Object.keys(t),i)}function u(e){var t,n=e.values,r=e.breakpoints,o=e.base||function(e,t){if("object"!==typeof e)return{};var n={},r=Object.keys(t);return Array.isArray(e)?r.forEach((function(t,r){r<e.length&&(n[t]=!0)})):r.forEach((function(t){null!=e[t]&&(n[t]=!0)})),n}(n,r),a=Object.keys(o);return 0===a.length?n:a.reduce((function(e,r,o){return Array.isArray(n)?(e[r]=null!=n[o]?n[o]:n[t],t=o):"object"===typeof n?(e[r]=null!=n[r]?n[r]:n[t],t=r):e[r]=n,e}),{})}},2065:function(e,t,n){"use strict";n.d(t,{$n:function(){return d},Fq:function(){return c},_j:function(){return u},mi:function(){return l}});var r=n(6189);function o(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:0,n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:1;return Math.min(Math.max(t,e),n)}function a(e){if(e.type)return e;if("#"===e.charAt(0))return a(function(e){e=e.slice(1);var t=new RegExp(".{1,".concat(e.length>=6?2:1,"}"),"g"),n=e.match(t);return n&&1===n[0].length&&(n=n.map((function(e){return e+e}))),n?"rgb".concat(4===n.length?"a":"","(").concat(n.map((function(e,t){return t<3?parseInt(e,16):Math.round(parseInt(e,16)/255*1e3)/1e3})).join(", "),")"):""}(e));var t=e.indexOf("("),n=e.substring(0,t);if(-1===["rgb","rgba","hsl","hsla","color"].indexOf(n))throw new Error((0,r.Z)(9,e));var o,i=e.substring(t+1,e.length-1);if("color"===n){if(o=(i=i.split(" ")).shift(),4===i.length&&"/"===i[3].charAt(0)&&(i[3]=i[3].slice(1)),-1===["srgb","display-p3","a98-rgb","prophoto-rgb","rec-2020"].indexOf(o))throw new Error((0,r.Z)(10,o))}else i=i.split(",");return{type:n,values:i=i.map((function(e){return parseFloat(e)})),colorSpace:o}}function i(e){var t=e.type,n=e.colorSpace,r=e.values;return-1!==t.indexOf("rgb")?r=r.map((function(e,t){return t<3?parseInt(e,10):e})):-1!==t.indexOf("hsl")&&(r[1]="".concat(r[1],"%"),r[2]="".concat(r[2],"%")),r=-1!==t.indexOf("color")?"".concat(n," ").concat(r.join(" ")):"".concat(r.join(", ")),"".concat(t,"(").concat(r,")")}function s(e){var t="hsl"===(e=a(e)).type||"hsla"===e.type?a(function(e){var t=(e=a(e)).values,n=t[0],r=t[1]/100,o=t[2]/100,s=r*Math.min(o,1-o),l=function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(e+n/30)%12;return o-s*Math.max(Math.min(t-3,9-t,1),-1)},c="rgb",u=[Math.round(255*l(0)),Math.round(255*l(8)),Math.round(255*l(4))];return"hsla"===e.type&&(c+="a",u.push(t[3])),i({type:c,values:u})}(e)).values:e.values;return t=t.map((function(t){return"color"!==e.type&&(t/=255),t<=.03928?t/12.92:Math.pow((t+.055)/1.055,2.4)})),Number((.2126*t[0]+.7152*t[1]+.0722*t[2]).toFixed(3))}function l(e,t){var n=s(e),r=s(t);return(Math.max(n,r)+.05)/(Math.min(n,r)+.05)}function c(e,t){return e=a(e),t=o(t),"rgb"!==e.type&&"hsl"!==e.type||(e.type+="a"),"color"===e.type?e.values[3]="/".concat(t):e.values[3]=t,i(e)}function u(e,t){if(e=a(e),t=o(t),-1!==e.type.indexOf("hsl"))e.values[2]*=1-t;else if(-1!==e.type.indexOf("rgb")||-1!==e.type.indexOf("color"))for(var n=0;n<3;n+=1)e.values[n]*=1-t;return i(e)}function d(e,t){if(e=a(e),t=o(t),-1!==e.type.indexOf("hsl"))e.values[2]+=(100-e.values[2])*t;else if(-1!==e.type.indexOf("rgb"))for(var n=0;n<3;n+=1)e.values[n]+=(255-e.values[n])*t;else if(-1!==e.type.indexOf("color"))for(var r=0;r<3;r+=1)e.values[r]+=(1-e.values[r])*t;return i(e)}},4046:function(e,t,n){"use strict";n.d(t,{ZP:function(){return P},x9:function(){return T}});var r=n(2982),o=n(885),a=n(3366),i=n(7462),s=n(2421),l=n(5080),c=n(7312),u=["variant"];function d(e){return 0===e.length}function f(e){var t=e.variant,n=(0,a.Z)(e,u),r=t||"";return Object.keys(n).sort().forEach((function(t){r+="color"===t?d(r)?e[t]:(0,c.Z)(e[t]):"".concat(d(r)?t:(0,c.Z)(t)).concat((0,c.Z)(e[t].toString()))})),r}var p=n(104),m=["name","slot","skipVariantsResolver","skipSx","overridesResolver"],h=["theme"],v=["theme"];function b(e){return 0===Object.keys(e).length}function y(e){return"string"===typeof e&&e.charCodeAt(0)>96}var g=function(e,t){return t.components&&t.components[e]&&t.components[e].styleOverrides?t.components[e].styleOverrides:null},_=function(e,t){var n=[];t&&t.components&&t.components[e]&&t.components[e].variants&&(n=t.components[e].variants);var r={};return n.forEach((function(e){var t=f(e.props);r[t]=e.style})),r},w=function(e,t,n,r){var o,a,i=e.ownerState,s=void 0===i?{}:i,l=[],c=null==n||null==(o=n.components)||null==(a=o[r])?void 0:a.variants;return c&&c.forEach((function(n){var r=!0;Object.keys(n.props).forEach((function(t){s[t]!==n.props[t]&&e[t]!==n.props[t]&&(r=!1)})),r&&l.push(t[f(n.props)])})),l};function T(e){return"ownerState"!==e&&"theme"!==e&&"sx"!==e&&"as"!==e}var S=(0,l.Z)();function P(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=e.defaultTheme,n=void 0===t?S:t,l=e.rootShouldForwardProp,c=void 0===l?T:l,u=e.slotShouldForwardProp,d=void 0===u?T:u,f=e.styleFunctionSx,P=void 0===f?p.Z:f,k=function(e){var t=b(e.theme)?n:e.theme;return P((0,i.Z)({},e,{theme:t}))};return k.__mui_systemSx=!0,function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{};(0,s.Co)(e,(function(e){return e.filter((function(e){return!(null!=e&&e.__mui_systemSx)}))}));var l,u=t.name,f=t.slot,p=t.skipVariantsResolver,S=t.skipSx,P=t.overridesResolver,x=(0,a.Z)(t,m),C=void 0!==p?p:f&&"Root"!==f||!1,A=S||!1;var M=T;"Root"===f?M=c:f?M=d:y(e)&&(M=void 0);var F=(0,s.ZP)(e,(0,i.Z)({shouldForwardProp:M,label:l},x)),E=function(e){for(var t=arguments.length,s=new Array(t>1?t-1:0),l=1;l<t;l++)s[l-1]=arguments[l];var c=s?s.map((function(e){return"function"===typeof e&&e.__emotion_real!==e?function(t){var r=t.theme,o=(0,a.Z)(t,h);return e((0,i.Z)({theme:b(r)?n:r},o))}:e})):[],d=e;u&&P&&c.push((function(e){var t=b(e.theme)?n:e.theme,r=g(u,t);if(r){var a={};return Object.entries(r).forEach((function(n){var r=(0,o.Z)(n,2),s=r[0],l=r[1];a[s]="function"===typeof l?l((0,i.Z)({},e,{theme:t})):l})),P(e,a)}return null})),u&&!C&&c.push((function(e){var t=b(e.theme)?n:e.theme;return w(e,_(u,t),t,u)})),A||c.push(k);var f=c.length-s.length;if(Array.isArray(e)&&f>0){var p=new Array(f).fill("");(d=[].concat((0,r.Z)(e),(0,r.Z)(p))).raw=[].concat((0,r.Z)(e.raw),(0,r.Z)(p))}else"function"===typeof e&&e.__emotion_real!==e&&(d=function(t){var r=t.theme,o=(0,a.Z)(t,v);return e((0,i.Z)({theme:b(r)?n:r},o))});var m=F.apply(void 0,[d].concat((0,r.Z)(c)));return m};return F.withConfig&&(E.withConfig=F.withConfig),E}}},5080:function(e,t,n){"use strict";n.d(t,{Z:function(){return p}});var r=n(7462),o=n(3366),a=n(2466),i=n(4942),s=["values","unit","step"];function l(e){var t=e.values,n=void 0===t?{xs:0,sm:600,md:900,lg:1200,xl:1536}:t,a=e.unit,l=void 0===a?"px":a,c=e.step,u=void 0===c?5:c,d=(0,o.Z)(e,s),f=function(e){var t=Object.keys(e).map((function(t){return{key:t,val:e[t]}}))||[];return t.sort((function(e,t){return e.val-t.val})),t.reduce((function(e,t){return(0,r.Z)({},e,(0,i.Z)({},t.key,t.val))}),{})}(n),p=Object.keys(f);function m(e){var t="number"===typeof n[e]?n[e]:e;return"@media (min-width:".concat(t).concat(l,")")}function h(e){var t="number"===typeof n[e]?n[e]:e;return"@media (max-width:".concat(t-u/100).concat(l,")")}function v(e,t){var r=p.indexOf(t);return"@media (min-width:".concat("number"===typeof n[e]?n[e]:e).concat(l,") and ")+"(max-width:".concat((-1!==r&&"number"===typeof n[p[r]]?n[p[r]]:t)-u/100).concat(l,")")}return(0,r.Z)({keys:p,values:f,up:m,down:h,between:v,only:function(e){return p.indexOf(e)+1<p.length?v(e,p[p.indexOf(e)+1]):m(e)},not:function(e){var t=p.indexOf(e);return 0===t?m(p[1]):t===p.length-1?h(p[t]):v(e,p[p.indexOf(e)+1]).replace("@media","@media not all and")},unit:l},d)}var c={borderRadius:4},u=n(5682);function d(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:8;if(e.mui)return e;var t=(0,u.hB)({spacing:e}),n=function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var o=0===n.length?[1]:n;return o.map((function(e){var n=t(e);return"number"===typeof n?"".concat(n,"px"):n})).join(" ")};return n.mui=!0,n}var f=["breakpoints","palette","spacing","shape"];var p=function(){for(var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=e.breakpoints,n=void 0===t?{}:t,i=e.palette,s=void 0===i?{}:i,u=e.spacing,p=e.shape,m=void 0===p?{}:p,h=(0,o.Z)(e,f),v=l(n),b=d(u),y=(0,a.Z)({breakpoints:v,direction:"ltr",components:{},palette:(0,r.Z)({mode:"light"},s),spacing:b,shape:(0,r.Z)({},c,m)},h),g=arguments.length,_=new Array(g>1?g-1:0),w=1;w<g;w++)_[w-1]=arguments[w];return y=_.reduce((function(e,t){return(0,a.Z)(e,t)}),y)}},114:function(e,t,n){"use strict";n.d(t,{Gc:function(){return J},G$:function(){return $}});var r=n(8529),o=n(8247);var a=function(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];var r=t.reduce((function(e,t){return t.filterProps.forEach((function(n){e[n]=t})),e}),{}),a=function(e){return Object.keys(e).reduce((function(t,n){return r[n]?(0,o.Z)(t,r[n](e)):t}),{})};return a.propTypes={},a.filterProps=t.reduce((function(e,t){return e.concat(t.filterProps)}),[]),a},i=n(5682),s=n(1184);function l(e){return"number"!==typeof e?e:"".concat(e,"px solid")}var c=(0,r.Z)({prop:"border",themeKey:"borders",transform:l}),u=(0,r.Z)({prop:"borderTop",themeKey:"borders",transform:l}),d=(0,r.Z)({prop:"borderRight",themeKey:"borders",transform:l}),f=(0,r.Z)({prop:"borderBottom",themeKey:"borders",transform:l}),p=(0,r.Z)({prop:"borderLeft",themeKey:"borders",transform:l}),m=(0,r.Z)({prop:"borderColor",themeKey:"palette"}),h=(0,r.Z)({prop:"borderTopColor",themeKey:"palette"}),v=(0,r.Z)({prop:"borderRightColor",themeKey:"palette"}),b=(0,r.Z)({prop:"borderBottomColor",themeKey:"palette"}),y=(0,r.Z)({prop:"borderLeftColor",themeKey:"palette"}),g=function(e){if(void 0!==e.borderRadius&&null!==e.borderRadius){var t=(0,i.eI)(e.theme,"shape.borderRadius",4,"borderRadius");return(0,s.k9)(e,e.borderRadius,(function(e){return{borderRadius:(0,i.NA)(t,e)}}))}return null};g.propTypes={},g.filterProps=["borderRadius"];var _=a(c,u,d,f,p,m,h,v,b,y,g),w=a((0,r.Z)({prop:"displayPrint",cssProperty:!1,transform:function(e){return{"@media print":{display:e}}}}),(0,r.Z)({prop:"display"}),(0,r.Z)({prop:"overflow"}),(0,r.Z)({prop:"textOverflow"}),(0,r.Z)({prop:"visibility"}),(0,r.Z)({prop:"whiteSpace"})),T=a((0,r.Z)({prop:"flexBasis"}),(0,r.Z)({prop:"flexDirection"}),(0,r.Z)({prop:"flexWrap"}),(0,r.Z)({prop:"justifyContent"}),(0,r.Z)({prop:"alignItems"}),(0,r.Z)({prop:"alignContent"}),(0,r.Z)({prop:"order"}),(0,r.Z)({prop:"flex"}),(0,r.Z)({prop:"flexGrow"}),(0,r.Z)({prop:"flexShrink"}),(0,r.Z)({prop:"alignSelf"}),(0,r.Z)({prop:"justifyItems"}),(0,r.Z)({prop:"justifySelf"})),S=function(e){if(void 0!==e.gap&&null!==e.gap){var t=(0,i.eI)(e.theme,"spacing",8,"gap");return(0,s.k9)(e,e.gap,(function(e){return{gap:(0,i.NA)(t,e)}}))}return null};S.propTypes={},S.filterProps=["gap"];var P=function(e){if(void 0!==e.columnGap&&null!==e.columnGap){var t=(0,i.eI)(e.theme,"spacing",8,"columnGap");return(0,s.k9)(e,e.columnGap,(function(e){return{columnGap:(0,i.NA)(t,e)}}))}return null};P.propTypes={},P.filterProps=["columnGap"];var k=function(e){if(void 0!==e.rowGap&&null!==e.rowGap){var t=(0,i.eI)(e.theme,"spacing",8,"rowGap");return(0,s.k9)(e,e.rowGap,(function(e){return{rowGap:(0,i.NA)(t,e)}}))}return null};k.propTypes={},k.filterProps=["rowGap"];var x=a(S,P,k,(0,r.Z)({prop:"gridColumn"}),(0,r.Z)({prop:"gridRow"}),(0,r.Z)({prop:"gridAutoFlow"}),(0,r.Z)({prop:"gridAutoColumns"}),(0,r.Z)({prop:"gridAutoRows"}),(0,r.Z)({prop:"gridTemplateColumns"}),(0,r.Z)({prop:"gridTemplateRows"}),(0,r.Z)({prop:"gridTemplateAreas"}),(0,r.Z)({prop:"gridArea"})),C=a((0,r.Z)({prop:"position"}),(0,r.Z)({prop:"zIndex",themeKey:"zIndex"}),(0,r.Z)({prop:"top"}),(0,r.Z)({prop:"right"}),(0,r.Z)({prop:"bottom"}),(0,r.Z)({prop:"left"})),A=a((0,r.Z)({prop:"color",themeKey:"palette"}),(0,r.Z)({prop:"bgcolor",cssProperty:"backgroundColor",themeKey:"palette"}),(0,r.Z)({prop:"backgroundColor",themeKey:"palette"})),M=(0,r.Z)({prop:"boxShadow",themeKey:"shadows"});function F(e){return e<=1&&0!==e?"".concat(100*e,"%"):e}var E=(0,r.Z)({prop:"width",transform:F}),R=function(e){if(void 0!==e.maxWidth&&null!==e.maxWidth){return(0,s.k9)(e,e.maxWidth,(function(t){var n,r,o;return{maxWidth:(null==(n=e.theme)||null==(r=n.breakpoints)||null==(o=r.values)?void 0:o[t])||s.VO[t]||F(t)}}))}return null};R.filterProps=["maxWidth"];var N=(0,r.Z)({prop:"minWidth",transform:F}),O=(0,r.Z)({prop:"height",transform:F}),V=(0,r.Z)({prop:"maxHeight",transform:F}),L=(0,r.Z)({prop:"minHeight",transform:F}),D=((0,r.Z)({prop:"size",cssProperty:"width",transform:F}),(0,r.Z)({prop:"size",cssProperty:"height",transform:F}),a(E,R,N,O,V,L,(0,r.Z)({prop:"boxSizing"}))),z=(0,r.Z)({prop:"fontFamily",themeKey:"typography"}),I=(0,r.Z)({prop:"fontSize",themeKey:"typography"}),H=(0,r.Z)({prop:"fontStyle",themeKey:"typography"}),j=(0,r.Z)({prop:"fontWeight",themeKey:"typography"}),Z=(0,r.Z)({prop:"letterSpacing"}),B=(0,r.Z)({prop:"textTransform"}),G=(0,r.Z)({prop:"lineHeight"}),W=(0,r.Z)({prop:"textAlign"}),U=a((0,r.Z)({prop:"typography",cssProperty:!1,themeKey:"typography"}),z,I,H,j,Z,G,W,B),q={borders:_.filterProps,display:w.filterProps,flexbox:T.filterProps,grid:x.filterProps,positions:C.filterProps,palette:A.filterProps,shadows:M.filterProps,sizing:D.filterProps,spacing:i.ZP.filterProps,typography:U.filterProps},$={borders:_,display:w,flexbox:T,grid:x,positions:C,palette:A,shadows:M,sizing:D,spacing:i.ZP,typography:U},J=Object.keys(q).reduce((function(e,t){return q[t].forEach((function(n){e[n]=$[t]})),e}),{})},8247:function(e,t,n){"use strict";var r=n(2466);t.Z=function(e,t){return t?(0,r.Z)(e,t,{clone:!1}):e}},5682:function(e,t,n){"use strict";n.d(t,{hB:function(){return h},eI:function(){return m},ZP:function(){return T},NA:function(){return v}});var r=n(885),o=n(1184),a=n(8529),i=n(8247);var s={m:"margin",p:"padding"},l={t:"Top",r:"Right",b:"Bottom",l:"Left",x:["Left","Right"],y:["Top","Bottom"]},c={marginX:"mx",marginY:"my",paddingX:"px",paddingY:"py"},u=function(e){var t={};return function(n){return void 0===t[n]&&(t[n]=e(n)),t[n]}}((function(e){if(e.length>2){if(!c[e])return[e];e=c[e]}var t=e.split(""),n=(0,r.Z)(t,2),o=n[0],a=n[1],i=s[o],u=l[a]||"";return Array.isArray(u)?u.map((function(e){return i+e})):[i+u]})),d=["m","mt","mr","mb","ml","mx","my","margin","marginTop","marginRight","marginBottom","marginLeft","marginX","marginY","marginInline","marginInlineStart","marginInlineEnd","marginBlock","marginBlockStart","marginBlockEnd"],f=["p","pt","pr","pb","pl","px","py","padding","paddingTop","paddingRight","paddingBottom","paddingLeft","paddingX","paddingY","paddingInline","paddingInlineStart","paddingInlineEnd","paddingBlock","paddingBlockStart","paddingBlockEnd"],p=[].concat(d,f);function m(e,t,n,r){var o,i=null!=(o=(0,a.D)(e,t,!1))?o:n;return"number"===typeof i?function(e){return"string"===typeof e?e:i*e}:Array.isArray(i)?function(e){return"string"===typeof e?e:i[e]}:"function"===typeof i?i:function(){}}function h(e){return m(e,"spacing",8)}function v(e,t){if("string"===typeof t||null==t)return t;var n=e(Math.abs(t));return t>=0?n:"number"===typeof n?-n:"-".concat(n)}function b(e,t,n,r){if(-1===t.indexOf(n))return null;var a=function(e,t){return function(n){return e.reduce((function(e,r){return e[r]=v(t,n),e}),{})}}(u(n),r),i=e[n];return(0,o.k9)(e,i,a)}function y(e,t){var n=h(e.theme);return Object.keys(e).map((function(r){return b(e,t,r,n)})).reduce(i.Z,{})}function g(e){return y(e,d)}function _(e){return y(e,f)}function w(e){return y(e,p)}g.propTypes={},g.filterProps=d,_.propTypes={},_.filterProps=f,w.propTypes={},w.filterProps=p;var T=w},8529:function(e,t,n){"use strict";n.d(t,{D:function(){return i}});var r=n(4942),o=n(7312),a=n(1184);function i(e,t){var n=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(!t||"string"!==typeof t)return null;if(e&&e.vars&&n){var r="vars.".concat(t).split(".").reduce((function(e,t){return e&&e[t]?e[t]:null}),e);if(null!=r)return r}return t.split(".").reduce((function(e,t){return e&&null!=e[t]?e[t]:null}),e)}function s(e,t,n){var r,o=arguments.length>3&&void 0!==arguments[3]?arguments[3]:n;return r="function"===typeof e?e(n):Array.isArray(e)?e[n]||o:i(e,n)||o,t&&(r=t(r)),r}t.Z=function(e){var t=e.prop,n=e.cssProperty,l=void 0===n?e.prop:n,c=e.themeKey,u=e.transform,d=function(e){if(null==e[t])return null;var n=e[t],d=i(e.theme,c)||{};return(0,a.k9)(e,n,(function(e){var n=s(d,u,e);return e===n&&"string"===typeof e&&(n=s(d,u,"".concat(t).concat("default"===e?"":(0,o.Z)(e)),e)),!1===l?n:(0,r.Z)({},l,n)}))};return d.propTypes={},d.filterProps=[t],d}},104:function(e,t,n){"use strict";var r=n(4942),o=n(8247),a=n(114),i=n(1184);function s(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];var r=t.reduce((function(e,t){return e.concat(Object.keys(t))}),[]),o=new Set(r);return t.every((function(e){return o.size===Object.keys(e).length}))}function l(e,t){return"function"===typeof e?e(t):e}var c=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:a.G$,t=Object.keys(e).reduce((function(t,n){return e[n].filterProps.forEach((function(r){t[r]=e[n]})),t}),{});function n(e,n,o){var a,i=(a={},(0,r.Z)(a,e,n),(0,r.Z)(a,"theme",o),a),s=t[e];return s?s(i):(0,r.Z)({},e,n)}function c(e){var a=e||{},u=a.sx,d=a.theme,f=void 0===d?{}:d;if(!u)return null;function p(e){var a=e;if("function"===typeof e)a=e(f);else if("object"!==typeof e)return e;if(!a)return null;var u=(0,i.W8)(f.breakpoints),d=Object.keys(u),p=u;return Object.keys(a).forEach((function(e){var u=l(a[e],f);if(null!==u&&void 0!==u)if("object"===typeof u)if(t[e])p=(0,o.Z)(p,n(e,u,f));else{var d=(0,i.k9)({theme:f},u,(function(t){return(0,r.Z)({},e,t)}));s(d,u)?p[e]=c({sx:u,theme:f}):p=(0,o.Z)(p,d)}else p=(0,o.Z)(p,n(e,u,f))})),(0,i.L7)(d,p)}return Array.isArray(u)?u.map(p):p(u)}return c}();c.filterProps=["sx"],t.Z=c},886:function(e,t,n){"use strict";n.d(t,{Z:function(){return u}});var r=n(5080),o=n(2791);var a=o.createContext(null);function i(){return o.useContext(a)}function s(e){return 0===Object.keys(e).length}var l=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:null,t=i();return!t||s(t)?e:t},c=(0,r.Z)();var u=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:c;return l(e)}},8691:function(e,t,n){"use strict";n.d(t,{Z:function(){return i}});var r=n(7462);function o(e){var t=e.theme,n=e.name,o=e.props;return t&&t.components&&t.components[n]&&t.components[n].defaultProps?function(e,t){var n=(0,r.Z)({},t);return Object.keys(e).forEach((function(t){void 0===n[t]&&(n[t]=e[t])})),n}(t.components[n].defaultProps,o):o}var a=n(886);function i(e){var t=e.props,n=e.name,r=e.defaultTheme;return o({theme:(0,a.Z)(r),name:n,props:t})}},5902:function(e,t){"use strict";var n=function(e){return e},r=function(){var e=n;return{configure:function(t){e=t},generate:function(t){return e(t)},reset:function(){e=n}}}();t.Z=r},7312:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(6189);function o(e){if("string"!==typeof e)throw new Error((0,r.Z)(7));return e.charAt(0).toUpperCase()+e.slice(1)}},4419:function(e,t,n){"use strict";function r(e,t,n){var r={};return Object.keys(e).forEach((function(o){r[o]=e[o].reduce((function(e,r){return r&&(e.push(t(r)),n&&n[r]&&e.push(n[r])),e}),[]).join(" ")})),r}n.d(t,{Z:function(){return r}})},2466:function(e,t,n){"use strict";n.d(t,{P:function(){return o},Z:function(){return a}});var r=n(7462);function o(e){return null!==e&&"object"===typeof e&&e.constructor===Object}function a(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{clone:!0},i=n.clone?(0,r.Z)({},e):e;return o(e)&&o(t)&&Object.keys(t).forEach((function(r){"__proto__"!==r&&(o(t[r])&&r in e&&o(e[r])?i[r]=a(e[r],t[r],n):i[r]=t[r])})),i}},6189:function(e,t,n){"use strict";function r(e){for(var t="https://mui.com/production-error/?code="+e,n=1;n<arguments.length;n+=1)t+="&args[]="+encodeURIComponent(arguments[n]);return"Minified MUI error #"+e+"; visit "+t+" for the full message."}n.d(t,{Z:function(){return r}})},1217:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(5902),o={active:"active",checked:"checked",completed:"completed",disabled:"disabled",error:"error",expanded:"expanded",focused:"focused",focusVisible:"focusVisible",required:"required",selected:"selected"};function a(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:"Mui",a=o[t];return a?"".concat(n,"-").concat(a):"".concat(r.Z.generate(e),"-").concat(t)}},5878:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(1217);function o(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:"Mui",o={};return t.forEach((function(t){o[t]=(0,r.Z)(e,t,n)})),o}},2971:function(e,t,n){"use strict";function r(e,t){"function"===typeof e?e(t):e&&(e.current=t)}n.d(t,{Z:function(){return r}})},5721:function(e,t,n){"use strict";var r=n(2791),o="undefined"!==typeof window?r.useLayoutEffect:r.useEffect;t.Z=o},1694:function(e,t){var n;!function(){"use strict";var r={}.hasOwnProperty;function o(){for(var e=[],t=0;t<arguments.length;t++){var n=arguments[t];if(n){var a=typeof n;if("string"===a||"number"===a)e.push(n);else if(Array.isArray(n)){if(n.length){var i=o.apply(null,n);i&&e.push(i)}}else if("object"===a){if(n.toString!==Object.prototype.toString&&!n.toString.toString().includes("[native code]")){e.push(n.toString());continue}for(var s in n)r.call(n,s)&&n[s]&&e.push(s)}}}return e.join(" ")}e.exports?(o.default=o,e.exports=o):void 0===(n=function(){return o}.apply(t,[]))||(e.exports=n)}()},8182:function(e,t,n){"use strict";function r(e){var t,n,o="";if("string"==typeof e||"number"==typeof e)o+=e;else if("object"==typeof e)if(Array.isArray(e))for(t=0;t<e.length;t++)e[t]&&(n=r(e[t]))&&(o&&(o+=" "),o+=n);else for(t in e)e[t]&&(o&&(o+=" "),o+=t);return o}t.Z=function(){for(var e,t,n=0,o="";n<arguments.length;)(e=arguments[n++])&&(t=r(e))&&(o&&(o+=" "),o+=t);return o}},4173:function(e,t){!function(e){"use strict";function t(){}function n(e,t,n,r,o){for(var a=0,i=t.length,s=0,l=0;a<i;a++){var c=t[a];if(c.removed){if(c.value=e.join(r.slice(l,l+c.count)),l+=c.count,a&&t[a-1].added){var u=t[a-1];t[a-1]=t[a],t[a]=u}}else{if(!c.added&&o){var d=n.slice(s,s+c.count);d=d.map((function(e,t){var n=r[l+t];return n.length>e.length?n:e})),c.value=e.join(d)}else c.value=e.join(n.slice(s,s+c.count));s+=c.count,c.added||(l+=c.count)}}var f=t[i-1];return i>1&&"string"===typeof f.value&&(f.added||f.removed)&&e.equals("",f.value)&&(t[i-2].value+=f.value,t.pop()),t}function r(e){return{newPos:e.newPos,components:e.components.slice(0)}}t.prototype={diff:function(e,t){var o=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{},a=o.callback;"function"===typeof o&&(a=o,o={}),this.options=o;var i=this;function s(e){return a?(setTimeout((function(){a(void 0,e)}),0),!0):e}e=this.castInput(e),t=this.castInput(t),e=this.removeEmpty(this.tokenize(e));var l=(t=this.removeEmpty(this.tokenize(t))).length,c=e.length,u=1,d=l+c,f=[{newPos:-1,components:[]}],p=this.extractCommon(f[0],t,e,0);if(f[0].newPos+1>=l&&p+1>=c)return s([{value:this.join(t),count:t.length}]);function m(){for(var o=-1*u;o<=u;o+=2){var a=void 0,d=f[o-1],p=f[o+1],m=(p?p.newPos:0)-o;d&&(f[o-1]=void 0);var h=d&&d.newPos+1<l,v=p&&0<=m&&m<c;if(h||v){if(!h||v&&d.newPos<p.newPos?(a=r(p),i.pushComponent(a.components,void 0,!0)):((a=d).newPos++,i.pushComponent(a.components,!0,void 0)),m=i.extractCommon(a,t,e,o),a.newPos+1>=l&&m+1>=c)return s(n(i,a.components,t,e,i.useLongestToken));f[o]=a}else f[o]=void 0}u++}if(a)!function e(){setTimeout((function(){if(u>d)return a();m()||e()}),0)}();else for(;u<=d;){var h=m();if(h)return h}},pushComponent:function(e,t,n){var r=e[e.length-1];r&&r.added===t&&r.removed===n?e[e.length-1]={count:r.count+1,added:t,removed:n}:e.push({count:1,added:t,removed:n})},extractCommon:function(e,t,n,r){for(var o=t.length,a=n.length,i=e.newPos,s=i-r,l=0;i+1<o&&s+1<a&&this.equals(t[i+1],n[s+1]);)i++,s++,l++;return l&&e.components.push({count:l}),e.newPos=i,s},equals:function(e,t){return this.options.comparator?this.options.comparator(e,t):e===t||this.options.ignoreCase&&e.toLowerCase()===t.toLowerCase()},removeEmpty:function(e){for(var t=[],n=0;n<e.length;n++)e[n]&&t.push(e[n]);return t},castInput:function(e){return e},tokenize:function(e){return e.split("")},join:function(e){return e.join("")}};var o=new t;function a(e,t,n){return o.diff(e,t,n)}function i(e,t){if("function"===typeof e)t.callback=e;else if(e)for(var n in e)e.hasOwnProperty(n)&&(t[n]=e[n]);return t}var s=/^[A-Za-z\xC0-\u02C6\u02C8-\u02D7\u02DE-\u02FF\u1E00-\u1EFF]+$/,l=/\S/,c=new t;function u(e,t,n){return n=i(n,{ignoreWhitespace:!0}),c.diff(e,t,n)}function d(e,t,n){return c.diff(e,t,n)}c.equals=function(e,t){return this.options.ignoreCase&&(e=e.toLowerCase(),t=t.toLowerCase()),e===t||this.options.ignoreWhitespace&&!l.test(e)&&!l.test(t)},c.tokenize=function(e){for(var t=e.split(/(\s+|[()[\]{}'"]|\b)/),n=0;n<t.length-1;n++)!t[n+1]&&t[n+2]&&s.test(t[n])&&s.test(t[n+2])&&(t[n]+=t[n+2],t.splice(n+1,2),n--);return t};var f=new t;function p(e,t,n){return f.diff(e,t,n)}function m(e,t,n){var r=i(n,{ignoreWhitespace:!0});return f.diff(e,t,r)}f.tokenize=function(e){var t=[],n=e.split(/(\n|\r\n)/);n[n.length-1]||n.pop();for(var r=0;r<n.length;r++){var o=n[r];r%2&&!this.options.newlineIsToken?t[t.length-1]+=o:(this.options.ignoreWhitespace&&(o=o.trim()),t.push(o))}return t};var h=new t;function v(e,t,n){return h.diff(e,t,n)}h.tokenize=function(e){return e.split(/(\S.+?[.!?])(?=\s+|$)/)};var b=new t;function y(e,t,n){return b.diff(e,t,n)}function g(e){return g="function"===typeof Symbol&&"symbol"===typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"===typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e},g(e)}function _(e){return w(e)||T(e)||S()}function w(e){if(Array.isArray(e)){for(var t=0,n=new Array(e.length);t<e.length;t++)n[t]=e[t];return n}}function T(e){if(Symbol.iterator in Object(e)||"[object Arguments]"===Object.prototype.toString.call(e))return Array.from(e)}function S(){throw new TypeError("Invalid attempt to spread non-iterable instance")}b.tokenize=function(e){return e.split(/([{}:;,]|\s+)/)};var P=Object.prototype.toString,k=new t;function x(e,t,n){return k.diff(e,t,n)}function C(e,t,n,r,o){var a,i;for(t=t||[],n=n||[],r&&(e=r(o,e)),a=0;a<t.length;a+=1)if(t[a]===e)return n[a];if("[object Array]"===P.call(e)){for(t.push(e),i=new Array(e.length),n.push(i),a=0;a<e.length;a+=1)i[a]=C(e[a],t,n,r,o);return t.pop(),n.pop(),i}if(e&&e.toJSON&&(e=e.toJSON()),"object"===g(e)&&null!==e){t.push(e),i={},n.push(i);var s,l=[];for(s in e)e.hasOwnProperty(s)&&l.push(s);for(l.sort(),a=0;a<l.length;a+=1)i[s=l[a]]=C(e[s],t,n,r,s);t.pop(),n.pop()}else i=e;return i}k.useLongestToken=!0,k.tokenize=f.tokenize,k.castInput=function(e){var t=this.options,n=t.undefinedReplacement,r=t.stringifyReplacer,o=void 0===r?function(e,t){return"undefined"===typeof t?n:t}:r;return"string"===typeof e?e:JSON.stringify(C(e,null,null,o),o,"  ")},k.equals=function(e,n){return t.prototype.equals.call(k,e.replace(/,([\r\n])/g,"$1"),n.replace(/,([\r\n])/g,"$1"))};var A=new t;function M(e,t,n){return A.diff(e,t,n)}function F(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},n=e.split(/\r\n|[\n\v\f\r\x85]/),r=e.match(/\r\n|[\n\v\f\r\x85]/g)||[],o=[],a=0;function i(){var e={};for(o.push(e);a<n.length;){var r=n[a];if(/^(\-\-\-|\+\+\+|@@)\s/.test(r))break;var i=/^(?:Index:|diff(?: -r \w+)+)\s+(.+?)\s*$/.exec(r);i&&(e.index=i[1]),a++}for(s(e),s(e),e.hunks=[];a<n.length;){var c=n[a];if(/^(Index:|diff|\-\-\-|\+\+\+)\s/.test(c))break;if(/^@@/.test(c))e.hunks.push(l());else{if(c&&t.strict)throw new Error("Unknown line "+(a+1)+" "+JSON.stringify(c));a++}}}function s(e){var t=/^(---|\+\+\+)\s+(.*)$/.exec(n[a]);if(t){var r="---"===t[1]?"old":"new",o=t[2].split("\t",2),i=o[0].replace(/\\\\/g,"\\");/^".*"$/.test(i)&&(i=i.substr(1,i.length-2)),e[r+"FileName"]=i,e[r+"Header"]=(o[1]||"").trim(),a++}}function l(){for(var e=a,o=n[a++].split(/@@ -(\d+)(?:,(\d+))? \+(\d+)(?:,(\d+))? @@/),i={oldStart:+o[1],oldLines:+o[2]||1,newStart:+o[3],newLines:+o[4]||1,lines:[],linedelimiters:[]},s=0,l=0;a<n.length&&!(0===n[a].indexOf("--- ")&&a+2<n.length&&0===n[a+1].indexOf("+++ ")&&0===n[a+2].indexOf("@@"));a++){var c=0==n[a].length&&a!=n.length-1?" ":n[a][0];if("+"!==c&&"-"!==c&&" "!==c&&"\\"!==c)break;i.lines.push(n[a]),i.linedelimiters.push(r[a]||"\n"),"+"===c?s++:"-"===c?l++:" "===c&&(s++,l++)}if(s||1!==i.newLines||(i.newLines=0),l||1!==i.oldLines||(i.oldLines=0),t.strict){if(s!==i.newLines)throw new Error("Added line count did not match for hunk at line "+(e+1));if(l!==i.oldLines)throw new Error("Removed line count did not match for hunk at line "+(e+1))}return i}for(;a<n.length;)i();return o}function E(e,t,n){var r=!0,o=!1,a=!1,i=1;return function s(){if(r&&!a){if(o?i++:r=!1,e+i<=n)return i;a=!0}if(!o)return a||(r=!0),t<=e-i?-i++:(o=!0,s())}}function R(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{};if("string"===typeof t&&(t=F(t)),Array.isArray(t)){if(t.length>1)throw new Error("applyPatch only works with a single input.");t=t[0]}var r,o,a=e.split(/\r\n|[\n\v\f\r\x85]/),i=e.match(/\r\n|[\n\v\f\r\x85]/g)||[],s=t.hunks,l=n.compareLine||function(e,t,n,r){return t===r},c=0,u=n.fuzzFactor||0,d=0,f=0;function p(e,t){for(var n=0;n<e.lines.length;n++){var r=e.lines[n],o=r.length>0?r[0]:" ",i=r.length>0?r.substr(1):r;if(" "===o||"-"===o){if(!l(t+1,a[t],o,i)&&++c>u)return!1;t++}}return!0}for(var m=0;m<s.length;m++){for(var h=s[m],v=a.length-h.oldLines,b=0,y=f+h.oldStart-1,g=E(y,d,v);void 0!==b;b=g())if(p(h,y+b)){h.offset=f+=b;break}if(void 0===b)return!1;d=h.offset+h.oldStart+h.oldLines}for(var _=0,w=0;w<s.length;w++){var T=s[w],S=T.oldStart+T.offset+_-1;_+=T.newLines-T.oldLines,S<0&&(S=0);for(var P=0;P<T.lines.length;P++){var k=T.lines[P],x=k.length>0?k[0]:" ",C=k.length>0?k.substr(1):k,A=T.linedelimiters[P];if(" "===x)S++;else if("-"===x)a.splice(S,1),i.splice(S,1);else if("+"===x)a.splice(S,0,C),i.splice(S,0,A),S++;else if("\\"===x){var M=T.lines[P-1]?T.lines[P-1][0]:null;"+"===M?r=!0:"-"===M&&(o=!0)}}}if(r)for(;!a[a.length-1];)a.pop(),i.pop();else o&&(a.push(""),i.push("\n"));for(var R=0;R<a.length-1;R++)a[R]=a[R]+i[R];return a.join("")}function N(e,t){"string"===typeof e&&(e=F(e));var n=0;function r(){var o=e[n++];if(!o)return t.complete();t.loadFile(o,(function(e,n){if(e)return t.complete(e);var a=R(n,o,t);t.patched(o,a,(function(e){if(e)return t.complete(e);r()}))}))}r()}function O(e,t,n,r,o,a,i){i||(i={}),"undefined"===typeof i.context&&(i.context=4);var s=p(n,r,i);function l(e){return e.map((function(e){return" "+e}))}s.push({value:"",lines:[]});for(var c=[],u=0,d=0,f=[],m=1,h=1,v=function(e){var t=s[e],o=t.lines||t.value.replace(/\n$/,"").split("\n");if(t.lines=o,t.added||t.removed){var a;if(!u){var p=s[e-1];u=m,d=h,p&&(f=i.context>0?l(p.lines.slice(-i.context)):[],u-=f.length,d-=f.length)}(a=f).push.apply(a,_(o.map((function(e){return(t.added?"+":"-")+e})))),t.added?h+=o.length:m+=o.length}else{if(u)if(o.length<=2*i.context&&e<s.length-2){var v;(v=f).push.apply(v,_(l(o)))}else{var b,y=Math.min(o.length,i.context);(b=f).push.apply(b,_(l(o.slice(0,y))));var g={oldStart:u,oldLines:m-u+y,newStart:d,newLines:h-d+y,lines:f};if(e>=s.length-2&&o.length<=i.context){var w=/\n$/.test(n),T=/\n$/.test(r),S=0==o.length&&f.length>g.oldLines;!w&&S&&f.splice(g.oldLines,0,"\\ No newline at end of file"),(w||S)&&T||f.push("\\ No newline at end of file")}c.push(g),u=0,d=0,f=[]}m+=o.length,h+=o.length}},b=0;b<s.length;b++)v(b);return{oldFileName:e,newFileName:t,oldHeader:o,newHeader:a,hunks:c}}function V(e,t,n,r,o,a,i){var s=O(e,t,n,r,o,a,i),l=[];e==t&&l.push("Index: "+e),l.push("==================================================================="),l.push("--- "+s.oldFileName+("undefined"===typeof s.oldHeader?"":"\t"+s.oldHeader)),l.push("+++ "+s.newFileName+("undefined"===typeof s.newHeader?"":"\t"+s.newHeader));for(var c=0;c<s.hunks.length;c++){var u=s.hunks[c];l.push("@@ -"+u.oldStart+","+u.oldLines+" +"+u.newStart+","+u.newLines+" @@"),l.push.apply(l,u.lines)}return l.join("\n")+"\n"}function L(e,t,n,r,o,a){return V(e,e,t,n,r,o,a)}function D(e,t){return e.length===t.length&&z(e,t)}function z(e,t){if(t.length>e.length)return!1;for(var n=0;n<t.length;n++)if(t[n]!==e[n])return!1;return!0}function I(e){var t=ne(e.lines),n=t.oldLines,r=t.newLines;void 0!==n?e.oldLines=n:delete e.oldLines,void 0!==r?e.newLines=r:delete e.newLines}function H(e,t,n){e=j(e,n),t=j(t,n);var r={};(e.index||t.index)&&(r.index=e.index||t.index),(e.newFileName||t.newFileName)&&(Z(e)?Z(t)?(r.oldFileName=B(r,e.oldFileName,t.oldFileName),r.newFileName=B(r,e.newFileName,t.newFileName),r.oldHeader=B(r,e.oldHeader,t.oldHeader),r.newHeader=B(r,e.newHeader,t.newHeader)):(r.oldFileName=e.oldFileName,r.newFileName=e.newFileName,r.oldHeader=e.oldHeader,r.newHeader=e.newHeader):(r.oldFileName=t.oldFileName||e.oldFileName,r.newFileName=t.newFileName||e.newFileName,r.oldHeader=t.oldHeader||e.oldHeader,r.newHeader=t.newHeader||e.newHeader)),r.hunks=[];for(var o=0,a=0,i=0,s=0;o<e.hunks.length||a<t.hunks.length;){var l=e.hunks[o]||{oldStart:1/0},c=t.hunks[a]||{oldStart:1/0};if(G(l,c))r.hunks.push(W(l,i)),o++,s+=l.newLines-l.oldLines;else if(G(c,l))r.hunks.push(W(c,s)),a++,i+=c.newLines-c.oldLines;else{var u={oldStart:Math.min(l.oldStart,c.oldStart),oldLines:0,newStart:Math.min(l.newStart+i,c.oldStart+s),newLines:0,lines:[]};U(u,l.oldStart,l.lines,c.oldStart,c.lines),a++,o++,r.hunks.push(u)}}return r}function j(e,t){if("string"===typeof e){if(/^@@/m.test(e)||/^Index:/m.test(e))return F(e)[0];if(!t)throw new Error("Must provide a base reference or pass in a patch");return O(void 0,void 0,t,e)}return e}function Z(e){return e.newFileName&&e.newFileName!==e.oldFileName}function B(e,t,n){return t===n?t:(e.conflict=!0,{mine:t,theirs:n})}function G(e,t){return e.oldStart<t.oldStart&&e.oldStart+e.oldLines<t.oldStart}function W(e,t){return{oldStart:e.oldStart,oldLines:e.oldLines,newStart:e.newStart+t,newLines:e.newLines,lines:e.lines}}function U(e,t,n,r,o){var a={offset:t,lines:n,index:0},i={offset:r,lines:o,index:0};for(K(e,a,i),K(e,i,a);a.index<a.lines.length&&i.index<i.lines.length;){var s=a.lines[a.index],l=i.lines[i.index];if("-"!==s[0]&&"+"!==s[0]||"-"!==l[0]&&"+"!==l[0])if("+"===s[0]&&" "===l[0]){var c;(c=e.lines).push.apply(c,_(Y(a)))}else if("+"===l[0]&&" "===s[0]){var u;(u=e.lines).push.apply(u,_(Y(i)))}else"-"===s[0]&&" "===l[0]?$(e,a,i):"-"===l[0]&&" "===s[0]?$(e,i,a,!0):s===l?(e.lines.push(s),a.index++,i.index++):J(e,Y(a),Y(i));else q(e,a,i)}Q(e,a),Q(e,i),I(e)}function q(e,t,n){var r=Y(t),o=Y(n);if(ee(r)&&ee(o)){var a,i;if(z(r,o)&&te(n,r,r.length-o.length))return void(a=e.lines).push.apply(a,_(r));if(z(o,r)&&te(t,o,o.length-r.length))return void(i=e.lines).push.apply(i,_(o))}else if(D(r,o)){var s;return void(s=e.lines).push.apply(s,_(r))}J(e,r,o)}function $(e,t,n,r){var o,a=Y(t),i=X(n,a);i.merged?(o=e.lines).push.apply(o,_(i.merged)):J(e,r?i:a,r?a:i)}function J(e,t,n){e.conflict=!0,e.lines.push({conflict:!0,mine:t,theirs:n})}function K(e,t,n){for(;t.offset<n.offset&&t.index<t.lines.length;){var r=t.lines[t.index++];e.lines.push(r),t.offset++}}function Q(e,t){for(;t.index<t.lines.length;){var n=t.lines[t.index++];e.lines.push(n)}}function Y(e){for(var t=[],n=e.lines[e.index][0];e.index<e.lines.length;){var r=e.lines[e.index];if("-"===n&&"+"===r[0]&&(n="+"),n!==r[0])break;t.push(r),e.index++}return t}function X(e,t){for(var n=[],r=[],o=0,a=!1,i=!1;o<t.length&&e.index<e.lines.length;){var s=e.lines[e.index],l=t[o];if("+"===l[0])break;if(a=a||" "!==s[0],r.push(l),o++,"+"===s[0])for(i=!0;"+"===s[0];)n.push(s),s=e.lines[++e.index];l.substr(1)===s.substr(1)?(n.push(s),e.index++):i=!0}if("+"===(t[o]||"")[0]&&a&&(i=!0),i)return n;for(;o<t.length;)r.push(t[o++]);return{merged:r,changes:n}}function ee(e){return e.reduce((function(e,t){return e&&"-"===t[0]}),!0)}function te(e,t,n){for(var r=0;r<n;r++){var o=t[t.length-n+r].substr(1);if(e.lines[e.index+r]!==" "+o)return!1}return e.index+=n,!0}function ne(e){var t=0,n=0;return e.forEach((function(e){if("string"!==typeof e){var r=ne(e.mine),o=ne(e.theirs);void 0!==t&&(r.oldLines===o.oldLines?t+=r.oldLines:t=void 0),void 0!==n&&(r.newLines===o.newLines?n+=r.newLines:n=void 0)}else void 0===n||"+"!==e[0]&&" "!==e[0]||n++,void 0===t||"-"!==e[0]&&" "!==e[0]||t++})),{oldLines:t,newLines:n}}function re(e){for(var t,n,r=[],o=0;o<e.length;o++)n=(t=e[o]).added?1:t.removed?-1:0,r.push([n,t.value]);return r}function oe(e){for(var t=[],n=0;n<e.length;n++){var r=e[n];r.added?t.push("<ins>"):r.removed&&t.push("<del>"),t.push(ae(r.value)),r.added?t.push("</ins>"):r.removed&&t.push("</del>")}return t.join("")}function ae(e){var t=e;return t=(t=(t=(t=t.replace(/&/g,"&amp;")).replace(/</g,"&lt;")).replace(/>/g,"&gt;")).replace(/"/g,"&quot;")}A.tokenize=function(e){return e.slice()},A.join=A.removeEmpty=function(e){return e},e.Diff=t,e.diffChars=a,e.diffWords=u,e.diffWordsWithSpace=d,e.diffLines=p,e.diffTrimmedLines=m,e.diffSentences=v,e.diffCss=y,e.diffJson=x,e.diffArrays=M,e.structuredPatch=O,e.createTwoFilesPatch=V,e.createPatch=L,e.applyPatch=R,e.applyPatches=N,e.parsePatch=F,e.merge=H,e.convertChangesToDMP=re,e.convertChangesToXML=oe,e.canonicalize=C,Object.defineProperty(e,"__esModule",{value:!0})}(t)},6025:function(e,t,n){"use strict";n.r(t),n.d(t,{cache:function(){return I},css:function(){return D},cx:function(){return R},flush:function(){return F},getRegisteredStyles:function(){return O},hydrate:function(){return E},injectGlobal:function(){return V},keyframes:function(){return L},merge:function(){return N},sheet:function(){return z}});var r=function(){function e(e){this.isSpeedy=void 0===e.speedy||e.speedy,this.tags=[],this.ctr=0,this.nonce=e.nonce,this.key=e.key,this.container=e.container,this.before=null}var t=e.prototype;return t.insert=function(e){if(this.ctr%(this.isSpeedy?65e3:1)===0){var t,n=function(e){var t=document.createElement("style");return t.setAttribute("data-emotion",e.key),void 0!==e.nonce&&t.setAttribute("nonce",e.nonce),t.appendChild(document.createTextNode("")),t}(this);t=0===this.tags.length?this.before:this.tags[this.tags.length-1].nextSibling,this.container.insertBefore(n,t),this.tags.push(n)}var r=this.tags[this.tags.length-1];if(this.isSpeedy){var o=function(e){if(e.sheet)return e.sheet;for(var t=0;t<document.styleSheets.length;t++)if(document.styleSheets[t].ownerNode===e)return document.styleSheets[t]}(r);try{var a=105===e.charCodeAt(1)&&64===e.charCodeAt(0);o.insertRule(e,a?0:o.cssRules.length)}catch(i){0}}else r.appendChild(document.createTextNode(e));this.ctr++},t.flush=function(){this.tags.forEach((function(e){return e.parentNode.removeChild(e)})),this.tags=[],this.ctr=0},e}();var o=function(e){function t(e,r,l,c,f){for(var p,m,h,v,_,T=0,S=0,P=0,k=0,x=0,R=0,O=h=p=0,L=0,D=0,z=0,I=0,H=l.length,j=H-1,Z="",B="",G="",W="";L<H;){if(m=l.charCodeAt(L),L===j&&0!==S+k+P+T&&(0!==S&&(m=47===S?10:47),k=P=T=0,H++,j++),0===S+k+P+T){if(L===j&&(0<D&&(Z=Z.replace(d,"")),0<Z.trim().length)){switch(m){case 32:case 9:case 59:case 13:case 10:break;default:Z+=l.charAt(L)}m=59}switch(m){case 123:for(p=(Z=Z.trim()).charCodeAt(0),h=1,I=++L;L<H;){switch(m=l.charCodeAt(L)){case 123:h++;break;case 125:h--;break;case 47:switch(m=l.charCodeAt(L+1)){case 42:case 47:e:{for(O=L+1;O<j;++O)switch(l.charCodeAt(O)){case 47:if(42===m&&42===l.charCodeAt(O-1)&&L+2!==O){L=O+1;break e}break;case 10:if(47===m){L=O+1;break e}}L=O}}break;case 91:m++;case 40:m++;case 34:case 39:for(;L++<j&&l.charCodeAt(L)!==m;);}if(0===h)break;L++}if(h=l.substring(I,L),0===p&&(p=(Z=Z.replace(u,"").trim()).charCodeAt(0)),64===p){switch(0<D&&(Z=Z.replace(d,"")),m=Z.charCodeAt(1)){case 100:case 109:case 115:case 45:D=r;break;default:D=E}if(I=(h=t(r,D,h,m,f+1)).length,0<N&&(_=s(3,h,D=n(E,Z,z),r,A,C,I,m,f,c),Z=D.join(""),void 0!==_&&0===(I=(h=_.trim()).length)&&(m=0,h="")),0<I)switch(m){case 115:Z=Z.replace(w,i);case 100:case 109:case 45:h=Z+"{"+h+"}";break;case 107:h=(Z=Z.replace(b,"$1 $2"))+"{"+h+"}",h=1===F||2===F&&a("@"+h,3)?"@-webkit-"+h+"@"+h:"@"+h;break;default:h=Z+h,112===c&&(B+=h,h="")}else h=""}else h=t(r,n(r,Z,z),h,c,f+1);G+=h,h=z=D=O=p=0,Z="",m=l.charCodeAt(++L);break;case 125:case 59:if(1<(I=(Z=(0<D?Z.replace(d,""):Z).trim()).length))switch(0===O&&(p=Z.charCodeAt(0),45===p||96<p&&123>p)&&(I=(Z=Z.replace(" ",":")).length),0<N&&void 0!==(_=s(1,Z,r,e,A,C,B.length,c,f,c))&&0===(I=(Z=_.trim()).length)&&(Z="\0\0"),p=Z.charCodeAt(0),m=Z.charCodeAt(1),p){case 0:break;case 64:if(105===m||99===m){W+=Z+l.charAt(L);break}default:58!==Z.charCodeAt(I-1)&&(B+=o(Z,p,m,Z.charCodeAt(2)))}z=D=O=p=0,Z="",m=l.charCodeAt(++L)}}switch(m){case 13:case 10:47===S?S=0:0===1+p&&107!==c&&0<Z.length&&(D=1,Z+="\0"),0<N*V&&s(0,Z,r,e,A,C,B.length,c,f,c),C=1,A++;break;case 59:case 125:if(0===S+k+P+T){C++;break}default:switch(C++,v=l.charAt(L),m){case 9:case 32:if(0===k+T+S)switch(x){case 44:case 58:case 9:case 32:v="";break;default:32!==m&&(v=" ")}break;case 0:v="\\0";break;case 12:v="\\f";break;case 11:v="\\v";break;case 38:0===k+S+T&&(D=z=1,v="\f"+v);break;case 108:if(0===k+S+T+M&&0<O)switch(L-O){case 2:112===x&&58===l.charCodeAt(L-3)&&(M=x);case 8:111===R&&(M=R)}break;case 58:0===k+S+T&&(O=L);break;case 44:0===S+P+k+T&&(D=1,v+="\r");break;case 34:case 39:0===S&&(k=k===m?0:0===k?m:k);break;case 91:0===k+S+P&&T++;break;case 93:0===k+S+P&&T--;break;case 41:0===k+S+T&&P--;break;case 40:if(0===k+S+T){if(0===p)if(2*x+3*R===533);else p=1;P++}break;case 64:0===S+P+k+T+O+h&&(h=1);break;case 42:case 47:if(!(0<k+T+P))switch(S){case 0:switch(2*m+3*l.charCodeAt(L+1)){case 235:S=47;break;case 220:I=L,S=42}break;case 42:47===m&&42===x&&I+2!==L&&(33===l.charCodeAt(I+2)&&(B+=l.substring(I,L+1)),v="",S=0)}}0===S&&(Z+=v)}R=x,x=m,L++}if(0<(I=B.length)){if(D=r,0<N&&(void 0!==(_=s(2,B,D,e,A,C,I,c,f,c))&&0===(B=_).length))return W+B+G;if(B=D.join(",")+"{"+B+"}",0!==F*M){switch(2!==F||a(B,2)||(M=0),M){case 111:B=B.replace(g,":-moz-$1")+B;break;case 112:B=B.replace(y,"::-webkit-input-$1")+B.replace(y,"::-moz-$1")+B.replace(y,":-ms-input-$1")+B}M=0}}return W+B+G}function n(e,t,n){var o=t.trim().split(h);t=o;var a=o.length,i=e.length;switch(i){case 0:case 1:var s=0;for(e=0===i?"":e[0]+" ";s<a;++s)t[s]=r(e,t[s],n).trim();break;default:var l=s=0;for(t=[];s<a;++s)for(var c=0;c<i;++c)t[l++]=r(e[c]+" ",o[s],n).trim()}return t}function r(e,t,n){var r=t.charCodeAt(0);switch(33>r&&(r=(t=t.trim()).charCodeAt(0)),r){case 38:return t.replace(v,"$1"+e.trim());case 58:return e.trim()+t.replace(v,"$1"+e.trim());default:if(0<1*n&&0<t.indexOf("\f"))return t.replace(v,(58===e.charCodeAt(0)?"":"$1")+e.trim())}return e+t}function o(e,t,n,r){var i=e+";",s=2*t+3*n+4*r;if(944===s){e=i.indexOf(":",9)+1;var l=i.substring(e,i.length-1).trim();return l=i.substring(0,e).trim()+l+";",1===F||2===F&&a(l,1)?"-webkit-"+l+l:l}if(0===F||2===F&&!a(i,1))return i;switch(s){case 1015:return 97===i.charCodeAt(10)?"-webkit-"+i+i:i;case 951:return 116===i.charCodeAt(3)?"-webkit-"+i+i:i;case 963:return 110===i.charCodeAt(5)?"-webkit-"+i+i:i;case 1009:if(100!==i.charCodeAt(4))break;case 969:case 942:return"-webkit-"+i+i;case 978:return"-webkit-"+i+"-moz-"+i+i;case 1019:case 983:return"-webkit-"+i+"-moz-"+i+"-ms-"+i+i;case 883:if(45===i.charCodeAt(8))return"-webkit-"+i+i;if(0<i.indexOf("image-set(",11))return i.replace(x,"$1-webkit-$2")+i;break;case 932:if(45===i.charCodeAt(4))switch(i.charCodeAt(5)){case 103:return"-webkit-box-"+i.replace("-grow","")+"-webkit-"+i+"-ms-"+i.replace("grow","positive")+i;case 115:return"-webkit-"+i+"-ms-"+i.replace("shrink","negative")+i;case 98:return"-webkit-"+i+"-ms-"+i.replace("basis","preferred-size")+i}return"-webkit-"+i+"-ms-"+i+i;case 964:return"-webkit-"+i+"-ms-flex-"+i+i;case 1023:if(99!==i.charCodeAt(8))break;return"-webkit-box-pack"+(l=i.substring(i.indexOf(":",15)).replace("flex-","").replace("space-between","justify"))+"-webkit-"+i+"-ms-flex-pack"+l+i;case 1005:return p.test(i)?i.replace(f,":-webkit-")+i.replace(f,":-moz-")+i:i;case 1e3:switch(t=(l=i.substring(13).trim()).indexOf("-")+1,l.charCodeAt(0)+l.charCodeAt(t)){case 226:l=i.replace(_,"tb");break;case 232:l=i.replace(_,"tb-rl");break;case 220:l=i.replace(_,"lr");break;default:return i}return"-webkit-"+i+"-ms-"+l+i;case 1017:if(-1===i.indexOf("sticky",9))break;case 975:switch(t=(i=e).length-10,s=(l=(33===i.charCodeAt(t)?i.substring(0,t):i).substring(e.indexOf(":",7)+1).trim()).charCodeAt(0)+(0|l.charCodeAt(7))){case 203:if(111>l.charCodeAt(8))break;case 115:i=i.replace(l,"-webkit-"+l)+";"+i;break;case 207:case 102:i=i.replace(l,"-webkit-"+(102<s?"inline-":"")+"box")+";"+i.replace(l,"-webkit-"+l)+";"+i.replace(l,"-ms-"+l+"box")+";"+i}return i+";";case 938:if(45===i.charCodeAt(5))switch(i.charCodeAt(6)){case 105:return l=i.replace("-items",""),"-webkit-"+i+"-webkit-box-"+l+"-ms-flex-"+l+i;case 115:return"-webkit-"+i+"-ms-flex-item-"+i.replace(S,"")+i;default:return"-webkit-"+i+"-ms-flex-line-pack"+i.replace("align-content","").replace(S,"")+i}break;case 973:case 989:if(45!==i.charCodeAt(3)||122===i.charCodeAt(4))break;case 931:case 953:if(!0===k.test(e))return 115===(l=e.substring(e.indexOf(":")+1)).charCodeAt(0)?o(e.replace("stretch","fill-available"),t,n,r).replace(":fill-available",":stretch"):i.replace(l,"-webkit-"+l)+i.replace(l,"-moz-"+l.replace("fill-",""))+i;break;case 962:if(i="-webkit-"+i+(102===i.charCodeAt(5)?"-ms-"+i:"")+i,211===n+r&&105===i.charCodeAt(13)&&0<i.indexOf("transform",10))return i.substring(0,i.indexOf(";",27)+1).replace(m,"$1-webkit-$2")+i}return i}function a(e,t){var n=e.indexOf(1===t?":":"{"),r=e.substring(0,3!==t?n:10);return n=e.substring(n+1,e.length-1),O(2!==t?r:r.replace(P,"$1"),n,t)}function i(e,t){var n=o(t,t.charCodeAt(0),t.charCodeAt(1),t.charCodeAt(2));return n!==t+";"?n.replace(T," or ($1)").substring(4):"("+t+")"}function s(e,t,n,r,o,a,i,s,l,u){for(var d,f=0,p=t;f<N;++f)switch(d=R[f].call(c,e,p,n,r,o,a,i,s,l,u)){case void 0:case!1:case!0:case null:break;default:p=d}if(p!==t)return p}function l(e){return void 0!==(e=e.prefix)&&(O=null,e?"function"!==typeof e?F=1:(F=2,O=e):F=0),l}function c(e,n){var r=e;if(33>r.charCodeAt(0)&&(r=r.trim()),r=[r],0<N){var o=s(-1,n,r,r,A,C,0,0,0,0);void 0!==o&&"string"===typeof o&&(n=o)}var a=t(E,r,n,0,0);return 0<N&&(void 0!==(o=s(-2,a,r,r,A,C,a.length,0,0,0))&&(a=o)),"",M=0,C=A=1,a}var u=/^\0+/g,d=/[\0\r\f]/g,f=/: */g,p=/zoo|gra/,m=/([,: ])(transform)/g,h=/,\r+?/g,v=/([\t\r\n ])*\f?&/g,b=/@(k\w+)\s*(\S*)\s*/,y=/::(place)/g,g=/:(read-only)/g,_=/[svh]\w+-[tblr]{2}/,w=/\(\s*(.*)\s*\)/g,T=/([\s\S]*?);/g,S=/-self|flex-/g,P=/[^]*?(:[rp][el]a[\w-]+)[^]*/,k=/stretch|:\s*\w+\-(?:conte|avail)/,x=/([^-])(image-set\()/,C=1,A=1,M=0,F=1,E=[],R=[],N=0,O=null,V=0;return c.use=function e(t){switch(t){case void 0:case null:N=R.length=0;break;default:if("function"===typeof t)R[N++]=t;else if("object"===typeof t)for(var n=0,r=t.length;n<r;++n)e(t[n]);else V=0|!!t}return e},c.set=l,void 0!==e&&l(e),c},a="/*|*/";function i(e){e&&s.current.insert(e+"}")}var s={current:null},l=function(e,t,n,r,o,l,c,u,d,f){switch(e){case 1:switch(t.charCodeAt(0)){case 64:return s.current.insert(t+";"),"";case 108:if(98===t.charCodeAt(2))return""}break;case 2:if(0===u)return t+a;break;case 3:switch(u){case 102:case 112:return s.current.insert(n[0]+t),"";default:return t+(0===f?a:"")}case-2:t.split("/*|*/}").forEach(i)}},c=function(e){void 0===e&&(e={});var t,n=e.key||"css";void 0!==e.prefix&&(t={prefix:e.prefix});var a=new o(t);var i,c={};i=e.container||document.head;var u,d=document.querySelectorAll("style[data-emotion-"+n+"]");Array.prototype.forEach.call(d,(function(e){e.getAttribute("data-emotion-"+n).split(" ").forEach((function(e){c[e]=!0})),e.parentNode!==i&&i.appendChild(e)})),a.use(e.stylisPlugins)(l),u=function(e,t,n,r){var o=t.name;s.current=n,a(e,t.styles),r&&(f.inserted[o]=!0)};var f={key:n,sheet:new r({key:n,container:i,nonce:e.nonce,speedy:e.speedy}),nonce:e.nonce,inserted:c,registered:{},insert:u};return f};var u=function(e){for(var t,n=0,r=0,o=e.length;o>=4;++r,o-=4)t=1540483477*(65535&(t=255&e.charCodeAt(r)|(255&e.charCodeAt(++r))<<8|(255&e.charCodeAt(++r))<<16|(255&e.charCodeAt(++r))<<24))+(59797*(t>>>16)<<16),n=1540483477*(65535&(t^=t>>>24))+(59797*(t>>>16)<<16)^1540483477*(65535&n)+(59797*(n>>>16)<<16);switch(o){case 3:n^=(255&e.charCodeAt(r+2))<<16;case 2:n^=(255&e.charCodeAt(r+1))<<8;case 1:n=1540483477*(65535&(n^=255&e.charCodeAt(r)))+(59797*(n>>>16)<<16)}return(((n=1540483477*(65535&(n^=n>>>13))+(59797*(n>>>16)<<16))^n>>>15)>>>0).toString(36)},d={animationIterationCount:1,borderImageOutset:1,borderImageSlice:1,borderImageWidth:1,boxFlex:1,boxFlexGroup:1,boxOrdinalGroup:1,columnCount:1,columns:1,flex:1,flexGrow:1,flexPositive:1,flexShrink:1,flexNegative:1,flexOrder:1,gridRow:1,gridRowEnd:1,gridRowSpan:1,gridRowStart:1,gridColumn:1,gridColumnEnd:1,gridColumnSpan:1,gridColumnStart:1,msGridRow:1,msGridRowSpan:1,msGridColumn:1,msGridColumnSpan:1,fontWeight:1,lineHeight:1,opacity:1,order:1,orphans:1,tabSize:1,widows:1,zIndex:1,zoom:1,WebkitLineClamp:1,fillOpacity:1,floodOpacity:1,stopOpacity:1,strokeDasharray:1,strokeDashoffset:1,strokeMiterlimit:1,strokeOpacity:1,strokeWidth:1};var f=function(e){var t={};return function(n){return void 0===t[n]&&(t[n]=e(n)),t[n]}},p=/[A-Z]|^ms/g,m=/_EMO_([^_]+?)_([^]*?)_EMO_/g,h=function(e){return 45===e.charCodeAt(1)},v=function(e){return null!=e&&"boolean"!==typeof e},b=f((function(e){return h(e)?e:e.replace(p,"-$&").toLowerCase()})),y=function(e,t){switch(e){case"animation":case"animationName":if("string"===typeof t)return t.replace(m,(function(e,t,n){return _={name:t,styles:n,next:_},t}))}return 1===d[e]||h(e)||"number"!==typeof t||0===t?t:t+"px"};function g(e,t,n,r){if(null==n)return"";if(void 0!==n.__emotion_styles)return n;switch(typeof n){case"boolean":return"";case"object":if(1===n.anim)return _={name:n.name,styles:n.styles,next:_},n.name;if(void 0!==n.styles){var o=n.next;if(void 0!==o)for(;void 0!==o;)_={name:o.name,styles:o.styles,next:_},o=o.next;return n.styles+";"}return function(e,t,n){var r="";if(Array.isArray(n))for(var o=0;o<n.length;o++)r+=g(e,t,n[o],!1);else for(var a in n){var i=n[a];if("object"!==typeof i)null!=t&&void 0!==t[i]?r+=a+"{"+t[i]+"}":v(i)&&(r+=b(a)+":"+y(a,i)+";");else if(!Array.isArray(i)||"string"!==typeof i[0]||null!=t&&void 0!==t[i[0]]){var s=g(e,t,i,!1);switch(a){case"animation":case"animationName":r+=b(a)+":"+s+";";break;default:r+=a+"{"+s+"}"}}else for(var l=0;l<i.length;l++)v(i[l])&&(r+=b(a)+":"+y(a,i[l])+";")}return r}(e,t,n);case"function":if(void 0!==e){var a=_,i=n(e);return _=a,g(e,t,i,r)}}if(null==t)return n;var s=t[n];return void 0===s||r?n:s}var _,w=/label:\s*([^\s;\n{]+)\s*;/g;var T=function(e,t,n){if(1===e.length&&"object"===typeof e[0]&&null!==e[0]&&void 0!==e[0].styles)return e[0];var r=!0,o="";_=void 0;var a=e[0];null==a||void 0===a.raw?(r=!1,o+=g(n,t,a,!1)):o+=a[0];for(var i=1;i<e.length;i++)o+=g(n,t,e[i],46===o.charCodeAt(o.length-1)),r&&(o+=a[i]);w.lastIndex=0;for(var s,l="";null!==(s=w.exec(o));)l+="-"+s[1];return{name:u(o)+l,styles:o,next:_}};function S(e,t,n){var r="";return n.split(" ").forEach((function(n){void 0!==e[n]?t.push(e[n]):r+=n+" "})),r}var P=function(e,t,n){var r=e.key+"-"+t.name;if(!1===n&&void 0===e.registered[r]&&(e.registered[r]=t.styles),void 0===e.inserted[t.name]){var o=t;do{e.insert("."+r,o,e.sheet,!0);o=o.next}while(void 0!==o)}};function k(e,t){if(void 0===e.inserted[t.name])return e.insert("",t,e.sheet,!0)}function x(e,t,n){var r=[],o=S(e,r,n);return r.length<2?n:o+t(r)}var C=function e(t){for(var n="",r=0;r<t.length;r++){var o=t[r];if(null!=o){var a=void 0;switch(typeof o){case"boolean":break;case"object":if(Array.isArray(o))a=e(o);else for(var i in a="",o)o[i]&&i&&(a&&(a+=" "),a+=i);break;default:a=o}a&&(n&&(n+=" "),n+=a)}}return n},A=function(e){var t=c(e);t.sheet.speedy=function(e){this.isSpeedy=e},t.compat=!0;var n=function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var o=T(n,t.registered,void 0);return P(t,o,!1),t.key+"-"+o.name};return{css:n,cx:function(){for(var e=arguments.length,r=new Array(e),o=0;o<e;o++)r[o]=arguments[o];return x(t.registered,n,C(r))},injectGlobal:function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var o=T(n,t.registered);k(t,o)},keyframes:function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var o=T(n,t.registered),a="animation-"+o.name;return k(t,{name:o.name,styles:"@keyframes "+a+"{"+o.styles+"}"}),a},hydrate:function(e){e.forEach((function(e){t.inserted[e]=!0}))},flush:function(){t.registered={},t.inserted={},t.sheet.flush()},sheet:t.sheet,cache:t,getRegisteredStyles:S.bind(null,t.registered),merge:x.bind(null,t.registered,n)}},M=A(),F=M.flush,E=M.hydrate,R=M.cx,N=M.merge,O=M.getRegisteredStyles,V=M.injectGlobal,L=M.keyframes,D=M.css,z=M.sheet,I=M.cache},2110:function(e,t,n){"use strict";var r=n(8309),o={childContextTypes:!0,contextType:!0,contextTypes:!0,defaultProps:!0,displayName:!0,getDefaultProps:!0,getDerivedStateFromError:!0,getDerivedStateFromProps:!0,mixins:!0,propTypes:!0,type:!0},a={name:!0,length:!0,prototype:!0,caller:!0,callee:!0,arguments:!0,arity:!0},i={$$typeof:!0,compare:!0,defaultProps:!0,displayName:!0,propTypes:!0,type:!0},s={};function l(e){return r.isMemo(e)?i:s[e.$$typeof]||o}s[r.ForwardRef]={$$typeof:!0,render:!0,defaultProps:!0,displayName:!0,propTypes:!0},s[r.Memo]=i;var c=Object.defineProperty,u=Object.getOwnPropertyNames,d=Object.getOwnPropertySymbols,f=Object.getOwnPropertyDescriptor,p=Object.getPrototypeOf,m=Object.prototype;e.exports=function e(t,n,r){if("string"!==typeof n){if(m){var o=p(n);o&&o!==m&&e(t,o,r)}var i=u(n);d&&(i=i.concat(d(n)));for(var s=l(t),h=l(n),v=0;v<i.length;++v){var b=i[v];if(!a[b]&&(!r||!r[b])&&(!h||!h[b])&&(!s||!s[b])){var y=f(n,b);try{c(t,b,y)}catch(g){}}}}return t}},746:function(e,t){"use strict";var n="function"===typeof Symbol&&Symbol.for,r=n?Symbol.for("react.element"):60103,o=n?Symbol.for("react.portal"):60106,a=n?Symbol.for("react.fragment"):60107,i=n?Symbol.for("react.strict_mode"):60108,s=n?Symbol.for("react.profiler"):60114,l=n?Symbol.for("react.provider"):60109,c=n?Symbol.for("react.context"):60110,u=n?Symbol.for("react.async_mode"):60111,d=n?Symbol.for("react.concurrent_mode"):60111,f=n?Symbol.for("react.forward_ref"):60112,p=n?Symbol.for("react.suspense"):60113,m=n?Symbol.for("react.suspense_list"):60120,h=n?Symbol.for("react.memo"):60115,v=n?Symbol.for("react.lazy"):60116,b=n?Symbol.for("react.block"):60121,y=n?Symbol.for("react.fundamental"):60117,g=n?Symbol.for("react.responder"):60118,_=n?Symbol.for("react.scope"):60119;function w(e){if("object"===typeof e&&null!==e){var t=e.$$typeof;switch(t){case r:switch(e=e.type){case u:case d:case a:case s:case i:case p:return e;default:switch(e=e&&e.$$typeof){case c:case f:case v:case h:case l:return e;default:return t}}case o:return t}}}function T(e){return w(e)===d}t.AsyncMode=u,t.ConcurrentMode=d,t.ContextConsumer=c,t.ContextProvider=l,t.Element=r,t.ForwardRef=f,t.Fragment=a,t.Lazy=v,t.Memo=h,t.Portal=o,t.Profiler=s,t.StrictMode=i,t.Suspense=p,t.isAsyncMode=function(e){return T(e)||w(e)===u},t.isConcurrentMode=T,t.isContextConsumer=function(e){return w(e)===c},t.isContextProvider=function(e){return w(e)===l},t.isElement=function(e){return"object"===typeof e&&null!==e&&e.$$typeof===r},t.isForwardRef=function(e){return w(e)===f},t.isFragment=function(e){return w(e)===a},t.isLazy=function(e){return w(e)===v},t.isMemo=function(e){return w(e)===h},t.isPortal=function(e){return w(e)===o},t.isProfiler=function(e){return w(e)===s},t.isStrictMode=function(e){return w(e)===i},t.isSuspense=function(e){return w(e)===p},t.isValidElementType=function(e){return"string"===typeof e||"function"===typeof e||e===a||e===d||e===s||e===i||e===p||e===m||"object"===typeof e&&null!==e&&(e.$$typeof===v||e.$$typeof===h||e.$$typeof===l||e.$$typeof===c||e.$$typeof===f||e.$$typeof===y||e.$$typeof===g||e.$$typeof===_||e.$$typeof===b)},t.typeOf=w},8309:function(e,t,n){"use strict";e.exports=n(746)},5781:function(e,t,n){"use strict";n.r(t);var r=Number.isNaN||function(e){return"number"===typeof e&&e!==e};function o(e,t){if(e.length!==t.length)return!1;for(var n=0;n<e.length;n++)if(o=e[n],a=t[n],!(o===a||r(o)&&r(a)))return!1;var o,a;return!0}t.default=function(e,t){var n;void 0===t&&(t=o);var r,a=[],i=!1;return function(){for(var o=[],s=0;s<arguments.length;s++)o[s]=arguments[s];return i&&n===this&&t(o,a)||(r=e.apply(this,o),i=!0,n=this,a=o),r}}},888:function(e,t,n){"use strict";var r=n(9047);function o(){}function a(){}a.resetWarningCache=o,e.exports=function(){function e(e,t,n,o,a,i){if(i!==r){var s=new Error("Calling PropTypes validators directly is not supported by the `prop-types` package. Use PropTypes.checkPropTypes() to call them. Read more at http://fb.me/use-check-prop-types");throw s.name="Invariant Violation",s}}function t(){return e}e.isRequired=e;var n={array:e,bigint:e,bool:e,func:e,number:e,object:e,string:e,symbol:e,any:e,arrayOf:t,element:e,elementType:e,instanceOf:t,node:e,objectOf:t,oneOf:t,oneOfType:t,shape:t,exact:t,checkPropTypes:a,resetWarningCache:o};return n.PropTypes=n,n}},2007:function(e,t,n){e.exports=n(888)()},9047:function(e){"use strict";e.exports="SECRET_DO_NOT_PASS_THIS_OR_YOU_WILL_BE_FIRED"},8472:function(e,t,n){n(3561)},8015:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0});var r,o=function(){function e(e,t){for(var n=0;n<t.length;n++){var r=t[n];r.enumerable=r.enumerable||!1,r.configurable=!0,"value"in r&&(r.writable=!0),Object.defineProperty(e,r.key,r)}}return function(t,n,r){return n&&e(t.prototype,n),r&&e(t,r),t}}(),a=n(2791),i=(r=a)&&r.__esModule?r:{default:r},s=n(1509),l=n(8333);var c=function(e){function t(e){!function(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}(this,t);var n=function(e,t){if(!e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return!t||"object"!==typeof t&&"function"!==typeof t?e:t}(this,(t.__proto__||Object.getPrototypeOf(t)).call(this,e));return n.state={},n}return function(e,t){if("function"!==typeof t&&null!==t)throw new TypeError("Super expression must either be null or a function, not "+typeof t);e.prototype=Object.create(t&&t.prototype,{constructor:{value:e,enumerable:!1,writable:!0,configurable:!0}}),t&&(Object.setPrototypeOf?Object.setPrototypeOf(e,t):e.__proto__=t)}(t,e),o(t,[{key:"buildURI",value:function(){return s.buildURI.apply(void 0,arguments)}},{key:"componentDidMount",value:function(){var e=this.props,t=e.data,n=e.headers,r=e.separator,o=e.enclosingCharacter,a=e.uFEFF,i=e.target,s=e.specs,l=e.replace;this.state.page=window.open(this.buildURI(t,a,n,r,o),i,s,l)}},{key:"getWindow",value:function(){return this.state.page}},{key:"render",value:function(){return null}}]),t}(i.default.Component);c.defaultProps=Object.assign(l.defaultProps,{target:"_blank"}),c.propTypes=l.propTypes,t.default=c},9088:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0});var r,o=Object.assign||function(e){for(var t=1;t<arguments.length;t++){var n=arguments[t];for(var r in n)Object.prototype.hasOwnProperty.call(n,r)&&(e[r]=n[r])}return e},a=function(){function e(e,t){for(var n=0;n<t.length;n++){var r=t[n];r.enumerable=r.enumerable||!1,r.configurable=!0,"value"in r&&(r.writable=!0),Object.defineProperty(e,r.key,r)}}return function(t,n,r){return n&&e(t.prototype,n),r&&e(t,r),t}}(),i=n(2791),s=(r=i)&&r.__esModule?r:{default:r},l=n(1509),c=n(8333);var u=function(e){function t(e){!function(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}(this,t);var n=function(e,t){if(!e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return!t||"object"!==typeof t&&"function"!==typeof t?e:t}(this,(t.__proto__||Object.getPrototypeOf(t)).call(this,e));return n.buildURI=n.buildURI.bind(n),n}return function(e,t){if("function"!==typeof t&&null!==t)throw new TypeError("Super expression must either be null or a function, not "+typeof t);e.prototype=Object.create(t&&t.prototype,{constructor:{value:e,enumerable:!1,writable:!0,configurable:!0}}),t&&(Object.setPrototypeOf?Object.setPrototypeOf(e,t):e.__proto__=t)}(t,e),a(t,[{key:"buildURI",value:function(){return l.buildURI.apply(void 0,arguments)}},{key:"handleLegacy",value:function(e){var t=arguments.length>1&&void 0!==arguments[1]&&arguments[1];if(window.navigator.msSaveOrOpenBlob){e.preventDefault();var n=this.props,r=n.data,o=n.headers,a=n.separator,i=n.filename,s=n.enclosingCharacter,c=n.uFEFF,u=t&&"function"===typeof r?r():r,d=new Blob([c?"\ufeff":"",(0,l.toCSV)(u,o,a,s)]);return window.navigator.msSaveBlob(d,i),!1}}},{key:"handleAsyncClick",value:function(e){var t=this;this.props.onClick(e,(function(n){!1!==n?t.handleLegacy(e,!0):e.preventDefault()}))}},{key:"handleSyncClick",value:function(e){!1===this.props.onClick(e)?e.preventDefault():this.handleLegacy(e)}},{key:"handleClick",value:function(){var e=this;return function(t){if("function"===typeof e.props.onClick)return e.props.asyncOnClick?e.handleAsyncClick(t):e.handleSyncClick(t);e.handleLegacy(t)}}},{key:"render",value:function(){var e=this,t=this.props,n=t.data,r=t.headers,a=t.separator,i=t.filename,l=t.uFEFF,c=t.children,u=(t.onClick,t.asyncOnClick,t.enclosingCharacter),d=function(e,t){var n={};for(var r in e)t.indexOf(r)>=0||Object.prototype.hasOwnProperty.call(e,r)&&(n[r]=e[r]);return n}(t,["data","headers","separator","filename","uFEFF","children","onClick","asyncOnClick","enclosingCharacter"]),f="undefined"===typeof window?"":this.buildURI(n,l,r,a,u);return s.default.createElement("a",o({download:i},d,{ref:function(t){return e.link=t},target:"_self",href:f,onClick:this.handleClick()}),c)}}]),t}(s.default.Component);u.defaultProps=c.defaultProps,u.propTypes=c.propTypes,t.default=u},1509:function(e,t){"use strict";Object.defineProperty(t,"__esModule",{value:!0});var n="function"===typeof Symbol&&"symbol"===typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"===typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e};function r(e){if(Array.isArray(e)){for(var t=0,n=Array(e.length);t<e.length;t++)n[t]=e[t];return n}return Array.from(e)}var o=t.isSafari=function(){return/^((?!chrome|android).)*safari/i.test(navigator.userAgent)},a=t.isJsons=function(e){return Array.isArray(e)&&e.every((function(e){return"object"===("undefined"===typeof e?"undefined":n(e))&&!(e instanceof Array)}))},i=t.isArrays=function(e){return Array.isArray(e)&&e.every((function(e){return Array.isArray(e)}))},s=t.jsonsHeaders=function(e){return Array.from(e.map((function(e){return Object.keys(e)})).reduce((function(e,t){return new Set([].concat(r(e),r(t)))}),[]))},l=t.jsons2arrays=function(e,t){var n=t=t||s(e),o=t;a(t)&&(n=t.map((function(e){return e.label})),o=t.map((function(e){return e.key})));var i=e.map((function(e){return o.map((function(t){return c(t,e)}))}));return[n].concat(r(i))},c=t.getHeaderValue=function(e,t){var n=e.replace(/\[([^\]]+)]/g,".$1").split(".").reduce((function(e,t,n,r){var o=e[t];if(void 0!==o&&null!==o)return o;r.splice(1)}),t);return void 0===n?e in t?t[e]:"":n},u=t.elementOrEmpty=function(e){return"undefined"===typeof e||null===e?"":e},d=t.joiner=function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:",",n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:'"';return e.filter((function(e){return e})).map((function(e){return e.map((function(e){return u(e)})).map((function(e){return""+n+e+n})).join(t)})).join("\n")},f=t.arrays2csv=function(e,t,n,o){return d(t?[t].concat(r(e)):e,n,o)},p=t.jsons2csv=function(e,t,n,r){return d(l(e,t),n,r)},m=t.string2csv=function(e,t,n,r){return t?t.join(n)+"\n"+e:e.replace(/"/g,'""')},h=t.toCSV=function(e,t,n,r){if(a(e))return p(e,t,n,r);if(i(e))return f(e,t,n,r);if("string"===typeof e)return m(e,t,n);throw new TypeError('Data should be a "String", "Array of arrays" OR "Array of objects" ')};t.buildURI=function(e,t,n,r,a){var i=h(e,n,r,a),s=o()?"application/csv":"text/csv",l=new Blob([t?"\ufeff":"",i],{type:s}),c="data:"+s+";charset=utf-8,"+(t?"\ufeff":"")+i,u=window.URL||window.webkitURL;return"undefined"===typeof u.createObjectURL?c:u.createObjectURL(l)}},3561:function(e,t,n){"use strict";var r=a(n(8015)),o=a(n(9088));function a(e){return e&&e.__esModule?e:{default:e}}r.default,o.default},8333:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0}),t.PropsNotForwarded=t.defaultProps=t.propTypes=void 0;var r,o=n(2791),a=((r=o)&&r.__esModule,n(2007));t.propTypes={data:(0,a.oneOfType)([a.string,a.array,a.func]).isRequired,headers:a.array,target:a.string,separator:a.string,filename:a.string,uFEFF:a.bool,onClick:a.func,asyncOnClick:a.bool,enclosingCharacter:a.string},t.defaultProps={separator:",",filename:"generatedBy_react-csv.csv",uFEFF:!0,asyncOnClick:!1,enclosingCharacter:'"'},t.PropsNotForwarded=["data","headers"]},7786:function(e,t,n){"use strict";var r=this&&this.__read||function(e,t){var n="function"===typeof Symbol&&e[Symbol.iterator];if(!n)return e;var r,o,a=n.call(e),i=[];try{for(;(void 0===t||t-- >0)&&!(r=a.next()).done;)i.push(r.value)}catch(s){o={error:s}}finally{try{r&&!r.done&&(n=a.return)&&n.call(a)}finally{if(o)throw o.error}}return i},o=this&&this.__spread||function(){for(var e=[],t=0;t<arguments.length;t++)e=e.concat(r(arguments[t]));return e};Object.defineProperty(t,"__esModule",{value:!0});var a,i,s=n(4173),l=s;!function(e){e[e.DEFAULT=0]="DEFAULT",e[e.ADDED=1]="ADDED",e[e.REMOVED=2]="REMOVED"}(a=t.DiffType||(t.DiffType={})),function(e){e.CHARS="diffChars",e.WORDS="diffWords",e.WORDS_WITH_SPACE="diffWordsWithSpace",e.LINES="diffLines",e.TRIMMED_LINES="diffTrimmedLines",e.SENTENCES="diffSentences",e.CSS="diffCss"}(i=t.DiffMethod||(t.DiffMethod={}));var c=function(e){var t=e.split("\n");if(t.every((function(e){return!e})))return 2===t.length?[]:(t.pop(),t);var n=t[t.length-1],r=t[0];return n||t.pop(),r||t.shift(),t};t.computeLineInformation=function(e,t,n,r,u){void 0===n&&(n=!1),void 0===r&&(r=i.CHARS),void 0===u&&(u=0);var d=s.diffLines(e.trimRight(),t.trimRight(),{newlineIsToken:!0,ignoreWhitespace:!1,ignoreCase:!1}),f=u,p=u,m=[],h=0,v=[],b=[],y=function e(t,o,s,u,m){return c(t).map((function(t,y){var g={},_={};if(!(b.includes(o+"-"+y)||m&&0!==y)){if(s||u)if(v.includes(h)||v.push(h),u){p+=1,g.lineNumber=p,g.type=a.REMOVED,g.value=t||" ";var w=d[o+1];if(w&&w.added)if(c(w.value)[y]){var T=e(w.value,o,!0,!1,!0)[0].right,S=T.value,P=T.lineNumber,k=T.type;if(b.push(o+1+"-"+y),_.lineNumber=P,_.type=k,n)_.value=S;else{var x=function(e,t,n){void 0===n&&(n=i.CHARS);var r=l[n](e,t),o={left:[],right:[]};return r.forEach((function(e){var t=e.added,n=e.removed,r=e.value,i={};return t&&(i.type=a.ADDED,i.value=r,o.right.push(i)),n&&(i.type=a.REMOVED,i.value=r,o.left.push(i)),n||t||(i.type=a.DEFAULT,i.value=r,o.right.push(i),o.left.push(i)),i})),o}(t,S,r);_.value=x.right,g.value=x.left}}}else f+=1,_.lineNumber=f,_.type=a.ADDED,_.value=t;else p+=1,f+=1,g.lineNumber=p,g.type=a.DEFAULT,g.value=t,_.lineNumber=f,_.type=a.DEFAULT,_.value=t;return h+=1,{right:_,left:g}}})).filter(Boolean)};return d.forEach((function(e,t){var n=e.added,r=e.removed,a=e.value;m=o(m,y(a,t,n,r))})),{lineInformation:m,diffLines:v}}},1774:function(e,t,n){"use strict";var r=this&&this.__extends||function(){var e=function(t,n){return e=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var n in t)t.hasOwnProperty(n)&&(e[n]=t[n])},e(t,n)};return function(t,n){function r(){this.constructor=t}e(t,n),t.prototype=null===n?Object.create(n):(r.prototype=n.prototype,new r)}}();Object.defineProperty(t,"__esModule",{value:!0});var o=n(2791),a=n(2007),i=n(1694),s=n(7786);t.DiffMethod=s.DiffMethod;var l,c=n(2813),u=n(5781),d=u.default||u;!function(e){e.LEFT="L",e.RIGHT="R"}(l=t.LineNumberPrefix||(t.LineNumberPrefix={}));var f=function(e){function t(t){var n=e.call(this,t)||this;return n.resetCodeBlocks=function(){return n.state.expandedBlocks.length>0&&(n.setState({expandedBlocks:[]}),!0)},n.onBlockExpand=function(e){var t=n.state.expandedBlocks.slice();t.push(e),n.setState({expandedBlocks:t})},n.computeStyles=d(c.default),n.onLineNumberClickProxy=function(e){return n.props.onLineNumberClick?function(t){return n.props.onLineNumberClick(e,t)}:function(){}},n.renderWordDiff=function(e,t){return e.map((function(e,r){var a;return o.createElement("span",{key:r,className:i.default(n.styles.wordDiff,(a={},a[n.styles.wordAdded]=e.type===s.DiffType.ADDED,a[n.styles.wordRemoved]=e.type===s.DiffType.REMOVED,a))},t?t(e.value):e.value)}))},n.renderLine=function(e,t,r,a,l,c){var u,d,f,p,m,h=r+"-"+e,v=c+"-"+l,b=n.props.highlightLines.includes(h)||n.props.highlightLines.includes(v),y=t===s.DiffType.ADDED,g=t===s.DiffType.REMOVED;return m=Array.isArray(a)?n.renderWordDiff(a,n.props.renderContent):n.props.renderContent?n.props.renderContent(a):a,o.createElement(o.Fragment,null,!n.props.hideLineNumbers&&o.createElement("td",{onClick:e&&n.onLineNumberClickProxy(h),className:i.default(n.styles.gutter,(u={},u[n.styles.emptyGutter]=!e,u[n.styles.diffAdded]=y,u[n.styles.diffRemoved]=g,u[n.styles.highlightedGutter]=b,u))},o.createElement("pre",{className:n.styles.lineNumber},e)),!n.props.splitView&&!n.props.hideLineNumbers&&o.createElement("td",{onClick:l&&n.onLineNumberClickProxy(v),className:i.default(n.styles.gutter,(d={},d[n.styles.emptyGutter]=!l,d[n.styles.diffAdded]=y,d[n.styles.diffRemoved]=g,d[n.styles.highlightedGutter]=b,d))},o.createElement("pre",{className:n.styles.lineNumber},l)),o.createElement("td",{className:i.default(n.styles.marker,(f={},f[n.styles.emptyLine]=!m,f[n.styles.diffAdded]=y,f[n.styles.diffRemoved]=g,f[n.styles.highlightedLine]=b,f))},o.createElement("pre",null,y&&"+",g&&"-")),o.createElement("td",{className:i.default(n.styles.content,(p={},p[n.styles.emptyLine]=!m,p[n.styles.diffAdded]=y,p[n.styles.diffRemoved]=g,p[n.styles.highlightedLine]=b,p))},o.createElement("pre",{className:n.styles.contentText},m)))},n.renderSplitView=function(e,t){var r=e.left,a=e.right;return o.createElement("tr",{key:t,className:n.styles.line},n.renderLine(r.lineNumber,r.type,l.LEFT,r.value),n.renderLine(a.lineNumber,a.type,l.RIGHT,a.value))},n.renderInlineView=function(e,t){var r,a=e.left,i=e.right;return a.type===s.DiffType.REMOVED&&i.type===s.DiffType.ADDED?o.createElement(o.Fragment,{key:t},o.createElement("tr",{className:n.styles.line},n.renderLine(a.lineNumber,a.type,l.LEFT,a.value,null)),o.createElement("tr",{className:n.styles.line},n.renderLine(null,i.type,l.RIGHT,i.value,i.lineNumber))):(a.type===s.DiffType.REMOVED&&(r=n.renderLine(a.lineNumber,a.type,l.LEFT,a.value,null)),a.type===s.DiffType.DEFAULT&&(r=n.renderLine(a.lineNumber,a.type,l.LEFT,a.value,i.lineNumber,l.RIGHT)),i.type===s.DiffType.ADDED&&(r=n.renderLine(null,i.type,l.RIGHT,i.value,i.lineNumber)),o.createElement("tr",{key:t,className:n.styles.line},r))},n.onBlockClickProxy=function(e){return function(){return n.onBlockExpand(e)}},n.renderSkippedLineIndicator=function(e,t,r,a){var s,l=n.props,c=l.hideLineNumbers,u=l.splitView,d=n.props.codeFoldMessageRenderer?n.props.codeFoldMessageRenderer(e,r,a):o.createElement("pre",{className:n.styles.codeFoldContent},"Expand ",e," lines ..."),f=o.createElement("td",null,o.createElement("a",{onClick:n.onBlockClickProxy(t),tabIndex:0},d)),p=!u&&!c;return o.createElement("tr",{key:r+"-"+a,className:n.styles.codeFold},!c&&o.createElement("td",{className:n.styles.codeFoldGutter}),o.createElement("td",{className:i.default((s={},s[n.styles.codeFoldGutter]=p,s))}),p?o.createElement(o.Fragment,null,o.createElement("td",null),f):o.createElement(o.Fragment,null,f,o.createElement("td",null)),o.createElement("td",null),o.createElement("td",null))},n.renderDiff=function(){var e=n.props,t=e.oldValue,r=e.newValue,a=e.splitView,i=e.disableWordDiff,l=e.compareMethod,c=e.linesOffset,u=s.computeLineInformation(t,r,i,l,c),d=u.lineInformation,f=u.diffLines,p=n.props.extraLinesSurroundingDiff<0?0:n.props.extraLinesSurroundingDiff,m=[];return d.map((function(e,t){var r=f[0],i=r-t;if(n.props.showDiffOnly&&(i===-p&&(m=[],f.shift()),e.left.type===s.DiffType.DEFAULT&&(i>p||"undefined"===typeof r)&&!n.state.expandedBlocks.includes(r)))return m.push(t+1),t===d.length-1&&m.length>1?n.renderSkippedLineIndicator(m.length,r,e.left.lineNumber,e.right.lineNumber):null;var l=a?n.renderSplitView(e,t):n.renderInlineView(e,t);if(i===p&&m.length>0){var c=m.length;return m=[],o.createElement(o.Fragment,{key:t},n.renderSkippedLineIndicator(c,r,e.left.lineNumber,e.right.lineNumber),l)}return l}))},n.render=function(){var e,t=n.props,r=t.oldValue,a=t.newValue,s=t.useDarkTheme,l=t.leftTitle,c=t.rightTitle,u=t.splitView,d=t.hideLineNumbers;if("string"!==typeof r||"string"!==typeof a)throw Error('"oldValue" and "newValue" should be strings');n.styles=n.computeStyles(n.props.styles,s);var f=n.renderDiff(),p=d?2:3,m=d?2:4,h=(l||c)&&o.createElement("tr",null,o.createElement("td",{colSpan:u?p:m,className:n.styles.titleBlock},o.createElement("pre",{className:n.styles.contentText},l)),u&&o.createElement("td",{colSpan:p,className:n.styles.titleBlock},o.createElement("pre",{className:n.styles.contentText},c)));return o.createElement("table",{className:i.default(n.styles.diffContainer,(e={},e[n.styles.splitView]=u,e))},o.createElement("tbody",null,h,f))},n.state={expandedBlocks:[]},n}return r(t,e),t.defaultProps={oldValue:"",newValue:"",splitView:!0,highlightLines:[],disableWordDiff:!1,compareMethod:s.DiffMethod.CHARS,styles:{},hideLineNumbers:!1,extraLinesSurroundingDiff:3,showDiffOnly:!0,useDarkTheme:!1,linesOffset:0},t.propTypes={oldValue:a.string.isRequired,newValue:a.string.isRequired,splitView:a.bool,disableWordDiff:a.bool,compareMethod:a.oneOf(Object.values(s.DiffMethod)),renderContent:a.func,onLineNumberClick:a.func,extraLinesSurroundingDiff:a.number,styles:a.object,hideLineNumbers:a.bool,showDiffOnly:a.bool,highlightLines:a.arrayOf(a.string),leftTitle:a.oneOfType([a.string,a.element]),rightTitle:a.oneOfType([a.string,a.element]),linesOffset:a.number},t}(o.Component);t.default=f},2813:function(e,t,n){"use strict";var r=this&&this.__assign||function(){return r=Object.assign||function(e){for(var t,n=1,r=arguments.length;n<r;n++)for(var o in t=arguments[n])Object.prototype.hasOwnProperty.call(t,o)&&(e[o]=t[o]);return e},r.apply(this,arguments)},o=this&&this.__rest||function(e,t){var n={};for(var r in e)Object.prototype.hasOwnProperty.call(e,r)&&t.indexOf(r)<0&&(n[r]=e[r]);if(null!=e&&"function"===typeof Object.getOwnPropertySymbols){var o=0;for(r=Object.getOwnPropertySymbols(e);o<r.length;o++)t.indexOf(r[o])<0&&Object.prototype.propertyIsEnumerable.call(e,r[o])&&(n[r[o]]=e[r[o]])}return n};Object.defineProperty(t,"__esModule",{value:!0});var a=n(6025);t.default=function(e,t){var n,i,s,l,c,u,d;void 0===t&&(t=!1);var f=e.variables,p=void 0===f?{}:f,m=o(e,["variables"]),h={light:r({diffViewerBackground:"#fff",diffViewerColor:"212529",addedBackground:"#e6ffed",addedColor:"#24292e",removedBackground:"#ffeef0",removedColor:"#24292e",wordAddedBackground:"#acf2bd",wordRemovedBackground:"#fdb8c0",addedGutterBackground:"#cdffd8",removedGutterBackground:"#ffdce0",gutterBackground:"#f7f7f7",gutterBackgroundDark:"#f3f1f1",highlightBackground:"#fffbdd",highlightGutterBackground:"#fff5b1",codeFoldGutterBackground:"#dbedff",codeFoldBackground:"#f1f8ff",emptyLineBackground:"#fafbfc",gutterColor:"#212529",addedGutterColor:"#212529",removedGutterColor:"#212529",codeFoldContentColor:"#212529",diffViewerTitleBackground:"#fafbfc",diffViewerTitleColor:"#212529",diffViewerTitleBorderColor:"#eee"},p.light||{}),dark:r({diffViewerBackground:"#2e303c",diffViewerColor:"#FFF",addedBackground:"#044B53",addedColor:"white",removedBackground:"#632F34",removedColor:"white",wordAddedBackground:"#055d67",wordRemovedBackground:"#7d383f",addedGutterBackground:"#034148",removedGutterBackground:"#632b30",gutterBackground:"#2c2f3a",gutterBackgroundDark:"#262933",highlightBackground:"#2a3967",highlightGutterBackground:"#2d4077",codeFoldGutterBackground:"#21232b",codeFoldBackground:"#262831",emptyLineBackground:"#363946",gutterColor:"#464c67",addedGutterColor:"#8c8c8c",removedGutterColor:"#8c8c8c",codeFoldContentColor:"#555a7b",diffViewerTitleBackground:"#2f323e",diffViewerTitleColor:"#555a7b",diffViewerTitleBorderColor:"#353846"},p.dark||{})},v=t?h.dark:h.light,b=a.css({width:"100%",label:"content"}),y=a.css(((n={})["."+b]={width:"50%"},n.label="split-view",n)),g=a.css({width:"100%",background:v.diffViewerBackground,pre:{margin:0,whiteSpace:"pre-wrap",lineHeight:"25px"},label:"diff-container",borderCollapse:"collapse"}),_=a.css({color:v.codeFoldContentColor,label:"code-fold-content"}),w=a.css({color:v.diffViewerColor,label:"content-text"}),T=a.css(((i={background:v.diffViewerTitleBackground,padding:10,borderBottom:"1px solid "+v.diffViewerTitleBorderColor,label:"title-block",":last-child":{borderLeft:"1px solid "+v.diffViewerTitleBorderColor}})["."+w]={color:v.diffViewerTitleColor},i)),S=a.css({color:v.gutterColor,label:"line-number"}),P=a.css(((s={background:v.removedBackground,color:v.removedColor,pre:{color:v.removedColor}})["."+S]={color:v.removedGutterColor},s.label="diff-removed",s)),k=a.css(((l={background:v.addedBackground,color:v.addedColor,pre:{color:v.addedColor}})["."+S]={color:v.addedGutterColor},l.label="diff-added",l)),x=a.css({padding:2,display:"inline-flex",borderRadius:1,label:"word-diff"}),C=a.css({background:v.wordAddedBackground,label:"word-added"}),A=a.css({background:v.wordRemovedBackground,label:"word-removed"}),M=a.css({backgroundColor:v.codeFoldGutterBackground,label:"code-fold-gutter"}),F=a.css({backgroundColor:v.codeFoldBackground,height:40,fontSize:14,fontWeight:700,label:"code-fold",a:{textDecoration:"underline !important",cursor:"pointer",pre:{display:"inline"}}}),E=a.css({backgroundColor:v.emptyLineBackground,label:"empty-line"}),R=a.css(((c={width:25,paddingLeft:10,paddingRight:10,userSelect:"none",label:"marker"})["&."+k]={pre:{color:v.addedColor}},c["&."+P]={pre:{color:v.removedColor}},c)),N=a.css(((u={background:v.highlightBackground,label:"highlighted-line"})["."+C+", ."+A]={backgroundColor:"initial"},u)),O=a.css({label:"highlighted-gutter"}),V=a.css(((d={userSelect:"none",minWidth:50,padding:"0 10px",label:"gutter",textAlign:"right",background:v.gutterBackground,"&:hover":{cursor:"pointer",background:v.gutterBackgroundDark,pre:{opacity:1}},pre:{opacity:.5}})["&."+k]={background:v.addedGutterBackground},d["&."+P]={background:v.removedGutterBackground},d["&."+O]={background:v.highlightGutterBackground,"&:hover":{background:v.highlightGutterBackground}},d)),L=a.css({"&:hover":{background:v.gutterBackground,cursor:"initial"},label:"empty-gutter"}),D={diffContainer:g,diffRemoved:P,diffAdded:k,splitView:y,marker:R,highlightedGutter:O,highlightedLine:N,gutter:V,line:a.css({verticalAlign:"baseline",label:"line"}),wordDiff:x,wordAdded:C,wordRemoved:A,codeFoldGutter:M,codeFold:F,emptyGutter:L,emptyLine:E,lineNumber:S,contentText:w,content:b,codeFoldContent:_,titleBlock:T},z=Object.keys(m).reduce((function(e,t){var n;return r({},e,((n={})[t]=a.css(m[t]),n))}),{});return Object.keys(D).reduce((function(e,t){var n;return r({},e,((n={})[t]=z[t]?a.cx(D[t],z[t]):D[t],n))}),{})}},4463:function(e,t,n){"use strict";var r=n(2791),o=n(5296);function a(e){for(var t="https://reactjs.org/docs/error-decoder.html?invariant="+e,n=1;n<arguments.length;n++)t+="&args[]="+encodeURIComponent(arguments[n]);return"Minified React error #"+e+"; visit "+t+" for the full message or use the non-minified dev environment for full errors and additional helpful warnings."}var i=new Set,s={};function l(e,t){c(e,t),c(e+"Capture",t)}function c(e,t){for(s[e]=t,e=0;e<t.length;e++)i.add(t[e])}var u=!("undefined"===typeof window||"undefined"===typeof window.document||"undefined"===typeof window.document.createElement),d=Object.prototype.hasOwnProperty,f=/^[:A-Z_a-z\u00C0-\u00D6\u00D8-\u00F6\u00F8-\u02FF\u0370-\u037D\u037F-\u1FFF\u200C-\u200D\u2070-\u218F\u2C00-\u2FEF\u3001-\uD7FF\uF900-\uFDCF\uFDF0-\uFFFD][:A-Z_a-z\u00C0-\u00D6\u00D8-\u00F6\u00F8-\u02FF\u0370-\u037D\u037F-\u1FFF\u200C-\u200D\u2070-\u218F\u2C00-\u2FEF\u3001-\uD7FF\uF900-\uFDCF\uFDF0-\uFFFD\-.0-9\u00B7\u0300-\u036F\u203F-\u2040]*$/,p={},m={};function h(e,t,n,r,o,a,i){this.acceptsBooleans=2===t||3===t||4===t,this.attributeName=r,this.attributeNamespace=o,this.mustUseProperty=n,this.propertyName=e,this.type=t,this.sanitizeURL=a,this.removeEmptyString=i}var v={};"children dangerouslySetInnerHTML defaultValue defaultChecked innerHTML suppressContentEditableWarning suppressHydrationWarning style".split(" ").forEach((function(e){v[e]=new h(e,0,!1,e,null,!1,!1)})),[["acceptCharset","accept-charset"],["className","class"],["htmlFor","for"],["httpEquiv","http-equiv"]].forEach((function(e){var t=e[0];v[t]=new h(t,1,!1,e[1],null,!1,!1)})),["contentEditable","draggable","spellCheck","value"].forEach((function(e){v[e]=new h(e,2,!1,e.toLowerCase(),null,!1,!1)})),["autoReverse","externalResourcesRequired","focusable","preserveAlpha"].forEach((function(e){v[e]=new h(e,2,!1,e,null,!1,!1)})),"allowFullScreen async autoFocus autoPlay controls default defer disabled disablePictureInPicture disableRemotePlayback formNoValidate hidden loop noModule noValidate open playsInline readOnly required reversed scoped seamless itemScope".split(" ").forEach((function(e){v[e]=new h(e,3,!1,e.toLowerCase(),null,!1,!1)})),["checked","multiple","muted","selected"].forEach((function(e){v[e]=new h(e,3,!0,e,null,!1,!1)})),["capture","download"].forEach((function(e){v[e]=new h(e,4,!1,e,null,!1,!1)})),["cols","rows","size","span"].forEach((function(e){v[e]=new h(e,6,!1,e,null,!1,!1)})),["rowSpan","start"].forEach((function(e){v[e]=new h(e,5,!1,e.toLowerCase(),null,!1,!1)}));var b=/[\-:]([a-z])/g;function y(e){return e[1].toUpperCase()}function g(e,t,n,r){var o=v.hasOwnProperty(t)?v[t]:null;(null!==o?0!==o.type:r||!(2<t.length)||"o"!==t[0]&&"O"!==t[0]||"n"!==t[1]&&"N"!==t[1])&&(function(e,t,n,r){if(null===t||"undefined"===typeof t||function(e,t,n,r){if(null!==n&&0===n.type)return!1;switch(typeof t){case"function":case"symbol":return!0;case"boolean":return!r&&(null!==n?!n.acceptsBooleans:"data-"!==(e=e.toLowerCase().slice(0,5))&&"aria-"!==e);default:return!1}}(e,t,n,r))return!0;if(r)return!1;if(null!==n)switch(n.type){case 3:return!t;case 4:return!1===t;case 5:return isNaN(t);case 6:return isNaN(t)||1>t}return!1}(t,n,o,r)&&(n=null),r||null===o?function(e){return!!d.call(m,e)||!d.call(p,e)&&(f.test(e)?m[e]=!0:(p[e]=!0,!1))}(t)&&(null===n?e.removeAttribute(t):e.setAttribute(t,""+n)):o.mustUseProperty?e[o.propertyName]=null===n?3!==o.type&&"":n:(t=o.attributeName,r=o.attributeNamespace,null===n?e.removeAttribute(t):(n=3===(o=o.type)||4===o&&!0===n?"":""+n,r?e.setAttributeNS(r,t,n):e.setAttribute(t,n))))}"accent-height alignment-baseline arabic-form baseline-shift cap-height clip-path clip-rule color-interpolation color-interpolation-filters color-profile color-rendering dominant-baseline enable-background fill-opacity fill-rule flood-color flood-opacity font-family font-size font-size-adjust font-stretch font-style font-variant font-weight glyph-name glyph-orientation-horizontal glyph-orientation-vertical horiz-adv-x horiz-origin-x image-rendering letter-spacing lighting-color marker-end marker-mid marker-start overline-position overline-thickness paint-order panose-1 pointer-events rendering-intent shape-rendering stop-color stop-opacity strikethrough-position strikethrough-thickness stroke-dasharray stroke-dashoffset stroke-linecap stroke-linejoin stroke-miterlimit stroke-opacity stroke-width text-anchor text-decoration text-rendering underline-position underline-thickness unicode-bidi unicode-range units-per-em v-alphabetic v-hanging v-ideographic v-mathematical vector-effect vert-adv-y vert-origin-x vert-origin-y word-spacing writing-mode xmlns:xlink x-height".split(" ").forEach((function(e){var t=e.replace(b,y);v[t]=new h(t,1,!1,e,null,!1,!1)})),"xlink:actuate xlink:arcrole xlink:role xlink:show xlink:title xlink:type".split(" ").forEach((function(e){var t=e.replace(b,y);v[t]=new h(t,1,!1,e,"http://www.w3.org/1999/xlink",!1,!1)})),["xml:base","xml:lang","xml:space"].forEach((function(e){var t=e.replace(b,y);v[t]=new h(t,1,!1,e,"http://www.w3.org/XML/1998/namespace",!1,!1)})),["tabIndex","crossOrigin"].forEach((function(e){v[e]=new h(e,1,!1,e.toLowerCase(),null,!1,!1)})),v.xlinkHref=new h("xlinkHref",1,!1,"xlink:href","http://www.w3.org/1999/xlink",!0,!1),["src","href","action","formAction"].forEach((function(e){v[e]=new h(e,1,!1,e.toLowerCase(),null,!0,!0)}));var _=r.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED,w=Symbol.for("react.element"),T=Symbol.for("react.portal"),S=Symbol.for("react.fragment"),P=Symbol.for("react.strict_mode"),k=Symbol.for("react.profiler"),x=Symbol.for("react.provider"),C=Symbol.for("react.context"),A=Symbol.for("react.forward_ref"),M=Symbol.for("react.suspense"),F=Symbol.for("react.suspense_list"),E=Symbol.for("react.memo"),R=Symbol.for("react.lazy");Symbol.for("react.scope"),Symbol.for("react.debug_trace_mode");var N=Symbol.for("react.offscreen");Symbol.for("react.legacy_hidden"),Symbol.for("react.cache"),Symbol.for("react.tracing_marker");var O=Symbol.iterator;function V(e){return null===e||"object"!==typeof e?null:"function"===typeof(e=O&&e[O]||e["@@iterator"])?e:null}var L,D=Object.assign;function z(e){if(void 0===L)try{throw Error()}catch(n){var t=n.stack.trim().match(/\n( *(at )?)/);L=t&&t[1]||""}return"\n"+L+e}var I=!1;function H(e,t){if(!e||I)return"";I=!0;var n=Error.prepareStackTrace;Error.prepareStackTrace=void 0;try{if(t)if(t=function(){throw Error()},Object.defineProperty(t.prototype,"props",{set:function(){throw Error()}}),"object"===typeof Reflect&&Reflect.construct){try{Reflect.construct(t,[])}catch(c){var r=c}Reflect.construct(e,[],t)}else{try{t.call()}catch(c){r=c}e.call(t.prototype)}else{try{throw Error()}catch(c){r=c}e()}}catch(c){if(c&&r&&"string"===typeof c.stack){for(var o=c.stack.split("\n"),a=r.stack.split("\n"),i=o.length-1,s=a.length-1;1<=i&&0<=s&&o[i]!==a[s];)s--;for(;1<=i&&0<=s;i--,s--)if(o[i]!==a[s]){if(1!==i||1!==s)do{if(i--,0>--s||o[i]!==a[s]){var l="\n"+o[i].replace(" at new "," at ");return e.displayName&&l.includes("<anonymous>")&&(l=l.replace("<anonymous>",e.displayName)),l}}while(1<=i&&0<=s);break}}}finally{I=!1,Error.prepareStackTrace=n}return(e=e?e.displayName||e.name:"")?z(e):""}function j(e){switch(e.tag){case 5:return z(e.type);case 16:return z("Lazy");case 13:return z("Suspense");case 19:return z("SuspenseList");case 0:case 2:case 15:return e=H(e.type,!1);case 11:return e=H(e.type.render,!1);case 1:return e=H(e.type,!0);default:return""}}function Z(e){if(null==e)return null;if("function"===typeof e)return e.displayName||e.name||null;if("string"===typeof e)return e;switch(e){case S:return"Fragment";case T:return"Portal";case k:return"Profiler";case P:return"StrictMode";case M:return"Suspense";case F:return"SuspenseList"}if("object"===typeof e)switch(e.$$typeof){case C:return(e.displayName||"Context")+".Consumer";case x:return(e._context.displayName||"Context")+".Provider";case A:var t=e.render;return(e=e.displayName)||(e=""!==(e=t.displayName||t.name||"")?"ForwardRef("+e+")":"ForwardRef"),e;case E:return null!==(t=e.displayName||null)?t:Z(e.type)||"Memo";case R:t=e._payload,e=e._init;try{return Z(e(t))}catch(n){}}return null}function B(e){var t=e.type;switch(e.tag){case 24:return"Cache";case 9:return(t.displayName||"Context")+".Consumer";case 10:return(t._context.displayName||"Context")+".Provider";case 18:return"DehydratedFragment";case 11:return e=(e=t.render).displayName||e.name||"",t.displayName||(""!==e?"ForwardRef("+e+")":"ForwardRef");case 7:return"Fragment";case 5:return t;case 4:return"Portal";case 3:return"Root";case 6:return"Text";case 16:return Z(t);case 8:return t===P?"StrictMode":"Mode";case 22:return"Offscreen";case 12:return"Profiler";case 21:return"Scope";case 13:return"Suspense";case 19:return"SuspenseList";case 25:return"TracingMarker";case 1:case 0:case 17:case 2:case 14:case 15:if("function"===typeof t)return t.displayName||t.name||null;if("string"===typeof t)return t}return null}function G(e){switch(typeof e){case"boolean":case"number":case"string":case"undefined":case"object":return e;default:return""}}function W(e){var t=e.type;return(e=e.nodeName)&&"input"===e.toLowerCase()&&("checkbox"===t||"radio"===t)}function U(e){e._valueTracker||(e._valueTracker=function(e){var t=W(e)?"checked":"value",n=Object.getOwnPropertyDescriptor(e.constructor.prototype,t),r=""+e[t];if(!e.hasOwnProperty(t)&&"undefined"!==typeof n&&"function"===typeof n.get&&"function"===typeof n.set){var o=n.get,a=n.set;return Object.defineProperty(e,t,{configurable:!0,get:function(){return o.call(this)},set:function(e){r=""+e,a.call(this,e)}}),Object.defineProperty(e,t,{enumerable:n.enumerable}),{getValue:function(){return r},setValue:function(e){r=""+e},stopTracking:function(){e._valueTracker=null,delete e[t]}}}}(e))}function q(e){if(!e)return!1;var t=e._valueTracker;if(!t)return!0;var n=t.getValue(),r="";return e&&(r=W(e)?e.checked?"true":"false":e.value),(e=r)!==n&&(t.setValue(e),!0)}function $(e){if("undefined"===typeof(e=e||("undefined"!==typeof document?document:void 0)))return null;try{return e.activeElement||e.body}catch(t){return e.body}}function J(e,t){var n=t.checked;return D({},t,{defaultChecked:void 0,defaultValue:void 0,value:void 0,checked:null!=n?n:e._wrapperState.initialChecked})}function K(e,t){var n=null==t.defaultValue?"":t.defaultValue,r=null!=t.checked?t.checked:t.defaultChecked;n=G(null!=t.value?t.value:n),e._wrapperState={initialChecked:r,initialValue:n,controlled:"checkbox"===t.type||"radio"===t.type?null!=t.checked:null!=t.value}}function Q(e,t){null!=(t=t.checked)&&g(e,"checked",t,!1)}function Y(e,t){Q(e,t);var n=G(t.value),r=t.type;if(null!=n)"number"===r?(0===n&&""===e.value||e.value!=n)&&(e.value=""+n):e.value!==""+n&&(e.value=""+n);else if("submit"===r||"reset"===r)return void e.removeAttribute("value");t.hasOwnProperty("value")?ee(e,t.type,n):t.hasOwnProperty("defaultValue")&&ee(e,t.type,G(t.defaultValue)),null==t.checked&&null!=t.defaultChecked&&(e.defaultChecked=!!t.defaultChecked)}function X(e,t,n){if(t.hasOwnProperty("value")||t.hasOwnProperty("defaultValue")){var r=t.type;if(!("submit"!==r&&"reset"!==r||void 0!==t.value&&null!==t.value))return;t=""+e._wrapperState.initialValue,n||t===e.value||(e.value=t),e.defaultValue=t}""!==(n=e.name)&&(e.name=""),e.defaultChecked=!!e._wrapperState.initialChecked,""!==n&&(e.name=n)}function ee(e,t,n){"number"===t&&$(e.ownerDocument)===e||(null==n?e.defaultValue=""+e._wrapperState.initialValue:e.defaultValue!==""+n&&(e.defaultValue=""+n))}var te=Array.isArray;function ne(e,t,n,r){if(e=e.options,t){t={};for(var o=0;o<n.length;o++)t["$"+n[o]]=!0;for(n=0;n<e.length;n++)o=t.hasOwnProperty("$"+e[n].value),e[n].selected!==o&&(e[n].selected=o),o&&r&&(e[n].defaultSelected=!0)}else{for(n=""+G(n),t=null,o=0;o<e.length;o++){if(e[o].value===n)return e[o].selected=!0,void(r&&(e[o].defaultSelected=!0));null!==t||e[o].disabled||(t=e[o])}null!==t&&(t.selected=!0)}}function re(e,t){if(null!=t.dangerouslySetInnerHTML)throw Error(a(91));return D({},t,{value:void 0,defaultValue:void 0,children:""+e._wrapperState.initialValue})}function oe(e,t){var n=t.value;if(null==n){if(n=t.children,t=t.defaultValue,null!=n){if(null!=t)throw Error(a(92));if(te(n)){if(1<n.length)throw Error(a(93));n=n[0]}t=n}null==t&&(t=""),n=t}e._wrapperState={initialValue:G(n)}}function ae(e,t){var n=G(t.value),r=G(t.defaultValue);null!=n&&((n=""+n)!==e.value&&(e.value=n),null==t.defaultValue&&e.defaultValue!==n&&(e.defaultValue=n)),null!=r&&(e.defaultValue=""+r)}function ie(e){var t=e.textContent;t===e._wrapperState.initialValue&&""!==t&&null!==t&&(e.value=t)}function se(e){switch(e){case"svg":return"http://www.w3.org/2000/svg";case"math":return"http://www.w3.org/1998/Math/MathML";default:return"http://www.w3.org/1999/xhtml"}}function le(e,t){return null==e||"http://www.w3.org/1999/xhtml"===e?se(t):"http://www.w3.org/2000/svg"===e&&"foreignObject"===t?"http://www.w3.org/1999/xhtml":e}var ce,ue,de=(ue=function(e,t){if("http://www.w3.org/2000/svg"!==e.namespaceURI||"innerHTML"in e)e.innerHTML=t;else{for((ce=ce||document.createElement("div")).innerHTML="<svg>"+t.valueOf().toString()+"</svg>",t=ce.firstChild;e.firstChild;)e.removeChild(e.firstChild);for(;t.firstChild;)e.appendChild(t.firstChild)}},"undefined"!==typeof MSApp&&MSApp.execUnsafeLocalFunction?function(e,t,n,r){MSApp.execUnsafeLocalFunction((function(){return ue(e,t)}))}:ue);function fe(e,t){if(t){var n=e.firstChild;if(n&&n===e.lastChild&&3===n.nodeType)return void(n.nodeValue=t)}e.textContent=t}var pe={animationIterationCount:!0,aspectRatio:!0,borderImageOutset:!0,borderImageSlice:!0,borderImageWidth:!0,boxFlex:!0,boxFlexGroup:!0,boxOrdinalGroup:!0,columnCount:!0,columns:!0,flex:!0,flexGrow:!0,flexPositive:!0,flexShrink:!0,flexNegative:!0,flexOrder:!0,gridArea:!0,gridRow:!0,gridRowEnd:!0,gridRowSpan:!0,gridRowStart:!0,gridColumn:!0,gridColumnEnd:!0,gridColumnSpan:!0,gridColumnStart:!0,fontWeight:!0,lineClamp:!0,lineHeight:!0,opacity:!0,order:!0,orphans:!0,tabSize:!0,widows:!0,zIndex:!0,zoom:!0,fillOpacity:!0,floodOpacity:!0,stopOpacity:!0,strokeDasharray:!0,strokeDashoffset:!0,strokeMiterlimit:!0,strokeOpacity:!0,strokeWidth:!0},me=["Webkit","ms","Moz","O"];function he(e,t,n){return null==t||"boolean"===typeof t||""===t?"":n||"number"!==typeof t||0===t||pe.hasOwnProperty(e)&&pe[e]?(""+t).trim():t+"px"}function ve(e,t){for(var n in e=e.style,t)if(t.hasOwnProperty(n)){var r=0===n.indexOf("--"),o=he(n,t[n],r);"float"===n&&(n="cssFloat"),r?e.setProperty(n,o):e[n]=o}}Object.keys(pe).forEach((function(e){me.forEach((function(t){t=t+e.charAt(0).toUpperCase()+e.substring(1),pe[t]=pe[e]}))}));var be=D({menuitem:!0},{area:!0,base:!0,br:!0,col:!0,embed:!0,hr:!0,img:!0,input:!0,keygen:!0,link:!0,meta:!0,param:!0,source:!0,track:!0,wbr:!0});function ye(e,t){if(t){if(be[e]&&(null!=t.children||null!=t.dangerouslySetInnerHTML))throw Error(a(137,e));if(null!=t.dangerouslySetInnerHTML){if(null!=t.children)throw Error(a(60));if("object"!==typeof t.dangerouslySetInnerHTML||!("__html"in t.dangerouslySetInnerHTML))throw Error(a(61))}if(null!=t.style&&"object"!==typeof t.style)throw Error(a(62))}}function ge(e,t){if(-1===e.indexOf("-"))return"string"===typeof t.is;switch(e){case"annotation-xml":case"color-profile":case"font-face":case"font-face-src":case"font-face-uri":case"font-face-format":case"font-face-name":case"missing-glyph":return!1;default:return!0}}var _e=null;function we(e){return(e=e.target||e.srcElement||window).correspondingUseElement&&(e=e.correspondingUseElement),3===e.nodeType?e.parentNode:e}var Te=null,Se=null,Pe=null;function ke(e){if(e=_o(e)){if("function"!==typeof Te)throw Error(a(280));var t=e.stateNode;t&&(t=To(t),Te(e.stateNode,e.type,t))}}function xe(e){Se?Pe?Pe.push(e):Pe=[e]:Se=e}function Ce(){if(Se){var e=Se,t=Pe;if(Pe=Se=null,ke(e),t)for(e=0;e<t.length;e++)ke(t[e])}}function Ae(e,t){return e(t)}function Me(){}var Fe=!1;function Ee(e,t,n){if(Fe)return e(t,n);Fe=!0;try{return Ae(e,t,n)}finally{Fe=!1,(null!==Se||null!==Pe)&&(Me(),Ce())}}function Re(e,t){var n=e.stateNode;if(null===n)return null;var r=To(n);if(null===r)return null;n=r[t];e:switch(t){case"onClick":case"onClickCapture":case"onDoubleClick":case"onDoubleClickCapture":case"onMouseDown":case"onMouseDownCapture":case"onMouseMove":case"onMouseMoveCapture":case"onMouseUp":case"onMouseUpCapture":case"onMouseEnter":(r=!r.disabled)||(r=!("button"===(e=e.type)||"input"===e||"select"===e||"textarea"===e)),e=!r;break e;default:e=!1}if(e)return null;if(n&&"function"!==typeof n)throw Error(a(231,t,typeof n));return n}var Ne=!1;if(u)try{var Oe={};Object.defineProperty(Oe,"passive",{get:function(){Ne=!0}}),window.addEventListener("test",Oe,Oe),window.removeEventListener("test",Oe,Oe)}catch(ue){Ne=!1}function Ve(e,t,n,r,o,a,i,s,l){var c=Array.prototype.slice.call(arguments,3);try{t.apply(n,c)}catch(u){this.onError(u)}}var Le=!1,De=null,ze=!1,Ie=null,He={onError:function(e){Le=!0,De=e}};function je(e,t,n,r,o,a,i,s,l){Le=!1,De=null,Ve.apply(He,arguments)}function Ze(e){var t=e,n=e;if(e.alternate)for(;t.return;)t=t.return;else{e=t;do{0!==(4098&(t=e).flags)&&(n=t.return),e=t.return}while(e)}return 3===t.tag?n:null}function Be(e){if(13===e.tag){var t=e.memoizedState;if(null===t&&(null!==(e=e.alternate)&&(t=e.memoizedState)),null!==t)return t.dehydrated}return null}function Ge(e){if(Ze(e)!==e)throw Error(a(188))}function We(e){return null!==(e=function(e){var t=e.alternate;if(!t){if(null===(t=Ze(e)))throw Error(a(188));return t!==e?null:e}for(var n=e,r=t;;){var o=n.return;if(null===o)break;var i=o.alternate;if(null===i){if(null!==(r=o.return)){n=r;continue}break}if(o.child===i.child){for(i=o.child;i;){if(i===n)return Ge(o),e;if(i===r)return Ge(o),t;i=i.sibling}throw Error(a(188))}if(n.return!==r.return)n=o,r=i;else{for(var s=!1,l=o.child;l;){if(l===n){s=!0,n=o,r=i;break}if(l===r){s=!0,r=o,n=i;break}l=l.sibling}if(!s){for(l=i.child;l;){if(l===n){s=!0,n=i,r=o;break}if(l===r){s=!0,r=i,n=o;break}l=l.sibling}if(!s)throw Error(a(189))}}if(n.alternate!==r)throw Error(a(190))}if(3!==n.tag)throw Error(a(188));return n.stateNode.current===n?e:t}(e))?Ue(e):null}function Ue(e){if(5===e.tag||6===e.tag)return e;for(e=e.child;null!==e;){var t=Ue(e);if(null!==t)return t;e=e.sibling}return null}var qe=o.unstable_scheduleCallback,$e=o.unstable_cancelCallback,Je=o.unstable_shouldYield,Ke=o.unstable_requestPaint,Qe=o.unstable_now,Ye=o.unstable_getCurrentPriorityLevel,Xe=o.unstable_ImmediatePriority,et=o.unstable_UserBlockingPriority,tt=o.unstable_NormalPriority,nt=o.unstable_LowPriority,rt=o.unstable_IdlePriority,ot=null,at=null;var it=Math.clz32?Math.clz32:function(e){return 0===(e>>>=0)?32:31-(st(e)/lt|0)|0},st=Math.log,lt=Math.LN2;var ct=64,ut=4194304;function dt(e){switch(e&-e){case 1:return 1;case 2:return 2;case 4:return 4;case 8:return 8;case 16:return 16;case 32:return 32;case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:return 4194240&e;case 4194304:case 8388608:case 16777216:case 33554432:case 67108864:return 130023424&e;case 134217728:return 134217728;case 268435456:return 268435456;case 536870912:return 536870912;case 1073741824:return 1073741824;default:return e}}function ft(e,t){var n=e.pendingLanes;if(0===n)return 0;var r=0,o=e.suspendedLanes,a=e.pingedLanes,i=268435455&n;if(0!==i){var s=i&~o;0!==s?r=dt(s):0!==(a&=i)&&(r=dt(a))}else 0!==(i=n&~o)?r=dt(i):0!==a&&(r=dt(a));if(0===r)return 0;if(0!==t&&t!==r&&0===(t&o)&&((o=r&-r)>=(a=t&-t)||16===o&&0!==(4194240&a)))return t;if(0!==(4&r)&&(r|=16&n),0!==(t=e.entangledLanes))for(e=e.entanglements,t&=r;0<t;)o=1<<(n=31-it(t)),r|=e[n],t&=~o;return r}function pt(e,t){switch(e){case 1:case 2:case 4:return t+250;case 8:case 16:case 32:case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:return t+5e3;default:return-1}}function mt(e){return 0!==(e=-1073741825&e.pendingLanes)?e:1073741824&e?1073741824:0}function ht(){var e=ct;return 0===(4194240&(ct<<=1))&&(ct=64),e}function vt(e){for(var t=[],n=0;31>n;n++)t.push(e);return t}function bt(e,t,n){e.pendingLanes|=t,536870912!==t&&(e.suspendedLanes=0,e.pingedLanes=0),(e=e.eventTimes)[t=31-it(t)]=n}function yt(e,t){var n=e.entangledLanes|=t;for(e=e.entanglements;n;){var r=31-it(n),o=1<<r;o&t|e[r]&t&&(e[r]|=t),n&=~o}}var gt=0;function _t(e){return 1<(e&=-e)?4<e?0!==(268435455&e)?16:536870912:4:1}var wt,Tt,St,Pt,kt,xt=!1,Ct=[],At=null,Mt=null,Ft=null,Et=new Map,Rt=new Map,Nt=[],Ot="mousedown mouseup touchcancel touchend touchstart auxclick dblclick pointercancel pointerdown pointerup dragend dragstart drop compositionend compositionstart keydown keypress keyup input textInput copy cut paste click change contextmenu reset submit".split(" ");function Vt(e,t){switch(e){case"focusin":case"focusout":At=null;break;case"dragenter":case"dragleave":Mt=null;break;case"mouseover":case"mouseout":Ft=null;break;case"pointerover":case"pointerout":Et.delete(t.pointerId);break;case"gotpointercapture":case"lostpointercapture":Rt.delete(t.pointerId)}}function Lt(e,t,n,r,o,a){return null===e||e.nativeEvent!==a?(e={blockedOn:t,domEventName:n,eventSystemFlags:r,nativeEvent:a,targetContainers:[o]},null!==t&&(null!==(t=_o(t))&&Tt(t)),e):(e.eventSystemFlags|=r,t=e.targetContainers,null!==o&&-1===t.indexOf(o)&&t.push(o),e)}function Dt(e){var t=go(e.target);if(null!==t){var n=Ze(t);if(null!==n)if(13===(t=n.tag)){if(null!==(t=Be(n)))return e.blockedOn=t,void kt(e.priority,(function(){St(n)}))}else if(3===t&&n.stateNode.current.memoizedState.isDehydrated)return void(e.blockedOn=3===n.tag?n.stateNode.containerInfo:null)}e.blockedOn=null}function zt(e){if(null!==e.blockedOn)return!1;for(var t=e.targetContainers;0<t.length;){var n=Jt(e.domEventName,e.eventSystemFlags,t[0],e.nativeEvent);if(null!==n)return null!==(t=_o(n))&&Tt(t),e.blockedOn=n,!1;var r=new(n=e.nativeEvent).constructor(n.type,n);_e=r,n.target.dispatchEvent(r),_e=null,t.shift()}return!0}function It(e,t,n){zt(e)&&n.delete(t)}function Ht(){xt=!1,null!==At&&zt(At)&&(At=null),null!==Mt&&zt(Mt)&&(Mt=null),null!==Ft&&zt(Ft)&&(Ft=null),Et.forEach(It),Rt.forEach(It)}function jt(e,t){e.blockedOn===t&&(e.blockedOn=null,xt||(xt=!0,o.unstable_scheduleCallback(o.unstable_NormalPriority,Ht)))}function Zt(e){function t(t){return jt(t,e)}if(0<Ct.length){jt(Ct[0],e);for(var n=1;n<Ct.length;n++){var r=Ct[n];r.blockedOn===e&&(r.blockedOn=null)}}for(null!==At&&jt(At,e),null!==Mt&&jt(Mt,e),null!==Ft&&jt(Ft,e),Et.forEach(t),Rt.forEach(t),n=0;n<Nt.length;n++)(r=Nt[n]).blockedOn===e&&(r.blockedOn=null);for(;0<Nt.length&&null===(n=Nt[0]).blockedOn;)Dt(n),null===n.blockedOn&&Nt.shift()}var Bt=_.ReactCurrentBatchConfig,Gt=!0;function Wt(e,t,n,r){var o=gt,a=Bt.transition;Bt.transition=null;try{gt=1,qt(e,t,n,r)}finally{gt=o,Bt.transition=a}}function Ut(e,t,n,r){var o=gt,a=Bt.transition;Bt.transition=null;try{gt=4,qt(e,t,n,r)}finally{gt=o,Bt.transition=a}}function qt(e,t,n,r){if(Gt){var o=Jt(e,t,n,r);if(null===o)Gr(e,t,r,$t,n),Vt(e,r);else if(function(e,t,n,r,o){switch(t){case"focusin":return At=Lt(At,e,t,n,r,o),!0;case"dragenter":return Mt=Lt(Mt,e,t,n,r,o),!0;case"mouseover":return Ft=Lt(Ft,e,t,n,r,o),!0;case"pointerover":var a=o.pointerId;return Et.set(a,Lt(Et.get(a)||null,e,t,n,r,o)),!0;case"gotpointercapture":return a=o.pointerId,Rt.set(a,Lt(Rt.get(a)||null,e,t,n,r,o)),!0}return!1}(o,e,t,n,r))r.stopPropagation();else if(Vt(e,r),4&t&&-1<Ot.indexOf(e)){for(;null!==o;){var a=_o(o);if(null!==a&&wt(a),null===(a=Jt(e,t,n,r))&&Gr(e,t,r,$t,n),a===o)break;o=a}null!==o&&r.stopPropagation()}else Gr(e,t,r,null,n)}}var $t=null;function Jt(e,t,n,r){if($t=null,null!==(e=go(e=we(r))))if(null===(t=Ze(e)))e=null;else if(13===(n=t.tag)){if(null!==(e=Be(t)))return e;e=null}else if(3===n){if(t.stateNode.current.memoizedState.isDehydrated)return 3===t.tag?t.stateNode.containerInfo:null;e=null}else t!==e&&(e=null);return $t=e,null}function Kt(e){switch(e){case"cancel":case"click":case"close":case"contextmenu":case"copy":case"cut":case"auxclick":case"dblclick":case"dragend":case"dragstart":case"drop":case"focusin":case"focusout":case"input":case"invalid":case"keydown":case"keypress":case"keyup":case"mousedown":case"mouseup":case"paste":case"pause":case"play":case"pointercancel":case"pointerdown":case"pointerup":case"ratechange":case"reset":case"resize":case"seeked":case"submit":case"touchcancel":case"touchend":case"touchstart":case"volumechange":case"change":case"selectionchange":case"textInput":case"compositionstart":case"compositionend":case"compositionupdate":case"beforeblur":case"afterblur":case"beforeinput":case"blur":case"fullscreenchange":case"focus":case"hashchange":case"popstate":case"select":case"selectstart":return 1;case"drag":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"mousemove":case"mouseout":case"mouseover":case"pointermove":case"pointerout":case"pointerover":case"scroll":case"toggle":case"touchmove":case"wheel":case"mouseenter":case"mouseleave":case"pointerenter":case"pointerleave":return 4;case"message":switch(Ye()){case Xe:return 1;case et:return 4;case tt:case nt:return 16;case rt:return 536870912;default:return 16}default:return 16}}var Qt=null,Yt=null,Xt=null;function en(){if(Xt)return Xt;var e,t,n=Yt,r=n.length,o="value"in Qt?Qt.value:Qt.textContent,a=o.length;for(e=0;e<r&&n[e]===o[e];e++);var i=r-e;for(t=1;t<=i&&n[r-t]===o[a-t];t++);return Xt=o.slice(e,1<t?1-t:void 0)}function tn(e){var t=e.keyCode;return"charCode"in e?0===(e=e.charCode)&&13===t&&(e=13):e=t,10===e&&(e=13),32<=e||13===e?e:0}function nn(){return!0}function rn(){return!1}function on(e){function t(t,n,r,o,a){for(var i in this._reactName=t,this._targetInst=r,this.type=n,this.nativeEvent=o,this.target=a,this.currentTarget=null,e)e.hasOwnProperty(i)&&(t=e[i],this[i]=t?t(o):o[i]);return this.isDefaultPrevented=(null!=o.defaultPrevented?o.defaultPrevented:!1===o.returnValue)?nn:rn,this.isPropagationStopped=rn,this}return D(t.prototype,{preventDefault:function(){this.defaultPrevented=!0;var e=this.nativeEvent;e&&(e.preventDefault?e.preventDefault():"unknown"!==typeof e.returnValue&&(e.returnValue=!1),this.isDefaultPrevented=nn)},stopPropagation:function(){var e=this.nativeEvent;e&&(e.stopPropagation?e.stopPropagation():"unknown"!==typeof e.cancelBubble&&(e.cancelBubble=!0),this.isPropagationStopped=nn)},persist:function(){},isPersistent:nn}),t}var an,sn,ln,cn={eventPhase:0,bubbles:0,cancelable:0,timeStamp:function(e){return e.timeStamp||Date.now()},defaultPrevented:0,isTrusted:0},un=on(cn),dn=D({},cn,{view:0,detail:0}),fn=on(dn),pn=D({},dn,{screenX:0,screenY:0,clientX:0,clientY:0,pageX:0,pageY:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,getModifierState:kn,button:0,buttons:0,relatedTarget:function(e){return void 0===e.relatedTarget?e.fromElement===e.srcElement?e.toElement:e.fromElement:e.relatedTarget},movementX:function(e){return"movementX"in e?e.movementX:(e!==ln&&(ln&&"mousemove"===e.type?(an=e.screenX-ln.screenX,sn=e.screenY-ln.screenY):sn=an=0,ln=e),an)},movementY:function(e){return"movementY"in e?e.movementY:sn}}),mn=on(pn),hn=on(D({},pn,{dataTransfer:0})),vn=on(D({},dn,{relatedTarget:0})),bn=on(D({},cn,{animationName:0,elapsedTime:0,pseudoElement:0})),yn=D({},cn,{clipboardData:function(e){return"clipboardData"in e?e.clipboardData:window.clipboardData}}),gn=on(yn),_n=on(D({},cn,{data:0})),wn={Esc:"Escape",Spacebar:" ",Left:"ArrowLeft",Up:"ArrowUp",Right:"ArrowRight",Down:"ArrowDown",Del:"Delete",Win:"OS",Menu:"ContextMenu",Apps:"ContextMenu",Scroll:"ScrollLock",MozPrintableKey:"Unidentified"},Tn={8:"Backspace",9:"Tab",12:"Clear",13:"Enter",16:"Shift",17:"Control",18:"Alt",19:"Pause",20:"CapsLock",27:"Escape",32:" ",33:"PageUp",34:"PageDown",35:"End",36:"Home",37:"ArrowLeft",38:"ArrowUp",39:"ArrowRight",40:"ArrowDown",45:"Insert",46:"Delete",112:"F1",113:"F2",114:"F3",115:"F4",116:"F5",117:"F6",118:"F7",119:"F8",120:"F9",121:"F10",122:"F11",123:"F12",144:"NumLock",145:"ScrollLock",224:"Meta"},Sn={Alt:"altKey",Control:"ctrlKey",Meta:"metaKey",Shift:"shiftKey"};function Pn(e){var t=this.nativeEvent;return t.getModifierState?t.getModifierState(e):!!(e=Sn[e])&&!!t[e]}function kn(){return Pn}var xn=D({},dn,{key:function(e){if(e.key){var t=wn[e.key]||e.key;if("Unidentified"!==t)return t}return"keypress"===e.type?13===(e=tn(e))?"Enter":String.fromCharCode(e):"keydown"===e.type||"keyup"===e.type?Tn[e.keyCode]||"Unidentified":""},code:0,location:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,repeat:0,locale:0,getModifierState:kn,charCode:function(e){return"keypress"===e.type?tn(e):0},keyCode:function(e){return"keydown"===e.type||"keyup"===e.type?e.keyCode:0},which:function(e){return"keypress"===e.type?tn(e):"keydown"===e.type||"keyup"===e.type?e.keyCode:0}}),Cn=on(xn),An=on(D({},pn,{pointerId:0,width:0,height:0,pressure:0,tangentialPressure:0,tiltX:0,tiltY:0,twist:0,pointerType:0,isPrimary:0})),Mn=on(D({},dn,{touches:0,targetTouches:0,changedTouches:0,altKey:0,metaKey:0,ctrlKey:0,shiftKey:0,getModifierState:kn})),Fn=on(D({},cn,{propertyName:0,elapsedTime:0,pseudoElement:0})),En=D({},pn,{deltaX:function(e){return"deltaX"in e?e.deltaX:"wheelDeltaX"in e?-e.wheelDeltaX:0},deltaY:function(e){return"deltaY"in e?e.deltaY:"wheelDeltaY"in e?-e.wheelDeltaY:"wheelDelta"in e?-e.wheelDelta:0},deltaZ:0,deltaMode:0}),Rn=on(En),Nn=[9,13,27,32],On=u&&"CompositionEvent"in window,Vn=null;u&&"documentMode"in document&&(Vn=document.documentMode);var Ln=u&&"TextEvent"in window&&!Vn,Dn=u&&(!On||Vn&&8<Vn&&11>=Vn),zn=String.fromCharCode(32),In=!1;function Hn(e,t){switch(e){case"keyup":return-1!==Nn.indexOf(t.keyCode);case"keydown":return 229!==t.keyCode;case"keypress":case"mousedown":case"focusout":return!0;default:return!1}}function jn(e){return"object"===typeof(e=e.detail)&&"data"in e?e.data:null}var Zn=!1;var Bn={color:!0,date:!0,datetime:!0,"datetime-local":!0,email:!0,month:!0,number:!0,password:!0,range:!0,search:!0,tel:!0,text:!0,time:!0,url:!0,week:!0};function Gn(e){var t=e&&e.nodeName&&e.nodeName.toLowerCase();return"input"===t?!!Bn[e.type]:"textarea"===t}function Wn(e,t,n,r){xe(r),0<(t=Ur(t,"onChange")).length&&(n=new un("onChange","change",null,n,r),e.push({event:n,listeners:t}))}var Un=null,qn=null;function $n(e){zr(e,0)}function Jn(e){if(q(wo(e)))return e}function Kn(e,t){if("change"===e)return t}var Qn=!1;if(u){var Yn;if(u){var Xn="oninput"in document;if(!Xn){var er=document.createElement("div");er.setAttribute("oninput","return;"),Xn="function"===typeof er.oninput}Yn=Xn}else Yn=!1;Qn=Yn&&(!document.documentMode||9<document.documentMode)}function tr(){Un&&(Un.detachEvent("onpropertychange",nr),qn=Un=null)}function nr(e){if("value"===e.propertyName&&Jn(qn)){var t=[];Wn(t,qn,e,we(e)),Ee($n,t)}}function rr(e,t,n){"focusin"===e?(tr(),qn=n,(Un=t).attachEvent("onpropertychange",nr)):"focusout"===e&&tr()}function or(e){if("selectionchange"===e||"keyup"===e||"keydown"===e)return Jn(qn)}function ar(e,t){if("click"===e)return Jn(t)}function ir(e,t){if("input"===e||"change"===e)return Jn(t)}var sr="function"===typeof Object.is?Object.is:function(e,t){return e===t&&(0!==e||1/e===1/t)||e!==e&&t!==t};function lr(e,t){if(sr(e,t))return!0;if("object"!==typeof e||null===e||"object"!==typeof t||null===t)return!1;var n=Object.keys(e),r=Object.keys(t);if(n.length!==r.length)return!1;for(r=0;r<n.length;r++){var o=n[r];if(!d.call(t,o)||!sr(e[o],t[o]))return!1}return!0}function cr(e){for(;e&&e.firstChild;)e=e.firstChild;return e}function ur(e,t){var n,r=cr(e);for(e=0;r;){if(3===r.nodeType){if(n=e+r.textContent.length,e<=t&&n>=t)return{node:r,offset:t-e};e=n}e:{for(;r;){if(r.nextSibling){r=r.nextSibling;break e}r=r.parentNode}r=void 0}r=cr(r)}}function dr(e,t){return!(!e||!t)&&(e===t||(!e||3!==e.nodeType)&&(t&&3===t.nodeType?dr(e,t.parentNode):"contains"in e?e.contains(t):!!e.compareDocumentPosition&&!!(16&e.compareDocumentPosition(t))))}function fr(){for(var e=window,t=$();t instanceof e.HTMLIFrameElement;){try{var n="string"===typeof t.contentWindow.location.href}catch(r){n=!1}if(!n)break;t=$((e=t.contentWindow).document)}return t}function pr(e){var t=e&&e.nodeName&&e.nodeName.toLowerCase();return t&&("input"===t&&("text"===e.type||"search"===e.type||"tel"===e.type||"url"===e.type||"password"===e.type)||"textarea"===t||"true"===e.contentEditable)}function mr(e){var t=fr(),n=e.focusedElem,r=e.selectionRange;if(t!==n&&n&&n.ownerDocument&&dr(n.ownerDocument.documentElement,n)){if(null!==r&&pr(n))if(t=r.start,void 0===(e=r.end)&&(e=t),"selectionStart"in n)n.selectionStart=t,n.selectionEnd=Math.min(e,n.value.length);else if((e=(t=n.ownerDocument||document)&&t.defaultView||window).getSelection){e=e.getSelection();var o=n.textContent.length,a=Math.min(r.start,o);r=void 0===r.end?a:Math.min(r.end,o),!e.extend&&a>r&&(o=r,r=a,a=o),o=ur(n,a);var i=ur(n,r);o&&i&&(1!==e.rangeCount||e.anchorNode!==o.node||e.anchorOffset!==o.offset||e.focusNode!==i.node||e.focusOffset!==i.offset)&&((t=t.createRange()).setStart(o.node,o.offset),e.removeAllRanges(),a>r?(e.addRange(t),e.extend(i.node,i.offset)):(t.setEnd(i.node,i.offset),e.addRange(t)))}for(t=[],e=n;e=e.parentNode;)1===e.nodeType&&t.push({element:e,left:e.scrollLeft,top:e.scrollTop});for("function"===typeof n.focus&&n.focus(),n=0;n<t.length;n++)(e=t[n]).element.scrollLeft=e.left,e.element.scrollTop=e.top}}var hr=u&&"documentMode"in document&&11>=document.documentMode,vr=null,br=null,yr=null,gr=!1;function _r(e,t,n){var r=n.window===n?n.document:9===n.nodeType?n:n.ownerDocument;gr||null==vr||vr!==$(r)||("selectionStart"in(r=vr)&&pr(r)?r={start:r.selectionStart,end:r.selectionEnd}:r={anchorNode:(r=(r.ownerDocument&&r.ownerDocument.defaultView||window).getSelection()).anchorNode,anchorOffset:r.anchorOffset,focusNode:r.focusNode,focusOffset:r.focusOffset},yr&&lr(yr,r)||(yr=r,0<(r=Ur(br,"onSelect")).length&&(t=new un("onSelect","select",null,t,n),e.push({event:t,listeners:r}),t.target=vr)))}function wr(e,t){var n={};return n[e.toLowerCase()]=t.toLowerCase(),n["Webkit"+e]="webkit"+t,n["Moz"+e]="moz"+t,n}var Tr={animationend:wr("Animation","AnimationEnd"),animationiteration:wr("Animation","AnimationIteration"),animationstart:wr("Animation","AnimationStart"),transitionend:wr("Transition","TransitionEnd")},Sr={},Pr={};function kr(e){if(Sr[e])return Sr[e];if(!Tr[e])return e;var t,n=Tr[e];for(t in n)if(n.hasOwnProperty(t)&&t in Pr)return Sr[e]=n[t];return e}u&&(Pr=document.createElement("div").style,"AnimationEvent"in window||(delete Tr.animationend.animation,delete Tr.animationiteration.animation,delete Tr.animationstart.animation),"TransitionEvent"in window||delete Tr.transitionend.transition);var xr=kr("animationend"),Cr=kr("animationiteration"),Ar=kr("animationstart"),Mr=kr("transitionend"),Fr=new Map,Er="abort auxClick cancel canPlay canPlayThrough click close contextMenu copy cut drag dragEnd dragEnter dragExit dragLeave dragOver dragStart drop durationChange emptied encrypted ended error gotPointerCapture input invalid keyDown keyPress keyUp load loadedData loadedMetadata loadStart lostPointerCapture mouseDown mouseMove mouseOut mouseOver mouseUp paste pause play playing pointerCancel pointerDown pointerMove pointerOut pointerOver pointerUp progress rateChange reset resize seeked seeking stalled submit suspend timeUpdate touchCancel touchEnd touchStart volumeChange scroll toggle touchMove waiting wheel".split(" ");function Rr(e,t){Fr.set(e,t),l(t,[e])}for(var Nr=0;Nr<Er.length;Nr++){var Or=Er[Nr];Rr(Or.toLowerCase(),"on"+(Or[0].toUpperCase()+Or.slice(1)))}Rr(xr,"onAnimationEnd"),Rr(Cr,"onAnimationIteration"),Rr(Ar,"onAnimationStart"),Rr("dblclick","onDoubleClick"),Rr("focusin","onFocus"),Rr("focusout","onBlur"),Rr(Mr,"onTransitionEnd"),c("onMouseEnter",["mouseout","mouseover"]),c("onMouseLeave",["mouseout","mouseover"]),c("onPointerEnter",["pointerout","pointerover"]),c("onPointerLeave",["pointerout","pointerover"]),l("onChange","change click focusin focusout input keydown keyup selectionchange".split(" ")),l("onSelect","focusout contextmenu dragend focusin keydown keyup mousedown mouseup selectionchange".split(" ")),l("onBeforeInput",["compositionend","keypress","textInput","paste"]),l("onCompositionEnd","compositionend focusout keydown keypress keyup mousedown".split(" ")),l("onCompositionStart","compositionstart focusout keydown keypress keyup mousedown".split(" ")),l("onCompositionUpdate","compositionupdate focusout keydown keypress keyup mousedown".split(" "));var Vr="abort canplay canplaythrough durationchange emptied encrypted ended error loadeddata loadedmetadata loadstart pause play playing progress ratechange resize seeked seeking stalled suspend timeupdate volumechange waiting".split(" "),Lr=new Set("cancel close invalid load scroll toggle".split(" ").concat(Vr));function Dr(e,t,n){var r=e.type||"unknown-event";e.currentTarget=n,function(e,t,n,r,o,i,s,l,c){if(je.apply(this,arguments),Le){if(!Le)throw Error(a(198));var u=De;Le=!1,De=null,ze||(ze=!0,Ie=u)}}(r,t,void 0,e),e.currentTarget=null}function zr(e,t){t=0!==(4&t);for(var n=0;n<e.length;n++){var r=e[n],o=r.event;r=r.listeners;e:{var a=void 0;if(t)for(var i=r.length-1;0<=i;i--){var s=r[i],l=s.instance,c=s.currentTarget;if(s=s.listener,l!==a&&o.isPropagationStopped())break e;Dr(o,s,c),a=l}else for(i=0;i<r.length;i++){if(l=(s=r[i]).instance,c=s.currentTarget,s=s.listener,l!==a&&o.isPropagationStopped())break e;Dr(o,s,c),a=l}}}if(ze)throw e=Ie,ze=!1,Ie=null,e}function Ir(e,t){var n=t[vo];void 0===n&&(n=t[vo]=new Set);var r=e+"__bubble";n.has(r)||(Br(t,e,2,!1),n.add(r))}function Hr(e,t,n){var r=0;t&&(r|=4),Br(n,e,r,t)}var jr="_reactListening"+Math.random().toString(36).slice(2);function Zr(e){if(!e[jr]){e[jr]=!0,i.forEach((function(t){"selectionchange"!==t&&(Lr.has(t)||Hr(t,!1,e),Hr(t,!0,e))}));var t=9===e.nodeType?e:e.ownerDocument;null===t||t[jr]||(t[jr]=!0,Hr("selectionchange",!1,t))}}function Br(e,t,n,r){switch(Kt(t)){case 1:var o=Wt;break;case 4:o=Ut;break;default:o=qt}n=o.bind(null,t,n,e),o=void 0,!Ne||"touchstart"!==t&&"touchmove"!==t&&"wheel"!==t||(o=!0),r?void 0!==o?e.addEventListener(t,n,{capture:!0,passive:o}):e.addEventListener(t,n,!0):void 0!==o?e.addEventListener(t,n,{passive:o}):e.addEventListener(t,n,!1)}function Gr(e,t,n,r,o){var a=r;if(0===(1&t)&&0===(2&t)&&null!==r)e:for(;;){if(null===r)return;var i=r.tag;if(3===i||4===i){var s=r.stateNode.containerInfo;if(s===o||8===s.nodeType&&s.parentNode===o)break;if(4===i)for(i=r.return;null!==i;){var l=i.tag;if((3===l||4===l)&&((l=i.stateNode.containerInfo)===o||8===l.nodeType&&l.parentNode===o))return;i=i.return}for(;null!==s;){if(null===(i=go(s)))return;if(5===(l=i.tag)||6===l){r=a=i;continue e}s=s.parentNode}}r=r.return}Ee((function(){var r=a,o=we(n),i=[];e:{var s=Fr.get(e);if(void 0!==s){var l=un,c=e;switch(e){case"keypress":if(0===tn(n))break e;case"keydown":case"keyup":l=Cn;break;case"focusin":c="focus",l=vn;break;case"focusout":c="blur",l=vn;break;case"beforeblur":case"afterblur":l=vn;break;case"click":if(2===n.button)break e;case"auxclick":case"dblclick":case"mousedown":case"mousemove":case"mouseup":case"mouseout":case"mouseover":case"contextmenu":l=mn;break;case"drag":case"dragend":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"dragstart":case"drop":l=hn;break;case"touchcancel":case"touchend":case"touchmove":case"touchstart":l=Mn;break;case xr:case Cr:case Ar:l=bn;break;case Mr:l=Fn;break;case"scroll":l=fn;break;case"wheel":l=Rn;break;case"copy":case"cut":case"paste":l=gn;break;case"gotpointercapture":case"lostpointercapture":case"pointercancel":case"pointerdown":case"pointermove":case"pointerout":case"pointerover":case"pointerup":l=An}var u=0!==(4&t),d=!u&&"scroll"===e,f=u?null!==s?s+"Capture":null:s;u=[];for(var p,m=r;null!==m;){var h=(p=m).stateNode;if(5===p.tag&&null!==h&&(p=h,null!==f&&(null!=(h=Re(m,f))&&u.push(Wr(m,h,p)))),d)break;m=m.return}0<u.length&&(s=new l(s,c,null,n,o),i.push({event:s,listeners:u}))}}if(0===(7&t)){if(l="mouseout"===e||"pointerout"===e,(!(s="mouseover"===e||"pointerover"===e)||n===_e||!(c=n.relatedTarget||n.fromElement)||!go(c)&&!c[ho])&&(l||s)&&(s=o.window===o?o:(s=o.ownerDocument)?s.defaultView||s.parentWindow:window,l?(l=r,null!==(c=(c=n.relatedTarget||n.toElement)?go(c):null)&&(c!==(d=Ze(c))||5!==c.tag&&6!==c.tag)&&(c=null)):(l=null,c=r),l!==c)){if(u=mn,h="onMouseLeave",f="onMouseEnter",m="mouse","pointerout"!==e&&"pointerover"!==e||(u=An,h="onPointerLeave",f="onPointerEnter",m="pointer"),d=null==l?s:wo(l),p=null==c?s:wo(c),(s=new u(h,m+"leave",l,n,o)).target=d,s.relatedTarget=p,h=null,go(o)===r&&((u=new u(f,m+"enter",c,n,o)).target=p,u.relatedTarget=d,h=u),d=h,l&&c)e:{for(f=c,m=0,p=u=l;p;p=qr(p))m++;for(p=0,h=f;h;h=qr(h))p++;for(;0<m-p;)u=qr(u),m--;for(;0<p-m;)f=qr(f),p--;for(;m--;){if(u===f||null!==f&&u===f.alternate)break e;u=qr(u),f=qr(f)}u=null}else u=null;null!==l&&$r(i,s,l,u,!1),null!==c&&null!==d&&$r(i,d,c,u,!0)}if("select"===(l=(s=r?wo(r):window).nodeName&&s.nodeName.toLowerCase())||"input"===l&&"file"===s.type)var v=Kn;else if(Gn(s))if(Qn)v=ir;else{v=or;var b=rr}else(l=s.nodeName)&&"input"===l.toLowerCase()&&("checkbox"===s.type||"radio"===s.type)&&(v=ar);switch(v&&(v=v(e,r))?Wn(i,v,n,o):(b&&b(e,s,r),"focusout"===e&&(b=s._wrapperState)&&b.controlled&&"number"===s.type&&ee(s,"number",s.value)),b=r?wo(r):window,e){case"focusin":(Gn(b)||"true"===b.contentEditable)&&(vr=b,br=r,yr=null);break;case"focusout":yr=br=vr=null;break;case"mousedown":gr=!0;break;case"contextmenu":case"mouseup":case"dragend":gr=!1,_r(i,n,o);break;case"selectionchange":if(hr)break;case"keydown":case"keyup":_r(i,n,o)}var y;if(On)e:{switch(e){case"compositionstart":var g="onCompositionStart";break e;case"compositionend":g="onCompositionEnd";break e;case"compositionupdate":g="onCompositionUpdate";break e}g=void 0}else Zn?Hn(e,n)&&(g="onCompositionEnd"):"keydown"===e&&229===n.keyCode&&(g="onCompositionStart");g&&(Dn&&"ko"!==n.locale&&(Zn||"onCompositionStart"!==g?"onCompositionEnd"===g&&Zn&&(y=en()):(Yt="value"in(Qt=o)?Qt.value:Qt.textContent,Zn=!0)),0<(b=Ur(r,g)).length&&(g=new _n(g,e,null,n,o),i.push({event:g,listeners:b}),y?g.data=y:null!==(y=jn(n))&&(g.data=y))),(y=Ln?function(e,t){switch(e){case"compositionend":return jn(t);case"keypress":return 32!==t.which?null:(In=!0,zn);case"textInput":return(e=t.data)===zn&&In?null:e;default:return null}}(e,n):function(e,t){if(Zn)return"compositionend"===e||!On&&Hn(e,t)?(e=en(),Xt=Yt=Qt=null,Zn=!1,e):null;switch(e){case"paste":default:return null;case"keypress":if(!(t.ctrlKey||t.altKey||t.metaKey)||t.ctrlKey&&t.altKey){if(t.char&&1<t.char.length)return t.char;if(t.which)return String.fromCharCode(t.which)}return null;case"compositionend":return Dn&&"ko"!==t.locale?null:t.data}}(e,n))&&(0<(r=Ur(r,"onBeforeInput")).length&&(o=new _n("onBeforeInput","beforeinput",null,n,o),i.push({event:o,listeners:r}),o.data=y))}zr(i,t)}))}function Wr(e,t,n){return{instance:e,listener:t,currentTarget:n}}function Ur(e,t){for(var n=t+"Capture",r=[];null!==e;){var o=e,a=o.stateNode;5===o.tag&&null!==a&&(o=a,null!=(a=Re(e,n))&&r.unshift(Wr(e,a,o)),null!=(a=Re(e,t))&&r.push(Wr(e,a,o))),e=e.return}return r}function qr(e){if(null===e)return null;do{e=e.return}while(e&&5!==e.tag);return e||null}function $r(e,t,n,r,o){for(var a=t._reactName,i=[];null!==n&&n!==r;){var s=n,l=s.alternate,c=s.stateNode;if(null!==l&&l===r)break;5===s.tag&&null!==c&&(s=c,o?null!=(l=Re(n,a))&&i.unshift(Wr(n,l,s)):o||null!=(l=Re(n,a))&&i.push(Wr(n,l,s))),n=n.return}0!==i.length&&e.push({event:t,listeners:i})}var Jr=/\r\n?/g,Kr=/\u0000|\uFFFD/g;function Qr(e){return("string"===typeof e?e:""+e).replace(Jr,"\n").replace(Kr,"")}function Yr(e,t,n){if(t=Qr(t),Qr(e)!==t&&n)throw Error(a(425))}function Xr(){}var eo=null,to=null;function no(e,t){return"textarea"===e||"noscript"===e||"string"===typeof t.children||"number"===typeof t.children||"object"===typeof t.dangerouslySetInnerHTML&&null!==t.dangerouslySetInnerHTML&&null!=t.dangerouslySetInnerHTML.__html}var ro="function"===typeof setTimeout?setTimeout:void 0,oo="function"===typeof clearTimeout?clearTimeout:void 0,ao="function"===typeof Promise?Promise:void 0,io="function"===typeof queueMicrotask?queueMicrotask:"undefined"!==typeof ao?function(e){return ao.resolve(null).then(e).catch(so)}:ro;function so(e){setTimeout((function(){throw e}))}function lo(e,t){var n=t,r=0;do{var o=n.nextSibling;if(e.removeChild(n),o&&8===o.nodeType)if("/$"===(n=o.data)){if(0===r)return e.removeChild(o),void Zt(t);r--}else"$"!==n&&"$?"!==n&&"$!"!==n||r++;n=o}while(n);Zt(t)}function co(e){for(;null!=e;e=e.nextSibling){var t=e.nodeType;if(1===t||3===t)break;if(8===t){if("$"===(t=e.data)||"$!"===t||"$?"===t)break;if("/$"===t)return null}}return e}function uo(e){e=e.previousSibling;for(var t=0;e;){if(8===e.nodeType){var n=e.data;if("$"===n||"$!"===n||"$?"===n){if(0===t)return e;t--}else"/$"===n&&t++}e=e.previousSibling}return null}var fo=Math.random().toString(36).slice(2),po="__reactFiber$"+fo,mo="__reactProps$"+fo,ho="__reactContainer$"+fo,vo="__reactEvents$"+fo,bo="__reactListeners$"+fo,yo="__reactHandles$"+fo;function go(e){var t=e[po];if(t)return t;for(var n=e.parentNode;n;){if(t=n[ho]||n[po]){if(n=t.alternate,null!==t.child||null!==n&&null!==n.child)for(e=uo(e);null!==e;){if(n=e[po])return n;e=uo(e)}return t}n=(e=n).parentNode}return null}function _o(e){return!(e=e[po]||e[ho])||5!==e.tag&&6!==e.tag&&13!==e.tag&&3!==e.tag?null:e}function wo(e){if(5===e.tag||6===e.tag)return e.stateNode;throw Error(a(33))}function To(e){return e[mo]||null}var So=[],Po=-1;function ko(e){return{current:e}}function xo(e){0>Po||(e.current=So[Po],So[Po]=null,Po--)}function Co(e,t){Po++,So[Po]=e.current,e.current=t}var Ao={},Mo=ko(Ao),Fo=ko(!1),Eo=Ao;function Ro(e,t){var n=e.type.contextTypes;if(!n)return Ao;var r=e.stateNode;if(r&&r.__reactInternalMemoizedUnmaskedChildContext===t)return r.__reactInternalMemoizedMaskedChildContext;var o,a={};for(o in n)a[o]=t[o];return r&&((e=e.stateNode).__reactInternalMemoizedUnmaskedChildContext=t,e.__reactInternalMemoizedMaskedChildContext=a),a}function No(e){return null!==(e=e.childContextTypes)&&void 0!==e}function Oo(){xo(Fo),xo(Mo)}function Vo(e,t,n){if(Mo.current!==Ao)throw Error(a(168));Co(Mo,t),Co(Fo,n)}function Lo(e,t,n){var r=e.stateNode;if(t=t.childContextTypes,"function"!==typeof r.getChildContext)return n;for(var o in r=r.getChildContext())if(!(o in t))throw Error(a(108,B(e)||"Unknown",o));return D({},n,r)}function Do(e){return e=(e=e.stateNode)&&e.__reactInternalMemoizedMergedChildContext||Ao,Eo=Mo.current,Co(Mo,e),Co(Fo,Fo.current),!0}function zo(e,t,n){var r=e.stateNode;if(!r)throw Error(a(169));n?(e=Lo(e,t,Eo),r.__reactInternalMemoizedMergedChildContext=e,xo(Fo),xo(Mo),Co(Mo,e)):xo(Fo),Co(Fo,n)}var Io=null,Ho=!1,jo=!1;function Zo(e){null===Io?Io=[e]:Io.push(e)}function Bo(){if(!jo&&null!==Io){jo=!0;var e=0,t=gt;try{var n=Io;for(gt=1;e<n.length;e++){var r=n[e];do{r=r(!0)}while(null!==r)}Io=null,Ho=!1}catch(o){throw null!==Io&&(Io=Io.slice(e+1)),qe(Xe,Bo),o}finally{gt=t,jo=!1}}return null}var Go=[],Wo=0,Uo=null,qo=0,$o=[],Jo=0,Ko=null,Qo=1,Yo="";function Xo(e,t){Go[Wo++]=qo,Go[Wo++]=Uo,Uo=e,qo=t}function ea(e,t,n){$o[Jo++]=Qo,$o[Jo++]=Yo,$o[Jo++]=Ko,Ko=e;var r=Qo;e=Yo;var o=32-it(r)-1;r&=~(1<<o),n+=1;var a=32-it(t)+o;if(30<a){var i=o-o%5;a=(r&(1<<i)-1).toString(32),r>>=i,o-=i,Qo=1<<32-it(t)+o|n<<o|r,Yo=a+e}else Qo=1<<a|n<<o|r,Yo=e}function ta(e){null!==e.return&&(Xo(e,1),ea(e,1,0))}function na(e){for(;e===Uo;)Uo=Go[--Wo],Go[Wo]=null,qo=Go[--Wo],Go[Wo]=null;for(;e===Ko;)Ko=$o[--Jo],$o[Jo]=null,Yo=$o[--Jo],$o[Jo]=null,Qo=$o[--Jo],$o[Jo]=null}var ra=null,oa=null,aa=!1,ia=null;function sa(e,t){var n=Ec(5,null,null,0);n.elementType="DELETED",n.stateNode=t,n.return=e,null===(t=e.deletions)?(e.deletions=[n],e.flags|=16):t.push(n)}function la(e,t){switch(e.tag){case 5:var n=e.type;return null!==(t=1!==t.nodeType||n.toLowerCase()!==t.nodeName.toLowerCase()?null:t)&&(e.stateNode=t,ra=e,oa=co(t.firstChild),!0);case 6:return null!==(t=""===e.pendingProps||3!==t.nodeType?null:t)&&(e.stateNode=t,ra=e,oa=null,!0);case 13:return null!==(t=8!==t.nodeType?null:t)&&(n=null!==Ko?{id:Qo,overflow:Yo}:null,e.memoizedState={dehydrated:t,treeContext:n,retryLane:1073741824},(n=Ec(18,null,null,0)).stateNode=t,n.return=e,e.child=n,ra=e,oa=null,!0);default:return!1}}function ca(e){return 0!==(1&e.mode)&&0===(128&e.flags)}function ua(e){if(aa){var t=oa;if(t){var n=t;if(!la(e,t)){if(ca(e))throw Error(a(418));t=co(n.nextSibling);var r=ra;t&&la(e,t)?sa(r,n):(e.flags=-4097&e.flags|2,aa=!1,ra=e)}}else{if(ca(e))throw Error(a(418));e.flags=-4097&e.flags|2,aa=!1,ra=e}}}function da(e){for(e=e.return;null!==e&&5!==e.tag&&3!==e.tag&&13!==e.tag;)e=e.return;ra=e}function fa(e){if(e!==ra)return!1;if(!aa)return da(e),aa=!0,!1;var t;if((t=3!==e.tag)&&!(t=5!==e.tag)&&(t="head"!==(t=e.type)&&"body"!==t&&!no(e.type,e.memoizedProps)),t&&(t=oa)){if(ca(e))throw pa(),Error(a(418));for(;t;)sa(e,t),t=co(t.nextSibling)}if(da(e),13===e.tag){if(!(e=null!==(e=e.memoizedState)?e.dehydrated:null))throw Error(a(317));e:{for(e=e.nextSibling,t=0;e;){if(8===e.nodeType){var n=e.data;if("/$"===n){if(0===t){oa=co(e.nextSibling);break e}t--}else"$"!==n&&"$!"!==n&&"$?"!==n||t++}e=e.nextSibling}oa=null}}else oa=ra?co(e.stateNode.nextSibling):null;return!0}function pa(){for(var e=oa;e;)e=co(e.nextSibling)}function ma(){oa=ra=null,aa=!1}function ha(e){null===ia?ia=[e]:ia.push(e)}var va=_.ReactCurrentBatchConfig;function ba(e,t){if(e&&e.defaultProps){for(var n in t=D({},t),e=e.defaultProps)void 0===t[n]&&(t[n]=e[n]);return t}return t}var ya=ko(null),ga=null,_a=null,wa=null;function Ta(){wa=_a=ga=null}function Sa(e){var t=ya.current;xo(ya),e._currentValue=t}function Pa(e,t,n){for(;null!==e;){var r=e.alternate;if((e.childLanes&t)!==t?(e.childLanes|=t,null!==r&&(r.childLanes|=t)):null!==r&&(r.childLanes&t)!==t&&(r.childLanes|=t),e===n)break;e=e.return}}function ka(e,t){ga=e,wa=_a=null,null!==(e=e.dependencies)&&null!==e.firstContext&&(0!==(e.lanes&t)&&(_s=!0),e.firstContext=null)}function xa(e){var t=e._currentValue;if(wa!==e)if(e={context:e,memoizedValue:t,next:null},null===_a){if(null===ga)throw Error(a(308));_a=e,ga.dependencies={lanes:0,firstContext:e}}else _a=_a.next=e;return t}var Ca=null;function Aa(e){null===Ca?Ca=[e]:Ca.push(e)}function Ma(e,t,n,r){var o=t.interleaved;return null===o?(n.next=n,Aa(t)):(n.next=o.next,o.next=n),t.interleaved=n,Fa(e,r)}function Fa(e,t){e.lanes|=t;var n=e.alternate;for(null!==n&&(n.lanes|=t),n=e,e=e.return;null!==e;)e.childLanes|=t,null!==(n=e.alternate)&&(n.childLanes|=t),n=e,e=e.return;return 3===n.tag?n.stateNode:null}var Ea=!1;function Ra(e){e.updateQueue={baseState:e.memoizedState,firstBaseUpdate:null,lastBaseUpdate:null,shared:{pending:null,interleaved:null,lanes:0},effects:null}}function Na(e,t){e=e.updateQueue,t.updateQueue===e&&(t.updateQueue={baseState:e.baseState,firstBaseUpdate:e.firstBaseUpdate,lastBaseUpdate:e.lastBaseUpdate,shared:e.shared,effects:e.effects})}function Oa(e,t){return{eventTime:e,lane:t,tag:0,payload:null,callback:null,next:null}}function Va(e,t,n){var r=e.updateQueue;if(null===r)return null;if(r=r.shared,0!==(2&Al)){var o=r.pending;return null===o?t.next=t:(t.next=o.next,o.next=t),r.pending=t,Fa(e,n)}return null===(o=r.interleaved)?(t.next=t,Aa(r)):(t.next=o.next,o.next=t),r.interleaved=t,Fa(e,n)}function La(e,t,n){if(null!==(t=t.updateQueue)&&(t=t.shared,0!==(4194240&n))){var r=t.lanes;n|=r&=e.pendingLanes,t.lanes=n,yt(e,n)}}function Da(e,t){var n=e.updateQueue,r=e.alternate;if(null!==r&&n===(r=r.updateQueue)){var o=null,a=null;if(null!==(n=n.firstBaseUpdate)){do{var i={eventTime:n.eventTime,lane:n.lane,tag:n.tag,payload:n.payload,callback:n.callback,next:null};null===a?o=a=i:a=a.next=i,n=n.next}while(null!==n);null===a?o=a=t:a=a.next=t}else o=a=t;return n={baseState:r.baseState,firstBaseUpdate:o,lastBaseUpdate:a,shared:r.shared,effects:r.effects},void(e.updateQueue=n)}null===(e=n.lastBaseUpdate)?n.firstBaseUpdate=t:e.next=t,n.lastBaseUpdate=t}function za(e,t,n,r){var o=e.updateQueue;Ea=!1;var a=o.firstBaseUpdate,i=o.lastBaseUpdate,s=o.shared.pending;if(null!==s){o.shared.pending=null;var l=s,c=l.next;l.next=null,null===i?a=c:i.next=c,i=l;var u=e.alternate;null!==u&&((s=(u=u.updateQueue).lastBaseUpdate)!==i&&(null===s?u.firstBaseUpdate=c:s.next=c,u.lastBaseUpdate=l))}if(null!==a){var d=o.baseState;for(i=0,u=c=l=null,s=a;;){var f=s.lane,p=s.eventTime;if((r&f)===f){null!==u&&(u=u.next={eventTime:p,lane:0,tag:s.tag,payload:s.payload,callback:s.callback,next:null});e:{var m=e,h=s;switch(f=t,p=n,h.tag){case 1:if("function"===typeof(m=h.payload)){d=m.call(p,d,f);break e}d=m;break e;case 3:m.flags=-65537&m.flags|128;case 0:if(null===(f="function"===typeof(m=h.payload)?m.call(p,d,f):m)||void 0===f)break e;d=D({},d,f);break e;case 2:Ea=!0}}null!==s.callback&&0!==s.lane&&(e.flags|=64,null===(f=o.effects)?o.effects=[s]:f.push(s))}else p={eventTime:p,lane:f,tag:s.tag,payload:s.payload,callback:s.callback,next:null},null===u?(c=u=p,l=d):u=u.next=p,i|=f;if(null===(s=s.next)){if(null===(s=o.shared.pending))break;s=(f=s).next,f.next=null,o.lastBaseUpdate=f,o.shared.pending=null}}if(null===u&&(l=d),o.baseState=l,o.firstBaseUpdate=c,o.lastBaseUpdate=u,null!==(t=o.shared.interleaved)){o=t;do{i|=o.lane,o=o.next}while(o!==t)}else null===a&&(o.shared.lanes=0);Ll|=i,e.lanes=i,e.memoizedState=d}}function Ia(e,t,n){if(e=t.effects,t.effects=null,null!==e)for(t=0;t<e.length;t++){var r=e[t],o=r.callback;if(null!==o){if(r.callback=null,r=n,"function"!==typeof o)throw Error(a(191,o));o.call(r)}}}var Ha=(new r.Component).refs;function ja(e,t,n,r){n=null===(n=n(r,t=e.memoizedState))||void 0===n?t:D({},t,n),e.memoizedState=n,0===e.lanes&&(e.updateQueue.baseState=n)}var Za={isMounted:function(e){return!!(e=e._reactInternals)&&Ze(e)===e},enqueueSetState:function(e,t,n){e=e._reactInternals;var r=ec(),o=tc(e),a=Oa(r,o);a.payload=t,void 0!==n&&null!==n&&(a.callback=n),null!==(t=Va(e,a,o))&&(nc(t,e,o,r),La(t,e,o))},enqueueReplaceState:function(e,t,n){e=e._reactInternals;var r=ec(),o=tc(e),a=Oa(r,o);a.tag=1,a.payload=t,void 0!==n&&null!==n&&(a.callback=n),null!==(t=Va(e,a,o))&&(nc(t,e,o,r),La(t,e,o))},enqueueForceUpdate:function(e,t){e=e._reactInternals;var n=ec(),r=tc(e),o=Oa(n,r);o.tag=2,void 0!==t&&null!==t&&(o.callback=t),null!==(t=Va(e,o,r))&&(nc(t,e,r,n),La(t,e,r))}};function Ba(e,t,n,r,o,a,i){return"function"===typeof(e=e.stateNode).shouldComponentUpdate?e.shouldComponentUpdate(r,a,i):!t.prototype||!t.prototype.isPureReactComponent||(!lr(n,r)||!lr(o,a))}function Ga(e,t,n){var r=!1,o=Ao,a=t.contextType;return"object"===typeof a&&null!==a?a=xa(a):(o=No(t)?Eo:Mo.current,a=(r=null!==(r=t.contextTypes)&&void 0!==r)?Ro(e,o):Ao),t=new t(n,a),e.memoizedState=null!==t.state&&void 0!==t.state?t.state:null,t.updater=Za,e.stateNode=t,t._reactInternals=e,r&&((e=e.stateNode).__reactInternalMemoizedUnmaskedChildContext=o,e.__reactInternalMemoizedMaskedChildContext=a),t}function Wa(e,t,n,r){e=t.state,"function"===typeof t.componentWillReceiveProps&&t.componentWillReceiveProps(n,r),"function"===typeof t.UNSAFE_componentWillReceiveProps&&t.UNSAFE_componentWillReceiveProps(n,r),t.state!==e&&Za.enqueueReplaceState(t,t.state,null)}function Ua(e,t,n,r){var o=e.stateNode;o.props=n,o.state=e.memoizedState,o.refs=Ha,Ra(e);var a=t.contextType;"object"===typeof a&&null!==a?o.context=xa(a):(a=No(t)?Eo:Mo.current,o.context=Ro(e,a)),o.state=e.memoizedState,"function"===typeof(a=t.getDerivedStateFromProps)&&(ja(e,t,a,n),o.state=e.memoizedState),"function"===typeof t.getDerivedStateFromProps||"function"===typeof o.getSnapshotBeforeUpdate||"function"!==typeof o.UNSAFE_componentWillMount&&"function"!==typeof o.componentWillMount||(t=o.state,"function"===typeof o.componentWillMount&&o.componentWillMount(),"function"===typeof o.UNSAFE_componentWillMount&&o.UNSAFE_componentWillMount(),t!==o.state&&Za.enqueueReplaceState(o,o.state,null),za(e,n,o,r),o.state=e.memoizedState),"function"===typeof o.componentDidMount&&(e.flags|=4194308)}function qa(e,t,n){if(null!==(e=n.ref)&&"function"!==typeof e&&"object"!==typeof e){if(n._owner){if(n=n._owner){if(1!==n.tag)throw Error(a(309));var r=n.stateNode}if(!r)throw Error(a(147,e));var o=r,i=""+e;return null!==t&&null!==t.ref&&"function"===typeof t.ref&&t.ref._stringRef===i?t.ref:(t=function(e){var t=o.refs;t===Ha&&(t=o.refs={}),null===e?delete t[i]:t[i]=e},t._stringRef=i,t)}if("string"!==typeof e)throw Error(a(284));if(!n._owner)throw Error(a(290,e))}return e}function $a(e,t){throw e=Object.prototype.toString.call(t),Error(a(31,"[object Object]"===e?"object with keys {"+Object.keys(t).join(", ")+"}":e))}function Ja(e){return(0,e._init)(e._payload)}function Ka(e){function t(t,n){if(e){var r=t.deletions;null===r?(t.deletions=[n],t.flags|=16):r.push(n)}}function n(n,r){if(!e)return null;for(;null!==r;)t(n,r),r=r.sibling;return null}function r(e,t){for(e=new Map;null!==t;)null!==t.key?e.set(t.key,t):e.set(t.index,t),t=t.sibling;return e}function o(e,t){return(e=Nc(e,t)).index=0,e.sibling=null,e}function i(t,n,r){return t.index=r,e?null!==(r=t.alternate)?(r=r.index)<n?(t.flags|=2,n):r:(t.flags|=2,n):(t.flags|=1048576,n)}function s(t){return e&&null===t.alternate&&(t.flags|=2),t}function l(e,t,n,r){return null===t||6!==t.tag?((t=Dc(n,e.mode,r)).return=e,t):((t=o(t,n)).return=e,t)}function c(e,t,n,r){var a=n.type;return a===S?d(e,t,n.props.children,r,n.key):null!==t&&(t.elementType===a||"object"===typeof a&&null!==a&&a.$$typeof===R&&Ja(a)===t.type)?((r=o(t,n.props)).ref=qa(e,t,n),r.return=e,r):((r=Oc(n.type,n.key,n.props,null,e.mode,r)).ref=qa(e,t,n),r.return=e,r)}function u(e,t,n,r){return null===t||4!==t.tag||t.stateNode.containerInfo!==n.containerInfo||t.stateNode.implementation!==n.implementation?((t=zc(n,e.mode,r)).return=e,t):((t=o(t,n.children||[])).return=e,t)}function d(e,t,n,r,a){return null===t||7!==t.tag?((t=Vc(n,e.mode,r,a)).return=e,t):((t=o(t,n)).return=e,t)}function f(e,t,n){if("string"===typeof t&&""!==t||"number"===typeof t)return(t=Dc(""+t,e.mode,n)).return=e,t;if("object"===typeof t&&null!==t){switch(t.$$typeof){case w:return(n=Oc(t.type,t.key,t.props,null,e.mode,n)).ref=qa(e,null,t),n.return=e,n;case T:return(t=zc(t,e.mode,n)).return=e,t;case R:return f(e,(0,t._init)(t._payload),n)}if(te(t)||V(t))return(t=Vc(t,e.mode,n,null)).return=e,t;$a(e,t)}return null}function p(e,t,n,r){var o=null!==t?t.key:null;if("string"===typeof n&&""!==n||"number"===typeof n)return null!==o?null:l(e,t,""+n,r);if("object"===typeof n&&null!==n){switch(n.$$typeof){case w:return n.key===o?c(e,t,n,r):null;case T:return n.key===o?u(e,t,n,r):null;case R:return p(e,t,(o=n._init)(n._payload),r)}if(te(n)||V(n))return null!==o?null:d(e,t,n,r,null);$a(e,n)}return null}function m(e,t,n,r,o){if("string"===typeof r&&""!==r||"number"===typeof r)return l(t,e=e.get(n)||null,""+r,o);if("object"===typeof r&&null!==r){switch(r.$$typeof){case w:return c(t,e=e.get(null===r.key?n:r.key)||null,r,o);case T:return u(t,e=e.get(null===r.key?n:r.key)||null,r,o);case R:return m(e,t,n,(0,r._init)(r._payload),o)}if(te(r)||V(r))return d(t,e=e.get(n)||null,r,o,null);$a(t,r)}return null}function h(o,a,s,l){for(var c=null,u=null,d=a,h=a=0,v=null;null!==d&&h<s.length;h++){d.index>h?(v=d,d=null):v=d.sibling;var b=p(o,d,s[h],l);if(null===b){null===d&&(d=v);break}e&&d&&null===b.alternate&&t(o,d),a=i(b,a,h),null===u?c=b:u.sibling=b,u=b,d=v}if(h===s.length)return n(o,d),aa&&Xo(o,h),c;if(null===d){for(;h<s.length;h++)null!==(d=f(o,s[h],l))&&(a=i(d,a,h),null===u?c=d:u.sibling=d,u=d);return aa&&Xo(o,h),c}for(d=r(o,d);h<s.length;h++)null!==(v=m(d,o,h,s[h],l))&&(e&&null!==v.alternate&&d.delete(null===v.key?h:v.key),a=i(v,a,h),null===u?c=v:u.sibling=v,u=v);return e&&d.forEach((function(e){return t(o,e)})),aa&&Xo(o,h),c}function v(o,s,l,c){var u=V(l);if("function"!==typeof u)throw Error(a(150));if(null==(l=u.call(l)))throw Error(a(151));for(var d=u=null,h=s,v=s=0,b=null,y=l.next();null!==h&&!y.done;v++,y=l.next()){h.index>v?(b=h,h=null):b=h.sibling;var g=p(o,h,y.value,c);if(null===g){null===h&&(h=b);break}e&&h&&null===g.alternate&&t(o,h),s=i(g,s,v),null===d?u=g:d.sibling=g,d=g,h=b}if(y.done)return n(o,h),aa&&Xo(o,v),u;if(null===h){for(;!y.done;v++,y=l.next())null!==(y=f(o,y.value,c))&&(s=i(y,s,v),null===d?u=y:d.sibling=y,d=y);return aa&&Xo(o,v),u}for(h=r(o,h);!y.done;v++,y=l.next())null!==(y=m(h,o,v,y.value,c))&&(e&&null!==y.alternate&&h.delete(null===y.key?v:y.key),s=i(y,s,v),null===d?u=y:d.sibling=y,d=y);return e&&h.forEach((function(e){return t(o,e)})),aa&&Xo(o,v),u}return function e(r,a,i,l){if("object"===typeof i&&null!==i&&i.type===S&&null===i.key&&(i=i.props.children),"object"===typeof i&&null!==i){switch(i.$$typeof){case w:e:{for(var c=i.key,u=a;null!==u;){if(u.key===c){if((c=i.type)===S){if(7===u.tag){n(r,u.sibling),(a=o(u,i.props.children)).return=r,r=a;break e}}else if(u.elementType===c||"object"===typeof c&&null!==c&&c.$$typeof===R&&Ja(c)===u.type){n(r,u.sibling),(a=o(u,i.props)).ref=qa(r,u,i),a.return=r,r=a;break e}n(r,u);break}t(r,u),u=u.sibling}i.type===S?((a=Vc(i.props.children,r.mode,l,i.key)).return=r,r=a):((l=Oc(i.type,i.key,i.props,null,r.mode,l)).ref=qa(r,a,i),l.return=r,r=l)}return s(r);case T:e:{for(u=i.key;null!==a;){if(a.key===u){if(4===a.tag&&a.stateNode.containerInfo===i.containerInfo&&a.stateNode.implementation===i.implementation){n(r,a.sibling),(a=o(a,i.children||[])).return=r,r=a;break e}n(r,a);break}t(r,a),a=a.sibling}(a=zc(i,r.mode,l)).return=r,r=a}return s(r);case R:return e(r,a,(u=i._init)(i._payload),l)}if(te(i))return h(r,a,i,l);if(V(i))return v(r,a,i,l);$a(r,i)}return"string"===typeof i&&""!==i||"number"===typeof i?(i=""+i,null!==a&&6===a.tag?(n(r,a.sibling),(a=o(a,i)).return=r,r=a):(n(r,a),(a=Dc(i,r.mode,l)).return=r,r=a),s(r)):n(r,a)}}var Qa=Ka(!0),Ya=Ka(!1),Xa={},ei=ko(Xa),ti=ko(Xa),ni=ko(Xa);function ri(e){if(e===Xa)throw Error(a(174));return e}function oi(e,t){switch(Co(ni,t),Co(ti,e),Co(ei,Xa),e=t.nodeType){case 9:case 11:t=(t=t.documentElement)?t.namespaceURI:le(null,"");break;default:t=le(t=(e=8===e?t.parentNode:t).namespaceURI||null,e=e.tagName)}xo(ei),Co(ei,t)}function ai(){xo(ei),xo(ti),xo(ni)}function ii(e){ri(ni.current);var t=ri(ei.current),n=le(t,e.type);t!==n&&(Co(ti,e),Co(ei,n))}function si(e){ti.current===e&&(xo(ei),xo(ti))}var li=ko(0);function ci(e){for(var t=e;null!==t;){if(13===t.tag){var n=t.memoizedState;if(null!==n&&(null===(n=n.dehydrated)||"$?"===n.data||"$!"===n.data))return t}else if(19===t.tag&&void 0!==t.memoizedProps.revealOrder){if(0!==(128&t.flags))return t}else if(null!==t.child){t.child.return=t,t=t.child;continue}if(t===e)break;for(;null===t.sibling;){if(null===t.return||t.return===e)return null;t=t.return}t.sibling.return=t.return,t=t.sibling}return null}var ui=[];function di(){for(var e=0;e<ui.length;e++)ui[e]._workInProgressVersionPrimary=null;ui.length=0}var fi=_.ReactCurrentDispatcher,pi=_.ReactCurrentBatchConfig,mi=0,hi=null,vi=null,bi=null,yi=!1,gi=!1,_i=0,wi=0;function Ti(){throw Error(a(321))}function Si(e,t){if(null===t)return!1;for(var n=0;n<t.length&&n<e.length;n++)if(!sr(e[n],t[n]))return!1;return!0}function Pi(e,t,n,r,o,i){if(mi=i,hi=t,t.memoizedState=null,t.updateQueue=null,t.lanes=0,fi.current=null===e||null===e.memoizedState?ss:ls,e=n(r,o),gi){i=0;do{if(gi=!1,_i=0,25<=i)throw Error(a(301));i+=1,bi=vi=null,t.updateQueue=null,fi.current=cs,e=n(r,o)}while(gi)}if(fi.current=is,t=null!==vi&&null!==vi.next,mi=0,bi=vi=hi=null,yi=!1,t)throw Error(a(300));return e}function ki(){var e=0!==_i;return _i=0,e}function xi(){var e={memoizedState:null,baseState:null,baseQueue:null,queue:null,next:null};return null===bi?hi.memoizedState=bi=e:bi=bi.next=e,bi}function Ci(){if(null===vi){var e=hi.alternate;e=null!==e?e.memoizedState:null}else e=vi.next;var t=null===bi?hi.memoizedState:bi.next;if(null!==t)bi=t,vi=e;else{if(null===e)throw Error(a(310));e={memoizedState:(vi=e).memoizedState,baseState:vi.baseState,baseQueue:vi.baseQueue,queue:vi.queue,next:null},null===bi?hi.memoizedState=bi=e:bi=bi.next=e}return bi}function Ai(e,t){return"function"===typeof t?t(e):t}function Mi(e){var t=Ci(),n=t.queue;if(null===n)throw Error(a(311));n.lastRenderedReducer=e;var r=vi,o=r.baseQueue,i=n.pending;if(null!==i){if(null!==o){var s=o.next;o.next=i.next,i.next=s}r.baseQueue=o=i,n.pending=null}if(null!==o){i=o.next,r=r.baseState;var l=s=null,c=null,u=i;do{var d=u.lane;if((mi&d)===d)null!==c&&(c=c.next={lane:0,action:u.action,hasEagerState:u.hasEagerState,eagerState:u.eagerState,next:null}),r=u.hasEagerState?u.eagerState:e(r,u.action);else{var f={lane:d,action:u.action,hasEagerState:u.hasEagerState,eagerState:u.eagerState,next:null};null===c?(l=c=f,s=r):c=c.next=f,hi.lanes|=d,Ll|=d}u=u.next}while(null!==u&&u!==i);null===c?s=r:c.next=l,sr(r,t.memoizedState)||(_s=!0),t.memoizedState=r,t.baseState=s,t.baseQueue=c,n.lastRenderedState=r}if(null!==(e=n.interleaved)){o=e;do{i=o.lane,hi.lanes|=i,Ll|=i,o=o.next}while(o!==e)}else null===o&&(n.lanes=0);return[t.memoizedState,n.dispatch]}function Fi(e){var t=Ci(),n=t.queue;if(null===n)throw Error(a(311));n.lastRenderedReducer=e;var r=n.dispatch,o=n.pending,i=t.memoizedState;if(null!==o){n.pending=null;var s=o=o.next;do{i=e(i,s.action),s=s.next}while(s!==o);sr(i,t.memoizedState)||(_s=!0),t.memoizedState=i,null===t.baseQueue&&(t.baseState=i),n.lastRenderedState=i}return[i,r]}function Ei(){}function Ri(e,t){var n=hi,r=Ci(),o=t(),i=!sr(r.memoizedState,o);if(i&&(r.memoizedState=o,_s=!0),r=r.queue,Gi(Vi.bind(null,n,r,e),[e]),r.getSnapshot!==t||i||null!==bi&&1&bi.memoizedState.tag){if(n.flags|=2048,Ii(9,Oi.bind(null,n,r,o,t),void 0,null),null===Ml)throw Error(a(349));0!==(30&mi)||Ni(n,t,o)}return o}function Ni(e,t,n){e.flags|=16384,e={getSnapshot:t,value:n},null===(t=hi.updateQueue)?(t={lastEffect:null,stores:null},hi.updateQueue=t,t.stores=[e]):null===(n=t.stores)?t.stores=[e]:n.push(e)}function Oi(e,t,n,r){t.value=n,t.getSnapshot=r,Li(t)&&Di(e)}function Vi(e,t,n){return n((function(){Li(t)&&Di(e)}))}function Li(e){var t=e.getSnapshot;e=e.value;try{var n=t();return!sr(e,n)}catch(r){return!0}}function Di(e){var t=Fa(e,1);null!==t&&nc(t,e,1,-1)}function zi(e){var t=xi();return"function"===typeof e&&(e=e()),t.memoizedState=t.baseState=e,e={pending:null,interleaved:null,lanes:0,dispatch:null,lastRenderedReducer:Ai,lastRenderedState:e},t.queue=e,e=e.dispatch=ns.bind(null,hi,e),[t.memoizedState,e]}function Ii(e,t,n,r){return e={tag:e,create:t,destroy:n,deps:r,next:null},null===(t=hi.updateQueue)?(t={lastEffect:null,stores:null},hi.updateQueue=t,t.lastEffect=e.next=e):null===(n=t.lastEffect)?t.lastEffect=e.next=e:(r=n.next,n.next=e,e.next=r,t.lastEffect=e),e}function Hi(){return Ci().memoizedState}function ji(e,t,n,r){var o=xi();hi.flags|=e,o.memoizedState=Ii(1|t,n,void 0,void 0===r?null:r)}function Zi(e,t,n,r){var o=Ci();r=void 0===r?null:r;var a=void 0;if(null!==vi){var i=vi.memoizedState;if(a=i.destroy,null!==r&&Si(r,i.deps))return void(o.memoizedState=Ii(t,n,a,r))}hi.flags|=e,o.memoizedState=Ii(1|t,n,a,r)}function Bi(e,t){return ji(8390656,8,e,t)}function Gi(e,t){return Zi(2048,8,e,t)}function Wi(e,t){return Zi(4,2,e,t)}function Ui(e,t){return Zi(4,4,e,t)}function qi(e,t){return"function"===typeof t?(e=e(),t(e),function(){t(null)}):null!==t&&void 0!==t?(e=e(),t.current=e,function(){t.current=null}):void 0}function $i(e,t,n){return n=null!==n&&void 0!==n?n.concat([e]):null,Zi(4,4,qi.bind(null,t,e),n)}function Ji(){}function Ki(e,t){var n=Ci();t=void 0===t?null:t;var r=n.memoizedState;return null!==r&&null!==t&&Si(t,r[1])?r[0]:(n.memoizedState=[e,t],e)}function Qi(e,t){var n=Ci();t=void 0===t?null:t;var r=n.memoizedState;return null!==r&&null!==t&&Si(t,r[1])?r[0]:(e=e(),n.memoizedState=[e,t],e)}function Yi(e,t,n){return 0===(21&mi)?(e.baseState&&(e.baseState=!1,_s=!0),e.memoizedState=n):(sr(n,t)||(n=ht(),hi.lanes|=n,Ll|=n,e.baseState=!0),t)}function Xi(e,t){var n=gt;gt=0!==n&&4>n?n:4,e(!0);var r=pi.transition;pi.transition={};try{e(!1),t()}finally{gt=n,pi.transition=r}}function es(){return Ci().memoizedState}function ts(e,t,n){var r=tc(e);if(n={lane:r,action:n,hasEagerState:!1,eagerState:null,next:null},rs(e))os(t,n);else if(null!==(n=Ma(e,t,n,r))){nc(n,e,r,ec()),as(n,t,r)}}function ns(e,t,n){var r=tc(e),o={lane:r,action:n,hasEagerState:!1,eagerState:null,next:null};if(rs(e))os(t,o);else{var a=e.alternate;if(0===e.lanes&&(null===a||0===a.lanes)&&null!==(a=t.lastRenderedReducer))try{var i=t.lastRenderedState,s=a(i,n);if(o.hasEagerState=!0,o.eagerState=s,sr(s,i)){var l=t.interleaved;return null===l?(o.next=o,Aa(t)):(o.next=l.next,l.next=o),void(t.interleaved=o)}}catch(c){}null!==(n=Ma(e,t,o,r))&&(nc(n,e,r,o=ec()),as(n,t,r))}}function rs(e){var t=e.alternate;return e===hi||null!==t&&t===hi}function os(e,t){gi=yi=!0;var n=e.pending;null===n?t.next=t:(t.next=n.next,n.next=t),e.pending=t}function as(e,t,n){if(0!==(4194240&n)){var r=t.lanes;n|=r&=e.pendingLanes,t.lanes=n,yt(e,n)}}var is={readContext:xa,useCallback:Ti,useContext:Ti,useEffect:Ti,useImperativeHandle:Ti,useInsertionEffect:Ti,useLayoutEffect:Ti,useMemo:Ti,useReducer:Ti,useRef:Ti,useState:Ti,useDebugValue:Ti,useDeferredValue:Ti,useTransition:Ti,useMutableSource:Ti,useSyncExternalStore:Ti,useId:Ti,unstable_isNewReconciler:!1},ss={readContext:xa,useCallback:function(e,t){return xi().memoizedState=[e,void 0===t?null:t],e},useContext:xa,useEffect:Bi,useImperativeHandle:function(e,t,n){return n=null!==n&&void 0!==n?n.concat([e]):null,ji(4194308,4,qi.bind(null,t,e),n)},useLayoutEffect:function(e,t){return ji(4194308,4,e,t)},useInsertionEffect:function(e,t){return ji(4,2,e,t)},useMemo:function(e,t){var n=xi();return t=void 0===t?null:t,e=e(),n.memoizedState=[e,t],e},useReducer:function(e,t,n){var r=xi();return t=void 0!==n?n(t):t,r.memoizedState=r.baseState=t,e={pending:null,interleaved:null,lanes:0,dispatch:null,lastRenderedReducer:e,lastRenderedState:t},r.queue=e,e=e.dispatch=ts.bind(null,hi,e),[r.memoizedState,e]},useRef:function(e){return e={current:e},xi().memoizedState=e},useState:zi,useDebugValue:Ji,useDeferredValue:function(e){return xi().memoizedState=e},useTransition:function(){var e=zi(!1),t=e[0];return e=Xi.bind(null,e[1]),xi().memoizedState=e,[t,e]},useMutableSource:function(){},useSyncExternalStore:function(e,t,n){var r=hi,o=xi();if(aa){if(void 0===n)throw Error(a(407));n=n()}else{if(n=t(),null===Ml)throw Error(a(349));0!==(30&mi)||Ni(r,t,n)}o.memoizedState=n;var i={value:n,getSnapshot:t};return o.queue=i,Bi(Vi.bind(null,r,i,e),[e]),r.flags|=2048,Ii(9,Oi.bind(null,r,i,n,t),void 0,null),n},useId:function(){var e=xi(),t=Ml.identifierPrefix;if(aa){var n=Yo;t=":"+t+"R"+(n=(Qo&~(1<<32-it(Qo)-1)).toString(32)+n),0<(n=_i++)&&(t+="H"+n.toString(32)),t+=":"}else t=":"+t+"r"+(n=wi++).toString(32)+":";return e.memoizedState=t},unstable_isNewReconciler:!1},ls={readContext:xa,useCallback:Ki,useContext:xa,useEffect:Gi,useImperativeHandle:$i,useInsertionEffect:Wi,useLayoutEffect:Ui,useMemo:Qi,useReducer:Mi,useRef:Hi,useState:function(){return Mi(Ai)},useDebugValue:Ji,useDeferredValue:function(e){return Yi(Ci(),vi.memoizedState,e)},useTransition:function(){return[Mi(Ai)[0],Ci().memoizedState]},useMutableSource:Ei,useSyncExternalStore:Ri,useId:es,unstable_isNewReconciler:!1},cs={readContext:xa,useCallback:Ki,useContext:xa,useEffect:Gi,useImperativeHandle:$i,useInsertionEffect:Wi,useLayoutEffect:Ui,useMemo:Qi,useReducer:Fi,useRef:Hi,useState:function(){return Fi(Ai)},useDebugValue:Ji,useDeferredValue:function(e){var t=Ci();return null===vi?t.memoizedState=e:Yi(t,vi.memoizedState,e)},useTransition:function(){return[Fi(Ai)[0],Ci().memoizedState]},useMutableSource:Ei,useSyncExternalStore:Ri,useId:es,unstable_isNewReconciler:!1};function us(e,t){try{var n="",r=t;do{n+=j(r),r=r.return}while(r);var o=n}catch(a){o="\nError generating stack: "+a.message+"\n"+a.stack}return{value:e,source:t,stack:o,digest:null}}function ds(e,t,n){return{value:e,source:null,stack:null!=n?n:null,digest:null!=t?t:null}}function fs(e,t){try{console.error(t.value)}catch(n){setTimeout((function(){throw n}))}}var ps="function"===typeof WeakMap?WeakMap:Map;function ms(e,t,n){(n=Oa(-1,n)).tag=3,n.payload={element:null};var r=t.value;return n.callback=function(){Gl||(Gl=!0,Wl=r),fs(0,t)},n}function hs(e,t,n){(n=Oa(-1,n)).tag=3;var r=e.type.getDerivedStateFromError;if("function"===typeof r){var o=t.value;n.payload=function(){return r(o)},n.callback=function(){fs(0,t)}}var a=e.stateNode;return null!==a&&"function"===typeof a.componentDidCatch&&(n.callback=function(){fs(0,t),"function"!==typeof r&&(null===Ul?Ul=new Set([this]):Ul.add(this));var e=t.stack;this.componentDidCatch(t.value,{componentStack:null!==e?e:""})}),n}function vs(e,t,n){var r=e.pingCache;if(null===r){r=e.pingCache=new ps;var o=new Set;r.set(t,o)}else void 0===(o=r.get(t))&&(o=new Set,r.set(t,o));o.has(n)||(o.add(n),e=kc.bind(null,e,t,n),t.then(e,e))}function bs(e){do{var t;if((t=13===e.tag)&&(t=null===(t=e.memoizedState)||null!==t.dehydrated),t)return e;e=e.return}while(null!==e);return null}function ys(e,t,n,r,o){return 0===(1&e.mode)?(e===t?e.flags|=65536:(e.flags|=128,n.flags|=131072,n.flags&=-52805,1===n.tag&&(null===n.alternate?n.tag=17:((t=Oa(-1,1)).tag=2,Va(n,t,1))),n.lanes|=1),e):(e.flags|=65536,e.lanes=o,e)}var gs=_.ReactCurrentOwner,_s=!1;function ws(e,t,n,r){t.child=null===e?Ya(t,null,n,r):Qa(t,e.child,n,r)}function Ts(e,t,n,r,o){n=n.render;var a=t.ref;return ka(t,o),r=Pi(e,t,n,r,a,o),n=ki(),null===e||_s?(aa&&n&&ta(t),t.flags|=1,ws(e,t,r,o),t.child):(t.updateQueue=e.updateQueue,t.flags&=-2053,e.lanes&=~o,Gs(e,t,o))}function Ss(e,t,n,r,o){if(null===e){var a=n.type;return"function"!==typeof a||Rc(a)||void 0!==a.defaultProps||null!==n.compare||void 0!==n.defaultProps?((e=Oc(n.type,null,r,t,t.mode,o)).ref=t.ref,e.return=t,t.child=e):(t.tag=15,t.type=a,Ps(e,t,a,r,o))}if(a=e.child,0===(e.lanes&o)){var i=a.memoizedProps;if((n=null!==(n=n.compare)?n:lr)(i,r)&&e.ref===t.ref)return Gs(e,t,o)}return t.flags|=1,(e=Nc(a,r)).ref=t.ref,e.return=t,t.child=e}function Ps(e,t,n,r,o){if(null!==e){var a=e.memoizedProps;if(lr(a,r)&&e.ref===t.ref){if(_s=!1,t.pendingProps=r=a,0===(e.lanes&o))return t.lanes=e.lanes,Gs(e,t,o);0!==(131072&e.flags)&&(_s=!0)}}return Cs(e,t,n,r,o)}function ks(e,t,n){var r=t.pendingProps,o=r.children,a=null!==e?e.memoizedState:null;if("hidden"===r.mode)if(0===(1&t.mode))t.memoizedState={baseLanes:0,cachePool:null,transitions:null},Co(Nl,Rl),Rl|=n;else{if(0===(1073741824&n))return e=null!==a?a.baseLanes|n:n,t.lanes=t.childLanes=1073741824,t.memoizedState={baseLanes:e,cachePool:null,transitions:null},t.updateQueue=null,Co(Nl,Rl),Rl|=e,null;t.memoizedState={baseLanes:0,cachePool:null,transitions:null},r=null!==a?a.baseLanes:n,Co(Nl,Rl),Rl|=r}else null!==a?(r=a.baseLanes|n,t.memoizedState=null):r=n,Co(Nl,Rl),Rl|=r;return ws(e,t,o,n),t.child}function xs(e,t){var n=t.ref;(null===e&&null!==n||null!==e&&e.ref!==n)&&(t.flags|=512,t.flags|=2097152)}function Cs(e,t,n,r,o){var a=No(n)?Eo:Mo.current;return a=Ro(t,a),ka(t,o),n=Pi(e,t,n,r,a,o),r=ki(),null===e||_s?(aa&&r&&ta(t),t.flags|=1,ws(e,t,n,o),t.child):(t.updateQueue=e.updateQueue,t.flags&=-2053,e.lanes&=~o,Gs(e,t,o))}function As(e,t,n,r,o){if(No(n)){var a=!0;Do(t)}else a=!1;if(ka(t,o),null===t.stateNode)Bs(e,t),Ga(t,n,r),Ua(t,n,r,o),r=!0;else if(null===e){var i=t.stateNode,s=t.memoizedProps;i.props=s;var l=i.context,c=n.contextType;"object"===typeof c&&null!==c?c=xa(c):c=Ro(t,c=No(n)?Eo:Mo.current);var u=n.getDerivedStateFromProps,d="function"===typeof u||"function"===typeof i.getSnapshotBeforeUpdate;d||"function"!==typeof i.UNSAFE_componentWillReceiveProps&&"function"!==typeof i.componentWillReceiveProps||(s!==r||l!==c)&&Wa(t,i,r,c),Ea=!1;var f=t.memoizedState;i.state=f,za(t,r,i,o),l=t.memoizedState,s!==r||f!==l||Fo.current||Ea?("function"===typeof u&&(ja(t,n,u,r),l=t.memoizedState),(s=Ea||Ba(t,n,s,r,f,l,c))?(d||"function"!==typeof i.UNSAFE_componentWillMount&&"function"!==typeof i.componentWillMount||("function"===typeof i.componentWillMount&&i.componentWillMount(),"function"===typeof i.UNSAFE_componentWillMount&&i.UNSAFE_componentWillMount()),"function"===typeof i.componentDidMount&&(t.flags|=4194308)):("function"===typeof i.componentDidMount&&(t.flags|=4194308),t.memoizedProps=r,t.memoizedState=l),i.props=r,i.state=l,i.context=c,r=s):("function"===typeof i.componentDidMount&&(t.flags|=4194308),r=!1)}else{i=t.stateNode,Na(e,t),s=t.memoizedProps,c=t.type===t.elementType?s:ba(t.type,s),i.props=c,d=t.pendingProps,f=i.context,"object"===typeof(l=n.contextType)&&null!==l?l=xa(l):l=Ro(t,l=No(n)?Eo:Mo.current);var p=n.getDerivedStateFromProps;(u="function"===typeof p||"function"===typeof i.getSnapshotBeforeUpdate)||"function"!==typeof i.UNSAFE_componentWillReceiveProps&&"function"!==typeof i.componentWillReceiveProps||(s!==d||f!==l)&&Wa(t,i,r,l),Ea=!1,f=t.memoizedState,i.state=f,za(t,r,i,o);var m=t.memoizedState;s!==d||f!==m||Fo.current||Ea?("function"===typeof p&&(ja(t,n,p,r),m=t.memoizedState),(c=Ea||Ba(t,n,c,r,f,m,l)||!1)?(u||"function"!==typeof i.UNSAFE_componentWillUpdate&&"function"!==typeof i.componentWillUpdate||("function"===typeof i.componentWillUpdate&&i.componentWillUpdate(r,m,l),"function"===typeof i.UNSAFE_componentWillUpdate&&i.UNSAFE_componentWillUpdate(r,m,l)),"function"===typeof i.componentDidUpdate&&(t.flags|=4),"function"===typeof i.getSnapshotBeforeUpdate&&(t.flags|=1024)):("function"!==typeof i.componentDidUpdate||s===e.memoizedProps&&f===e.memoizedState||(t.flags|=4),"function"!==typeof i.getSnapshotBeforeUpdate||s===e.memoizedProps&&f===e.memoizedState||(t.flags|=1024),t.memoizedProps=r,t.memoizedState=m),i.props=r,i.state=m,i.context=l,r=c):("function"!==typeof i.componentDidUpdate||s===e.memoizedProps&&f===e.memoizedState||(t.flags|=4),"function"!==typeof i.getSnapshotBeforeUpdate||s===e.memoizedProps&&f===e.memoizedState||(t.flags|=1024),r=!1)}return Ms(e,t,n,r,a,o)}function Ms(e,t,n,r,o,a){xs(e,t);var i=0!==(128&t.flags);if(!r&&!i)return o&&zo(t,n,!1),Gs(e,t,a);r=t.stateNode,gs.current=t;var s=i&&"function"!==typeof n.getDerivedStateFromError?null:r.render();return t.flags|=1,null!==e&&i?(t.child=Qa(t,e.child,null,a),t.child=Qa(t,null,s,a)):ws(e,t,s,a),t.memoizedState=r.state,o&&zo(t,n,!0),t.child}function Fs(e){var t=e.stateNode;t.pendingContext?Vo(0,t.pendingContext,t.pendingContext!==t.context):t.context&&Vo(0,t.context,!1),oi(e,t.containerInfo)}function Es(e,t,n,r,o){return ma(),ha(o),t.flags|=256,ws(e,t,n,r),t.child}var Rs,Ns,Os,Vs={dehydrated:null,treeContext:null,retryLane:0};function Ls(e){return{baseLanes:e,cachePool:null,transitions:null}}function Ds(e,t,n){var r,o=t.pendingProps,i=li.current,s=!1,l=0!==(128&t.flags);if((r=l)||(r=(null===e||null!==e.memoizedState)&&0!==(2&i)),r?(s=!0,t.flags&=-129):null!==e&&null===e.memoizedState||(i|=1),Co(li,1&i),null===e)return ua(t),null!==(e=t.memoizedState)&&null!==(e=e.dehydrated)?(0===(1&t.mode)?t.lanes=1:"$!"===e.data?t.lanes=8:t.lanes=1073741824,null):(l=o.children,e=o.fallback,s?(o=t.mode,s=t.child,l={mode:"hidden",children:l},0===(1&o)&&null!==s?(s.childLanes=0,s.pendingProps=l):s=Lc(l,o,0,null),e=Vc(e,o,n,null),s.return=t,e.return=t,s.sibling=e,t.child=s,t.child.memoizedState=Ls(n),t.memoizedState=Vs,e):zs(t,l));if(null!==(i=e.memoizedState)&&null!==(r=i.dehydrated))return function(e,t,n,r,o,i,s){if(n)return 256&t.flags?(t.flags&=-257,Is(e,t,s,r=ds(Error(a(422))))):null!==t.memoizedState?(t.child=e.child,t.flags|=128,null):(i=r.fallback,o=t.mode,r=Lc({mode:"visible",children:r.children},o,0,null),(i=Vc(i,o,s,null)).flags|=2,r.return=t,i.return=t,r.sibling=i,t.child=r,0!==(1&t.mode)&&Qa(t,e.child,null,s),t.child.memoizedState=Ls(s),t.memoizedState=Vs,i);if(0===(1&t.mode))return Is(e,t,s,null);if("$!"===o.data){if(r=o.nextSibling&&o.nextSibling.dataset)var l=r.dgst;return r=l,Is(e,t,s,r=ds(i=Error(a(419)),r,void 0))}if(l=0!==(s&e.childLanes),_s||l){if(null!==(r=Ml)){switch(s&-s){case 4:o=2;break;case 16:o=8;break;case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:case 4194304:case 8388608:case 16777216:case 33554432:case 67108864:o=32;break;case 536870912:o=268435456;break;default:o=0}0!==(o=0!==(o&(r.suspendedLanes|s))?0:o)&&o!==i.retryLane&&(i.retryLane=o,Fa(e,o),nc(r,e,o,-1))}return hc(),Is(e,t,s,r=ds(Error(a(421))))}return"$?"===o.data?(t.flags|=128,t.child=e.child,t=Cc.bind(null,e),o._reactRetry=t,null):(e=i.treeContext,oa=co(o.nextSibling),ra=t,aa=!0,ia=null,null!==e&&($o[Jo++]=Qo,$o[Jo++]=Yo,$o[Jo++]=Ko,Qo=e.id,Yo=e.overflow,Ko=t),(t=zs(t,r.children)).flags|=4096,t)}(e,t,l,o,r,i,n);if(s){s=o.fallback,l=t.mode,r=(i=e.child).sibling;var c={mode:"hidden",children:o.children};return 0===(1&l)&&t.child!==i?((o=t.child).childLanes=0,o.pendingProps=c,t.deletions=null):(o=Nc(i,c)).subtreeFlags=14680064&i.subtreeFlags,null!==r?s=Nc(r,s):(s=Vc(s,l,n,null)).flags|=2,s.return=t,o.return=t,o.sibling=s,t.child=o,o=s,s=t.child,l=null===(l=e.child.memoizedState)?Ls(n):{baseLanes:l.baseLanes|n,cachePool:null,transitions:l.transitions},s.memoizedState=l,s.childLanes=e.childLanes&~n,t.memoizedState=Vs,o}return e=(s=e.child).sibling,o=Nc(s,{mode:"visible",children:o.children}),0===(1&t.mode)&&(o.lanes=n),o.return=t,o.sibling=null,null!==e&&(null===(n=t.deletions)?(t.deletions=[e],t.flags|=16):n.push(e)),t.child=o,t.memoizedState=null,o}function zs(e,t){return(t=Lc({mode:"visible",children:t},e.mode,0,null)).return=e,e.child=t}function Is(e,t,n,r){return null!==r&&ha(r),Qa(t,e.child,null,n),(e=zs(t,t.pendingProps.children)).flags|=2,t.memoizedState=null,e}function Hs(e,t,n){e.lanes|=t;var r=e.alternate;null!==r&&(r.lanes|=t),Pa(e.return,t,n)}function js(e,t,n,r,o){var a=e.memoizedState;null===a?e.memoizedState={isBackwards:t,rendering:null,renderingStartTime:0,last:r,tail:n,tailMode:o}:(a.isBackwards=t,a.rendering=null,a.renderingStartTime=0,a.last=r,a.tail=n,a.tailMode=o)}function Zs(e,t,n){var r=t.pendingProps,o=r.revealOrder,a=r.tail;if(ws(e,t,r.children,n),0!==(2&(r=li.current)))r=1&r|2,t.flags|=128;else{if(null!==e&&0!==(128&e.flags))e:for(e=t.child;null!==e;){if(13===e.tag)null!==e.memoizedState&&Hs(e,n,t);else if(19===e.tag)Hs(e,n,t);else if(null!==e.child){e.child.return=e,e=e.child;continue}if(e===t)break e;for(;null===e.sibling;){if(null===e.return||e.return===t)break e;e=e.return}e.sibling.return=e.return,e=e.sibling}r&=1}if(Co(li,r),0===(1&t.mode))t.memoizedState=null;else switch(o){case"forwards":for(n=t.child,o=null;null!==n;)null!==(e=n.alternate)&&null===ci(e)&&(o=n),n=n.sibling;null===(n=o)?(o=t.child,t.child=null):(o=n.sibling,n.sibling=null),js(t,!1,o,n,a);break;case"backwards":for(n=null,o=t.child,t.child=null;null!==o;){if(null!==(e=o.alternate)&&null===ci(e)){t.child=o;break}e=o.sibling,o.sibling=n,n=o,o=e}js(t,!0,n,null,a);break;case"together":js(t,!1,null,null,void 0);break;default:t.memoizedState=null}return t.child}function Bs(e,t){0===(1&t.mode)&&null!==e&&(e.alternate=null,t.alternate=null,t.flags|=2)}function Gs(e,t,n){if(null!==e&&(t.dependencies=e.dependencies),Ll|=t.lanes,0===(n&t.childLanes))return null;if(null!==e&&t.child!==e.child)throw Error(a(153));if(null!==t.child){for(n=Nc(e=t.child,e.pendingProps),t.child=n,n.return=t;null!==e.sibling;)e=e.sibling,(n=n.sibling=Nc(e,e.pendingProps)).return=t;n.sibling=null}return t.child}function Ws(e,t){if(!aa)switch(e.tailMode){case"hidden":t=e.tail;for(var n=null;null!==t;)null!==t.alternate&&(n=t),t=t.sibling;null===n?e.tail=null:n.sibling=null;break;case"collapsed":n=e.tail;for(var r=null;null!==n;)null!==n.alternate&&(r=n),n=n.sibling;null===r?t||null===e.tail?e.tail=null:e.tail.sibling=null:r.sibling=null}}function Us(e){var t=null!==e.alternate&&e.alternate.child===e.child,n=0,r=0;if(t)for(var o=e.child;null!==o;)n|=o.lanes|o.childLanes,r|=14680064&o.subtreeFlags,r|=14680064&o.flags,o.return=e,o=o.sibling;else for(o=e.child;null!==o;)n|=o.lanes|o.childLanes,r|=o.subtreeFlags,r|=o.flags,o.return=e,o=o.sibling;return e.subtreeFlags|=r,e.childLanes=n,t}function qs(e,t,n){var r=t.pendingProps;switch(na(t),t.tag){case 2:case 16:case 15:case 0:case 11:case 7:case 8:case 12:case 9:case 14:return Us(t),null;case 1:case 17:return No(t.type)&&Oo(),Us(t),null;case 3:return r=t.stateNode,ai(),xo(Fo),xo(Mo),di(),r.pendingContext&&(r.context=r.pendingContext,r.pendingContext=null),null!==e&&null!==e.child||(fa(t)?t.flags|=4:null===e||e.memoizedState.isDehydrated&&0===(256&t.flags)||(t.flags|=1024,null!==ia&&(ic(ia),ia=null))),Us(t),null;case 5:si(t);var o=ri(ni.current);if(n=t.type,null!==e&&null!=t.stateNode)Ns(e,t,n,r),e.ref!==t.ref&&(t.flags|=512,t.flags|=2097152);else{if(!r){if(null===t.stateNode)throw Error(a(166));return Us(t),null}if(e=ri(ei.current),fa(t)){r=t.stateNode,n=t.type;var i=t.memoizedProps;switch(r[po]=t,r[mo]=i,e=0!==(1&t.mode),n){case"dialog":Ir("cancel",r),Ir("close",r);break;case"iframe":case"object":case"embed":Ir("load",r);break;case"video":case"audio":for(o=0;o<Vr.length;o++)Ir(Vr[o],r);break;case"source":Ir("error",r);break;case"img":case"image":case"link":Ir("error",r),Ir("load",r);break;case"details":Ir("toggle",r);break;case"input":K(r,i),Ir("invalid",r);break;case"select":r._wrapperState={wasMultiple:!!i.multiple},Ir("invalid",r);break;case"textarea":oe(r,i),Ir("invalid",r)}for(var l in ye(n,i),o=null,i)if(i.hasOwnProperty(l)){var c=i[l];"children"===l?"string"===typeof c?r.textContent!==c&&(!0!==i.suppressHydrationWarning&&Yr(r.textContent,c,e),o=["children",c]):"number"===typeof c&&r.textContent!==""+c&&(!0!==i.suppressHydrationWarning&&Yr(r.textContent,c,e),o=["children",""+c]):s.hasOwnProperty(l)&&null!=c&&"onScroll"===l&&Ir("scroll",r)}switch(n){case"input":U(r),X(r,i,!0);break;case"textarea":U(r),ie(r);break;case"select":case"option":break;default:"function"===typeof i.onClick&&(r.onclick=Xr)}r=o,t.updateQueue=r,null!==r&&(t.flags|=4)}else{l=9===o.nodeType?o:o.ownerDocument,"http://www.w3.org/1999/xhtml"===e&&(e=se(n)),"http://www.w3.org/1999/xhtml"===e?"script"===n?((e=l.createElement("div")).innerHTML="<script><\/script>",e=e.removeChild(e.firstChild)):"string"===typeof r.is?e=l.createElement(n,{is:r.is}):(e=l.createElement(n),"select"===n&&(l=e,r.multiple?l.multiple=!0:r.size&&(l.size=r.size))):e=l.createElementNS(e,n),e[po]=t,e[mo]=r,Rs(e,t),t.stateNode=e;e:{switch(l=ge(n,r),n){case"dialog":Ir("cancel",e),Ir("close",e),o=r;break;case"iframe":case"object":case"embed":Ir("load",e),o=r;break;case"video":case"audio":for(o=0;o<Vr.length;o++)Ir(Vr[o],e);o=r;break;case"source":Ir("error",e),o=r;break;case"img":case"image":case"link":Ir("error",e),Ir("load",e),o=r;break;case"details":Ir("toggle",e),o=r;break;case"input":K(e,r),o=J(e,r),Ir("invalid",e);break;case"option":default:o=r;break;case"select":e._wrapperState={wasMultiple:!!r.multiple},o=D({},r,{value:void 0}),Ir("invalid",e);break;case"textarea":oe(e,r),o=re(e,r),Ir("invalid",e)}for(i in ye(n,o),c=o)if(c.hasOwnProperty(i)){var u=c[i];"style"===i?ve(e,u):"dangerouslySetInnerHTML"===i?null!=(u=u?u.__html:void 0)&&de(e,u):"children"===i?"string"===typeof u?("textarea"!==n||""!==u)&&fe(e,u):"number"===typeof u&&fe(e,""+u):"suppressContentEditableWarning"!==i&&"suppressHydrationWarning"!==i&&"autoFocus"!==i&&(s.hasOwnProperty(i)?null!=u&&"onScroll"===i&&Ir("scroll",e):null!=u&&g(e,i,u,l))}switch(n){case"input":U(e),X(e,r,!1);break;case"textarea":U(e),ie(e);break;case"option":null!=r.value&&e.setAttribute("value",""+G(r.value));break;case"select":e.multiple=!!r.multiple,null!=(i=r.value)?ne(e,!!r.multiple,i,!1):null!=r.defaultValue&&ne(e,!!r.multiple,r.defaultValue,!0);break;default:"function"===typeof o.onClick&&(e.onclick=Xr)}switch(n){case"button":case"input":case"select":case"textarea":r=!!r.autoFocus;break e;case"img":r=!0;break e;default:r=!1}}r&&(t.flags|=4)}null!==t.ref&&(t.flags|=512,t.flags|=2097152)}return Us(t),null;case 6:if(e&&null!=t.stateNode)Os(0,t,e.memoizedProps,r);else{if("string"!==typeof r&&null===t.stateNode)throw Error(a(166));if(n=ri(ni.current),ri(ei.current),fa(t)){if(r=t.stateNode,n=t.memoizedProps,r[po]=t,(i=r.nodeValue!==n)&&null!==(e=ra))switch(e.tag){case 3:Yr(r.nodeValue,n,0!==(1&e.mode));break;case 5:!0!==e.memoizedProps.suppressHydrationWarning&&Yr(r.nodeValue,n,0!==(1&e.mode))}i&&(t.flags|=4)}else(r=(9===n.nodeType?n:n.ownerDocument).createTextNode(r))[po]=t,t.stateNode=r}return Us(t),null;case 13:if(xo(li),r=t.memoizedState,null===e||null!==e.memoizedState&&null!==e.memoizedState.dehydrated){if(aa&&null!==oa&&0!==(1&t.mode)&&0===(128&t.flags))pa(),ma(),t.flags|=98560,i=!1;else if(i=fa(t),null!==r&&null!==r.dehydrated){if(null===e){if(!i)throw Error(a(318));if(!(i=null!==(i=t.memoizedState)?i.dehydrated:null))throw Error(a(317));i[po]=t}else ma(),0===(128&t.flags)&&(t.memoizedState=null),t.flags|=4;Us(t),i=!1}else null!==ia&&(ic(ia),ia=null),i=!0;if(!i)return 65536&t.flags?t:null}return 0!==(128&t.flags)?(t.lanes=n,t):((r=null!==r)!==(null!==e&&null!==e.memoizedState)&&r&&(t.child.flags|=8192,0!==(1&t.mode)&&(null===e||0!==(1&li.current)?0===Ol&&(Ol=3):hc())),null!==t.updateQueue&&(t.flags|=4),Us(t),null);case 4:return ai(),null===e&&Zr(t.stateNode.containerInfo),Us(t),null;case 10:return Sa(t.type._context),Us(t),null;case 19:if(xo(li),null===(i=t.memoizedState))return Us(t),null;if(r=0!==(128&t.flags),null===(l=i.rendering))if(r)Ws(i,!1);else{if(0!==Ol||null!==e&&0!==(128&e.flags))for(e=t.child;null!==e;){if(null!==(l=ci(e))){for(t.flags|=128,Ws(i,!1),null!==(r=l.updateQueue)&&(t.updateQueue=r,t.flags|=4),t.subtreeFlags=0,r=n,n=t.child;null!==n;)e=r,(i=n).flags&=14680066,null===(l=i.alternate)?(i.childLanes=0,i.lanes=e,i.child=null,i.subtreeFlags=0,i.memoizedProps=null,i.memoizedState=null,i.updateQueue=null,i.dependencies=null,i.stateNode=null):(i.childLanes=l.childLanes,i.lanes=l.lanes,i.child=l.child,i.subtreeFlags=0,i.deletions=null,i.memoizedProps=l.memoizedProps,i.memoizedState=l.memoizedState,i.updateQueue=l.updateQueue,i.type=l.type,e=l.dependencies,i.dependencies=null===e?null:{lanes:e.lanes,firstContext:e.firstContext}),n=n.sibling;return Co(li,1&li.current|2),t.child}e=e.sibling}null!==i.tail&&Qe()>Zl&&(t.flags|=128,r=!0,Ws(i,!1),t.lanes=4194304)}else{if(!r)if(null!==(e=ci(l))){if(t.flags|=128,r=!0,null!==(n=e.updateQueue)&&(t.updateQueue=n,t.flags|=4),Ws(i,!0),null===i.tail&&"hidden"===i.tailMode&&!l.alternate&&!aa)return Us(t),null}else 2*Qe()-i.renderingStartTime>Zl&&1073741824!==n&&(t.flags|=128,r=!0,Ws(i,!1),t.lanes=4194304);i.isBackwards?(l.sibling=t.child,t.child=l):(null!==(n=i.last)?n.sibling=l:t.child=l,i.last=l)}return null!==i.tail?(t=i.tail,i.rendering=t,i.tail=t.sibling,i.renderingStartTime=Qe(),t.sibling=null,n=li.current,Co(li,r?1&n|2:1&n),t):(Us(t),null);case 22:case 23:return dc(),r=null!==t.memoizedState,null!==e&&null!==e.memoizedState!==r&&(t.flags|=8192),r&&0!==(1&t.mode)?0!==(1073741824&Rl)&&(Us(t),6&t.subtreeFlags&&(t.flags|=8192)):Us(t),null;case 24:case 25:return null}throw Error(a(156,t.tag))}function $s(e,t){switch(na(t),t.tag){case 1:return No(t.type)&&Oo(),65536&(e=t.flags)?(t.flags=-65537&e|128,t):null;case 3:return ai(),xo(Fo),xo(Mo),di(),0!==(65536&(e=t.flags))&&0===(128&e)?(t.flags=-65537&e|128,t):null;case 5:return si(t),null;case 13:if(xo(li),null!==(e=t.memoizedState)&&null!==e.dehydrated){if(null===t.alternate)throw Error(a(340));ma()}return 65536&(e=t.flags)?(t.flags=-65537&e|128,t):null;case 19:return xo(li),null;case 4:return ai(),null;case 10:return Sa(t.type._context),null;case 22:case 23:return dc(),null;default:return null}}Rs=function(e,t){for(var n=t.child;null!==n;){if(5===n.tag||6===n.tag)e.appendChild(n.stateNode);else if(4!==n.tag&&null!==n.child){n.child.return=n,n=n.child;continue}if(n===t)break;for(;null===n.sibling;){if(null===n.return||n.return===t)return;n=n.return}n.sibling.return=n.return,n=n.sibling}},Ns=function(e,t,n,r){var o=e.memoizedProps;if(o!==r){e=t.stateNode,ri(ei.current);var a,i=null;switch(n){case"input":o=J(e,o),r=J(e,r),i=[];break;case"select":o=D({},o,{value:void 0}),r=D({},r,{value:void 0}),i=[];break;case"textarea":o=re(e,o),r=re(e,r),i=[];break;default:"function"!==typeof o.onClick&&"function"===typeof r.onClick&&(e.onclick=Xr)}for(u in ye(n,r),n=null,o)if(!r.hasOwnProperty(u)&&o.hasOwnProperty(u)&&null!=o[u])if("style"===u){var l=o[u];for(a in l)l.hasOwnProperty(a)&&(n||(n={}),n[a]="")}else"dangerouslySetInnerHTML"!==u&&"children"!==u&&"suppressContentEditableWarning"!==u&&"suppressHydrationWarning"!==u&&"autoFocus"!==u&&(s.hasOwnProperty(u)?i||(i=[]):(i=i||[]).push(u,null));for(u in r){var c=r[u];if(l=null!=o?o[u]:void 0,r.hasOwnProperty(u)&&c!==l&&(null!=c||null!=l))if("style"===u)if(l){for(a in l)!l.hasOwnProperty(a)||c&&c.hasOwnProperty(a)||(n||(n={}),n[a]="");for(a in c)c.hasOwnProperty(a)&&l[a]!==c[a]&&(n||(n={}),n[a]=c[a])}else n||(i||(i=[]),i.push(u,n)),n=c;else"dangerouslySetInnerHTML"===u?(c=c?c.__html:void 0,l=l?l.__html:void 0,null!=c&&l!==c&&(i=i||[]).push(u,c)):"children"===u?"string"!==typeof c&&"number"!==typeof c||(i=i||[]).push(u,""+c):"suppressContentEditableWarning"!==u&&"suppressHydrationWarning"!==u&&(s.hasOwnProperty(u)?(null!=c&&"onScroll"===u&&Ir("scroll",e),i||l===c||(i=[])):(i=i||[]).push(u,c))}n&&(i=i||[]).push("style",n);var u=i;(t.updateQueue=u)&&(t.flags|=4)}},Os=function(e,t,n,r){n!==r&&(t.flags|=4)};var Js=!1,Ks=!1,Qs="function"===typeof WeakSet?WeakSet:Set,Ys=null;function Xs(e,t){var n=e.ref;if(null!==n)if("function"===typeof n)try{n(null)}catch(r){Pc(e,t,r)}else n.current=null}function el(e,t,n){try{n()}catch(r){Pc(e,t,r)}}var tl=!1;function nl(e,t,n){var r=t.updateQueue;if(null!==(r=null!==r?r.lastEffect:null)){var o=r=r.next;do{if((o.tag&e)===e){var a=o.destroy;o.destroy=void 0,void 0!==a&&el(t,n,a)}o=o.next}while(o!==r)}}function rl(e,t){if(null!==(t=null!==(t=t.updateQueue)?t.lastEffect:null)){var n=t=t.next;do{if((n.tag&e)===e){var r=n.create;n.destroy=r()}n=n.next}while(n!==t)}}function ol(e){var t=e.ref;if(null!==t){var n=e.stateNode;e.tag,e=n,"function"===typeof t?t(e):t.current=e}}function al(e){var t=e.alternate;null!==t&&(e.alternate=null,al(t)),e.child=null,e.deletions=null,e.sibling=null,5===e.tag&&(null!==(t=e.stateNode)&&(delete t[po],delete t[mo],delete t[vo],delete t[bo],delete t[yo])),e.stateNode=null,e.return=null,e.dependencies=null,e.memoizedProps=null,e.memoizedState=null,e.pendingProps=null,e.stateNode=null,e.updateQueue=null}function il(e){return 5===e.tag||3===e.tag||4===e.tag}function sl(e){e:for(;;){for(;null===e.sibling;){if(null===e.return||il(e.return))return null;e=e.return}for(e.sibling.return=e.return,e=e.sibling;5!==e.tag&&6!==e.tag&&18!==e.tag;){if(2&e.flags)continue e;if(null===e.child||4===e.tag)continue e;e.child.return=e,e=e.child}if(!(2&e.flags))return e.stateNode}}function ll(e,t,n){var r=e.tag;if(5===r||6===r)e=e.stateNode,t?8===n.nodeType?n.parentNode.insertBefore(e,t):n.insertBefore(e,t):(8===n.nodeType?(t=n.parentNode).insertBefore(e,n):(t=n).appendChild(e),null!==(n=n._reactRootContainer)&&void 0!==n||null!==t.onclick||(t.onclick=Xr));else if(4!==r&&null!==(e=e.child))for(ll(e,t,n),e=e.sibling;null!==e;)ll(e,t,n),e=e.sibling}function cl(e,t,n){var r=e.tag;if(5===r||6===r)e=e.stateNode,t?n.insertBefore(e,t):n.appendChild(e);else if(4!==r&&null!==(e=e.child))for(cl(e,t,n),e=e.sibling;null!==e;)cl(e,t,n),e=e.sibling}var ul=null,dl=!1;function fl(e,t,n){for(n=n.child;null!==n;)pl(e,t,n),n=n.sibling}function pl(e,t,n){if(at&&"function"===typeof at.onCommitFiberUnmount)try{at.onCommitFiberUnmount(ot,n)}catch(s){}switch(n.tag){case 5:Ks||Xs(n,t);case 6:var r=ul,o=dl;ul=null,fl(e,t,n),dl=o,null!==(ul=r)&&(dl?(e=ul,n=n.stateNode,8===e.nodeType?e.parentNode.removeChild(n):e.removeChild(n)):ul.removeChild(n.stateNode));break;case 18:null!==ul&&(dl?(e=ul,n=n.stateNode,8===e.nodeType?lo(e.parentNode,n):1===e.nodeType&&lo(e,n),Zt(e)):lo(ul,n.stateNode));break;case 4:r=ul,o=dl,ul=n.stateNode.containerInfo,dl=!0,fl(e,t,n),ul=r,dl=o;break;case 0:case 11:case 14:case 15:if(!Ks&&(null!==(r=n.updateQueue)&&null!==(r=r.lastEffect))){o=r=r.next;do{var a=o,i=a.destroy;a=a.tag,void 0!==i&&(0!==(2&a)||0!==(4&a))&&el(n,t,i),o=o.next}while(o!==r)}fl(e,t,n);break;case 1:if(!Ks&&(Xs(n,t),"function"===typeof(r=n.stateNode).componentWillUnmount))try{r.props=n.memoizedProps,r.state=n.memoizedState,r.componentWillUnmount()}catch(s){Pc(n,t,s)}fl(e,t,n);break;case 21:fl(e,t,n);break;case 22:1&n.mode?(Ks=(r=Ks)||null!==n.memoizedState,fl(e,t,n),Ks=r):fl(e,t,n);break;default:fl(e,t,n)}}function ml(e){var t=e.updateQueue;if(null!==t){e.updateQueue=null;var n=e.stateNode;null===n&&(n=e.stateNode=new Qs),t.forEach((function(t){var r=Ac.bind(null,e,t);n.has(t)||(n.add(t),t.then(r,r))}))}}function hl(e,t){var n=t.deletions;if(null!==n)for(var r=0;r<n.length;r++){var o=n[r];try{var i=e,s=t,l=s;e:for(;null!==l;){switch(l.tag){case 5:ul=l.stateNode,dl=!1;break e;case 3:case 4:ul=l.stateNode.containerInfo,dl=!0;break e}l=l.return}if(null===ul)throw Error(a(160));pl(i,s,o),ul=null,dl=!1;var c=o.alternate;null!==c&&(c.return=null),o.return=null}catch(u){Pc(o,t,u)}}if(12854&t.subtreeFlags)for(t=t.child;null!==t;)vl(t,e),t=t.sibling}function vl(e,t){var n=e.alternate,r=e.flags;switch(e.tag){case 0:case 11:case 14:case 15:if(hl(t,e),bl(e),4&r){try{nl(3,e,e.return),rl(3,e)}catch(v){Pc(e,e.return,v)}try{nl(5,e,e.return)}catch(v){Pc(e,e.return,v)}}break;case 1:hl(t,e),bl(e),512&r&&null!==n&&Xs(n,n.return);break;case 5:if(hl(t,e),bl(e),512&r&&null!==n&&Xs(n,n.return),32&e.flags){var o=e.stateNode;try{fe(o,"")}catch(v){Pc(e,e.return,v)}}if(4&r&&null!=(o=e.stateNode)){var i=e.memoizedProps,s=null!==n?n.memoizedProps:i,l=e.type,c=e.updateQueue;if(e.updateQueue=null,null!==c)try{"input"===l&&"radio"===i.type&&null!=i.name&&Q(o,i),ge(l,s);var u=ge(l,i);for(s=0;s<c.length;s+=2){var d=c[s],f=c[s+1];"style"===d?ve(o,f):"dangerouslySetInnerHTML"===d?de(o,f):"children"===d?fe(o,f):g(o,d,f,u)}switch(l){case"input":Y(o,i);break;case"textarea":ae(o,i);break;case"select":var p=o._wrapperState.wasMultiple;o._wrapperState.wasMultiple=!!i.multiple;var m=i.value;null!=m?ne(o,!!i.multiple,m,!1):p!==!!i.multiple&&(null!=i.defaultValue?ne(o,!!i.multiple,i.defaultValue,!0):ne(o,!!i.multiple,i.multiple?[]:"",!1))}o[mo]=i}catch(v){Pc(e,e.return,v)}}break;case 6:if(hl(t,e),bl(e),4&r){if(null===e.stateNode)throw Error(a(162));o=e.stateNode,i=e.memoizedProps;try{o.nodeValue=i}catch(v){Pc(e,e.return,v)}}break;case 3:if(hl(t,e),bl(e),4&r&&null!==n&&n.memoizedState.isDehydrated)try{Zt(t.containerInfo)}catch(v){Pc(e,e.return,v)}break;case 4:default:hl(t,e),bl(e);break;case 13:hl(t,e),bl(e),8192&(o=e.child).flags&&(i=null!==o.memoizedState,o.stateNode.isHidden=i,!i||null!==o.alternate&&null!==o.alternate.memoizedState||(jl=Qe())),4&r&&ml(e);break;case 22:if(d=null!==n&&null!==n.memoizedState,1&e.mode?(Ks=(u=Ks)||d,hl(t,e),Ks=u):hl(t,e),bl(e),8192&r){if(u=null!==e.memoizedState,(e.stateNode.isHidden=u)&&!d&&0!==(1&e.mode))for(Ys=e,d=e.child;null!==d;){for(f=Ys=d;null!==Ys;){switch(m=(p=Ys).child,p.tag){case 0:case 11:case 14:case 15:nl(4,p,p.return);break;case 1:Xs(p,p.return);var h=p.stateNode;if("function"===typeof h.componentWillUnmount){r=p,n=p.return;try{t=r,h.props=t.memoizedProps,h.state=t.memoizedState,h.componentWillUnmount()}catch(v){Pc(r,n,v)}}break;case 5:Xs(p,p.return);break;case 22:if(null!==p.memoizedState){wl(f);continue}}null!==m?(m.return=p,Ys=m):wl(f)}d=d.sibling}e:for(d=null,f=e;;){if(5===f.tag){if(null===d){d=f;try{o=f.stateNode,u?"function"===typeof(i=o.style).setProperty?i.setProperty("display","none","important"):i.display="none":(l=f.stateNode,s=void 0!==(c=f.memoizedProps.style)&&null!==c&&c.hasOwnProperty("display")?c.display:null,l.style.display=he("display",s))}catch(v){Pc(e,e.return,v)}}}else if(6===f.tag){if(null===d)try{f.stateNode.nodeValue=u?"":f.memoizedProps}catch(v){Pc(e,e.return,v)}}else if((22!==f.tag&&23!==f.tag||null===f.memoizedState||f===e)&&null!==f.child){f.child.return=f,f=f.child;continue}if(f===e)break e;for(;null===f.sibling;){if(null===f.return||f.return===e)break e;d===f&&(d=null),f=f.return}d===f&&(d=null),f.sibling.return=f.return,f=f.sibling}}break;case 19:hl(t,e),bl(e),4&r&&ml(e);case 21:}}function bl(e){var t=e.flags;if(2&t){try{e:{for(var n=e.return;null!==n;){if(il(n)){var r=n;break e}n=n.return}throw Error(a(160))}switch(r.tag){case 5:var o=r.stateNode;32&r.flags&&(fe(o,""),r.flags&=-33),cl(e,sl(e),o);break;case 3:case 4:var i=r.stateNode.containerInfo;ll(e,sl(e),i);break;default:throw Error(a(161))}}catch(s){Pc(e,e.return,s)}e.flags&=-3}4096&t&&(e.flags&=-4097)}function yl(e,t,n){Ys=e,gl(e,t,n)}function gl(e,t,n){for(var r=0!==(1&e.mode);null!==Ys;){var o=Ys,a=o.child;if(22===o.tag&&r){var i=null!==o.memoizedState||Js;if(!i){var s=o.alternate,l=null!==s&&null!==s.memoizedState||Ks;s=Js;var c=Ks;if(Js=i,(Ks=l)&&!c)for(Ys=o;null!==Ys;)l=(i=Ys).child,22===i.tag&&null!==i.memoizedState?Tl(o):null!==l?(l.return=i,Ys=l):Tl(o);for(;null!==a;)Ys=a,gl(a,t,n),a=a.sibling;Ys=o,Js=s,Ks=c}_l(e)}else 0!==(8772&o.subtreeFlags)&&null!==a?(a.return=o,Ys=a):_l(e)}}function _l(e){for(;null!==Ys;){var t=Ys;if(0!==(8772&t.flags)){var n=t.alternate;try{if(0!==(8772&t.flags))switch(t.tag){case 0:case 11:case 15:Ks||rl(5,t);break;case 1:var r=t.stateNode;if(4&t.flags&&!Ks)if(null===n)r.componentDidMount();else{var o=t.elementType===t.type?n.memoizedProps:ba(t.type,n.memoizedProps);r.componentDidUpdate(o,n.memoizedState,r.__reactInternalSnapshotBeforeUpdate)}var i=t.updateQueue;null!==i&&Ia(t,i,r);break;case 3:var s=t.updateQueue;if(null!==s){if(n=null,null!==t.child)switch(t.child.tag){case 5:case 1:n=t.child.stateNode}Ia(t,s,n)}break;case 5:var l=t.stateNode;if(null===n&&4&t.flags){n=l;var c=t.memoizedProps;switch(t.type){case"button":case"input":case"select":case"textarea":c.autoFocus&&n.focus();break;case"img":c.src&&(n.src=c.src)}}break;case 6:case 4:case 12:case 19:case 17:case 21:case 22:case 23:case 25:break;case 13:if(null===t.memoizedState){var u=t.alternate;if(null!==u){var d=u.memoizedState;if(null!==d){var f=d.dehydrated;null!==f&&Zt(f)}}}break;default:throw Error(a(163))}Ks||512&t.flags&&ol(t)}catch(p){Pc(t,t.return,p)}}if(t===e){Ys=null;break}if(null!==(n=t.sibling)){n.return=t.return,Ys=n;break}Ys=t.return}}function wl(e){for(;null!==Ys;){var t=Ys;if(t===e){Ys=null;break}var n=t.sibling;if(null!==n){n.return=t.return,Ys=n;break}Ys=t.return}}function Tl(e){for(;null!==Ys;){var t=Ys;try{switch(t.tag){case 0:case 11:case 15:var n=t.return;try{rl(4,t)}catch(l){Pc(t,n,l)}break;case 1:var r=t.stateNode;if("function"===typeof r.componentDidMount){var o=t.return;try{r.componentDidMount()}catch(l){Pc(t,o,l)}}var a=t.return;try{ol(t)}catch(l){Pc(t,a,l)}break;case 5:var i=t.return;try{ol(t)}catch(l){Pc(t,i,l)}}}catch(l){Pc(t,t.return,l)}if(t===e){Ys=null;break}var s=t.sibling;if(null!==s){s.return=t.return,Ys=s;break}Ys=t.return}}var Sl,Pl=Math.ceil,kl=_.ReactCurrentDispatcher,xl=_.ReactCurrentOwner,Cl=_.ReactCurrentBatchConfig,Al=0,Ml=null,Fl=null,El=0,Rl=0,Nl=ko(0),Ol=0,Vl=null,Ll=0,Dl=0,zl=0,Il=null,Hl=null,jl=0,Zl=1/0,Bl=null,Gl=!1,Wl=null,Ul=null,ql=!1,$l=null,Jl=0,Kl=0,Ql=null,Yl=-1,Xl=0;function ec(){return 0!==(6&Al)?Qe():-1!==Yl?Yl:Yl=Qe()}function tc(e){return 0===(1&e.mode)?1:0!==(2&Al)&&0!==El?El&-El:null!==va.transition?(0===Xl&&(Xl=ht()),Xl):0!==(e=gt)?e:e=void 0===(e=window.event)?16:Kt(e.type)}function nc(e,t,n,r){if(50<Kl)throw Kl=0,Ql=null,Error(a(185));bt(e,n,r),0!==(2&Al)&&e===Ml||(e===Ml&&(0===(2&Al)&&(Dl|=n),4===Ol&&sc(e,El)),rc(e,r),1===n&&0===Al&&0===(1&t.mode)&&(Zl=Qe()+500,Ho&&Bo()))}function rc(e,t){var n=e.callbackNode;!function(e,t){for(var n=e.suspendedLanes,r=e.pingedLanes,o=e.expirationTimes,a=e.pendingLanes;0<a;){var i=31-it(a),s=1<<i,l=o[i];-1===l?0!==(s&n)&&0===(s&r)||(o[i]=pt(s,t)):l<=t&&(e.expiredLanes|=s),a&=~s}}(e,t);var r=ft(e,e===Ml?El:0);if(0===r)null!==n&&$e(n),e.callbackNode=null,e.callbackPriority=0;else if(t=r&-r,e.callbackPriority!==t){if(null!=n&&$e(n),1===t)0===e.tag?function(e){Ho=!0,Zo(e)}(lc.bind(null,e)):Zo(lc.bind(null,e)),io((function(){0===(6&Al)&&Bo()})),n=null;else{switch(_t(r)){case 1:n=Xe;break;case 4:n=et;break;case 16:default:n=tt;break;case 536870912:n=rt}n=Mc(n,oc.bind(null,e))}e.callbackPriority=t,e.callbackNode=n}}function oc(e,t){if(Yl=-1,Xl=0,0!==(6&Al))throw Error(a(327));var n=e.callbackNode;if(Tc()&&e.callbackNode!==n)return null;var r=ft(e,e===Ml?El:0);if(0===r)return null;if(0!==(30&r)||0!==(r&e.expiredLanes)||t)t=vc(e,r);else{t=r;var o=Al;Al|=2;var i=mc();for(Ml===e&&El===t||(Bl=null,Zl=Qe()+500,fc(e,t));;)try{yc();break}catch(l){pc(e,l)}Ta(),kl.current=i,Al=o,null!==Fl?t=0:(Ml=null,El=0,t=Ol)}if(0!==t){if(2===t&&(0!==(o=mt(e))&&(r=o,t=ac(e,o))),1===t)throw n=Vl,fc(e,0),sc(e,r),rc(e,Qe()),n;if(6===t)sc(e,r);else{if(o=e.current.alternate,0===(30&r)&&!function(e){for(var t=e;;){if(16384&t.flags){var n=t.updateQueue;if(null!==n&&null!==(n=n.stores))for(var r=0;r<n.length;r++){var o=n[r],a=o.getSnapshot;o=o.value;try{if(!sr(a(),o))return!1}catch(s){return!1}}}if(n=t.child,16384&t.subtreeFlags&&null!==n)n.return=t,t=n;else{if(t===e)break;for(;null===t.sibling;){if(null===t.return||t.return===e)return!0;t=t.return}t.sibling.return=t.return,t=t.sibling}}return!0}(o)&&(2===(t=vc(e,r))&&(0!==(i=mt(e))&&(r=i,t=ac(e,i))),1===t))throw n=Vl,fc(e,0),sc(e,r),rc(e,Qe()),n;switch(e.finishedWork=o,e.finishedLanes=r,t){case 0:case 1:throw Error(a(345));case 2:case 5:wc(e,Hl,Bl);break;case 3:if(sc(e,r),(130023424&r)===r&&10<(t=jl+500-Qe())){if(0!==ft(e,0))break;if(((o=e.suspendedLanes)&r)!==r){ec(),e.pingedLanes|=e.suspendedLanes&o;break}e.timeoutHandle=ro(wc.bind(null,e,Hl,Bl),t);break}wc(e,Hl,Bl);break;case 4:if(sc(e,r),(4194240&r)===r)break;for(t=e.eventTimes,o=-1;0<r;){var s=31-it(r);i=1<<s,(s=t[s])>o&&(o=s),r&=~i}if(r=o,10<(r=(120>(r=Qe()-r)?120:480>r?480:1080>r?1080:1920>r?1920:3e3>r?3e3:4320>r?4320:1960*Pl(r/1960))-r)){e.timeoutHandle=ro(wc.bind(null,e,Hl,Bl),r);break}wc(e,Hl,Bl);break;default:throw Error(a(329))}}}return rc(e,Qe()),e.callbackNode===n?oc.bind(null,e):null}function ac(e,t){var n=Il;return e.current.memoizedState.isDehydrated&&(fc(e,t).flags|=256),2!==(e=vc(e,t))&&(t=Hl,Hl=n,null!==t&&ic(t)),e}function ic(e){null===Hl?Hl=e:Hl.push.apply(Hl,e)}function sc(e,t){for(t&=~zl,t&=~Dl,e.suspendedLanes|=t,e.pingedLanes&=~t,e=e.expirationTimes;0<t;){var n=31-it(t),r=1<<n;e[n]=-1,t&=~r}}function lc(e){if(0!==(6&Al))throw Error(a(327));Tc();var t=ft(e,0);if(0===(1&t))return rc(e,Qe()),null;var n=vc(e,t);if(0!==e.tag&&2===n){var r=mt(e);0!==r&&(t=r,n=ac(e,r))}if(1===n)throw n=Vl,fc(e,0),sc(e,t),rc(e,Qe()),n;if(6===n)throw Error(a(345));return e.finishedWork=e.current.alternate,e.finishedLanes=t,wc(e,Hl,Bl),rc(e,Qe()),null}function cc(e,t){var n=Al;Al|=1;try{return e(t)}finally{0===(Al=n)&&(Zl=Qe()+500,Ho&&Bo())}}function uc(e){null!==$l&&0===$l.tag&&0===(6&Al)&&Tc();var t=Al;Al|=1;var n=Cl.transition,r=gt;try{if(Cl.transition=null,gt=1,e)return e()}finally{gt=r,Cl.transition=n,0===(6&(Al=t))&&Bo()}}function dc(){Rl=Nl.current,xo(Nl)}function fc(e,t){e.finishedWork=null,e.finishedLanes=0;var n=e.timeoutHandle;if(-1!==n&&(e.timeoutHandle=-1,oo(n)),null!==Fl)for(n=Fl.return;null!==n;){var r=n;switch(na(r),r.tag){case 1:null!==(r=r.type.childContextTypes)&&void 0!==r&&Oo();break;case 3:ai(),xo(Fo),xo(Mo),di();break;case 5:si(r);break;case 4:ai();break;case 13:case 19:xo(li);break;case 10:Sa(r.type._context);break;case 22:case 23:dc()}n=n.return}if(Ml=e,Fl=e=Nc(e.current,null),El=Rl=t,Ol=0,Vl=null,zl=Dl=Ll=0,Hl=Il=null,null!==Ca){for(t=0;t<Ca.length;t++)if(null!==(r=(n=Ca[t]).interleaved)){n.interleaved=null;var o=r.next,a=n.pending;if(null!==a){var i=a.next;a.next=o,r.next=i}n.pending=r}Ca=null}return e}function pc(e,t){for(;;){var n=Fl;try{if(Ta(),fi.current=is,yi){for(var r=hi.memoizedState;null!==r;){var o=r.queue;null!==o&&(o.pending=null),r=r.next}yi=!1}if(mi=0,bi=vi=hi=null,gi=!1,_i=0,xl.current=null,null===n||null===n.return){Ol=1,Vl=t,Fl=null;break}e:{var i=e,s=n.return,l=n,c=t;if(t=El,l.flags|=32768,null!==c&&"object"===typeof c&&"function"===typeof c.then){var u=c,d=l,f=d.tag;if(0===(1&d.mode)&&(0===f||11===f||15===f)){var p=d.alternate;p?(d.updateQueue=p.updateQueue,d.memoizedState=p.memoizedState,d.lanes=p.lanes):(d.updateQueue=null,d.memoizedState=null)}var m=bs(s);if(null!==m){m.flags&=-257,ys(m,s,l,0,t),1&m.mode&&vs(i,u,t),c=u;var h=(t=m).updateQueue;if(null===h){var v=new Set;v.add(c),t.updateQueue=v}else h.add(c);break e}if(0===(1&t)){vs(i,u,t),hc();break e}c=Error(a(426))}else if(aa&&1&l.mode){var b=bs(s);if(null!==b){0===(65536&b.flags)&&(b.flags|=256),ys(b,s,l,0,t),ha(us(c,l));break e}}i=c=us(c,l),4!==Ol&&(Ol=2),null===Il?Il=[i]:Il.push(i),i=s;do{switch(i.tag){case 3:i.flags|=65536,t&=-t,i.lanes|=t,Da(i,ms(0,c,t));break e;case 1:l=c;var y=i.type,g=i.stateNode;if(0===(128&i.flags)&&("function"===typeof y.getDerivedStateFromError||null!==g&&"function"===typeof g.componentDidCatch&&(null===Ul||!Ul.has(g)))){i.flags|=65536,t&=-t,i.lanes|=t,Da(i,hs(i,l,t));break e}}i=i.return}while(null!==i)}_c(n)}catch(_){t=_,Fl===n&&null!==n&&(Fl=n=n.return);continue}break}}function mc(){var e=kl.current;return kl.current=is,null===e?is:e}function hc(){0!==Ol&&3!==Ol&&2!==Ol||(Ol=4),null===Ml||0===(268435455&Ll)&&0===(268435455&Dl)||sc(Ml,El)}function vc(e,t){var n=Al;Al|=2;var r=mc();for(Ml===e&&El===t||(Bl=null,fc(e,t));;)try{bc();break}catch(o){pc(e,o)}if(Ta(),Al=n,kl.current=r,null!==Fl)throw Error(a(261));return Ml=null,El=0,Ol}function bc(){for(;null!==Fl;)gc(Fl)}function yc(){for(;null!==Fl&&!Je();)gc(Fl)}function gc(e){var t=Sl(e.alternate,e,Rl);e.memoizedProps=e.pendingProps,null===t?_c(e):Fl=t,xl.current=null}function _c(e){var t=e;do{var n=t.alternate;if(e=t.return,0===(32768&t.flags)){if(null!==(n=qs(n,t,Rl)))return void(Fl=n)}else{if(null!==(n=$s(n,t)))return n.flags&=32767,void(Fl=n);if(null===e)return Ol=6,void(Fl=null);e.flags|=32768,e.subtreeFlags=0,e.deletions=null}if(null!==(t=t.sibling))return void(Fl=t);Fl=t=e}while(null!==t);0===Ol&&(Ol=5)}function wc(e,t,n){var r=gt,o=Cl.transition;try{Cl.transition=null,gt=1,function(e,t,n,r){do{Tc()}while(null!==$l);if(0!==(6&Al))throw Error(a(327));n=e.finishedWork;var o=e.finishedLanes;if(null===n)return null;if(e.finishedWork=null,e.finishedLanes=0,n===e.current)throw Error(a(177));e.callbackNode=null,e.callbackPriority=0;var i=n.lanes|n.childLanes;if(function(e,t){var n=e.pendingLanes&~t;e.pendingLanes=t,e.suspendedLanes=0,e.pingedLanes=0,e.expiredLanes&=t,e.mutableReadLanes&=t,e.entangledLanes&=t,t=e.entanglements;var r=e.eventTimes;for(e=e.expirationTimes;0<n;){var o=31-it(n),a=1<<o;t[o]=0,r[o]=-1,e[o]=-1,n&=~a}}(e,i),e===Ml&&(Fl=Ml=null,El=0),0===(2064&n.subtreeFlags)&&0===(2064&n.flags)||ql||(ql=!0,Mc(tt,(function(){return Tc(),null}))),i=0!==(15990&n.flags),0!==(15990&n.subtreeFlags)||i){i=Cl.transition,Cl.transition=null;var s=gt;gt=1;var l=Al;Al|=4,xl.current=null,function(e,t){if(eo=Gt,pr(e=fr())){if("selectionStart"in e)var n={start:e.selectionStart,end:e.selectionEnd};else e:{var r=(n=(n=e.ownerDocument)&&n.defaultView||window).getSelection&&n.getSelection();if(r&&0!==r.rangeCount){n=r.anchorNode;var o=r.anchorOffset,i=r.focusNode;r=r.focusOffset;try{n.nodeType,i.nodeType}catch(w){n=null;break e}var s=0,l=-1,c=-1,u=0,d=0,f=e,p=null;t:for(;;){for(var m;f!==n||0!==o&&3!==f.nodeType||(l=s+o),f!==i||0!==r&&3!==f.nodeType||(c=s+r),3===f.nodeType&&(s+=f.nodeValue.length),null!==(m=f.firstChild);)p=f,f=m;for(;;){if(f===e)break t;if(p===n&&++u===o&&(l=s),p===i&&++d===r&&(c=s),null!==(m=f.nextSibling))break;p=(f=p).parentNode}f=m}n=-1===l||-1===c?null:{start:l,end:c}}else n=null}n=n||{start:0,end:0}}else n=null;for(to={focusedElem:e,selectionRange:n},Gt=!1,Ys=t;null!==Ys;)if(e=(t=Ys).child,0!==(1028&t.subtreeFlags)&&null!==e)e.return=t,Ys=e;else for(;null!==Ys;){t=Ys;try{var h=t.alternate;if(0!==(1024&t.flags))switch(t.tag){case 0:case 11:case 15:case 5:case 6:case 4:case 17:break;case 1:if(null!==h){var v=h.memoizedProps,b=h.memoizedState,y=t.stateNode,g=y.getSnapshotBeforeUpdate(t.elementType===t.type?v:ba(t.type,v),b);y.__reactInternalSnapshotBeforeUpdate=g}break;case 3:var _=t.stateNode.containerInfo;1===_.nodeType?_.textContent="":9===_.nodeType&&_.documentElement&&_.removeChild(_.documentElement);break;default:throw Error(a(163))}}catch(w){Pc(t,t.return,w)}if(null!==(e=t.sibling)){e.return=t.return,Ys=e;break}Ys=t.return}h=tl,tl=!1}(e,n),vl(n,e),mr(to),Gt=!!eo,to=eo=null,e.current=n,yl(n,e,o),Ke(),Al=l,gt=s,Cl.transition=i}else e.current=n;if(ql&&(ql=!1,$l=e,Jl=o),0===(i=e.pendingLanes)&&(Ul=null),function(e){if(at&&"function"===typeof at.onCommitFiberRoot)try{at.onCommitFiberRoot(ot,e,void 0,128===(128&e.current.flags))}catch(t){}}(n.stateNode),rc(e,Qe()),null!==t)for(r=e.onRecoverableError,n=0;n<t.length;n++)r((o=t[n]).value,{componentStack:o.stack,digest:o.digest});if(Gl)throw Gl=!1,e=Wl,Wl=null,e;0!==(1&Jl)&&0!==e.tag&&Tc(),0!==(1&(i=e.pendingLanes))?e===Ql?Kl++:(Kl=0,Ql=e):Kl=0,Bo()}(e,t,n,r)}finally{Cl.transition=o,gt=r}return null}function Tc(){if(null!==$l){var e=_t(Jl),t=Cl.transition,n=gt;try{if(Cl.transition=null,gt=16>e?16:e,null===$l)var r=!1;else{if(e=$l,$l=null,Jl=0,0!==(6&Al))throw Error(a(331));var o=Al;for(Al|=4,Ys=e.current;null!==Ys;){var i=Ys,s=i.child;if(0!==(16&Ys.flags)){var l=i.deletions;if(null!==l){for(var c=0;c<l.length;c++){var u=l[c];for(Ys=u;null!==Ys;){var d=Ys;switch(d.tag){case 0:case 11:case 15:nl(8,d,i)}var f=d.child;if(null!==f)f.return=d,Ys=f;else for(;null!==Ys;){var p=(d=Ys).sibling,m=d.return;if(al(d),d===u){Ys=null;break}if(null!==p){p.return=m,Ys=p;break}Ys=m}}}var h=i.alternate;if(null!==h){var v=h.child;if(null!==v){h.child=null;do{var b=v.sibling;v.sibling=null,v=b}while(null!==v)}}Ys=i}}if(0!==(2064&i.subtreeFlags)&&null!==s)s.return=i,Ys=s;else e:for(;null!==Ys;){if(0!==(2048&(i=Ys).flags))switch(i.tag){case 0:case 11:case 15:nl(9,i,i.return)}var y=i.sibling;if(null!==y){y.return=i.return,Ys=y;break e}Ys=i.return}}var g=e.current;for(Ys=g;null!==Ys;){var _=(s=Ys).child;if(0!==(2064&s.subtreeFlags)&&null!==_)_.return=s,Ys=_;else e:for(s=g;null!==Ys;){if(0!==(2048&(l=Ys).flags))try{switch(l.tag){case 0:case 11:case 15:rl(9,l)}}catch(T){Pc(l,l.return,T)}if(l===s){Ys=null;break e}var w=l.sibling;if(null!==w){w.return=l.return,Ys=w;break e}Ys=l.return}}if(Al=o,Bo(),at&&"function"===typeof at.onPostCommitFiberRoot)try{at.onPostCommitFiberRoot(ot,e)}catch(T){}r=!0}return r}finally{gt=n,Cl.transition=t}}return!1}function Sc(e,t,n){e=Va(e,t=ms(0,t=us(n,t),1),1),t=ec(),null!==e&&(bt(e,1,t),rc(e,t))}function Pc(e,t,n){if(3===e.tag)Sc(e,e,n);else for(;null!==t;){if(3===t.tag){Sc(t,e,n);break}if(1===t.tag){var r=t.stateNode;if("function"===typeof t.type.getDerivedStateFromError||"function"===typeof r.componentDidCatch&&(null===Ul||!Ul.has(r))){t=Va(t,e=hs(t,e=us(n,e),1),1),e=ec(),null!==t&&(bt(t,1,e),rc(t,e));break}}t=t.return}}function kc(e,t,n){var r=e.pingCache;null!==r&&r.delete(t),t=ec(),e.pingedLanes|=e.suspendedLanes&n,Ml===e&&(El&n)===n&&(4===Ol||3===Ol&&(130023424&El)===El&&500>Qe()-jl?fc(e,0):zl|=n),rc(e,t)}function xc(e,t){0===t&&(0===(1&e.mode)?t=1:(t=ut,0===(130023424&(ut<<=1))&&(ut=4194304)));var n=ec();null!==(e=Fa(e,t))&&(bt(e,t,n),rc(e,n))}function Cc(e){var t=e.memoizedState,n=0;null!==t&&(n=t.retryLane),xc(e,n)}function Ac(e,t){var n=0;switch(e.tag){case 13:var r=e.stateNode,o=e.memoizedState;null!==o&&(n=o.retryLane);break;case 19:r=e.stateNode;break;default:throw Error(a(314))}null!==r&&r.delete(t),xc(e,n)}function Mc(e,t){return qe(e,t)}function Fc(e,t,n,r){this.tag=e,this.key=n,this.sibling=this.child=this.return=this.stateNode=this.type=this.elementType=null,this.index=0,this.ref=null,this.pendingProps=t,this.dependencies=this.memoizedState=this.updateQueue=this.memoizedProps=null,this.mode=r,this.subtreeFlags=this.flags=0,this.deletions=null,this.childLanes=this.lanes=0,this.alternate=null}function Ec(e,t,n,r){return new Fc(e,t,n,r)}function Rc(e){return!(!(e=e.prototype)||!e.isReactComponent)}function Nc(e,t){var n=e.alternate;return null===n?((n=Ec(e.tag,t,e.key,e.mode)).elementType=e.elementType,n.type=e.type,n.stateNode=e.stateNode,n.alternate=e,e.alternate=n):(n.pendingProps=t,n.type=e.type,n.flags=0,n.subtreeFlags=0,n.deletions=null),n.flags=14680064&e.flags,n.childLanes=e.childLanes,n.lanes=e.lanes,n.child=e.child,n.memoizedProps=e.memoizedProps,n.memoizedState=e.memoizedState,n.updateQueue=e.updateQueue,t=e.dependencies,n.dependencies=null===t?null:{lanes:t.lanes,firstContext:t.firstContext},n.sibling=e.sibling,n.index=e.index,n.ref=e.ref,n}function Oc(e,t,n,r,o,i){var s=2;if(r=e,"function"===typeof e)Rc(e)&&(s=1);else if("string"===typeof e)s=5;else e:switch(e){case S:return Vc(n.children,o,i,t);case P:s=8,o|=8;break;case k:return(e=Ec(12,n,t,2|o)).elementType=k,e.lanes=i,e;case M:return(e=Ec(13,n,t,o)).elementType=M,e.lanes=i,e;case F:return(e=Ec(19,n,t,o)).elementType=F,e.lanes=i,e;case N:return Lc(n,o,i,t);default:if("object"===typeof e&&null!==e)switch(e.$$typeof){case x:s=10;break e;case C:s=9;break e;case A:s=11;break e;case E:s=14;break e;case R:s=16,r=null;break e}throw Error(a(130,null==e?e:typeof e,""))}return(t=Ec(s,n,t,o)).elementType=e,t.type=r,t.lanes=i,t}function Vc(e,t,n,r){return(e=Ec(7,e,r,t)).lanes=n,e}function Lc(e,t,n,r){return(e=Ec(22,e,r,t)).elementType=N,e.lanes=n,e.stateNode={isHidden:!1},e}function Dc(e,t,n){return(e=Ec(6,e,null,t)).lanes=n,e}function zc(e,t,n){return(t=Ec(4,null!==e.children?e.children:[],e.key,t)).lanes=n,t.stateNode={containerInfo:e.containerInfo,pendingChildren:null,implementation:e.implementation},t}function Ic(e,t,n,r,o){this.tag=t,this.containerInfo=e,this.finishedWork=this.pingCache=this.current=this.pendingChildren=null,this.timeoutHandle=-1,this.callbackNode=this.pendingContext=this.context=null,this.callbackPriority=0,this.eventTimes=vt(0),this.expirationTimes=vt(-1),this.entangledLanes=this.finishedLanes=this.mutableReadLanes=this.expiredLanes=this.pingedLanes=this.suspendedLanes=this.pendingLanes=0,this.entanglements=vt(0),this.identifierPrefix=r,this.onRecoverableError=o,this.mutableSourceEagerHydrationData=null}function Hc(e,t,n,r,o,a,i,s,l){return e=new Ic(e,t,n,s,l),1===t?(t=1,!0===a&&(t|=8)):t=0,a=Ec(3,null,null,t),e.current=a,a.stateNode=e,a.memoizedState={element:r,isDehydrated:n,cache:null,transitions:null,pendingSuspenseBoundaries:null},Ra(a),e}function jc(e,t,n){var r=3<arguments.length&&void 0!==arguments[3]?arguments[3]:null;return{$$typeof:T,key:null==r?null:""+r,children:e,containerInfo:t,implementation:n}}function Zc(e){if(!e)return Ao;e:{if(Ze(e=e._reactInternals)!==e||1!==e.tag)throw Error(a(170));var t=e;do{switch(t.tag){case 3:t=t.stateNode.context;break e;case 1:if(No(t.type)){t=t.stateNode.__reactInternalMemoizedMergedChildContext;break e}}t=t.return}while(null!==t);throw Error(a(171))}if(1===e.tag){var n=e.type;if(No(n))return Lo(e,n,t)}return t}function Bc(e,t,n,r,o,a,i,s,l){return(e=Hc(n,r,!0,e,0,a,0,s,l)).context=Zc(null),n=e.current,(a=Oa(r=ec(),o=tc(n))).callback=void 0!==t&&null!==t?t:null,Va(n,a,o),e.current.lanes=o,bt(e,o,r),rc(e,r),e}function Gc(e,t,n,r){var o=t.current,a=ec(),i=tc(o);return n=Zc(n),null===t.context?t.context=n:t.pendingContext=n,(t=Oa(a,i)).payload={element:e},null!==(r=void 0===r?null:r)&&(t.callback=r),null!==(e=Va(o,t,i))&&(nc(e,o,i,a),La(e,o,i)),i}function Wc(e){return(e=e.current).child?(e.child.tag,e.child.stateNode):null}function Uc(e,t){if(null!==(e=e.memoizedState)&&null!==e.dehydrated){var n=e.retryLane;e.retryLane=0!==n&&n<t?n:t}}function qc(e,t){Uc(e,t),(e=e.alternate)&&Uc(e,t)}Sl=function(e,t,n){if(null!==e)if(e.memoizedProps!==t.pendingProps||Fo.current)_s=!0;else{if(0===(e.lanes&n)&&0===(128&t.flags))return _s=!1,function(e,t,n){switch(t.tag){case 3:Fs(t),ma();break;case 5:ii(t);break;case 1:No(t.type)&&Do(t);break;case 4:oi(t,t.stateNode.containerInfo);break;case 10:var r=t.type._context,o=t.memoizedProps.value;Co(ya,r._currentValue),r._currentValue=o;break;case 13:if(null!==(r=t.memoizedState))return null!==r.dehydrated?(Co(li,1&li.current),t.flags|=128,null):0!==(n&t.child.childLanes)?Ds(e,t,n):(Co(li,1&li.current),null!==(e=Gs(e,t,n))?e.sibling:null);Co(li,1&li.current);break;case 19:if(r=0!==(n&t.childLanes),0!==(128&e.flags)){if(r)return Zs(e,t,n);t.flags|=128}if(null!==(o=t.memoizedState)&&(o.rendering=null,o.tail=null,o.lastEffect=null),Co(li,li.current),r)break;return null;case 22:case 23:return t.lanes=0,ks(e,t,n)}return Gs(e,t,n)}(e,t,n);_s=0!==(131072&e.flags)}else _s=!1,aa&&0!==(1048576&t.flags)&&ea(t,qo,t.index);switch(t.lanes=0,t.tag){case 2:var r=t.type;Bs(e,t),e=t.pendingProps;var o=Ro(t,Mo.current);ka(t,n),o=Pi(null,t,r,e,o,n);var i=ki();return t.flags|=1,"object"===typeof o&&null!==o&&"function"===typeof o.render&&void 0===o.$$typeof?(t.tag=1,t.memoizedState=null,t.updateQueue=null,No(r)?(i=!0,Do(t)):i=!1,t.memoizedState=null!==o.state&&void 0!==o.state?o.state:null,Ra(t),o.updater=Za,t.stateNode=o,o._reactInternals=t,Ua(t,r,e,n),t=Ms(null,t,r,!0,i,n)):(t.tag=0,aa&&i&&ta(t),ws(null,t,o,n),t=t.child),t;case 16:r=t.elementType;e:{switch(Bs(e,t),e=t.pendingProps,r=(o=r._init)(r._payload),t.type=r,o=t.tag=function(e){if("function"===typeof e)return Rc(e)?1:0;if(void 0!==e&&null!==e){if((e=e.$$typeof)===A)return 11;if(e===E)return 14}return 2}(r),e=ba(r,e),o){case 0:t=Cs(null,t,r,e,n);break e;case 1:t=As(null,t,r,e,n);break e;case 11:t=Ts(null,t,r,e,n);break e;case 14:t=Ss(null,t,r,ba(r.type,e),n);break e}throw Error(a(306,r,""))}return t;case 0:return r=t.type,o=t.pendingProps,Cs(e,t,r,o=t.elementType===r?o:ba(r,o),n);case 1:return r=t.type,o=t.pendingProps,As(e,t,r,o=t.elementType===r?o:ba(r,o),n);case 3:e:{if(Fs(t),null===e)throw Error(a(387));r=t.pendingProps,o=(i=t.memoizedState).element,Na(e,t),za(t,r,null,n);var s=t.memoizedState;if(r=s.element,i.isDehydrated){if(i={element:r,isDehydrated:!1,cache:s.cache,pendingSuspenseBoundaries:s.pendingSuspenseBoundaries,transitions:s.transitions},t.updateQueue.baseState=i,t.memoizedState=i,256&t.flags){t=Es(e,t,r,n,o=us(Error(a(423)),t));break e}if(r!==o){t=Es(e,t,r,n,o=us(Error(a(424)),t));break e}for(oa=co(t.stateNode.containerInfo.firstChild),ra=t,aa=!0,ia=null,n=Ya(t,null,r,n),t.child=n;n;)n.flags=-3&n.flags|4096,n=n.sibling}else{if(ma(),r===o){t=Gs(e,t,n);break e}ws(e,t,r,n)}t=t.child}return t;case 5:return ii(t),null===e&&ua(t),r=t.type,o=t.pendingProps,i=null!==e?e.memoizedProps:null,s=o.children,no(r,o)?s=null:null!==i&&no(r,i)&&(t.flags|=32),xs(e,t),ws(e,t,s,n),t.child;case 6:return null===e&&ua(t),null;case 13:return Ds(e,t,n);case 4:return oi(t,t.stateNode.containerInfo),r=t.pendingProps,null===e?t.child=Qa(t,null,r,n):ws(e,t,r,n),t.child;case 11:return r=t.type,o=t.pendingProps,Ts(e,t,r,o=t.elementType===r?o:ba(r,o),n);case 7:return ws(e,t,t.pendingProps,n),t.child;case 8:case 12:return ws(e,t,t.pendingProps.children,n),t.child;case 10:e:{if(r=t.type._context,o=t.pendingProps,i=t.memoizedProps,s=o.value,Co(ya,r._currentValue),r._currentValue=s,null!==i)if(sr(i.value,s)){if(i.children===o.children&&!Fo.current){t=Gs(e,t,n);break e}}else for(null!==(i=t.child)&&(i.return=t);null!==i;){var l=i.dependencies;if(null!==l){s=i.child;for(var c=l.firstContext;null!==c;){if(c.context===r){if(1===i.tag){(c=Oa(-1,n&-n)).tag=2;var u=i.updateQueue;if(null!==u){var d=(u=u.shared).pending;null===d?c.next=c:(c.next=d.next,d.next=c),u.pending=c}}i.lanes|=n,null!==(c=i.alternate)&&(c.lanes|=n),Pa(i.return,n,t),l.lanes|=n;break}c=c.next}}else if(10===i.tag)s=i.type===t.type?null:i.child;else if(18===i.tag){if(null===(s=i.return))throw Error(a(341));s.lanes|=n,null!==(l=s.alternate)&&(l.lanes|=n),Pa(s,n,t),s=i.sibling}else s=i.child;if(null!==s)s.return=i;else for(s=i;null!==s;){if(s===t){s=null;break}if(null!==(i=s.sibling)){i.return=s.return,s=i;break}s=s.return}i=s}ws(e,t,o.children,n),t=t.child}return t;case 9:return o=t.type,r=t.pendingProps.children,ka(t,n),r=r(o=xa(o)),t.flags|=1,ws(e,t,r,n),t.child;case 14:return o=ba(r=t.type,t.pendingProps),Ss(e,t,r,o=ba(r.type,o),n);case 15:return Ps(e,t,t.type,t.pendingProps,n);case 17:return r=t.type,o=t.pendingProps,o=t.elementType===r?o:ba(r,o),Bs(e,t),t.tag=1,No(r)?(e=!0,Do(t)):e=!1,ka(t,n),Ga(t,r,o),Ua(t,r,o,n),Ms(null,t,r,!0,e,n);case 19:return Zs(e,t,n);case 22:return ks(e,t,n)}throw Error(a(156,t.tag))};var $c="function"===typeof reportError?reportError:function(e){console.error(e)};function Jc(e){this._internalRoot=e}function Kc(e){this._internalRoot=e}function Qc(e){return!(!e||1!==e.nodeType&&9!==e.nodeType&&11!==e.nodeType)}function Yc(e){return!(!e||1!==e.nodeType&&9!==e.nodeType&&11!==e.nodeType&&(8!==e.nodeType||" react-mount-point-unstable "!==e.nodeValue))}function Xc(){}function eu(e,t,n,r,o){var a=n._reactRootContainer;if(a){var i=a;if("function"===typeof o){var s=o;o=function(){var e=Wc(i);s.call(e)}}Gc(t,i,e,o)}else i=function(e,t,n,r,o){if(o){if("function"===typeof r){var a=r;r=function(){var e=Wc(i);a.call(e)}}var i=Bc(t,r,e,0,null,!1,0,"",Xc);return e._reactRootContainer=i,e[ho]=i.current,Zr(8===e.nodeType?e.parentNode:e),uc(),i}for(;o=e.lastChild;)e.removeChild(o);if("function"===typeof r){var s=r;r=function(){var e=Wc(l);s.call(e)}}var l=Hc(e,0,!1,null,0,!1,0,"",Xc);return e._reactRootContainer=l,e[ho]=l.current,Zr(8===e.nodeType?e.parentNode:e),uc((function(){Gc(t,l,n,r)})),l}(n,t,e,o,r);return Wc(i)}Kc.prototype.render=Jc.prototype.render=function(e){var t=this._internalRoot;if(null===t)throw Error(a(409));Gc(e,t,null,null)},Kc.prototype.unmount=Jc.prototype.unmount=function(){var e=this._internalRoot;if(null!==e){this._internalRoot=null;var t=e.containerInfo;uc((function(){Gc(null,e,null,null)})),t[ho]=null}},Kc.prototype.unstable_scheduleHydration=function(e){if(e){var t=Pt();e={blockedOn:null,target:e,priority:t};for(var n=0;n<Nt.length&&0!==t&&t<Nt[n].priority;n++);Nt.splice(n,0,e),0===n&&Dt(e)}},wt=function(e){switch(e.tag){case 3:var t=e.stateNode;if(t.current.memoizedState.isDehydrated){var n=dt(t.pendingLanes);0!==n&&(yt(t,1|n),rc(t,Qe()),0===(6&Al)&&(Zl=Qe()+500,Bo()))}break;case 13:uc((function(){var t=Fa(e,1);if(null!==t){var n=ec();nc(t,e,1,n)}})),qc(e,1)}},Tt=function(e){if(13===e.tag){var t=Fa(e,134217728);if(null!==t)nc(t,e,134217728,ec());qc(e,134217728)}},St=function(e){if(13===e.tag){var t=tc(e),n=Fa(e,t);if(null!==n)nc(n,e,t,ec());qc(e,t)}},Pt=function(){return gt},kt=function(e,t){var n=gt;try{return gt=e,t()}finally{gt=n}},Te=function(e,t,n){switch(t){case"input":if(Y(e,n),t=n.name,"radio"===n.type&&null!=t){for(n=e;n.parentNode;)n=n.parentNode;for(n=n.querySelectorAll("input[name="+JSON.stringify(""+t)+'][type="radio"]'),t=0;t<n.length;t++){var r=n[t];if(r!==e&&r.form===e.form){var o=To(r);if(!o)throw Error(a(90));q(r),Y(r,o)}}}break;case"textarea":ae(e,n);break;case"select":null!=(t=n.value)&&ne(e,!!n.multiple,t,!1)}},Ae=cc,Me=uc;var tu={usingClientEntryPoint:!1,Events:[_o,wo,To,xe,Ce,cc]},nu={findFiberByHostInstance:go,bundleType:0,version:"18.2.0",rendererPackageName:"react-dom"},ru={bundleType:nu.bundleType,version:nu.version,rendererPackageName:nu.rendererPackageName,rendererConfig:nu.rendererConfig,overrideHookState:null,overrideHookStateDeletePath:null,overrideHookStateRenamePath:null,overrideProps:null,overridePropsDeletePath:null,overridePropsRenamePath:null,setErrorHandler:null,setSuspenseHandler:null,scheduleUpdate:null,currentDispatcherRef:_.ReactCurrentDispatcher,findHostInstanceByFiber:function(e){return null===(e=We(e))?null:e.stateNode},findFiberByHostInstance:nu.findFiberByHostInstance||function(){return null},findHostInstancesForRefresh:null,scheduleRefresh:null,scheduleRoot:null,setRefreshHandler:null,getCurrentFiber:null,reconcilerVersion:"18.2.0-next-9e3b772b8-20220608"};if("undefined"!==typeof __REACT_DEVTOOLS_GLOBAL_HOOK__){var ou=__REACT_DEVTOOLS_GLOBAL_HOOK__;if(!ou.isDisabled&&ou.supportsFiber)try{ot=ou.inject(ru),at=ou}catch(ue){}}t.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED=tu,t.createPortal=function(e,t){var n=2<arguments.length&&void 0!==arguments[2]?arguments[2]:null;if(!Qc(t))throw Error(a(200));return jc(e,t,null,n)},t.createRoot=function(e,t){if(!Qc(e))throw Error(a(299));var n=!1,r="",o=$c;return null!==t&&void 0!==t&&(!0===t.unstable_strictMode&&(n=!0),void 0!==t.identifierPrefix&&(r=t.identifierPrefix),void 0!==t.onRecoverableError&&(o=t.onRecoverableError)),t=Hc(e,1,!1,null,0,n,0,r,o),e[ho]=t.current,Zr(8===e.nodeType?e.parentNode:e),new Jc(t)},t.findDOMNode=function(e){if(null==e)return null;if(1===e.nodeType)return e;var t=e._reactInternals;if(void 0===t){if("function"===typeof e.render)throw Error(a(188));throw e=Object.keys(e).join(","),Error(a(268,e))}return e=null===(e=We(t))?null:e.stateNode},t.flushSync=function(e){return uc(e)},t.hydrate=function(e,t,n){if(!Yc(t))throw Error(a(200));return eu(null,e,t,!0,n)},t.hydrateRoot=function(e,t,n){if(!Qc(e))throw Error(a(405));var r=null!=n&&n.hydratedSources||null,o=!1,i="",s=$c;if(null!==n&&void 0!==n&&(!0===n.unstable_strictMode&&(o=!0),void 0!==n.identifierPrefix&&(i=n.identifierPrefix),void 0!==n.onRecoverableError&&(s=n.onRecoverableError)),t=Bc(t,null,e,1,null!=n?n:null,o,0,i,s),e[ho]=t.current,Zr(e),r)for(e=0;e<r.length;e++)o=(o=(n=r[e])._getVersion)(n._source),null==t.mutableSourceEagerHydrationData?t.mutableSourceEagerHydrationData=[n,o]:t.mutableSourceEagerHydrationData.push(n,o);return new Kc(t)},t.render=function(e,t,n){if(!Yc(t))throw Error(a(200));return eu(null,e,t,!1,n)},t.unmountComponentAtNode=function(e){if(!Yc(e))throw Error(a(40));return!!e._reactRootContainer&&(uc((function(){eu(null,null,e,!1,(function(){e._reactRootContainer=null,e[ho]=null}))})),!0)},t.unstable_batchedUpdates=cc,t.unstable_renderSubtreeIntoContainer=function(e,t,n,r){if(!Yc(n))throw Error(a(200));if(null==e||void 0===e._reactInternals)throw Error(a(38));return eu(e,t,n,!1,r)},t.version="18.2.0-next-9e3b772b8-20220608"},1250:function(e,t,n){"use strict";var r=n(4164);t.createRoot=r.createRoot,t.hydrateRoot=r.hydrateRoot},4164:function(e,t,n){"use strict";!function e(){if("undefined"!==typeof __REACT_DEVTOOLS_GLOBAL_HOOK__&&"function"===typeof __REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE)try{__REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE(e)}catch(t){console.error(t)}}(),e.exports=n(4463)},6374:function(e,t,n){"use strict";var r=n(2791),o=Symbol.for("react.element"),a=Symbol.for("react.fragment"),i=Object.prototype.hasOwnProperty,s=r.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED.ReactCurrentOwner,l={key:!0,ref:!0,__self:!0,__source:!0};function c(e,t,n){var r,a={},c=null,u=null;for(r in void 0!==n&&(c=""+n),void 0!==t.key&&(c=""+t.key),void 0!==t.ref&&(u=t.ref),t)i.call(t,r)&&!l.hasOwnProperty(r)&&(a[r]=t[r]);if(e&&e.defaultProps)for(r in t=e.defaultProps)void 0===a[r]&&(a[r]=t[r]);return{$$typeof:o,type:e,key:c,ref:u,props:a,_owner:s.current}}t.Fragment=a,t.jsx=c,t.jsxs=c},9117:function(e,t){"use strict";var n=Symbol.for("react.element"),r=Symbol.for("react.portal"),o=Symbol.for("react.fragment"),a=Symbol.for("react.strict_mode"),i=Symbol.for("react.profiler"),s=Symbol.for("react.provider"),l=Symbol.for("react.context"),c=Symbol.for("react.forward_ref"),u=Symbol.for("react.suspense"),d=Symbol.for("react.memo"),f=Symbol.for("react.lazy"),p=Symbol.iterator;var m={isMounted:function(){return!1},enqueueForceUpdate:function(){},enqueueReplaceState:function(){},enqueueSetState:function(){}},h=Object.assign,v={};function b(e,t,n){this.props=e,this.context=t,this.refs=v,this.updater=n||m}function y(){}function g(e,t,n){this.props=e,this.context=t,this.refs=v,this.updater=n||m}b.prototype.isReactComponent={},b.prototype.setState=function(e,t){if("object"!==typeof e&&"function"!==typeof e&&null!=e)throw Error("setState(...): takes an object of state variables to update or a function which returns an object of state variables.");this.updater.enqueueSetState(this,e,t,"setState")},b.prototype.forceUpdate=function(e){this.updater.enqueueForceUpdate(this,e,"forceUpdate")},y.prototype=b.prototype;var _=g.prototype=new y;_.constructor=g,h(_,b.prototype),_.isPureReactComponent=!0;var w=Array.isArray,T=Object.prototype.hasOwnProperty,S={current:null},P={key:!0,ref:!0,__self:!0,__source:!0};function k(e,t,r){var o,a={},i=null,s=null;if(null!=t)for(o in void 0!==t.ref&&(s=t.ref),void 0!==t.key&&(i=""+t.key),t)T.call(t,o)&&!P.hasOwnProperty(o)&&(a[o]=t[o]);var l=arguments.length-2;if(1===l)a.children=r;else if(1<l){for(var c=Array(l),u=0;u<l;u++)c[u]=arguments[u+2];a.children=c}if(e&&e.defaultProps)for(o in l=e.defaultProps)void 0===a[o]&&(a[o]=l[o]);return{$$typeof:n,type:e,key:i,ref:s,props:a,_owner:S.current}}function x(e){return"object"===typeof e&&null!==e&&e.$$typeof===n}var C=/\/+/g;function A(e,t){return"object"===typeof e&&null!==e&&null!=e.key?function(e){var t={"=":"=0",":":"=2"};return"$"+e.replace(/[=:]/g,(function(e){return t[e]}))}(""+e.key):t.toString(36)}function M(e,t,o,a,i){var s=typeof e;"undefined"!==s&&"boolean"!==s||(e=null);var l=!1;if(null===e)l=!0;else switch(s){case"string":case"number":l=!0;break;case"object":switch(e.$$typeof){case n:case r:l=!0}}if(l)return i=i(l=e),e=""===a?"."+A(l,0):a,w(i)?(o="",null!=e&&(o=e.replace(C,"$&/")+"/"),M(i,t,o,"",(function(e){return e}))):null!=i&&(x(i)&&(i=function(e,t){return{$$typeof:n,type:e.type,key:t,ref:e.ref,props:e.props,_owner:e._owner}}(i,o+(!i.key||l&&l.key===i.key?"":(""+i.key).replace(C,"$&/")+"/")+e)),t.push(i)),1;if(l=0,a=""===a?".":a+":",w(e))for(var c=0;c<e.length;c++){var u=a+A(s=e[c],c);l+=M(s,t,o,u,i)}else if(u=function(e){return null===e||"object"!==typeof e?null:"function"===typeof(e=p&&e[p]||e["@@iterator"])?e:null}(e),"function"===typeof u)for(e=u.call(e),c=0;!(s=e.next()).done;)l+=M(s=s.value,t,o,u=a+A(s,c++),i);else if("object"===s)throw t=String(e),Error("Objects are not valid as a React child (found: "+("[object Object]"===t?"object with keys {"+Object.keys(e).join(", ")+"}":t)+"). If you meant to render a collection of children, use an array instead.");return l}function F(e,t,n){if(null==e)return e;var r=[],o=0;return M(e,r,"","",(function(e){return t.call(n,e,o++)})),r}function E(e){if(-1===e._status){var t=e._result;(t=t()).then((function(t){0!==e._status&&-1!==e._status||(e._status=1,e._result=t)}),(function(t){0!==e._status&&-1!==e._status||(e._status=2,e._result=t)})),-1===e._status&&(e._status=0,e._result=t)}if(1===e._status)return e._result.default;throw e._result}var R={current:null},N={transition:null},O={ReactCurrentDispatcher:R,ReactCurrentBatchConfig:N,ReactCurrentOwner:S};t.Children={map:F,forEach:function(e,t,n){F(e,(function(){t.apply(this,arguments)}),n)},count:function(e){var t=0;return F(e,(function(){t++})),t},toArray:function(e){return F(e,(function(e){return e}))||[]},only:function(e){if(!x(e))throw Error("React.Children.only expected to receive a single React element child.");return e}},t.Component=b,t.Fragment=o,t.Profiler=i,t.PureComponent=g,t.StrictMode=a,t.Suspense=u,t.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED=O,t.cloneElement=function(e,t,r){if(null===e||void 0===e)throw Error("React.cloneElement(...): The argument must be a React element, but you passed "+e+".");var o=h({},e.props),a=e.key,i=e.ref,s=e._owner;if(null!=t){if(void 0!==t.ref&&(i=t.ref,s=S.current),void 0!==t.key&&(a=""+t.key),e.type&&e.type.defaultProps)var l=e.type.defaultProps;for(c in t)T.call(t,c)&&!P.hasOwnProperty(c)&&(o[c]=void 0===t[c]&&void 0!==l?l[c]:t[c])}var c=arguments.length-2;if(1===c)o.children=r;else if(1<c){l=Array(c);for(var u=0;u<c;u++)l[u]=arguments[u+2];o.children=l}return{$$typeof:n,type:e.type,key:a,ref:i,props:o,_owner:s}},t.createContext=function(e){return(e={$$typeof:l,_currentValue:e,_currentValue2:e,_threadCount:0,Provider:null,Consumer:null,_defaultValue:null,_globalName:null}).Provider={$$typeof:s,_context:e},e.Consumer=e},t.createElement=k,t.createFactory=function(e){var t=k.bind(null,e);return t.type=e,t},t.createRef=function(){return{current:null}},t.forwardRef=function(e){return{$$typeof:c,render:e}},t.isValidElement=x,t.lazy=function(e){return{$$typeof:f,_payload:{_status:-1,_result:e},_init:E}},t.memo=function(e,t){return{$$typeof:d,type:e,compare:void 0===t?null:t}},t.startTransition=function(e){var t=N.transition;N.transition={};try{e()}finally{N.transition=t}},t.unstable_act=function(){throw Error("act(...) is not supported in production builds of React.")},t.useCallback=function(e,t){return R.current.useCallback(e,t)},t.useContext=function(e){return R.current.useContext(e)},t.useDebugValue=function(){},t.useDeferredValue=function(e){return R.current.useDeferredValue(e)},t.useEffect=function(e,t){return R.current.useEffect(e,t)},t.useId=function(){return R.current.useId()},t.useImperativeHandle=function(e,t,n){return R.current.useImperativeHandle(e,t,n)},t.useInsertionEffect=function(e,t){return R.current.useInsertionEffect(e,t)},t.useLayoutEffect=function(e,t){return R.current.useLayoutEffect(e,t)},t.useMemo=function(e,t){return R.current.useMemo(e,t)},t.useReducer=function(e,t,n){return R.current.useReducer(e,t,n)},t.useRef=function(e){return R.current.useRef(e)},t.useState=function(e){return R.current.useState(e)},t.useSyncExternalStore=function(e,t,n){return R.current.useSyncExternalStore(e,t,n)},t.useTransition=function(){return R.current.useTransition()},t.version="18.2.0"},2791:function(e,t,n){"use strict";e.exports=n(9117)},184:function(e,t,n){"use strict";e.exports=n(6374)},6813:function(e,t){"use strict";function n(e,t){var n=e.length;e.push(t);e:for(;0<n;){var r=n-1>>>1,o=e[r];if(!(0<a(o,t)))break e;e[r]=t,e[n]=o,n=r}}function r(e){return 0===e.length?null:e[0]}function o(e){if(0===e.length)return null;var t=e[0],n=e.pop();if(n!==t){e[0]=n;e:for(var r=0,o=e.length,i=o>>>1;r<i;){var s=2*(r+1)-1,l=e[s],c=s+1,u=e[c];if(0>a(l,n))c<o&&0>a(u,l)?(e[r]=u,e[c]=n,r=c):(e[r]=l,e[s]=n,r=s);else{if(!(c<o&&0>a(u,n)))break e;e[r]=u,e[c]=n,r=c}}}return t}function a(e,t){var n=e.sortIndex-t.sortIndex;return 0!==n?n:e.id-t.id}if("object"===typeof performance&&"function"===typeof performance.now){var i=performance;t.unstable_now=function(){return i.now()}}else{var s=Date,l=s.now();t.unstable_now=function(){return s.now()-l}}var c=[],u=[],d=1,f=null,p=3,m=!1,h=!1,v=!1,b="function"===typeof setTimeout?setTimeout:null,y="function"===typeof clearTimeout?clearTimeout:null,g="undefined"!==typeof setImmediate?setImmediate:null;function _(e){for(var t=r(u);null!==t;){if(null===t.callback)o(u);else{if(!(t.startTime<=e))break;o(u),t.sortIndex=t.expirationTime,n(c,t)}t=r(u)}}function w(e){if(v=!1,_(e),!h)if(null!==r(c))h=!0,N(T);else{var t=r(u);null!==t&&O(w,t.startTime-e)}}function T(e,n){h=!1,v&&(v=!1,y(x),x=-1),m=!0;var a=p;try{for(_(n),f=r(c);null!==f&&(!(f.expirationTime>n)||e&&!M());){var i=f.callback;if("function"===typeof i){f.callback=null,p=f.priorityLevel;var s=i(f.expirationTime<=n);n=t.unstable_now(),"function"===typeof s?f.callback=s:f===r(c)&&o(c),_(n)}else o(c);f=r(c)}if(null!==f)var l=!0;else{var d=r(u);null!==d&&O(w,d.startTime-n),l=!1}return l}finally{f=null,p=a,m=!1}}"undefined"!==typeof navigator&&void 0!==navigator.scheduling&&void 0!==navigator.scheduling.isInputPending&&navigator.scheduling.isInputPending.bind(navigator.scheduling);var S,P=!1,k=null,x=-1,C=5,A=-1;function M(){return!(t.unstable_now()-A<C)}function F(){if(null!==k){var e=t.unstable_now();A=e;var n=!0;try{n=k(!0,e)}finally{n?S():(P=!1,k=null)}}else P=!1}if("function"===typeof g)S=function(){g(F)};else if("undefined"!==typeof MessageChannel){var E=new MessageChannel,R=E.port2;E.port1.onmessage=F,S=function(){R.postMessage(null)}}else S=function(){b(F,0)};function N(e){k=e,P||(P=!0,S())}function O(e,n){x=b((function(){e(t.unstable_now())}),n)}t.unstable_IdlePriority=5,t.unstable_ImmediatePriority=1,t.unstable_LowPriority=4,t.unstable_NormalPriority=3,t.unstable_Profiling=null,t.unstable_UserBlockingPriority=2,t.unstable_cancelCallback=function(e){e.callback=null},t.unstable_continueExecution=function(){h||m||(h=!0,N(T))},t.unstable_forceFrameRate=function(e){0>e||125<e?console.error("forceFrameRate takes a positive int between 0 and 125, forcing frame rates higher than 125 fps is not supported"):C=0<e?Math.floor(1e3/e):5},t.unstable_getCurrentPriorityLevel=function(){return p},t.unstable_getFirstCallbackNode=function(){return r(c)},t.unstable_next=function(e){switch(p){case 1:case 2:case 3:var t=3;break;default:t=p}var n=p;p=t;try{return e()}finally{p=n}},t.unstable_pauseExecution=function(){},t.unstable_requestPaint=function(){},t.unstable_runWithPriority=function(e,t){switch(e){case 1:case 2:case 3:case 4:case 5:break;default:e=3}var n=p;p=e;try{return t()}finally{p=n}},t.unstable_scheduleCallback=function(e,o,a){var i=t.unstable_now();switch("object"===typeof a&&null!==a?a="number"===typeof(a=a.delay)&&0<a?i+a:i:a=i,e){case 1:var s=-1;break;case 2:s=250;break;case 5:s=1073741823;break;case 4:s=1e4;break;default:s=5e3}return e={id:d++,callback:o,priorityLevel:e,startTime:a,expirationTime:s=a+s,sortIndex:-1},a>i?(e.sortIndex=a,n(u,e),null===r(c)&&e===r(u)&&(v?(y(x),x=-1):v=!0,O(w,a-i))):(e.sortIndex=s,n(c,e),h||m||(h=!0,N(T))),e},t.unstable_shouldYield=M,t.unstable_wrapCallback=function(e){var t=p;return function(){var n=p;p=t;try{return e.apply(this,arguments)}finally{p=n}}}},5296:function(e,t,n){"use strict";e.exports=n(6813)},4836:function(e){e.exports=function(e){return e&&e.__esModule?e:{default:e}},e.exports.__esModule=!0,e.exports.default=e.exports},907:function(e,t,n){"use strict";function r(e,t){(null==t||t>e.length)&&(t=e.length);for(var n=0,r=new Array(t);n<t;n++)r[n]=e[n];return r}n.d(t,{Z:function(){return r}})},4942:function(e,t,n){"use strict";function r(e,t,n){return t in e?Object.defineProperty(e,t,{value:n,enumerable:!0,configurable:!0,writable:!0}):e[t]=n,e}n.d(t,{Z:function(){return r}})},7462:function(e,t,n){"use strict";function r(){return r=Object.assign?Object.assign.bind():function(e){for(var t=1;t<arguments.length;t++){var n=arguments[t];for(var r in n)Object.prototype.hasOwnProperty.call(n,r)&&(e[r]=n[r])}return e},r.apply(this,arguments)}n.d(t,{Z:function(){return r}})},3366:function(e,t,n){"use strict";function r(e,t){if(null==e)return{};var n,r,o={},a=Object.keys(e);for(r=0;r<a.length;r++)n=a[r],t.indexOf(n)>=0||(o[n]=e[n]);return o}n.d(t,{Z:function(){return r}})},885:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(181);function o(e,t){return function(e){if(Array.isArray(e))return e}(e)||function(e,t){var n=null==e?null:"undefined"!==typeof Symbol&&e[Symbol.iterator]||e["@@iterator"];if(null!=n){var r,o,a=[],i=!0,s=!1;try{for(n=n.call(e);!(i=(r=n.next()).done)&&(a.push(r.value),!t||a.length!==t);i=!0);}catch(l){s=!0,o=l}finally{try{i||null==n.return||n.return()}finally{if(s)throw o}}return a}}(e,t)||(0,r.Z)(e,t)||function(){throw new TypeError("Invalid attempt to destructure non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}},2982:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(907);var o=n(181);function a(e){return function(e){if(Array.isArray(e))return(0,r.Z)(e)}(e)||function(e){if("undefined"!==typeof Symbol&&null!=e[Symbol.iterator]||null!=e["@@iterator"])return Array.from(e)}(e)||(0,o.Z)(e)||function(){throw new TypeError("Invalid attempt to spread non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}},181:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(907);function o(e,t){if(e){if("string"===typeof e)return(0,r.Z)(e,t);var n=Object.prototype.toString.call(e).slice(8,-1);return"Object"===n&&e.constructor&&(n=e.constructor.name),"Map"===n||"Set"===n?Array.from(e):"Arguments"===n||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(n)?(0,r.Z)(e,t):void 0}}}},t={};function n(r){var o=t[r];if(void 0!==o)return o.exports;var a=t[r]={exports:{}};return e[r].call(a.exports,a,a.exports,n),a.exports}n.n=function(e){var t=e&&e.__esModule?function(){return e.default}:function(){return e};return n.d(t,{a:t}),t},function(){var e,t=Object.getPrototypeOf?function(e){return Object.getPrototypeOf(e)}:function(e){return e.__proto__};n.t=function(r,o){if(1&o&&(r=this(r)),8&o)return r;if("object"===typeof r&&r){if(4&o&&r.__esModule)return r;if(16&o&&"function"===typeof r.then)return r}var a=Object.create(null);n.r(a);var i={};e=e||[null,t({}),t([]),t(t)];for(var s=2&o&&r;"object"==typeof s&&!~e.indexOf(s);s=t(s))Object.getOwnPropertyNames(s).forEach((function(e){i[e]=function(){return r[e]}}));return i.default=function(){return r},n.d(a,i),a}}(),n.d=function(e,t){for(var r in t)n.o(t,r)&&!n.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},n.o=function(e,t){return Object.prototype.hasOwnProperty.call(e,t)},n.r=function(e){"undefined"!==typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},function(){"use strict";var e=n(2791),t=n(1250),r=n(7462),o=n(5513),a=(n(76),n(9886)),i=(n(2110),n(5438)),s=n(9140),l=n(2561),c=(0,a.w)((function(t,n){var r=t.styles,o=(0,s.O)([r],void 0,(0,e.useContext)(a.T)),c=(0,e.useRef)();return(0,l.j)((function(){var e=n.key+"-global",t=new n.sheet.constructor({key:e,nonce:n.sheet.nonce,container:n.sheet.container,speedy:n.sheet.isSpeedy}),r=!1,a=document.querySelector('style[data-emotion="'+e+" "+o.name+'"]');return n.sheet.tags.length&&(t.before=n.sheet.tags[0]),null!==a&&(r=!0,a.setAttribute("data-emotion",e),t.hydrate([a])),c.current=[t,r],function(){t.flush()}}),[n]),(0,l.j)((function(){var e=c.current,t=e[0];if(e[1])e[1]=!1;else{if(void 0!==o.next&&(0,i.My)(n,o.next,!0),t.tags.length){var r=t.tags[t.tags.length-1].nextElementSibling;t.before=r,t.flush()}n.insert("",o,t,!1)}}),[n,o.name]),null}));function u(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];return(0,s.O)(t)}var d=function(){var e=u.apply(void 0,arguments),t="animation-"+e.name;return{name:t,styles:"@keyframes "+t+"{"+e.styles+"}",anim:1,toString:function(){return"_EMO_"+this.name+"_"+this.styles+"_EMO_"}}};var f=n(184);function p(e){var t=e.styles,n=e.defaultTheme,r=void 0===n?{}:n,o="function"===typeof t?function(e){return t(void 0===(n=e)||null===n||0===Object.keys(n).length?r:e);var n}:t;return(0,f.jsx)(c,{styles:o})}var m=n(4205);var h=function(e){return(0,f.jsx)(p,(0,r.Z)({},e,{defaultTheme:m.Z}))},v=function(e,t){return(0,r.Z)({WebkitFontSmoothing:"antialiased",MozOsxFontSmoothing:"grayscale",boxSizing:"border-box",WebkitTextSizeAdjust:"100%"},t&&{colorScheme:e.palette.mode})},b=function(e){return(0,r.Z)({color:(e.vars||e).palette.text.primary},e.typography.body1,{backgroundColor:(e.vars||e).palette.background.default,"@media print":{backgroundColor:(e.vars||e).palette.common.white}})};var y=function(t){var n=(0,o.Z)({props:t,name:"MuiCssBaseline"}),a=n.children,i=n.enableColorScheme,s=void 0!==i&&i;return(0,f.jsxs)(e.Fragment,{children:[(0,f.jsx)(h,{styles:function(e){return function(e){var t,n,o={html:v(e,arguments.length>1&&void 0!==arguments[1]&&arguments[1]),"*, *::before, *::after":{boxSizing:"inherit"},"strong, b":{fontWeight:e.typography.fontWeightBold},body:(0,r.Z)({margin:0},b(e),{"&::backdrop":{backgroundColor:(e.vars||e).palette.background.default}})},a=null==(t=e.components)||null==(n=t.MuiCssBaseline)?void 0:n.styleOverrides;return a&&(o=[o,a]),o}(e,s)}}),a]})},g=n(885),_=n(4942),w=n(3366),T=n(8182),S=n(7312),P=n(1217),k=n(4419),x=n(8691),C=(0,n(4046).ZP)(),A=n(5080),M=["className","component","disableGutters","fixed","maxWidth","classes"],F=(0,A.Z)(),E=C("div",{name:"MuiContainer",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t["maxWidth".concat((0,S.Z)(String(n.maxWidth)))],n.fixed&&t.fixed,n.disableGutters&&t.disableGutters]}}),R=function(e){return(0,x.Z)({props:e,name:"MuiContainer",defaultTheme:F})},N=function(e,t){var n=e.classes,r=e.fixed,o=e.disableGutters,a=e.maxWidth,i={root:["root",a&&"maxWidth".concat((0,S.Z)(String(a))),r&&"fixed",o&&"disableGutters"]};return(0,k.Z)(i,(function(e){return(0,P.Z)(t,e)}),n)};var O=n(9853),V=n(277),L=function(){var t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},n=t.createStyledComponent,o=void 0===n?E:n,a=t.useThemeProps,i=void 0===a?R:a,s=t.componentName,l=void 0===s?"MuiContainer":s,c=o((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({width:"100%",marginLeft:"auto",boxSizing:"border-box",marginRight:"auto",display:"block"},!n.disableGutters&&(0,_.Z)({paddingLeft:t.spacing(2),paddingRight:t.spacing(2)},t.breakpoints.up("sm"),{paddingLeft:t.spacing(3),paddingRight:t.spacing(3)}))}),(function(e){var t=e.theme;return e.ownerState.fixed&&Object.keys(t.breakpoints.values).reduce((function(e,n){var r=n,o=t.breakpoints.values[r];return 0!==o&&(e[t.breakpoints.up(r)]={maxWidth:"".concat(o).concat(t.breakpoints.unit)}),e}),{})}),(function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({},"xs"===n.maxWidth&&(0,_.Z)({},t.breakpoints.up("xs"),{maxWidth:Math.max(t.breakpoints.values.xs,444)}),n.maxWidth&&"xs"!==n.maxWidth&&(0,_.Z)({},t.breakpoints.up(n.maxWidth),{maxWidth:"".concat(t.breakpoints.values[n.maxWidth]).concat(t.breakpoints.unit)}))})),u=e.forwardRef((function(e,t){var n=i(e),o=n.className,a=n.component,s=void 0===a?"div":a,u=n.disableGutters,d=void 0!==u&&u,p=n.fixed,m=void 0!==p&&p,h=n.maxWidth,v=void 0===h?"lg":h,b=(0,w.Z)(n,M),y=(0,r.Z)({},n,{component:s,disableGutters:d,fixed:m,maxWidth:v}),g=N(y,l);return(0,f.jsx)(c,(0,r.Z)({as:s,ownerState:y,className:(0,T.Z)(g.root,o),ref:t},b))}));return u}({createStyledComponent:(0,V.ZP)("div",{name:"MuiContainer",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t["maxWidth".concat((0,O.Z)(String(n.maxWidth)))],n.fixed&&t.fixed,n.disableGutters&&t.disableGutters]}}),useThemeProps:function(e){return(0,o.Z)({props:e,name:"MuiContainer"})}}),D=L,z=n(2421),I=n(104),H=n(2982),j=n(2466),Z=n(114),B=["sx"];function G(e){var t,n=e.sx,o=function(e){var t={systemProps:{},otherProps:{}};return Object.keys(e).forEach((function(n){Z.Gc[n]?t.systemProps[n]=e[n]:t.otherProps[n]=e[n]})),t}((0,w.Z)(e,B)),a=o.systemProps,i=o.otherProps;return t=Array.isArray(n)?[a].concat((0,H.Z)(n)):"function"===typeof n?function(){var e=n.apply(void 0,arguments);return(0,j.P)(e)?(0,r.Z)({},a,e):a}:(0,r.Z)({},a,n),(0,r.Z)({},i,{sx:t})}var W=n(886),U=["className","component"];var q=n(5902),$=n(4360),J=function(){var t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},n=t.defaultTheme,o=t.defaultClassName,a=void 0===o?"MuiBox-root":o,i=t.generateClassName,s=t.styleFunctionSx,l=void 0===s?I.Z:s,c=(0,z.ZP)("div",{shouldForwardProp:function(e){return"theme"!==e&&"sx"!==e&&"as"!==e}})(l),u=e.forwardRef((function(e,t){var o=(0,W.Z)(n),s=G(e),l=s.className,u=s.component,d=void 0===u?"div":u,p=(0,w.Z)(s,U);return(0,f.jsx)(c,(0,r.Z)({as:d,ref:t,className:(0,T.Z)(l,i?i(a):a),theme:o},p))}));return u}({defaultTheme:(0,$.Z)(),defaultClassName:"MuiBox-root",generateClassName:q.Z.generate}),K=J,Q=JSON.parse('{"e":17,"C":[{"nctid":"NCT03958890","version_a":4,"version_b":5,"version_a_date":"2020-08-06","version_b_date":"2021-11-08","pom_a":[{"label":"1.","content":"PFS[ Time Frame: from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 2 years ]Progression-free survival (assessed by independent radiological review committee (IRRC) based on RECIST v1.1)"}],"pom_b":[{"label":"1.","content":"PFS[ Time Frame: from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 2 years ]Progression-free survival (assessed by independent radiological review committee (IRRC) based on RECIST v1.1)"},{"label":"2.","content":"OS[ Time Frame: from the date of first dose unitl the date of death from any cause\uff0cassessed up to 2 years ]Overall survival (OS)"}],"first_posted":"No date provided","completion_date":"December 30, 2022","primary_completion_date":"April 30, 2022","start_date":"June 19, 2019","last_update_posted":"April 29, 2022"},{"nctid":"NCT00785356","version_a":5,"version_b":6,"version_a_date":"2014-06-23","version_b_date":"2014-08-05","pom_a":[{"label":"1.","content":"The comparison between the 50 mg Proellex\xae dose level and placebo in the change in hemoglobin from baseline to 3 months.[ Time Frame: 3 months ]"}],"pom_b":[{"label":"1.","content":"The Comparison Between the 50 mg Proellex\xae Dose Level and Placebo in the Change in Hemoglobin From Baseline to 3 Months.[ Time Frame: 3 months ]"}],"first_posted":"August 21, 2014","completion_date":"August 2009","primary_completion_date":"August 2009","start_date":"October 2008","last_update_posted":"August 21, 2014"},{"nctid":"NCT00091676","version_a":5,"version_b":6,"version_a_date":"2007-09-11","version_b_date":"2007-11-29","pom_a":[{"label":"1.","content":"To demonstrate prolongation of the period of Disease Free Survival (significant prolongation of the period of complete remission) in idiotype vaccine treated patients"}],"pom_b":[{"label":"1.","content":"To demonstrate prolongation of the period of Disease Free Survival (significant prolongation of the period of complete remission) in idiotype vaccine treated patients[ Time Frame: until date of relapse ]"}],"first_posted":"No date provided","completion_date":"December 2012","primary_completion_date":"December 2012","start_date":"January 2000","last_update_posted":"February 3, 2012"},{"nctid":"NCT00384176","version_a":4,"version_b":5,"version_a_date":"2007-02-15","version_b_date":"2007-10-09","pom_a":[{"label":"1.","content":"The efficacy of AZD2171 in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."}],"pom_b":[{"label":"1.","content":"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."}],"first_posted":"November 28, 2012","completion_date":"August 19, 2015","primary_completion_date":"November 15, 2009","start_date":"August 30, 2006","last_update_posted":"April 14, 2017"},{"nctid":"NCT00384176","version_a":5,"version_b":6,"version_a_date":"2007-10-09","version_b_date":"2007-12-15","pom_a":[{"label":"1.","content":"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival."}],"pom_b":[{"label":"1.","content":"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival.[ Time Frame: assessed after each visit over 15 months ]"}],"first_posted":"November 28, 2012","completion_date":"August 19, 2015","primary_completion_date":"November 15, 2009","start_date":"August 30, 2006","last_update_posted":"April 14, 2017"},{"nctid":"NCT00384176","version_a":30,"version_b":31,"version_a_date":"2011-03-09","version_b_date":"2011-04-06","pom_a":[{"label":"1.","content":"The efficacy of Cediranib in combination with FOLFOX compared to the efficacy of bevacizumab in combination with FOLFOX by assessment of progression free survival.[ Time Frame: assessed after each visit over 15 months ]"}],"pom_b":[{"label":"1.","content":"Progression Free Survival[ Time Frame: Range of 15 months ]"}],"first_posted":"November 28, 2012","completion_date":"August 19, 2015","primary_completion_date":"November 15, 2009","start_date":"August 30, 2006","last_update_posted":"April 14, 2017"},{"nctid":"NCT00384176","version_a":32,"version_b":33,"version_a_date":"2011-06-13","version_b_date":"2012-10-29","pom_a":[{"label":"1.","content":"Progression Free Survival[ Time Frame: Range of 15 months ]"}],"pom_b":[{"label":"1.","content":"Progression Free Survival[ Time Frame: Baseline then at Weeks 8, 16, 24 and then every 12 weeks until progression ]Progression is defined as the number of months from randomisation until progressive disease based on RECIST (progression of target lesions, clear progression of existing non-target lesions or the appearance of one or more new lesions) or death in the absence of progression."}],"first_posted":"November 28, 2012","completion_date":"August 19, 2015","primary_completion_date":"November 15, 2009","start_date":"August 30, 2006","last_update_posted":"April 14, 2017"},{"nctid":"NCT00092547","version_a":2,"version_b":3,"version_a_date":"2005-09-29","version_b_date":"2006-01-12","pom_a":[],"pom_b":[{"label":"1.","content":"Tolerability."}],"first_posted":"May 4, 2010","completion_date":"June 1, 2015","primary_completion_date":"November 3, 2005","start_date":"October 8, 2003","last_update_posted":"February 20, 2018"},{"nctid":"NCT00092547","version_a":8,"version_b":9,"version_a_date":"2009-05-04","version_b_date":"2009-10-16","pom_a":[{"label":"1.","content":"Tolerability."}],"pom_b":[{"label":"1.","content":"Tolerability[ Time Frame: Days 1 to 15 postvaccination at Day 1, Month 2, and Month 6 ]"}],"first_posted":"May 4, 2010","completion_date":"June 1, 2015","primary_completion_date":"November 3, 2005","start_date":"October 8, 2003","last_update_posted":"February 20, 2018"},{"nctid":"NCT00092547","version_a":9,"version_b":10,"version_a_date":"2009-10-16","version_b_date":"2010-04-09","pom_a":[{"label":"1.","content":"Tolerability[ Time Frame: Days 1 to 15 postvaccination at Day 1, Month 2, and Month 6 ]"}],"pom_b":[{"label":"1.","content":"Number of Participants Reporting Serious Adverse Experiences (SAE) in the Vaccination and Follow-up Phases[ Time Frame: Day 1 through Month 18 ]Tolerability as assessed by the number of participants with clinical adverse experiences in the Vaccination and Follow-up Phases.A serious adverse event is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an \\"other important medical event\\" based on medical judgment."},{"label":"2.","content":"Number of Participants Reporting Serious Adverse Experiences (SAE) in the Extension Phases[ Time Frame: Month 18 to Month 37 ]Tolerability as assessed by the number of participants with clinical adverse experiences in the Extension Phases"},{"label":"3.","content":"Number of Participants Reporting Other (Non-serious) Adverse Experiences in the Vaccination and Follow-up Phases[ Time Frame: Injection site AE are collected from Days 1-5 and non-serious AE from Days 1-15, including the day of vaccination. Other AE (Not Including Serious AE) were not collected in the Extension Phases ]Tolerability as assessed by the number of participants with clinical adverse experiences in the Vaccination and Follow-up Phases"}],"first_posted":"May 4, 2010","completion_date":"June 1, 2015","primary_completion_date":"November 3, 2005","start_date":"October 8, 2003","last_update_posted":"February 20, 2018"},{"nctid":"NCT00092547","version_a":13,"version_b":14,"version_a_date":"2010-08-26","version_b_date":"2011-09-09","pom_a":[{"label":"1.","content":"Number of Participants Reporting Serious Adverse Experiences (SAE) in the Vaccination and Follow-up Phases[ Time Frame: Day 1 through Month 18 ]Tolerability as assessed by the number of participants with clinical adverse experiences in the Vaccination and Follow-up Phases.A serious adverse event is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an \\"other important medical event\\" based on medical judgment."},{"label":"2.","content":"Number of Participants Reporting Serious Adverse Experiences (SAE) in the Extension Phases[ Time Frame: Month 18 to Month 37 ]Tolerability as assessed by the number of participants with clinical adverse experiences in the Extension Phases"},{"label":"3.","content":"Number of Participants Reporting Other (Non-serious) Adverse Experiences in the Vaccination and Follow-up Phases[ Time Frame: Injection site AE are collected from Days 1-5 and non-serious AE from Days 1-15, including the day of vaccination. Other AE (Not Including Serious AE) were not collected in the Extension Phases ]Tolerability as assessed by the number of participants with clinical adverse experiences in the Vaccination and Follow-up Phases"}],"pom_b":[{"label":"1.","content":"Number of Participants Reporting Serious Adverse Experiences (SAE) in the Vaccination and Follow-up Phases[ Time Frame: Day 1 through Month 18 ]Tolerability as assessed by the number of participants with clinical adverse experiences in the Vaccination and Follow-up Phases.A serious adverse event is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an \\"other important medical event\\" based on medical judgment."},{"label":"2.","content":"Number of Participants Reporting Serious Adverse Experiences (SAE) in the Extension Phases[ Time Frame: Month 18 to Month 37 ]Tolerability as assessed by the number of participants with clinical adverse experiences in the Extension Phases"},{"label":"3.","content":"Number of Participants Reporting Other (Non-serious) Adverse Experiences in the Vaccination and Follow-up Phases[ Time Frame: Injection site AE are collected from Days 1-5 and non-serious AE from Days 1-15, including the day of vaccination. Other AE (Not Including Serious AE) were not collected in the Extension Phases ]Tolerability as assessed by the number of participants with clinical adverse experiences in the Vaccination and Follow-up Phases"},{"label":"4.","content":"Percentage of Participants Who Are Seropositive for HPV Type 6 (HPV 6 \u2265 20 mMU/mL) at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]A subject is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. (For HPV 6, the serostatus cutoff is \u2265 20 mMU/mL)."},{"label":"5.","content":"Percentage of Participants Who Are Seropositive for HPV Type 11 (HPV 11 \u2265 16 mMU/mL) at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]A subject is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. (For HPV 11, the serostatus cutoff is \u2265 16 mMU/mL)."},{"label":"6.","content":"Percentage of Participants Who Are Seropositive for HPV Type 16 (HPV 16 \u2265 20 mMU/mL) at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]A subject is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. (For HPV 16, the serostatus cutoff is \u2265 20 mMU/mL)."},{"label":"7.","content":"Percentage of Participants Who Are Seropositive for HPV Type 18 (HPV 18 \u2265 24 mMU/mL) at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]A subject is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. (For HPV 18, the serostatus cutoff is \u2265 24 mMU/mL)."},{"label":"8.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 6 at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]"},{"label":"9.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 11 at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]"},{"label":"10.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 16 at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]"},{"label":"11.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 18 at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]"}],"first_posted":"May 4, 2010","completion_date":"June 1, 2015","primary_completion_date":"November 3, 2005","start_date":"October 8, 2003","last_update_posted":"February 20, 2018"},{"nctid":"NCT00092547","version_a":21,"version_b":22,"version_a_date":"2015-03-24","version_b_date":"2015-06-23","pom_a":[{"label":"1.","content":"Number of Participants Reporting Serious Adverse Experiences (SAE) in the Vaccination and Follow-up Phases[ Time Frame: Day 1 through Month 18 ]Tolerability as assessed by the number of participants with clinical adverse experiences in the Vaccination and Follow-up Phases.A serious adverse event is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an \\"other important medical event\\" based on medical judgment."},{"label":"2.","content":"Number of Participants Reporting Serious Adverse Experiences (SAE) in the Extension Phases[ Time Frame: Month 18 to Month 37 ]Tolerability as assessed by the number of participants with clinical adverse experiences in the Extension Phases"},{"label":"3.","content":"Number of Participants Reporting Other (Non-serious) Adverse Experiences in the Vaccination and Follow-up Phases[ Time Frame: Injection site AE are collected from Days 1-5 and non-serious AE from Days 1-15, including the day of vaccination. Other AE (Not Including Serious AE) were not collected in the Extension Phases ]Tolerability as assessed by the number of participants with clinical adverse experiences in the Vaccination and Follow-up Phases"},{"label":"4.","content":"Percentage of Participants Who Are Seropositive for HPV Type 6 (HPV 6 \u2265 20 mMU/mL) at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]A subject is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. (For HPV 6, the serostatus cutoff is \u2265 20 mMU/mL)."},{"label":"5.","content":"Percentage of Participants Who Are Seropositive for HPV Type 11 (HPV 11 \u2265 16 mMU/mL) at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]A subject is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. (For HPV 11, the serostatus cutoff is \u2265 16 mMU/mL)."},{"label":"6.","content":"Percentage of Participants Who Are Seropositive for HPV Type 16 (HPV 16 \u2265 20 mMU/mL) at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]A subject is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. (For HPV 16, the serostatus cutoff is \u2265 20 mMU/mL)."},{"label":"7.","content":"Percentage of Participants Who Are Seropositive for HPV Type 18 (HPV 18 \u2265 24 mMU/mL) at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]A subject is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. (For HPV 18, the serostatus cutoff is \u2265 24 mMU/mL)."},{"label":"8.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 6 at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]"},{"label":"9.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 11 at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]"},{"label":"10.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 16 at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]"},{"label":"11.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 18 at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]"}],"pom_b":[{"label":"1.","content":"Number of Participants Reporting Serious Adverse Experiences (SAE) in the Vaccination and Follow-up Phases[ Time Frame: Day 1 through Month 18 ]Tolerability as assessed by the number of participants with clinical adverse experiences in the Vaccination and Follow-up Phases. A serious adverse event is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an \\"other important medical event\\" based on medical judgment."},{"label":"2.","content":"Number of Participants Reporting Serious Adverse Experiences (SAE) in the Extension Phases[ Time Frame: Month 18 to Month 37 ]Tolerability as assessed by the number of participants with clinical adverse experiences in the Extension Phases"},{"label":"3.","content":"Number of Participants Reporting Other (Non-serious) Adverse Experiences in the Vaccination and Follow-up Phases[ Time Frame: Injection site AE are collected from Days 1-5 and non-serious AE from Days 1-15, including the day of vaccination. Other AE (Not Including Serious AE) were not collected in the Extension Phases ]Tolerability as assessed by the number of participants with clinical adverse experiences in the Vaccination and Follow-up Phases"},{"label":"4.","content":"Percentage of Participants Who Are Seropositive for HPV Type 6 (HPV 6 \u2265 20 milliMerck Units [mMU]/mL) at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. (For HPV 6, the serostatus cutoff is \u2265 20 mMU/mL)."},{"label":"5.","content":"Percentage of Participants Who Are Seropositive for HPV Type 11 (HPV 11 \u2265 16 mMU/mL) at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. (For HPV 11, the serostatus cutoff is \u2265 16 mMU/mL)."},{"label":"6.","content":"Percentage of Participants Who Are Seropositive for HPV Type 16 (HPV 16 \u2265 20 mMU/mL) at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. (For HPV 16, the serostatus cutoff is \u2265 20 mMU/mL)."},{"label":"7.","content":"Percentage of Participants Who Are Seropositive for HPV Type 18 (HPV 18 \u2265 24 mMU/mL) at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. (For HPV 18, the serostatus cutoff is \u2265 24 mMU/mL)."},{"label":"8.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 6 at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]"},{"label":"9.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 11 at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]"},{"label":"10.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 16 at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]"},{"label":"11.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 18 at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]"},{"label":"12.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 6 at Month 96[ Time Frame: Month 96 (90 Months Post-dose 3 for Original qHPV Vaccine Group and 60 Months Post-dose 3 for Extension Group) ]"},{"label":"13.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 11 at Month 96[ Time Frame: Month 96 (90 Months Post-dose 3 for Original qHPV Vaccine Group and 60 Months Post-dose 3 for Extension Group) ]"},{"label":"14.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 16 at Month 96[ Time Frame: Month 96 (90 Months Post-dose 3 for Original qHPV Vaccine Group and 60 Months Post-dose 3 for Extension Group) ]"},{"label":"15.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 18 at Month 96[ Time Frame: Month 96 (90 Months Post-dose 3 for Original qHPV Vaccine Group and 60 Months Post-dose 3 for Extension Group) ]"},{"label":"16.","content":"Percentage of Participants Who Are Seropositive for HPV Type 6 (HPV 6 >=20 mMU/mL) at Month 96[ Time Frame: Month 96 (90 Months Post-dose 3 for Original qHPV Vaccine Cohort and 60 Months Post-dose 3 for Extension Group) ]"},{"label":"17.","content":"Percentage of Participants Who Are Seropositive for HPV Type 11 (HPV 11 >=16 mMU/mL) at Month 96[ Time Frame: Month 96 (90 Months Post-dose 3 for Original qHPV Vaccine Group and 60 Months Post-dose 3 for Extension Group) ]"},{"label":"18.","content":"Percentage of Participants Who Are Seropositive for HPV Type 16 (HPV 16 >=20 mMU/mL) at Month 96[ Time Frame: Month 96 (90 Months Post-dose 3 for Original qHPV Vaccine Group and 60 Months Post-dose 3 for Extension Group) ]"},{"label":"19.","content":"Percentage of Participants Who Are Seropositive for HPV Type 18 (HPV 18 >=24 mMU/mL) at Month 96[ Time Frame: Month 96 (90 Months Post-dose 3 for Original qHPV Vaccine Group and 60 Months Post-dose 3 for Extension Group) ]"},{"label":"20.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 6 at Month 126[ Time Frame: Month 126 (120 Months Post-dose 3 for Original qHPV Vaccine Cohort and 90 Months Post-dose 3 for Extension Group) ]"},{"label":"21.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 11 at Month 126[ Time Frame: Month 126 (120 Months Post-dose 3 for Original qHPV Vaccine Cohort and 90 Months Post-dose 3 for Extension Group) ]"},{"label":"22.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 16 at Month 126[ Time Frame: Month 126 (120 Months Post-dose 3 for Original qHPV Vaccine Cohort and 90 Months Post-dose 3 for Extension Group) ]"},{"label":"23.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 18 at Month 126[ Time Frame: Month 126 (120 Months Post-dose 3 for Original qHPV Vaccine Cohort and 90 Months Post-dose 3 for Extension Group) ]"},{"label":"24.","content":"Percentage of Participants Who Are Seropositive for HPV Type 6 (HPV 6 >=20 mMU/mL) at Month 126[ Time Frame: Month 126 (120 Months Post-dose 3 for Original qHPV Vaccine Cohort and 90 Months Post-dose 3 for Extension Group) ]"},{"label":"25.","content":"Percentage of Participants Who Are Seropositive for HPV Type 11 (HPV 11 >=16 mMU/mL) at Month 126[ Time Frame: Month 126 (120 Months Post-dose 3 for Original qHPV Vaccine Cohort and 90 Months Post-dose 3 for Extension Group) ]"},{"label":"26.","content":"Percentage of Participants Who Are Seropositive for HPV Type 16 (HPV 16 >=20 mMU/mL) at Month 126[ Time Frame: Month 126 (120 Months Post-dose 3 for Original qHPV Vaccine Cohort and 90 Months Post-dose 3 for Extension Group) ]"},{"label":"27.","content":"Percentage of Participants Who Are Seropositive for HPV Type 18 (HPV 18 >=24 mMU/mL) at Month 126[ Time Frame: Month 126 (120 Months Post-dose 3 for Original qHPV Vaccine Cohort and 90 Months Post-dose 3 for Extension Group) ]"},{"label":"28.","content":"Number of Participants Reporting SAEs Related to Study Vaccine or to a Study Procedure in the Long-Term Extension Study[ Time Frame: Up to Month 126 ]"}],"first_posted":"May 4, 2010","completion_date":"June 1, 2015","primary_completion_date":"November 3, 2005","start_date":"October 8, 2003","last_update_posted":"February 20, 2018"},{"nctid":"NCT00092547","version_a":24,"version_b":25,"version_a_date":"2015-08-18","version_b_date":"2016-02-09","pom_a":[{"label":"1.","content":"Number of Participants Reporting Serious Adverse Experiences (SAE) in the Vaccination and Follow-up Phases[ Time Frame: Day 1 through Month 18 ]Tolerability as assessed by the number of participants with clinical adverse experiences in the Vaccination and Follow-up Phases. A serious adverse event is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an \\"other important medical event\\" based on medical judgment."},{"label":"2.","content":"Number of Participants Reporting Serious Adverse Experiences (SAE) in the Extension Phases[ Time Frame: Month 18 to Month 37 ]Tolerability as assessed by the number of participants with clinical adverse experiences in the Extension Phases"},{"label":"3.","content":"Number of Participants Reporting Other (Non-serious) Adverse Experiences in the Vaccination and Follow-up Phases[ Time Frame: Injection site AE are collected from Days 1-5 and non-serious AE from Days 1-15, including the day of vaccination. Other AE (Not Including Serious AE) were not collected in the Extension Phases ]Tolerability as assessed by the number of participants with clinical adverse experiences in the Vaccination and Follow-up Phases"},{"label":"4.","content":"Percentage of Participants Who Are Seropositive for HPV Type 6 (HPV 6 \u2265 20 milliMerck Units [mMU]/mL) at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. (For HPV 6, the serostatus cutoff is \u2265 20 mMU/mL)."},{"label":"5.","content":"Percentage of Participants Who Are Seropositive for HPV Type 11 (HPV 11 \u2265 16 mMU/mL) at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. (For HPV 11, the serostatus cutoff is \u2265 16 mMU/mL)."},{"label":"6.","content":"Percentage of Participants Who Are Seropositive for HPV Type 16 (HPV 16 \u2265 20 mMU/mL) at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. (For HPV 16, the serostatus cutoff is \u2265 20 mMU/mL)."},{"label":"7.","content":"Percentage of Participants Who Are Seropositive for HPV Type 18 (HPV 18 \u2265 24 mMU/mL) at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. (For HPV 18, the serostatus cutoff is \u2265 24 mMU/mL)."},{"label":"8.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 6 at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]"},{"label":"9.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 11 at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]"},{"label":"10.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 16 at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]"},{"label":"11.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 18 at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]"},{"label":"12.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 6 at Month 96[ Time Frame: Month 96 (90 Months Post-dose 3 for Original qHPV Vaccine Group and 60 Months Post-dose 3 for Extension Group) ]"},{"label":"13.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 11 at Month 96[ Time Frame: Month 96 (90 Months Post-dose 3 for Original qHPV Vaccine Group and 60 Months Post-dose 3 for Extension Group) ]"},{"label":"14.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 16 at Month 96[ Time Frame: Month 96 (90 Months Post-dose 3 for Original qHPV Vaccine Group and 60 Months Post-dose 3 for Extension Group) ]"},{"label":"15.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 18 at Month 96[ Time Frame: Month 96 (90 Months Post-dose 3 for Original qHPV Vaccine Group and 60 Months Post-dose 3 for Extension Group) ]"},{"label":"16.","content":"Percentage of Participants Who Are Seropositive for HPV Type 6 (HPV 6 >=20 mMU/mL) at Month 96[ Time Frame: Month 96 (90 Months Post-dose 3 for Original qHPV Vaccine Cohort and 60 Months Post-dose 3 for Extension Group) ]"},{"label":"17.","content":"Percentage of Participants Who Are Seropositive for HPV Type 11 (HPV 11 >=16 mMU/mL) at Month 96[ Time Frame: Month 96 (90 Months Post-dose 3 for Original qHPV Vaccine Group and 60 Months Post-dose 3 for Extension Group) ]"},{"label":"18.","content":"Percentage of Participants Who Are Seropositive for HPV Type 16 (HPV 16 >=20 mMU/mL) at Month 96[ Time Frame: Month 96 (90 Months Post-dose 3 for Original qHPV Vaccine Group and 60 Months Post-dose 3 for Extension Group) ]"},{"label":"19.","content":"Percentage of Participants Who Are Seropositive for HPV Type 18 (HPV 18 >=24 mMU/mL) at Month 96[ Time Frame: Month 96 (90 Months Post-dose 3 for Original qHPV Vaccine Group and 60 Months Post-dose 3 for Extension Group) ]"},{"label":"20.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 6 at Month 126[ Time Frame: Month 126 (120 Months Post-dose 3 for Original qHPV Vaccine Cohort and 90 Months Post-dose 3 for Extension Group) ]"},{"label":"21.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 11 at Month 126[ Time Frame: Month 126 (120 Months Post-dose 3 for Original qHPV Vaccine Cohort and 90 Months Post-dose 3 for Extension Group) ]"},{"label":"22.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 16 at Month 126[ Time Frame: Month 126 (120 Months Post-dose 3 for Original qHPV Vaccine Cohort and 90 Months Post-dose 3 for Extension Group) ]"},{"label":"23.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 18 at Month 126[ Time Frame: Month 126 (120 Months Post-dose 3 for Original qHPV Vaccine Cohort and 90 Months Post-dose 3 for Extension Group) ]"},{"label":"24.","content":"Percentage of Participants Who Are Seropositive for HPV Type 6 (HPV 6 >=20 mMU/mL) at Month 126[ Time Frame: Month 126 (120 Months Post-dose 3 for Original qHPV Vaccine Cohort and 90 Months Post-dose 3 for Extension Group) ]"},{"label":"25.","content":"Percentage of Participants Who Are Seropositive for HPV Type 11 (HPV 11 >=16 mMU/mL) at Month 126[ Time Frame: Month 126 (120 Months Post-dose 3 for Original qHPV Vaccine Cohort and 90 Months Post-dose 3 for Extension Group) ]"},{"label":"26.","content":"Percentage of Participants Who Are Seropositive for HPV Type 16 (HPV 16 >=20 mMU/mL) at Month 126[ Time Frame: Month 126 (120 Months Post-dose 3 for Original qHPV Vaccine Cohort and 90 Months Post-dose 3 for Extension Group) ]"},{"label":"27.","content":"Percentage of Participants Who Are Seropositive for HPV Type 18 (HPV 18 >=24 mMU/mL) at Month 126[ Time Frame: Month 126 (120 Months Post-dose 3 for Original qHPV Vaccine Cohort and 90 Months Post-dose 3 for Extension Group) ]"},{"label":"28.","content":"Number of Participants Reporting SAEs Related to Study Vaccine or to a Study Procedure in the Long-Term Extension Study[ Time Frame: Up to Month 126 ]"}],"pom_b":[{"label":"1.","content":"Number of Participants Reporting Serious Adverse Experiences (SAEs) Through Month 18[ Time Frame: Up to Month 18 ]Tolerability as assessed by the number of participants with clinical adverse experiences through Month 18. A serious adverse event is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an \\"other important medical event\\" based on medical judgment."},{"label":"2.","content":"Number of Participants Reporting SAEs From Month 18 Through Month 37[ Time Frame: Month 18 to Month 37 ]Tolerability as assessed by the number of participants with clinical adverse experiences from Month 18 through Month 37"},{"label":"3.","content":"Number of Participants Reporting Other (Non-serious) AEs Through Month 18[ Time Frame: Up to Month 18: Injection site AEs were collected from Days 1-5 and other non-serious AEs from Days 1-15 after any vaccination ]Tolerability as assessed by the number of participants with clinical adverse experiences through Month 18"},{"label":"4.","content":"Percentage of Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are \u2265 20 mMU/mL for HPV 6 and 16, \u2265 16 mMU/mL for HPV 11, and \u2265 24 mMU/mL for HPV 18."},{"label":"5.","content":"Geometric Mean Titers (GMTs) for Anti-HPV 6, 11, 16, and 18 at Month 72[ Time Frame: Month 72 (66 Months Post-dose 3 for the Original qHPV Vaccine Cohort and 36 months Post-dose 3 for the Extension Group) ]"},{"label":"6.","content":"Geometric Mean Titers for Anti-HPV 6, 11, 16, and 18 at Month 96[ Time Frame: Month 96 (90 Months Post-dose 3 for Original qHPV Vaccine Group and 60 Months Post-dose 3 for Extension Group) ]"},{"label":"7.","content":"Percentage of Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 96[ Time Frame: Month 96 (90 Months Post-dose 3 for Original qHPV Vaccine Cohort and 60 Months Post-dose 3 for Extension Group) ]A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are \u2265 20 mMU/mL for HPV 6 and 16, \u2265 16 mMU/mL for HPV 11, and \u2265 24 mMU/mL for HPV 18."},{"label":"8.","content":"Geometric Mean Titers for Anti-HPV 6, 11, 16, and 18 at Month 126[ Time Frame: Month 126 (120 Months Post-dose 3 for Original qHPV Vaccine Cohort and 90 Months Post-dose 3 for Extension Group) ]"},{"label":"9.","content":"Percentage of Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 126[ Time Frame: Month 126 (120 Months Post-dose 3 for Original qHPV Vaccine Cohort and 90 Months Post-dose 3 for Extension Group) ]A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are \u2265 20 mMU/mL for HPV 6 and 16, \u2265 16 mMU/mL for HPV 11, and \u2265 24 mMU/mL for HPV 18."},{"label":"10.","content":"Number of Participants Reporting SAEs Related to Study Vaccine or to a Study Procedure in the Long-term Follow-up[ Time Frame: Month 37 to Month 126 ]A serious adverse event is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an \\"other important medical event\\" based on medical judgment. SAEs considered by the investigator to be possibly, probably, or definitely related to study vaccine or a study procedure were reported."}],"first_posted":"May 4, 2010","completion_date":"June 1, 2015","primary_completion_date":"November 3, 2005","start_date":"October 8, 2003","last_update_posted":"February 20, 2018"},{"nctid":"NCT00003873","version_a":11,"version_b":12,"version_a_date":"2010-10-30","version_b_date":"2013-01-23","pom_a":[],"pom_b":[{"label":"1.","content":"Overall survival[ Time Frame: Up to 1 year ]"}],"first_posted":"No date provided","completion_date":"No date provided","primary_completion_date":"July 2007","start_date":"April 1999","last_update_posted":"January 24, 2013"},{"nctid":"NCT00003600","version_a":23,"version_b":24,"version_a_date":"2012-02-19","version_b_date":"2015-07-07","pom_a":[],"pom_b":[{"label":"1.","content":"Quality of life[ Time Frame: Up to 12 months ]"}],"first_posted":"No date provided","completion_date":"January 2010","primary_completion_date":"December 2001","start_date":"December 1998","last_update_posted":"July 13, 2016"},{"nctid":"NCT01168791","version_a":1,"version_b":2,"version_a_date":"2010-07-21","version_b_date":"2010-07-28","pom_a":[{"label":"1.","content":"Overall Survival[ Time Frame: assessed every 6 weeks for 22 weeks, then 8 weeks for 6 months, then every 12 weeks until death ]"}],"pom_b":[{"label":"1.","content":"Progression Free Survival followed by Overall Survival[ Time Frame: assessed every 6 weeks for 22 weeks, then 8 weeks for 6 months/until progression, then every 12 weeks until then death ]"}],"first_posted":"No date provided","completion_date":"March 2013","primary_completion_date":"March 2013","start_date":"July 2010","last_update_posted":"July 18, 2013"},{"nctid":"NCT01387282","version_a":42,"version_b":43,"version_a_date":"2015-09-21","version_b_date":"2017-06-09","pom_a":[{"label":"1.","content":"Evaluate the effect of Anamorelin on lean body mass as measured by DXA scan[ Time Frame: 12 weeks ]"},{"label":"2.","content":"Evaluate the effect of Anamorelin on muscle strength as measured by hand-grip strength[ Time Frame: 12 weeks ]"}],"pom_b":[{"label":"1.","content":"Change in Lean Body Mass[ Time Frame: Change in Lean Body Mass from Baseline Over 12 Weeks ]Change in Lean Body Mass (LBM) from baseline over 12 weeks for the ITT Population. Change from baseline over 12 weeks was defined as the average of the change from baseline at Week 6 and the change from baseline at Week 12."},{"label":"2.","content":"Change in Handgrip Strength[ Time Frame: Change in Handgrip Strength of the Non-Dominant Hand from Baseline Over 12 Weeks ]Change in Handgrip Strength (HGS) of the non-dominant hand from baseline over 12 weeks for the ITT Population. Change from baseline over 12 weeks was defined as the average of the change from baseline at Week 6 and the change from baseline at Week 12."}],"first_posted":"July 11, 2017","completion_date":"February 2015","primary_completion_date":"November 2013","start_date":"July 2011","last_update_posted":"October 27, 2017"},{"nctid":"NCT00005838","version_a":10,"version_b":11,"version_a_date":"2006-02-23","version_b_date":"2007-02-20","pom_a":[],"pom_b":[{"label":"1.","content":"Overall survival every 3 months"}],"first_posted":"No date provided","completion_date":"No date provided","primary_completion_date":"February 2007","start_date":"March 2000","last_update_posted":"January 23, 2013"},{"nctid":"NCT00005838","version_a":22,"version_b":23,"version_a_date":"2011-02-26","version_b_date":"2013-01-22","pom_a":[{"label":"1.","content":"Overall survival every 3 months"}],"pom_b":[{"label":"1.","content":"Overall survival[ Time Frame: From randomization until date of death or last follow-up, assessed up to 7 years ]Survival distributions will be compared by use of the log-rank test. The stratified log-rank test (nominal or categorical covariates) may be used to simultaneously control for important prognostic factors. Kaplan-Meier curves will also be plotted to illustrate the comparative survival experience of both groups over the entire study period."}],"first_posted":"No date provided","completion_date":"No date provided","primary_completion_date":"February 2007","start_date":"March 2000","last_update_posted":"January 23, 2013"},{"nctid":"NCT03607539","version_a":2,"version_b":3,"version_a_date":"2020-01-07","version_b_date":"2021-01-27","pom_a":[{"label":"1.","content":"PFS (Progression Free Survival)[ Time Frame: up to 24 months after randomization ]Time from the first dose of study drug to the first disease progression (imaging)"}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Independent Radiographic Review Committee (IRRC)[ Time Frame: Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months) ]PFS was defined as the time from randomization to the first documented PD or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as \u226520% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of \u22655 mm. The appearance of one or more new lesions was also considered PD"}],"first_posted":"February 16, 2021","completion_date":"July 2021","primary_completion_date":"November 15, 2019","start_date":"August 23, 2018","last_update_posted":"February 16, 2021"},{"nctid":"NCT00295802","version_a":1,"version_b":2,"version_a_date":"2006-02-22","version_b_date":"2006-03-09","pom_a":[{"label":"1.","content":"Attainment achievement of PSA nadir < 0.5 ng/ml and stability of PSA according to ASTRO criteria through 15 month follow up without a positive biopsy."},{"label":"2.","content":"Study success is defined as the demonstration that the rate of patients in the Ablatherm treatment group with a nadir PSA within 6 months < 0.5 ng/ml and stability of PSA according to ASTRO criteria through 15 month follow up without a positive biopsy is"}],"pom_b":[{"label":"1.","content":"Attainment achievement of PSA nadir < 0.5 ng/ml and stability of PSA according to ASTRO criteria through 15 month follow up without a positive biopsy."}],"first_posted":"No date provided","completion_date":"September 2014","primary_completion_date":"August 2012","start_date":"April 2006","last_update_posted":"February 7, 2014"},{"nctid":"NCT00295802","version_a":6,"version_b":7,"version_a_date":"2006-05-09","version_b_date":"2006-05-19","pom_a":[{"label":"1.","content":"Attainment achievement of PSA nadir < 0.5 ng/ml and stability of PSA according to ASTRO criteria through 15 month follow up without a positive biopsy."}],"pom_b":[{"label":"1.","content":"Attainment achievement of PSA nadir < 0.5 ng/ml and stability of PSA according to ASTRO criteria through 24 month follow up without a positive biopsy."}],"first_posted":"No date provided","completion_date":"September 2014","primary_completion_date":"August 2012","start_date":"April 2006","last_update_posted":"February 7, 2014"},{"nctid":"NCT00295802","version_a":13,"version_b":14,"version_a_date":"2006-08-04","version_b_date":"2006-09-27","pom_a":[{"label":"1.","content":"Attainment achievement of PSA nadir < 0.5 ng/ml and stability of PSA according to ASTRO criteria through 24 month follow up without a positive biopsy."}],"pom_b":[{"label":"1.","content":"Attainment achievement of prostate-specific antigen (PSA) nadir < 0.5 ng/ml and stability of PSA according to American Society for Therapeutic Radiology and Oncology (ASTRO) criteria through 24 month follow up without a positive biopsy"}],"first_posted":"No date provided","completion_date":"September 2014","primary_completion_date":"August 2012","start_date":"April 2006","last_update_posted":"February 7, 2014"},{"nctid":"NCT00295802","version_a":38,"version_b":39,"version_a_date":"2012-01-26","version_b_date":"2014-02-06","pom_a":[{"label":"1.","content":"Attainment achievement of prostate-specific antigen (PSA) nadir < 0.5 ng/ml and stability of PSA according to American Society for Therapeutic Radiology and Oncology (ASTRO) criteria through 24 month follow up without a positive biopsy"}],"pom_b":[{"label":"1.","content":"Attainment achievement of prostate-specific antigen (PSA) nadir < 0.5 ng/ml and stability of PSA according to American Society for Therapeutic Radiology and Oncology (ASTRO) criteria through 24 month follow up without a positive biopsy[ Time Frame: Through 24 month period ]"}],"first_posted":"No date provided","completion_date":"September 2014","primary_completion_date":"August 2012","start_date":"April 2006","last_update_posted":"February 7, 2014"},{"nctid":"NCT00005094","version_a":16,"version_b":17,"version_a_date":"2012-07-24","version_b_date":"2013-04-11","pom_a":[],"pom_b":[{"label":"1.","content":"Percentage of subjects with newly detected adenomas, and will be estimated using the life table method for each treatment group[ Time Frame: Year 3 (cumulative for year one and year three) ]Will be estimated using the life table method for each treatment group and compared using a life-table extension of the Mantel-Haenszel statistics with stratification for aspirin use. Additional analysis will be performed for the primary endpoint to adjust for the baseline prognostic factors and colon cancer/adenoma risk factors using, for example, proportional hazard model or logistic model."},{"label":"2.","content":"Percentage of patients with adenomas, aspirin use at baseline, and covariates[ Time Frame: Year 5 ]This will be derived by treatment group (celecoxib 400 mg bid, celecoxib 200 mg bid, or placebo) and low-dose aspirin use at baseline and in relationship to the patient\'s adenoma history at the year 3 colonoscopy. Of particular interest is whether the conditional rate of adenomas at year 5 differs by treatment group and strata with control for potential differences in these groups by adenoma history at year 3 colonoscopy, age, sex, family history of colorectal cancer, smoking, concomitant use of NSAID\'s, total time on study drug, and other covariates."}],"first_posted":"No date provided","completion_date":"No date provided","primary_completion_date":"April 2006","start_date":"March 2000","last_update_posted":"April 12, 2013"},{"nctid":"NCT00393172","version_a":1,"version_b":2,"version_a_date":"2006-10-25","version_b_date":"2006-11-08","pom_a":[],"pom_b":[{"label":"1.","content":"Changes in urine levels of F2-isoprostanes"}],"first_posted":"No date provided","completion_date":"March 2010","primary_completion_date":"September 2009","start_date":"May 2006","last_update_posted":"November 1, 2019"},{"nctid":"NCT00393172","version_a":23,"version_b":24,"version_a_date":"2009-07-16","version_b_date":"2010-11-08","pom_a":[{"label":"1.","content":"Changes in urine levels of F2-isoprostanes"}],"pom_b":[{"label":"1.","content":"Changes in urine levels of F2-isoprostanes[ Time Frame: Before and after study ]"}],"first_posted":"No date provided","completion_date":"March 2010","primary_completion_date":"September 2009","start_date":"May 2006","last_update_posted":"November 1, 2019"},{"nctid":"NCT00003070","version_a":13,"version_b":14,"version_a_date":"2009-05-09","version_b_date":"2014-08-04","pom_a":[],"pom_b":[{"label":"1.","content":"Cardiac functional status and quality of life[ Time Frame: baseline, two and five years ]Cardiac functional status (depressed fractional shortening) and quality-of-life, will be assessed at baseline, two and five years into the study."}],"first_posted":"No date provided","completion_date":"March 2007","primary_completion_date":"July 2003","start_date":"September 2000","last_update_posted":"August 5, 2014"},{"nctid":"NCT00217438","version_a":14,"version_b":15,"version_a_date":"2006-09-29","version_b_date":"2006-11-08","pom_a":[],"pom_b":[{"label":"1.","content":"Compare complete response and near complete response rates of patients undergoing induction therapy comprising two different doses of high-dose melphalan +amifostine followed by a single autologous or syngeneic peripheral blood stem cell transplantation"}],"first_posted":"September 19, 2014","completion_date":"No date provided","primary_completion_date":"October 2012","start_date":"July 2005","last_update_posted":"August 21, 2015"},{"nctid":"NCT00217438","version_a":15,"version_b":16,"version_a_date":"2006-11-08","version_b_date":"2006-11-21","pom_a":[{"label":"1.","content":"Compare complete response and near complete response rates of patients undergoing induction therapy comprising two different doses of high-dose melphalan +amifostine followed by a single autologous or syngeneic peripheral blood stem cell transplantation"}],"pom_b":[{"label":"1.","content":"Compare complete response and near complete response rate after completion of the first transplant"}],"first_posted":"September 19, 2014","completion_date":"No date provided","primary_completion_date":"October 2012","start_date":"July 2005","last_update_posted":"August 21, 2015"},{"nctid":"NCT00217438","version_a":44,"version_b":45,"version_a_date":"2010-02-09","version_b_date":"2010-08-30","pom_a":[{"label":"1.","content":"Compare complete response and near complete response rate after completion of the first transplant"}],"pom_b":[{"label":"1.","content":"Complete response rate[ Time Frame: After completion of the first transplant ]"},{"label":"2.","content":"Near complete response rate[ Time Frame: After completion of the first transplant ]"}],"first_posted":"September 19, 2014","completion_date":"No date provided","primary_completion_date":"October 2012","start_date":"July 2005","last_update_posted":"August 21, 2015"},{"nctid":"NCT00217438","version_a":45,"version_b":46,"version_a_date":"2010-08-30","version_b_date":"2011-03-28","pom_a":[{"label":"1.","content":"Complete response rate[ Time Frame: After completion of the first transplant ]"},{"label":"2.","content":"Near complete response rate[ Time Frame: After completion of the first transplant ]"}],"pom_b":[{"label":"1.","content":"CR rate[ Time Frame: After completion of the first transplant ]"},{"label":"2.","content":"Near CR rate[ Time Frame: After completion of the first transplant ]"}],"first_posted":"September 19, 2014","completion_date":"No date provided","primary_completion_date":"October 2012","start_date":"July 2005","last_update_posted":"August 21, 2015"},{"nctid":"NCT00217438","version_a":46,"version_b":47,"version_a_date":"2011-03-28","version_b_date":"2011-07-11","pom_a":[{"label":"1.","content":"CR rate[ Time Frame: After completion of the first transplant ]"},{"label":"2.","content":"Near CR rate[ Time Frame: After completion of the first transplant ]"}],"pom_b":[{"label":"1.","content":"CR and near CR rates[ Time Frame: After transplant #1 ]Observe a statistically significant difference at the two-sided significance level of .05 with 80% and 90% power for various assumed-true CR rates."}],"first_posted":"September 19, 2014","completion_date":"No date provided","primary_completion_date":"October 2012","start_date":"July 2005","last_update_posted":"August 21, 2015"},{"nctid":"NCT00217438","version_a":49,"version_b":50,"version_a_date":"2012-06-18","version_b_date":"2012-06-22","pom_a":[{"label":"1.","content":"CR and near CR rates[ Time Frame: After transplant #1 ]Observe a statistically significant difference at the two-sided significance level of .05 with 80% and 90% power for various assumed-true CR rates."}],"pom_b":[{"label":"1.","content":"CR and near CR rates[ Time Frame: Up to 120 days after transplant ]Observe a statistically significant difference at the two-sided significance level of .05 with 80% and 90% power for various assumed-true CR rates."}],"first_posted":"September 19, 2014","completion_date":"No date provided","primary_completion_date":"October 2012","start_date":"July 2005","last_update_posted":"August 21, 2015"},{"nctid":"NCT00217438","version_a":51,"version_b":52,"version_a_date":"2012-12-26","version_b_date":"2014-09-16","pom_a":[{"label":"1.","content":"CR and near CR rates[ Time Frame: Up to 120 days after transplant ]Observe a statistically significant difference at the two-sided significance level of .05 with 80% and 90% power for various assumed-true CR rates."}],"pom_b":[{"label":"1.","content":"CR and Near CR Rates[ Time Frame: Up to 120 days after transplant ]Per modified European Group for Blood and Marrow Transplant (EBMT) response criteria for definition of response in patients with multiple myeloma treated by high-dose therapy and stem cell transplantation: Complete Response (CR): Complete disappearance of all clinically measurable disease, complete response requires negative tests for monoclonal proteins in serum and urine by immunofixation, no monoclonal plasma cells in marrow specimen by flow cytometry and no evidence of progressive bone disease by skeletal survey. \\"Near\\" Complete Response (nCR): Less than 0.1 gram/dL monoclonal protein detectable in serum by standard protein electrophoresis and less than 50 mg monoclonal protein detectable in urine on 24 hour collection. Less than 5% monoclonal plasma cells detectable in bone marrow by immunohistochemistry. No evidence of progressive bone disease by skeletal survey."}],"first_posted":"September 19, 2014","completion_date":"No date provided","primary_completion_date":"October 2012","start_date":"July 2005","last_update_posted":"August 21, 2015"},{"nctid":"NCT03281954","version_a":23,"version_b":24,"version_a_date":"2021-10-04","version_b_date":"2022-07-27","pom_a":[{"label":"1.","content":"Pathologic complete response in the breast and lymph nodes (ypT0/Tis ypN0)[ Time Frame: At the time of surgical resection ]The absence of any invasive component in the resected breast specimen and all resected lymph nodes following completion of neoadjuvant therapy"},{"label":"2.","content":"Event-free survival (EFS)[ Time Frame: From randomization until event, through study follow up to the time target number of events is obtained, up to 5 years ]Time from randomization until event"}],"pom_b":[{"label":"1.","content":"Event-free survival (EFS)[ Time Frame: From randomization until event, through study follow up to the time target number of events is obtained, up to 5 years ]Time from randomization until event"}],"first_posted":"No date provided","completion_date":"June 30, 2024","primary_completion_date":"December 31, 2023","start_date":"December 19, 2017","last_update_posted":"August 1, 2022"},{"nctid":"NCT00174837","version_a":6,"version_b":7,"version_a_date":"2008-06-12","version_b_date":"2008-06-20","pom_a":[],"pom_b":[{"label":"1.","content":"Overall survival[ Time Frame: Study period ]"}],"first_posted":"No date provided","completion_date":"January 2008","primary_completion_date":"January 2008","start_date":"April 2005","last_update_posted":"May 26, 2016"},{"nctid":"NCT00118209","version_a":54,"version_b":55,"version_a_date":"2006-10-25","version_b_date":"2006-11-09","pom_a":[],"pom_b":[{"label":"1.","content":"Event-free survival 5 years after completion of study treatment"}],"first_posted":"April 17, 2020","completion_date":"November 15, 2021","primary_completion_date":"October 2017","start_date":"May 2005","last_update_posted":"November 17, 2021"},{"nctid":"NCT00118209","version_a":507,"version_b":508,"version_a_date":"2013-02-13","version_b_date":"2015-03-19","pom_a":[{"label":"1.","content":"Event-free survival 5 years after completion of study treatment"}],"pom_b":[{"label":"1.","content":"Event-free survival[ Time Frame: Up to 5 years post-registration ]"}],"first_posted":"April 17, 2020","completion_date":"November 15, 2021","primary_completion_date":"October 2017","start_date":"May 2005","last_update_posted":"November 17, 2021"},{"nctid":"NCT00118209","version_a":513,"version_b":514,"version_a_date":"2018-07-09","version_b_date":"2020-04-06","pom_a":[{"label":"1.","content":"Event-free survival[ Time Frame: Up to 5 years post-registration ]"}],"pom_b":[{"label":"1.","content":"Progression-Free Survival Rate at 2 and 5 Years[ Time Frame: Up to 5 years post-registration ]Progression-free survival (PFS) is defined as the time from randomization to progression, relapse, or death from any cause, whichever occurred first. Progression (PD) or Relapse>\u2265 50% increase from nadir in the SPD of any previously identified abnormal node for PRs or nonresponders.>Appearance of any new lesion during or after completion of therapy.>PET+ is not a criterion for progressive disease. Patients only with PET+ findings must have evidence of progression on CT or biopsy proven.>The PFS rate (percentage of participants who are alive and progression-free) at 2 and 5 years Kaplan Meier estimates and 95% Confidence Intervals are reported below."}],"first_posted":"April 17, 2020","completion_date":"November 15, 2021","primary_completion_date":"October 2017","start_date":"May 2005","last_update_posted":"November 17, 2021"},{"nctid":"NCT02448381","version_a":2,"version_b":3,"version_a_date":"2015-05-20","version_b_date":"2015-12-11","pom_a":[{"label":"1.","content":"Treatment Response in 3 treated lesions as as defined to be a \u226550% improvement in the Composite Assessment of Index Lesion Disease Severity (CAILS) score when compared to patients receiving placebo[ Time Frame: 8 weeks ]To evaluate the ability of a 6-week course of SGX301 and visible light in patients with patch/plaque phase cutaneous T-cell lymphoma (CTCL, mycosis fungoides) to induce a treatment response in 3 lesions when compared to patients receiving placebo and visible light."}],"pom_b":[{"label":"1.","content":"Treatment Response in 3 treated lesions as defined as a \u226550% improvement in the Composite Assessment of Index Lesion Disease Severity (CAILS) score when compared to patients receiving placebo[ Time Frame: 8 weeks ]To evaluate the ability of a 6-week course of SGX301 and visible light in patients with patch/plaque phase cutaneous T-cell lymphoma (CTCL, mycosis fungoides) to induce a treatment response in 3 lesions when compared to patients receiving placebo and visible light."}],"first_posted":"April 15, 2022","completion_date":"November 2020","primary_completion_date":"June 2020","start_date":"December 2015","last_update_posted":"April 15, 2022"},{"nctid":"NCT02448381","version_a":31,"version_b":32,"version_a_date":"2022-01-07","version_b_date":"2022-03-22","pom_a":[{"label":"1.","content":"Treatment Response in 3 treated lesions as defined as a \u226550% improvement in the Composite Assessment of Index Lesion Disease Severity (CAILS) score when compared to patients receiving placebo[ Time Frame: 8 weeks ]To evaluate the ability of a 6-week course of SGX301 and visible light in patients with patch/plaque phase cutaneous T-cell lymphoma (CTCL, mycosis fungoides) to induce a treatment response in 3 lesions when compared to patients receiving placebo and visible light."}],"pom_b":[{"label":"1.","content":"Number of Responders and Non-Responders With a Treatment Response in 3 Treated Lesions as Defined as a \u226550% Improvement in the Composite Assessment of Index Lesion Disease Severity (CAILS) Score When Compared to Patients Receiving Placebo[ Time Frame: 8 weeks ]The percentage of patients achieving a treatment response in each of the 2 treatment groups. A treatment response was defined as a \u226550% improvement in CAILS score at Week 8 when compared to the CAILS score at baseline.The Composite Assessment of Index Lesion Disease Severity (CAILS) score measures: Erythema (or redness) on a scale of 0 (no redness) to 8 (very red), Scaling on a scale of 0 (no scaling) to 8 (all of the lesion is covered by a very rough surface), Plaque Elevation on a scale of 0 (no evidence of plaque above normal skin level) to 3 (plaque shows marked elevation above normal skin level) and Surface Area on a scale of 0 (no lesion/surface area is 0 cm^2) to 18 (the lesion is larger than 300 cm^2). A lower score means a better outcome.The overall CAILS score was calculated by adding the total score as described above for each of the 3 lesions. The overall CAILS score has a range of 0 to 111. A lower score means a better outcome."}],"first_posted":"April 15, 2022","completion_date":"November 2020","primary_completion_date":"June 2020","start_date":"December 2015","last_update_posted":"April 15, 2022"},{"nctid":"NCT00651261","version_a":209,"version_b":210,"version_a_date":"2010-12-30","version_b_date":"2010-12-31","pom_a":[{"label":"1.","content":"Overall survival"}],"pom_b":[{"label":"1.","content":"Overall survival (OS)"}],"first_posted":"February 6, 2017","completion_date":"No date provided","primary_completion_date":"July 2016","start_date":"April 2008","last_update_posted":"August 18, 2021"},{"nctid":"NCT00651261","version_a":272,"version_b":273,"version_a_date":"2011-10-18","version_b_date":"2013-02-20","pom_a":[{"label":"1.","content":"Overall survival (OS)"}],"pom_b":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: Duration of study (Up to 10 years) ]"}],"first_posted":"February 6, 2017","completion_date":"No date provided","primary_completion_date":"July 2016","start_date":"April 2008","last_update_posted":"August 18, 2021"},{"nctid":"NCT00651261","version_a":280,"version_b":281,"version_a_date":"2016-11-10","version_b_date":"2016-12-12","pom_a":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: Duration of study (Up to 10 years) ]"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Duration of study (Up to 10 years) ]Overall survival (OS) was defined as the time interval from randomization to death from any cause. The median OS with 95% CI was estimated using the Kaplan-Meier method."}],"first_posted":"February 6, 2017","completion_date":"No date provided","primary_completion_date":"July 2016","start_date":"April 2008","last_update_posted":"August 18, 2021"},{"nctid":"NCT05208047","version_a":8,"version_b":9,"version_a_date":"2022-04-18","version_b_date":"2022-05-16","pom_a":[{"label":"1.","content":"Part 1a - pharmacokinetics - Cmax[ Time Frame: 16 days ]Maximum plasma concentration (Cmax)"},{"label":"2.","content":"Part 1a - pharmacokinetics - AUC[ Time Frame: 16 days ]Area under the plasma concentration-time curve (AUC)"},{"label":"3.","content":"Part 1b - pharmacokinetics - Cmax[ Time Frame: 14 days ]Maximum plasma concentration (Cmax)"},{"label":"4.","content":"Part 1b - pharmacokinetics - AUC[ Time Frame: 14 days ]Area under the plasma concentration-time curve (AUC)"},{"label":"5.","content":"Part 1b - pharmacokinetics - Tmax[ Time Frame: 14 days ]Time to maximum observed plasma concentration (Tmax)"},{"label":"6.","content":"Part 1b - pharmacokinetics - T1/2[ Time Frame: 14 days ]Time to plasma concentration terminal half-life (T1/2)"},{"label":"7.","content":"Part 1b - pharmacokinetics - CLss/F[ Time Frame: 14 days ]Apparent total body clearance at steady state (CLss/F)"},{"label":"8.","content":"Part 2 - Progression Free Survival (PFS)[ Time Frame: Approximately 48 months ]Time from first dose to documented disease progression or death due to any cause, whichever occurs first"}],"pom_b":[{"label":"1.","content":"Part 1a - pharmacokinetics - Cmax[ Time Frame: 16 days ]Maximum plasma concentration (Cmax)"},{"label":"2.","content":"Part 1a - pharmacokinetics - AUC[ Time Frame: 16 days ]Area under the plasma concentration-time curve (AUC)"},{"label":"3.","content":"Part 1b - pharmacokinetics - Cmax[ Time Frame: 14 days ]Maximum plasma concentration (Cmax)"},{"label":"4.","content":"Part 1b - pharmacokinetics - AUC[ Time Frame: 14 days ]Area under the plasma concentration-time curve (AUC)"},{"label":"5.","content":"Part 1b - pharmacokinetics - Tmax[ Time Frame: 14 days ]Time to maximum observed plasma concentration (Tmax)"},{"label":"6.","content":"Part 2 - Progression Free Survival (PFS)[ Time Frame: Approximately 48 months ]Time from first dose to documented disease progression or death due to any cause, whichever occurs first"}],"first_posted":"No date provided","completion_date":"September 2026","primary_completion_date":"July 2025","start_date":"April 14, 2022","last_update_posted":"August 11, 2022"},{"nctid":"NCT02220894","version_a":40,"version_b":41,"version_a_date":"2018-04-11","version_b_date":"2019-03-14","pom_a":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: Up to 2.5 years ]"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of \u226550%[ Time Frame: Through Database Cutoff Date of 26-Feb-2018 (up to approximately 38 months) ]OS was determined for participants with a TPS of \u226550% and was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the interim analysis were censored at the date of the last follow-up. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. The efficacy hypothesis was analyzed using a sequential testing strategy that involved testing a hypothesis only if the superiority of pembrolizumab over chemotherapy was established for all the preceding hypotheses. The order of testing was OS in participants with TPS\u226550%, then with TPS\u226520%, and finally with TPS\u22651%. The OS for participants with a TPS \u226550% is presented."},{"label":"2.","content":"Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of \u226520%[ Time Frame: Through Database Cutoff Date of 26-Feb-2018 (up to approximately 38 months) ]OS was determined for participants with a TPS of \u226520% and was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the interim analysis were censored at the date of the last follow-up. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. The efficacy hypothesis was analyzed using a sequential testing strategy that involved testing a hypothesis only if the superiority of pembrolizumab over chemotherapy was established for all the preceding hypotheses. The order of testing was OS in participants with TPS\u226550%, then with TPS\u226520%, and finally with TPS\u22651%. The OS for participants with a TPS \u226520% is presented."},{"label":"3.","content":"Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of \u22651%[ Time Frame: Through Database Cutoff Date of 26-Feb-2018 (up to approximately 38 months) ]OS was determined for participants with a TPS of \u22651% and was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the interim analysis were censored at the date of the last follow-up. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. The efficacy hypothesis was analyzed using a sequential testing strategy that involved testing a hypothesis only if the superiority of pembrolizumab over chemotherapy was established for all the preceding hypotheses. The order of testing was OS in participants with TPS\u226550%, then with TPS\u226520%, and finally with TPS\u22651%. The OS for participants with a TPS \u22651% is presented."}],"first_posted":"March 15, 2019","completion_date":"September 12, 2022","primary_completion_date":"February 26, 2018","start_date":"October 30, 2014","last_update_posted":"August 19, 2022"},{"nctid":"NCT00357682","version_a":3,"version_b":4,"version_a_date":"2006-08-10","version_b_date":"2006-11-08","pom_a":[],"pom_b":[{"label":"1.","content":"Conversion of Barrett\'s esophagus to adenocarcinoma of the esophagus or high-grade dysplasia"}],"first_posted":"No date provided","completion_date":"May 2017","primary_completion_date":"May 2017","start_date":"March 2005","last_update_posted":"May 18, 2016"},{"nctid":"NCT00357682","version_a":29,"version_b":30,"version_a_date":"2011-08-05","version_b_date":"2012-02-21","pom_a":[{"label":"1.","content":"Conversion of Barrett\'s esophagus to adenocarcinoma of the esophagus or high-grade dysplasia"}],"pom_b":[{"label":"1.","content":"Conversion of Barrett\'s esophagus to adenocarcinoma of the esophagus or high-grade dysplasia[ Time Frame: assessed every 2 years ]"}],"first_posted":"No date provided","completion_date":"May 2017","primary_completion_date":"May 2017","start_date":"March 2005","last_update_posted":"May 18, 2016"},{"nctid":"NCT00005585","version_a":7,"version_b":8,"version_a_date":"2007-02-01","version_b_date":"2007-02-08","pom_a":[],"pom_b":[{"label":"1.","content":"Disease-free survival at multiple time points"}],"first_posted":"No date provided","completion_date":"No date provided","primary_completion_date":"July 2007","start_date":"April 2000","last_update_posted":"June 10, 2013"},{"nctid":"NCT00005585","version_a":28,"version_b":29,"version_a_date":"2012-08-05","version_b_date":"2013-06-07","pom_a":[{"label":"1.","content":"Disease-free survival at multiple time points"}],"pom_b":[{"label":"1.","content":"Event-free survival[ Time Frame: 4 years ]The test statistic will compare Kaplan-Meier curves with sample size derived from a modification of the Makuch-Simon method for historical controls"},{"label":"2.","content":"Occurrence of anticipated failures[ Time Frame: Up to 7 years ]An O\'Brien-Fleming analysis will be conducted, with significance declared if the observed logrank Z-statistic exceeds the z/sqrt(IF), where IF=fraction of anticipated failures that have occurred and z=critical value of the final analysis."},{"label":"3.","content":"Grade 3 or greater CNS toxicity rates assessed using NCI CTC version 2.0[ Time Frame: Up to 7 years ]"}],"first_posted":"No date provided","completion_date":"No date provided","primary_completion_date":"July 2007","start_date":"April 2000","last_update_posted":"June 10, 2013"},{"nctid":"NCT04478266","version_a":11,"version_b":12,"version_a_date":"2021-02-08","version_b_date":"2021-02-19","pom_a":[{"label":"1.","content":"Progression-free survival[ Time Frame: From randomization date to date of first documentation of progression OR death (up to approximately 3.5 years) ]Progression-free survival is defined as the time interval from the date of randomization to the date of first documented tumor progression as per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) or death (due to any cause), whichever come first."}],"pom_b":[{"label":"1.","content":"Progression-free survival[ Time Frame: From randomization date to date of first documentation of progression OR death (up to approximately 4 years) ]Progression-free survival is defined as the time interval from the date of randomization to the date of first documented tumor progression as per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) or death (due to any cause), whichever come first."}],"first_posted":"No date provided","completion_date":"June 15, 2027","primary_completion_date":"June 28, 2022","start_date":"October 14, 2020","last_update_posted":"September 7, 2022"},{"nctid":"NCT01651949","version_a":18,"version_b":19,"version_a_date":"2014-08-14","version_b_date":"2015-02-24","pom_a":[{"label":"1.","content":"Geometric mean titers (GMTs) to the HPV types contained in the V503 vaccine[ Time Frame: Four weeks post vaccination 3 ]"},{"label":"2.","content":"Number of participants with injection-site adverse experiences of erythema, pain, and swelling[ Time Frame: Day 1 through Day 5 following any vaccination ]"},{"label":"3.","content":"Number of participants with elevated body temperature (\u2265100\xb0 F)[ Time Frame: Day 1 through Day 5 following any vaccination ]"}],"pom_b":[{"label":"1.","content":"Geometric Mean Titers (GMTs) to the HPV Types Contained in the 9vHPV Vaccine[ Time Frame: Four weeks post vaccination 3 (Month 7) ]Serum antibodies to HPV types 6/11/16/18/31/33/45/52/58 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL"},{"label":"2.","content":"Percentage of Participants With One or More Injection-site Adverse Experiences Prompted on the Vaccination Report Card[ Time Frame: Up to 5 days after any vaccination ]An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Injection-site AEs prompted on the Vaccination Report Card (VRC) were erythema, pain, and swelling. Participants were instructed to use the Vaccination Report Card to record AEs daily after each study vaccination."},{"label":"3.","content":"Percentage of Participants With Elevated Oral Body Temperature (>=37.8\xb0 C, >=100\xb0 F)[ Time Frame: Up to 5 days after any vaccination ]Participants were instructed by the investigator to use the Vaccination Report Card to document evening oral temperature daily after each study vaccination"},{"label":"4.","content":"Percentage of Participants With an Adverse Event[ Time Frame: Up to Month 12 ]An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE."},{"label":"5.","content":"Percentage of Participants Who Had Study Vaccine Discontinued Due to an Adverse Event[ Time Frame: Up to Month 12 ]An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE."}],"first_posted":"March 9, 2015","completion_date":"August 4, 2014","primary_completion_date":"August 4, 2014","start_date":"October 29, 2012","last_update_posted":"November 27, 2018"},{"nctid":"NCT02263508","version_a":5,"version_b":6,"version_a_date":"2015-05-28","version_b_date":"2015-06-19","pom_a":[{"label":"1.","content":"Incidence of dose limiting toxicities (DLT)[ Time Frame: Start of treatment until 6 weeks from the initial administration of MK-3475 ]Phase 1b: To evaluate the safety, as assessed by incidence of dose limiting toxicity (DLT), of talimogene laherparepvec in combination with MK-3475"},{"label":"2.","content":"Confirmed objective response rate (ORR) (Phase 2)[ Time Frame: Week 24 of treatment ]Phase 2 part 1: to evaluate the efficacy, as assessed by confirmed ORR of treatment with talimogene laherparepvec in combination with MK-3475 as compared to MK-3475 alone Phase 2 part 2: to evaluate the efficacy, as assessed by confirmed ORR of treatment with talimogene laherparepvec in combination with MK-3475 following progression on MK-3475 alone in Phase 2 part 1"}],"pom_b":[{"label":"1.","content":"Incidence of dose limiting toxicities (DLT)[ Time Frame: Start of treatment until 6 weeks from the initial administration of pembrolizumab (MK-3475) ]Phase 1b: To evaluate the safety, as assessed by incidence of dose limiting toxicity (DLT), of talimogene laherparepvec in combination with pembrolizumab (MK-3475)"},{"label":"2.","content":"Progression Free Survival (PFS) (response evaluation by blinded central review assessed modified RECIST 1.1)[ Time Frame: up to 24 months of treatment ]Phase 3: To evaluate the efficacy of treatment with talimogene laherparepvec in combination with pembrolizumab, as compared to pembrolizumab alone as assessed by progression-free survival (PFS) (response evaluation by blinded central review using modified Response Evaluation Criteria in Solid Tumors 1.1 [RECIST]) and overall survival (OS)."}],"first_posted":"May 16, 2022","completion_date":"March 11, 2021","primary_completion_date":"March 11, 2021","start_date":"December 8, 2014","last_update_posted":"May 16, 2022"},{"nctid":"NCT02263508","version_a":7,"version_b":8,"version_a_date":"2015-09-01","version_b_date":"2015-12-09","pom_a":[{"label":"1.","content":"Incidence of dose limiting toxicities (DLT)[ Time Frame: Start of treatment until 6 weeks from the initial administration of pembrolizumab (MK-3475) ]Phase 1b: To evaluate the safety, as assessed by incidence of dose limiting toxicity (DLT), of talimogene laherparepvec in combination with pembrolizumab (MK-3475)"},{"label":"2.","content":"Progression Free Survival (PFS) (response evaluation by blinded central review assessed modified RECIST 1.1)[ Time Frame: up to 24 months of treatment ]Phase 3: To evaluate the efficacy of treatment with talimogene laherparepvec in combination with pembrolizumab, as compared to pembrolizumab alone as assessed by progression-free survival (PFS) (response evaluation by blinded central review using modified Response Evaluation Criteria in Solid Tumors 1.1 [RECIST]) and overall survival (OS)."}],"pom_b":[{"label":"1.","content":"Incidence of dose limiting toxicities (DLT)[ Time Frame: Start of treatment until 6 weeks from the initial administration of pembrolizumab (MK-3475) ]Phase 1b: To evaluate the safety, as assessed by incidence of dose limiting toxicity (DLT), of talimogene laherparepvec in combination with pembrolizumab (MK-3475)"},{"label":"2.","content":"Progression Free Survival (PFS) (response evaluation by blinded central review assessed modified RECIST 1.1)[ Time Frame: up to 24 months of treatment ]Phase 3: To evaluate the efficacy of talimogene laherparepvec with pembrolizumab versus placebo with pembrolizumab, as assessed by progression-free survival (PFS) (response evaluation by blinded central review using modified Response Evaluation Criteria in Solid Tumors 1.1 [RECIST])."},{"label":"3.","content":"Overall Survival[ Time Frame: up to 24 months of treatment ]Phase 3: To evaluate the efficacy of talimogene laherparepvec with pembrolizumab versus placebo with pembrolizumab, as assessed by overall survival (OS)."}],"first_posted":"May 16, 2022","completion_date":"March 11, 2021","primary_completion_date":"March 11, 2021","start_date":"December 8, 2014","last_update_posted":"May 16, 2022"},{"nctid":"NCT02263508","version_a":29,"version_b":30,"version_a_date":"2017-05-10","version_b_date":"2017-06-26","pom_a":[{"label":"1.","content":"Incidence of dose limiting toxicities (DLT)[ Time Frame: Start of treatment until 6 weeks from the initial administration of pembrolizumab (MK-3475) ]Phase 1b: To evaluate the safety, as assessed by incidence of dose limiting toxicity (DLT), of talimogene laherparepvec in combination with pembrolizumab (MK-3475)"},{"label":"2.","content":"Progression Free Survival (PFS) (response evaluation by blinded central review assessed modified RECIST 1.1)[ Time Frame: up to 24 months of treatment ]Phase 3: To evaluate the efficacy of talimogene laherparepvec with pembrolizumab versus placebo with pembrolizumab, as assessed by progression-free survival (PFS) (response evaluation by blinded central review using modified Response Evaluation Criteria in Solid Tumors 1.1 [RECIST])."},{"label":"3.","content":"Overall Survival[ Time Frame: up to 24 months of treatment ]Phase 3: To evaluate the efficacy of talimogene laherparepvec with pembrolizumab versus placebo with pembrolizumab, as assessed by overall survival (OS)."}],"pom_b":[{"label":"1.","content":"Incidence of dose limiting toxicities (DLT)[ Time Frame: Start of treatment until 6 weeks from the initial administration of pembrolizumab (MK-3475) ]Phase 1b: To evaluate the safety, as assessed by incidence of dose limiting toxicity (DLT), of talimogene laherparepvec in combination with pembrolizumab (MK-3475)"},{"label":"2.","content":"Progression Free Survival (PFS) (response evaluation by blinded central review assessed modified RECIST 1.1)[ Time Frame: up to 44 months ]Phase 3: To evaluate the efficacy of talimogene laherparepvec with pembrolizumab versus placebo with pembrolizumab, as assessed by progression-free survival (PFS) (response evaluation by blinded independent central review using modified Response Evaluation Criteria in Solid Tumors 1.1 [RECIST])."},{"label":"3.","content":"Overall Survival[ Time Frame: up to 62 months ]Phase 3: To evaluate the efficacy of talimogene laherparepvec with pembrolizumab versus placebo with pembrolizumab, as assessed by overall survival (OS)."}],"first_posted":"May 16, 2022","completion_date":"March 11, 2021","primary_completion_date":"March 11, 2021","start_date":"December 8, 2014","last_update_posted":"May 16, 2022"},{"nctid":"NCT02263508","version_a":54,"version_b":55,"version_a_date":"2021-11-30","version_b_date":"2022-04-22","pom_a":[{"label":"1.","content":"Incidence of dose limiting toxicities (DLT)[ Time Frame: Start of treatment until 6 weeks from the initial administration of pembrolizumab (MK-3475) ]Phase 1b: To evaluate the safety, as assessed by incidence of dose limiting toxicity (DLT), of talimogene laherparepvec in combination with pembrolizumab (MK-3475)"},{"label":"2.","content":"Progression Free Survival (PFS) (response evaluation by blinded central review assessed modified RECIST 1.1)[ Time Frame: up to 44 months ]Phase 3: To evaluate the efficacy of talimogene laherparepvec with pembrolizumab versus placebo with pembrolizumab, as assessed by progression-free survival (PFS) (response evaluation by blinded independent central review using modified Response Evaluation Criteria in Solid Tumors 1.1 [RECIST])."},{"label":"3.","content":"Overall Survival[ Time Frame: up to 62 months ]Phase 3: To evaluate the efficacy of talimogene laherparepvec with pembrolizumab versus placebo with pembrolizumab, as assessed by overall survival (OS)."}],"pom_b":[{"label":"1.","content":"Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs)[ Time Frame: The DLT evaluation period was 6 weeks from the initial administration of pembrolizumab (week 6 to 12). ]A DLT was defined as any toxicity related to study drug which met any of the following criteria based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.0:Grade 4 non-hematologic toxicity.Grade 3 or higher pneumonitis.Grade 3 non-hematologic toxicity lasting > 3 days despite optimal supportive care, excluding grade 3 fatigue.Any grade 3 or higher non-hematologic laboratory value if medical intervention was required, or the abnormality lead to hospitalization, or the abnormality persisted for > 1 week.Febrile neutropenia grade 3 or grade 4.Thrombocytopenia < 25 x 10^9/L if associated with a bleeding event which does not result in hemodynamic instability but required an elective platelet infusion, or a life-threatening bleeding event which resulted in urgent intervention and admission to intensive care unit.Grade 5 toxicity (ie, death).Any other intolerable toxicity leading to permanent discontinuation of talimogene laherparepvec or pembrolizumab."},{"label":"2.","content":"Phase 3: Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessed Using Modified RECIST 1.1[ Time Frame: From randomization until the data-cut-off date of 02 March 2020; median (range) time on follow-up was 25.5 (0.6, 44.7) months in the Placebo + Pembrolizumab arm and 25.6 (0.3, 45.8) months in the Talimogene Laherparepvec + Pembrolizumab arm. ]PFS per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 is defined as the interval from randomization to the earlier event of progressive disease (PD) per modified RECIST 1.1 or death from any cause.PD: Increase in size of target lesions from nadir by \u2265 20% and \u2265 5 mm absolute increase above nadir, or the appearance of a new lesion.Median PFS was calculated using the Kaplan-Meier method. Participants without an event were censored at their last evaluable tumor assessment if available; otherwise on their randomization date.The primary analysis of PFS was specified to be conducted when 407 PFS events had occurred (data cut-off date 02 March 2020)."},{"label":"3.","content":"Phase 3: Overall Survival[ Time Frame: From randomization until the end of study; median (range) time on follow-up was 34.8 (0.6, 58.3) months in the Placebo + Pembrolizumab arm and 36.8 (0.3, 58.4) months in the Talimogene Laherparepvec + Pembrolizumab arm. ]Overall survival (OS) is defined as the interval from randomization to death from any cause.Median overall survival was calculated using the Kaplan-Meier method. Participants without an event were censored at their last known alive date."}],"first_posted":"May 16, 2022","completion_date":"March 11, 2021","primary_completion_date":"March 11, 2021","start_date":"December 8, 2014","last_update_posted":"May 16, 2022"},{"nctid":"NCT01026220","version_a":3,"version_b":4,"version_a_date":"2009-12-31","version_b_date":"2010-01-08","pom_a":[{"label":"1.","content":"Toxic death, defined as death primarily attributable to treatment"},{"label":"2.","content":"Early response after 2 courses of ABVE-PC chemotherapy"},{"label":"3.","content":"\\"Second-event\\" free survival"}],"pom_b":[{"label":"1.","content":"Toxic death, defined as death primarily attributable to treatment"},{"label":"2.","content":"Early response after 2 courses of ABVE-PC chemotherapy"},{"label":"3.","content":"\\"Second-event\\"-free survival"}],"first_posted":"May 30, 2017","completion_date":"March 31, 2022","primary_completion_date":"March 1, 2012","start_date":"December 7, 2009","last_update_posted":"April 28, 2022"},{"nctid":"NCT01026220","version_a":152,"version_b":153,"version_a_date":"2012-08-03","version_b_date":"2013-06-10","pom_a":[{"label":"1.","content":"Toxic death, defined as death primarily attributable to treatment"},{"label":"2.","content":"Early response after 2 courses of ABVE-PC chemotherapy"},{"label":"3.","content":"\\"Second-event\\"-free survival"}],"pom_b":[{"label":"1.","content":"Second-event-free survival at or above 95%[ Time Frame: 4 years ]"},{"label":"2.","content":"Safety analysis and monitoring of toxic death[ Time Frame: Up to 10 years ]"}],"first_posted":"May 30, 2017","completion_date":"March 31, 2022","primary_completion_date":"March 1, 2012","start_date":"December 7, 2009","last_update_posted":"April 28, 2022"},{"nctid":"NCT01026220","version_a":156,"version_b":157,"version_a_date":"2016-07-12","version_b_date":"2016-11-10","pom_a":[{"label":"1.","content":"Second-event-free survival at or above 95%[ Time Frame: 4 years ]"},{"label":"2.","content":"Safety analysis and monitoring of toxic death[ Time Frame: Up to 10 years ]"}],"pom_b":[{"label":"1.","content":"Second-event-free survival[ Time Frame: 4 years ]"},{"label":"2.","content":"Safety analysis and monitoring of toxic death[ Time Frame: Up to 10 years ]"}],"first_posted":"May 30, 2017","completion_date":"March 31, 2022","primary_completion_date":"March 1, 2012","start_date":"December 7, 2009","last_update_posted":"April 28, 2022"},{"nctid":"NCT01026220","version_a":157,"version_b":158,"version_a_date":"2016-11-10","version_b_date":"2017-04-18","pom_a":[{"label":"1.","content":"Second-event-free survival[ Time Frame: 4 years ]"},{"label":"2.","content":"Safety analysis and monitoring of toxic death[ Time Frame: Up to 10 years ]"}],"pom_b":[{"label":"1.","content":"Second-event-free Survival[ Time Frame: At 4 years from enrollment ]Second event here is defined as any relapse/progression of Hodgkin Lymphoma (HL) or a previously reported second malignant neoplasm (SMN), a new SMN, or death after a first event which can be relapse/progression of HL, SMN, biopsy-proven HL following completion of Consolidation for Slow Early Response (SER) patient, positive bilateral bone marrow biopsy following completion of Consolidation for Stage IV patient, or death. If death occurs as the 1st event, it also counts as the 2nd event."},{"label":"2.","content":"Safety Analysis and Monitoring of Toxic Death[ Time Frame: Within 30 days of protocol treatment at median follow-up of 48 months (range: 1 to 70 months). ]The primary endpoint for safety analysis and monitoring is toxic death, which is death primarily attributable to treatment."}],"first_posted":"May 30, 2017","completion_date":"March 31, 2022","primary_completion_date":"March 1, 2012","start_date":"December 7, 2009","last_update_posted":"April 28, 2022"},{"nctid":"NCT01622569","version_a":8,"version_b":9,"version_a_date":"2015-04-20","version_b_date":"2015-05-21","pom_a":[],"pom_b":[{"label":"1.","content":"\u2022 reduction of nasal congestion/obstruction symptoms[ Time Frame: at the end of Week 4 of the double-blind treatment phase ]"},{"label":"2.","content":"reduction in total polyp grade (sum of scores from both nasal cavities) over the 16 weeks of the double-blind treatment phase as determined by a nasal polyp grading scale score measured by nasoendoscopy[ Time Frame: over the 16 weeks of the double-blind treatment phase ]"}],"first_posted":"December 5, 2018","completion_date":"October 1, 2015","primary_completion_date":"August 6, 2015","start_date":"November 19, 2013","last_update_posted":"December 26, 2018"},{"nctid":"NCT01622569","version_a":11,"version_b":12,"version_a_date":"2016-09-26","version_b_date":"2018-12-04","pom_a":[{"label":"1.","content":"\u2022 reduction of nasal congestion/obstruction symptoms[ Time Frame: at the end of Week 4 of the double-blind treatment phase ]"},{"label":"2.","content":"reduction in total polyp grade (sum of scores from both nasal cavities) over the 16 weeks of the double-blind treatment phase as determined by a nasal polyp grading scale score measured by nasoendoscopy[ Time Frame: over the 16 weeks of the double-blind treatment phase ]"}],"pom_b":[{"label":"1.","content":"Change in 7-day Average Instantaneous Morning Diary Congestion/Obstruction Symptoms[ Time Frame: Baseline, Week 4 of the double-blind treatment phase ]Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing.0: NoneMild, symptoms clearly present, but minimal awareness, and easily toleratedModerate, definite awareness of symptoms that is bothersome but tolerableSevere, symptoms that are hard to tolerate, cause interference with activities or daily livingThe change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 4 Visit of the double-blind treatment phase"},{"label":"2.","content":"Change in Total Polyp Grade[ Time Frame: Baseline, Week 16 of the double-blind treatment phase ]Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. A summary of the changes from baseline to Week 16 in total polyp grade.0: No polypsMild polyposis: polyps not reaching below the inferior border of the middle turbinateModerate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinateSevere polyposis large polyps reaching below the lower inferior border of the inferior turbinateReduction in total polyp grade (sum of scores from both nasal cavities) at Week 16 of double-blind treatment phase; Included patients with nasal polyps at baseline"}],"first_posted":"December 5, 2018","completion_date":"October 1, 2015","primary_completion_date":"August 6, 2015","start_date":"November 19, 2013","last_update_posted":"December 26, 2018"},{"nctid":"NCT01724021","version_a":115,"version_b":116,"version_a_date":"2016-03-01","version_b_date":"2016-07-19","pom_a":[{"label":"1.","content":"Proportion of patients indicating an overall preference via Patient Preference Questionnaire (PPQ) for either the subcutaneous (SC) or intravenous (IV) administration of MabThera/Rituxan[ Time Frame: approximately 1.5 years ]"}],"pom_b":[{"label":"1.","content":"Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 6[ Time Frame: Cycle 6 (up to 24 weeks) ]Participants who preferred rituximab SC over rituximab IV, along with the corresponding 95% confidence interval (CI), were estimated using the patient preference questionnaire (PPQ) after completing cycle 6."},{"label":"2.","content":"Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 8[ Time Frame: Cycle 8 (up to 32 weeks) ]Participants who preferred rituximab SC over rituximab IV, along with the corresponding 95% confidence interval (CI), were estimated using the patient preference questionnaire (PPQ) after completing cycle 8."}],"first_posted":"August 29, 2016","completion_date":"January 2015","primary_completion_date":"January 2015","start_date":"December 2012","last_update_posted":"January 23, 2018"},{"nctid":"NCT01724021","version_a":116,"version_b":117,"version_a_date":"2016-07-19","version_b_date":"2017-12-19","pom_a":[{"label":"1.","content":"Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 6[ Time Frame: Cycle 6 (up to 24 weeks) ]Participants who preferred rituximab SC over rituximab IV, along with the corresponding 95% confidence interval (CI), were estimated using the patient preference questionnaire (PPQ) after completing cycle 6."},{"label":"2.","content":"Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 8[ Time Frame: Cycle 8 (up to 32 weeks) ]Participants who preferred rituximab SC over rituximab IV, along with the corresponding 95% confidence interval (CI), were estimated using the patient preference questionnaire (PPQ) after completing cycle 8."}],"pom_b":[{"label":"1.","content":"Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 6[ Time Frame: Cycle 6 (Up to 24 weeks) ]Participants who preferred rituximab SC over rituximab IV, along with the corresponding 95% confidence interval (CI), were estimated using the patient preference questionnaire (PPQ) after completing cycle 6."},{"label":"2.","content":"Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 8[ Time Frame: Cycle 8 (Up to 32 weeks) ]Participants who preferred rituximab SC over rituximab IV, along with the corresponding 95% confidence interval (CI), were estimated using the patient preference questionnaire (PPQ) after completing Cycle 8."}],"first_posted":"August 29, 2016","completion_date":"January 2015","primary_completion_date":"January 2015","start_date":"December 2012","last_update_posted":"January 23, 2018"},{"nctid":"NCT05155254","version_a":1,"version_b":2,"version_a_date":"2021-11-30","version_b_date":"2022-01-03","pom_a":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: Approximately 40 months after first patient in ]PFS defined as the time from randomization to the first documented disease progression ((based on Independent Review Committee in accordance with RECIST v1.1) or death from any cause."}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: Approximately 3.5 years ]PFS defined as the time from randomization to the first documented disease progression ((based on Independent Review Committee in accordance with RECIST v1.1) or death from any cause."}],"first_posted":"No date provided","completion_date":"May 2027","primary_completion_date":"April 2025","start_date":"December 21, 2021","last_update_posted":"September 6, 2022"},{"nctid":"NCT01655641","version_a":2,"version_b":3,"version_a_date":"2012-10-12","version_b_date":"2012-10-14","pom_a":[{"label":"1.","content":"Primary objective of the study is to compare transfusion requirements and Mortality in patients receiving Tranexamic acid (Cyklokapron\xae) and those receiving water for injection.[ Time Frame: 30 days ]"}],"pom_b":[{"label":"1.","content":"Primary objective of the study is to compare transfusion requirements and Mortality in patients receiving Tranexamic acid (Cyklokapron\xae) and those not receiving it.[ Time Frame: 30 days ]"}],"first_posted":"No date provided","completion_date":"July 2014","primary_completion_date":"June 2013","start_date":"July 2012","last_update_posted":"October 16, 2012"},{"nctid":"NCT03976102","version_a":3,"version_b":4,"version_a_date":"2020-04-07","version_b_date":"2022-05-27","pom_a":[{"label":"1.","content":"Overall Response Rate (ORR) measured for follicular lymphoma[ Time Frame: Month 7 (Week 28) ]The primary endpoint is ORR, defined as the proportion of subjects in each treatment group that achieve complete response (CR), unconfirmed complete response (CRu) or partial response (PR) at Month 7 (Week 28) with the response criteria for malignant lymphoma"}],"pom_b":[{"label":"1.","content":"Best Overall Response Rate (BORR) measured for low tumor burden follicular lymphoma, up to week 28[ Time Frame: BORR up to Month 7 (Week 28)} ]Primary endpoint: The primary endpoint is Best Overall Response Rate (BORR), up to Month 7 (Week 28) based on central radiology review in accordance with the Cheson, 1999 response criteria for Non-Hodgkin\'s Lymphomas."}],"first_posted":"No date provided","completion_date":"March 31, 2023","primary_completion_date":"September 30, 2022","start_date":"February 1, 2019","last_update_posted":"June 2, 2022"},{"nctid":"NCT00136084","version_a":2,"version_b":3,"version_a_date":"2005-09-09","version_b_date":"2005-11-10","pom_a":[{"label":"1.","content":"To learn the remission and survival rates for children with AML / MDS who receive this treatment."},{"label":"2.","content":"To compare the remission rates in children who receive two different doses of cytarabine during induction therapy."},{"label":"3.","content":"To learn more about the effects (good and bad) of gemtuzumab ozogamicin (GO), when used either alone or with other chemotherapy drugs."},{"label":"4.","content":"To study how the leukemia cells react to chemotherapy during treatment."},{"label":"5.","content":"To compare the amounts of leukemia cells in the blood and bone marrow to study minimal residual disease (MRD)."},{"label":"6.","content":"To try to improve the ways that fungal infections are diagnosed in patients with AML / MDS."},{"label":"7.","content":"To study the patient\'s quality of life during treatment."},{"label":"8.","content":"To compare the results of magnetic resonance imaging (MRI) with lab tests of the bone marrow."}],"pom_b":[{"label":"1.","content":"To learn the remission and survival rates for children with AML/MDS who receive this treatment"},{"label":"2.","content":"To compare the remission rates in children who receive two different doses of cytarabine during induction therapy"},{"label":"3.","content":"To learn more about the effects (good and bad) of gemtuzumab ozogamicin (GO), when used either alone or with other chemotherapy drugs"},{"label":"4.","content":"To study how the leukemia cells react to chemotherapy during treatment"},{"label":"5.","content":"To compare the amounts of leukemia cells in the blood and bone marrow to study minimal residual disease (MRD)"},{"label":"6.","content":"To try to improve the ways that fungal infections are diagnosed in patients with AML/MDS"},{"label":"7.","content":"To study the patient\'s quality of life during treatment"},{"label":"8.","content":"To compare the results of magnetic resonance imaging (MRI) with lab tests of the bone marrow"}],"first_posted":"March 26, 2010","completion_date":"June 2012","primary_completion_date":"July 2008","start_date":"August 2002","last_update_posted":"December 5, 2012"},{"nctid":"NCT00136084","version_a":9,"version_b":10,"version_a_date":"2007-05-03","version_b_date":"2007-09-17","pom_a":[{"label":"1.","content":"To learn the remission and survival rates for children with AML/MDS who receive this treatment"},{"label":"2.","content":"To compare the remission rates in children who receive two different doses of cytarabine during induction therapy"},{"label":"3.","content":"To learn more about the effects (good and bad) of gemtuzumab ozogamicin (GO), when used either alone or with other chemotherapy drugs"},{"label":"4.","content":"To study how the leukemia cells react to chemotherapy during treatment"},{"label":"5.","content":"To compare the amounts of leukemia cells in the blood and bone marrow to study minimal residual disease (MRD)"},{"label":"6.","content":"To try to improve the ways that fungal infections are diagnosed in patients with AML/MDS"},{"label":"7.","content":"To study the patient\'s quality of life during treatment"},{"label":"8.","content":"To compare the results of magnetic resonance imaging (MRI) with lab tests of the bone marrow"}],"pom_b":[{"label":"1.","content":"To learn the remission and survival rates for children with AML/MDS who receive this treatment"},{"label":"2.","content":"To compare the remission rates in children who receive two different doses of cytarabine during induction therapy"},{"label":"3.","content":"To learn more about the effects (good and bad) of gemtuzumab ozogamicin (GO), when used either alone or with other chemotherapy drugs"},{"label":"4.","content":"To study how the leukemia cells react to chemotherapy during treatment"},{"label":"5.","content":"To compare the amounts of leukemia cells in the blood and bone marrow to study minimal residual disease (MRD)"},{"label":"6.","content":"To try to improve the ways that fungal infections are diagnosed in patients with AML/MDS"},{"label":"7.","content":"To study the patient\'s quality of life during treatment.(Not open for new patients)."},{"label":"8.","content":"To compare the results of magnetic resonance imaging (MRI) with lab tests of the bone marrow"}],"first_posted":"March 26, 2010","completion_date":"June 2012","primary_completion_date":"July 2008","start_date":"August 2002","last_update_posted":"December 5, 2012"},{"nctid":"NCT00136084","version_a":10,"version_b":11,"version_a_date":"2007-09-17","version_b_date":"2007-12-20","pom_a":[{"label":"1.","content":"To learn the remission and survival rates for children with AML/MDS who receive this treatment"},{"label":"2.","content":"To compare the remission rates in children who receive two different doses of cytarabine during induction therapy"},{"label":"3.","content":"To learn more about the effects (good and bad) of gemtuzumab ozogamicin (GO), when used either alone or with other chemotherapy drugs"},{"label":"4.","content":"To study how the leukemia cells react to chemotherapy during treatment"},{"label":"5.","content":"To compare the amounts of leukemia cells in the blood and bone marrow to study minimal residual disease (MRD)"},{"label":"6.","content":"To try to improve the ways that fungal infections are diagnosed in patients with AML/MDS"},{"label":"7.","content":"To study the patient\'s quality of life during treatment.(Not open for new patients)."},{"label":"8.","content":"To compare the results of magnetic resonance imaging (MRI) with lab tests of the bone marrow"}],"pom_b":[{"label":"1.","content":"Detection of minimal residual disease (MRD) following one course of chemotherapy.[ Time Frame: Day 22 MRD measurement ]"}],"first_posted":"March 26, 2010","completion_date":"June 2012","primary_completion_date":"July 2008","start_date":"August 2002","last_update_posted":"December 5, 2012"},{"nctid":"NCT00136084","version_a":16,"version_b":17,"version_a_date":"2009-10-30","version_b_date":"2010-03-05","pom_a":[{"label":"1.","content":"Detection of minimal residual disease (MRD) following one course of chemotherapy.[ Time Frame: Day 22 MRD measurement ]"}],"pom_b":[{"label":"1.","content":"Detection of Minimal Residual Disease (MRD) Following One Course of Chemotherapy.[ Time Frame: Day 22 MRD measurement ]"}],"first_posted":"March 26, 2010","completion_date":"June 2012","primary_completion_date":"July 2008","start_date":"August 2002","last_update_posted":"December 5, 2012"},{"nctid":"NCT00136084","version_a":17,"version_b":18,"version_a_date":"2010-03-05","version_b_date":"2010-03-26","pom_a":[{"label":"1.","content":"Detection of Minimal Residual Disease (MRD) Following One Course of Chemotherapy.[ Time Frame: Day 22 MRD measurement ]"}],"pom_b":[{"label":"1.","content":"Minimal Residual Disease[ Time Frame: Day 22 MRD measurement ]Detection of Minimal Residual Disease following one course of chemotherapy"}],"first_posted":"March 26, 2010","completion_date":"June 2012","primary_completion_date":"July 2008","start_date":"August 2002","last_update_posted":"December 5, 2012"},{"nctid":"NCT00136084","version_a":18,"version_b":19,"version_a_date":"2010-03-26","version_b_date":"2010-08-27","pom_a":[{"label":"1.","content":"Minimal Residual Disease[ Time Frame: Day 22 MRD measurement ]Detection of Minimal Residual Disease following one course of chemotherapy"}],"pom_b":[{"label":"1.","content":"Minimal Residual Disease (MRD).[ Time Frame: Day 22 MRD measurement ]Detection of Minimal Residual Disease following one course of chemotherapy where positive MRD was defined as one or more leukemic cell per 1000 mononuclear bone-marrow cells (>=0.1%)."}],"first_posted":"March 26, 2010","completion_date":"June 2012","primary_completion_date":"July 2008","start_date":"August 2002","last_update_posted":"December 5, 2012"},{"nctid":"NCT04619433","version_a":1,"version_b":2,"version_a_date":"2020-11-05","version_b_date":"2021-03-11","pom_a":[{"label":"1.","content":"PFS[ Time Frame: up to 24 months ]Progression-Free-Survival"}],"pom_b":[{"label":"1.","content":"Part 1\uff1aSerum concentrations of Camrelizumab[ Time Frame: Cycle 2; each cycle is 21 days (up to 42 days) ]"},{"label":"2.","content":"Part 1\uff1aPlasma concentrations of Famitinib[ Time Frame: Cycle 2; each cycle is 21 days (up to 42 days) ]"},{"label":"3.","content":"Part 1\uff1aArea Under the Plasma Concentration Versus Time Curve (AUC) of Famitinib.[ Time Frame: Cycle 2; each cycle is 21 days (up to 42 days) ]"},{"label":"4.","content":"Part 1\uff1aMaximum Concentration (Cmax) of Famitinib.[ Time Frame: Cycle 2; each cycle is 21 days (up to 42 days) ]"},{"label":"5.","content":"Part 1\uff1aTime to Maximum Concentration (Tmax) of Famitinib.[ Time Frame: Cycle 2; each cycle is 21 days (up to 42 days) ]"},{"label":"6.","content":"Part 1\uff1aHalf-life (t1/2 z) of Famitinib.[ Time Frame: Cycle 2; each cycle is 21 days (up to 42 days) ]"},{"label":"7.","content":"Part 1\uff1aApparent Clearance (CL/F) of Famitinib[ Time Frame: Cycle 2; each cycle is 21 days (up to 42 days\uff09 ]"},{"label":"8.","content":"Part 1\uff1aVz/F of Famitinib.[ Time Frame: Cycle 2; each cycle is 21 days (up to 42 days) ]"},{"label":"9.","content":"Part 2: Progression-free Survival (PFS) as Assessed by BICR according to RECIST 1.1.[ Time Frame: up to 24 months ]"}],"first_posted":"No date provided","completion_date":"October 15, 2023","primary_completion_date":"December 15, 2022","start_date":"February 1, 2021","last_update_posted":"March 16, 2021"},{"nctid":"NCT00408213","version_a":14,"version_b":15,"version_a_date":"2007-12-18","version_b_date":"2008-01-18","pom_a":[{"label":"1.","content":"Adverse events, lab tests, vital signs."}],"pom_b":[{"label":"1.","content":"AEs, laboratory parameters, vital signs.[ Time Frame: Throughout study ]"}],"first_posted":"No date provided","completion_date":"September 2007","primary_completion_date":"No date provided","start_date":"June 2004","last_update_posted":"May 23, 2008"},{"nctid":"NCT02678351","version_a":5,"version_b":6,"version_a_date":"2017-08-31","version_b_date":"2018-12-20","pom_a":[{"label":"1.","content":"Percentage of patients who had true lesions[ Time Frame: Day 1 ]Point estimates and 95% confidence intervals will be calculated."},{"label":"2.","content":"Sensitivity of gallium Ga 68-PSMA PET/MRI[ Time Frame: Day 1 ]Sites of suspected metastatic disease will be graded on a three-point scale (0=negative, 1=equivocal, 2=positive), with statistical analysis performed with equivocal score of 1 graded as positive or negative on two separate analysis, for a more sensitive or specific visual read, respectively. Point estimates and 95% confidence intervals will be calculated."},{"label":"3.","content":"Specificity of gallium Ga 68-PSMA PET/MRI[ Time Frame: Day 1 ]Sites of suspected metastatic disease will be graded on a three-point scale (0=negative, 1=equivocal, 2=positive), with statistical analysis performed with equivocal score of 1 graded as positive or negative on two separate analysis, for a more sensitive or specific visual read, respectively. Point estimates and 95% confidence intervals will be calculated."}],"pom_b":[{"label":"1.","content":"PSMA-11 PET for detection of regional nodal disease[ Time Frame: Day 1 ]68Ga PSMA-11 PET/MRI will be used to detect regional nodal and distant metastases in patients with intermediate and high risk prostate cancer scheduled to undergo prostatectomy with lymph node dissection. The data will be analyzed by imaging interpretation and pathological analysis. Each patient will be interpreted as positive or negative for the presence of pelvic nodal disease The results will be expressed as range (mean \xb1 SD) of number of lymph nodes identified by PET."},{"label":"2.","content":"Nodal histology evaluation from prostatectomy[ Time Frame: Day 1 ]All patients that undergo prostatectomy will be evaluated for the presence of nodal metastasis based on histopathology. This will be reported on a per patient basis as positive or negative. This will be expressed as range (mean \xb1 SD) of number of lymph nodes identified by dissection during surgery plus histopathology"}],"first_posted":"March 4, 2022","completion_date":"December 2021","primary_completion_date":"December 13, 2020","start_date":"April 18, 2016","last_update_posted":"March 4, 2022"},{"nctid":"NCT02678351","version_a":10,"version_b":11,"version_a_date":"2021-12-08","version_b_date":"2022-03-02","pom_a":[{"label":"1.","content":"PSMA-11 PET for detection of regional nodal disease[ Time Frame: Day 1 ]68Ga PSMA-11 PET/MRI will be used to detect regional nodal and distant metastases in patients with intermediate and high risk prostate cancer scheduled to undergo prostatectomy with lymph node dissection. The data will be analyzed by imaging interpretation and pathological analysis. Each patient will be interpreted as positive or negative for the presence of pelvic nodal disease The results will be expressed as range (mean \xb1 SD) of number of lymph nodes identified by PET."},{"label":"2.","content":"Nodal histology evaluation from prostatectomy[ Time Frame: Day 1 ]All patients that undergo prostatectomy will be evaluated for the presence of nodal metastasis based on histopathology. This will be reported on a per patient basis as positive or negative. This will be expressed as range (mean \xb1 SD) of number of lymph nodes identified by dissection during surgery plus histopathology"}],"pom_b":[{"label":"1.","content":"68Ga-PSMA-11 PET Detection of Prostate Cancer Metastasized to Lymph Nodes[ Time Frame: 1 Day ]68-gallium (68Ga)-prostate-specific membrane antigen (PSMA) positron emission tomography/magnetic resonance imaging (PET/MRI) will be used to detect regional nodal and distant metastases in participants with intermediate and high-risk prostate cancer scheduled to undergo prostatectomy with lymph node dissection. The data will be analyzed by imaging interpretation. Each participant will be interpreted as either positive or negative for the presence of metastatic disease by 68Ga-PSMA PET/MRI, as assessed by imaging interpretation. The outcome will be expressed as the number of participants with metastatic disease, as identified by PET/MRI, a number without dispersion."}],"first_posted":"March 4, 2022","completion_date":"December 2021","primary_completion_date":"December 13, 2020","start_date":"April 18, 2016","last_update_posted":"March 4, 2022"},{"nctid":"NCT03850444","version_a":2,"version_b":3,"version_a_date":"2019-06-26","version_b_date":"2019-08-05","pom_a":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Up to approximately 2 years ]OS is defined as the time from randomization to death due to any cause."}],"pom_b":[{"label":"1.","content":"Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of \u226550%[ Time Frame: Through Database Cutoff Date of 04-September-2018 (up to approximately 23 months) ]OS was determined for participants with a TPS of \u226550% and was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the interim analysis were censored at the date of the last follow-up. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. The OS for participants with a TPS \u226550% is presented."},{"label":"2.","content":"Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of \u226520%[ Time Frame: Through Database Cutoff Date of 04-September-2018 (up to approximately 23 months) ]OS was determined for participants with a TPS of \u226520% and was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the interim analysis were censored at the date of the last follow-up. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. The OS for participants with a TPS \u226520% is presented."},{"label":"3.","content":"Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of \u22651%[ Time Frame: Through Database Cutoff Date of 04-September-2018 (up to approximately 23 months) ]OS was determined for participants with a TPS of \u22651% and was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the interim analysis were censored at the date of the last follow-up. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. The OS for participants with a TPS \u22651% is presented."}],"first_posted":"August 26, 2019","completion_date":"September 12, 2022","primary_completion_date":"September 4, 2018","start_date":"August 1, 2016","last_update_posted":"August 19, 2022"},{"nctid":"NCT03631706","version_a":1,"version_b":2,"version_a_date":"2018-08-13","version_b_date":"2018-08-23","pom_a":[{"label":"1.","content":"Best Overall Response (BOR) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) as Evaluated by Independent Review Committee[ Time Frame: Time from randomization to planned final assessment for unconfirmed BOR, expected at 26 months ]"},{"label":"2.","content":"Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) as Evaluated by Independent Review Committee[ Time Frame: Time from randomization to planned final assessment for PFS after 192 events expected at 37 months ]"}],"pom_b":[{"label":"1.","content":"Best Overall Response (BOR) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) as Evaluated by Independent Review Committee[ Time Frame: Time from randomization to planned final assessment for unconfirmed BOR, expected at 26 months ]"},{"label":"2.","content":"Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) as Evaluated by Independent Review Committee[ Time Frame: Time from randomization to planned final assessment, expected at 37 months ]"}],"first_posted":"June 29, 2022","completion_date":"March 31, 2023","primary_completion_date":"June 7, 2021","start_date":"October 1, 2018","last_update_posted":"July 26, 2022"},{"nctid":"NCT03631706","version_a":16,"version_b":17,"version_a_date":"2020-02-12","version_b_date":"2020-03-30","pom_a":[{"label":"1.","content":"Best Overall Response (BOR) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) as Evaluated by Independent Review Committee[ Time Frame: Time from randomization to planned final assessment for unconfirmed BOR, expected at 26 months ]"},{"label":"2.","content":"Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) as Evaluated by Independent Review Committee[ Time Frame: Time from randomization to planned final assessment, expected at 37 months ]"}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) assessed by Independent Review Committee (IRC)[ Time Frame: Time from randomization to planned final assessment at approximately up to 60 months ]"},{"label":"2.","content":"Overall survival (OS)[ Time Frame: Randomization to approximately up to 60 months ]"}],"first_posted":"June 29, 2022","completion_date":"March 31, 2023","primary_completion_date":"June 7, 2021","start_date":"October 1, 2018","last_update_posted":"July 26, 2022"},{"nctid":"NCT03631706","version_a":26,"version_b":27,"version_a_date":"2022-01-21","version_b_date":"2022-06-06","pom_a":[{"label":"1.","content":"Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) assessed by Independent Review Committee (IRC)[ Time Frame: Time from randomization to planned final assessment at approximately up to 60 months ]"},{"label":"2.","content":"Overall survival (OS)[ Time Frame: Randomization to approximately up to 60 months ]"}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Independent Review Committee (IRC)[ Time Frame: Time from randomization of study drug until the first documentation of PD or death, assessed approximately up to 746 days ]Progression free survival was defined as the time from randomization of study intervention until the first documentation of disease progression (PD) or death due to any cause, whichever occurred first. PD: At least a 20 percent (%) increase in the sum of the longest diameter (SLD) taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions."},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Time from randomization of study drug assessed approximately up to 843 days ]Overall Survival was defined as the time from randomization of study intervention to the date of death due to any cause. The overall survival was analyzed by using the Kaplan-Meier method."}],"first_posted":"June 29, 2022","completion_date":"March 31, 2023","primary_completion_date":"June 7, 2021","start_date":"October 1, 2018","last_update_posted":"July 26, 2022"},{"nctid":"NCT02544763","version_a":3,"version_b":4,"version_a_date":"2015-09-25","version_b_date":"2016-04-13","pom_a":[{"label":"1.","content":"Change in focal seizure frequency[ Time Frame: Baseline and average over the 16-week treatment period (or up to the point of withdrawal) ]The percentage change from baseline in number of focal seizures (average per 28 days) during the treatment period (maintenance and titration) is presented."}],"pom_b":[{"label":"1.","content":"Change in seizure frequency[ Time Frame: Baseline and average over the 16-week treatment period (or up to the point of withdrawal) ]"}],"first_posted":"September 23, 2020","completion_date":"February 26, 2019","primary_completion_date":"January 22, 2019","start_date":"April 6, 2016","last_update_posted":"October 6, 2020"},{"nctid":"NCT02544763","version_a":9,"version_b":10,"version_a_date":"2020-01-21","version_b_date":"2020-09-02","pom_a":[{"label":"1.","content":"Change in seizure frequency[ Time Frame: Baseline and average over the 16-week treatment period (or up to the point of withdrawal) ]"}],"pom_b":[{"label":"1.","content":"Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration)[ Time Frame: Baseline; up to Week 16 ]TSC-associated seizures included: focal motor seizures without impairment of consciousness or awareness (Type 1 focal motor); focal seizures with impairment of consciousness or awareness (Type 2 focal); focal seizures evolving to bilateral generalized convulsive seizures (Type 3 focal); and tonic-clonic, tonic, clonic, or atonic seizures that are countable. Percent change from Baseline was calculated as the (post-Baseline value minus the Baseline value) divided by the Baseline value x 100."}],"first_posted":"September 23, 2020","completion_date":"February 26, 2019","primary_completion_date":"January 22, 2019","start_date":"April 6, 2016","last_update_posted":"October 6, 2020"},{"nctid":"NCT00003610","version_a":12,"version_b":13,"version_a_date":"2009-05-09","version_b_date":"2015-07-07","pom_a":[],"pom_b":[{"label":"1.","content":"frequency of mouth pain[ Time Frame: Up to 2 weeks post-radiation treatment ]"},{"label":"2.","content":"duration of mouth pain[ Time Frame: Up to 2 weeks post-radiation treatment ]"},{"label":"3.","content":"severity of mouth pain[ Time Frame: Up to 2 weeks post-radiation treatment ]"}],"first_posted":"No date provided","completion_date":"July 2006","primary_completion_date":"July 2006","start_date":"October 1998","last_update_posted":"July 13, 2016"},{"nctid":"NCT03425656","version_a":2,"version_b":3,"version_a_date":"2019-02-05","version_b_date":"2020-07-08","pom_a":[{"label":"1.","content":"pathologic Complete Response[ Time Frame: week 24 ]the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes"}],"pom_b":[{"label":"1.","content":"pathologic Complete Response[ Time Frame: week 23 ]the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes"}],"first_posted":"No date provided","completion_date":"August 5, 2018","primary_completion_date":"March 6, 2018","start_date":"July 9, 2016","last_update_posted":"July 10, 2020"},{"nctid":"NCT02912559","version_a":12,"version_b":13,"version_a_date":"2017-07-10","version_b_date":"2017-08-04","pom_a":[{"label":"1.","content":"DFS[ Time Frame: From the time from randomization to first documentation of disease recurrent or death, assessed up to 5 years ]DFS will be compared between treatment arms using the stratified log rank test at one-sided level 0.025. The hazard ratio (HR) for DFS will be estimated using a stratified Cox proportional hazards model and the 95% confidence interval (CI) for the HR will be provided. Results from an unstratified analysis will also be provided. Kaplan-Meier methodology will be used to estimate the median DFS for each treatment arm, and Kaplan-Meier curves will be produced. Brookmeyer Crowley methodology will be used to construct the 95% CI for the median DFS for each treatment arm."}],"pom_b":[{"label":"1.","content":"Disease free survival (DFS)[ Time Frame: From the time from randomization to first documentation of disease recurrent or death, assessed up to 5 years ]DFS will be compared between treatment arms using the stratified log rank test at one-sided level 0.025. The hazard ratio (HR) for DFS will be estimated using a stratified Cox proportional hazards model and the 95% confidence interval (CI) for the HR will be provided. Results from an unstratified analysis will also be provided. Kaplan-Meier methodology will be used to estimate the median DFS for each treatment arm, and Kaplan-Meier curves will be produced. Brookmeyer Crowley methodology will be used to construct the 95% CI for the median DFS for each treatment arm."}],"first_posted":"No date provided","completion_date":"April 2, 2024","primary_completion_date":"April 2, 2024","start_date":"September 12, 2017","last_update_posted":"September 19, 2022"},{"nctid":"NCT02912559","version_a":750,"version_b":751,"version_a_date":"2021-11-17","version_b_date":"2021-12-04","pom_a":[{"label":"1.","content":"Disease free survival (DFS)[ Time Frame: From the time from randomization to first documentation of disease recurrent or death, assessed up to 5 years ]DFS will be compared between treatment arms using the stratified log rank test at one-sided level 0.025. The hazard ratio (HR) for DFS will be estimated using a stratified Cox proportional hazards model and the 95% confidence interval (CI) for the HR will be provided. Results from an unstratified analysis will also be provided. Kaplan-Meier methodology will be used to estimate the median DFS for each treatment arm, and Kaplan-Meier curves will be produced. Brookmeyer Crowley methodology will be used to construct the 95% CI for the median DFS for each treatment arm."}],"pom_b":[{"label":"1.","content":"Disease free survival (DFS)[ Time Frame: From the time from randomization to first documentation of disease recurrent or death, assessed up to 5 years ]DFS will be compared between treatment arms using the stratified log rank test at one-sided level 0.025. If zero DFS events are observed in a certain stratum at an interim analysis and unstratified log-rank is used, all subsequent analyses for DFS will use unstratified log-rank test. The hazard ratio (HR) for DFS will be estimated using a stratified Cox proportional hazards model and the 95 percent confidence interval (CI) for the HR will be provided. Results from an unstratified analysis will also be provided. Kaplan-Meier methodology will be used to estimate the median DFS for each treatment arm, and Kaplan-Meier curves will be produced. Brookmeyer Crowley methodology will be used to construct the 95 percent CI for the median DFS for each treatment arm."}],"first_posted":"No date provided","completion_date":"April 2, 2024","primary_completion_date":"April 2, 2024","start_date":"September 12, 2017","last_update_posted":"September 19, 2022"},{"nctid":"NCT00548548","version_a":2,"version_b":3,"version_a_date":"2007-11-08","version_b_date":"2007-12-21","pom_a":[{"label":"1.","content":"Overall survival"}],"pom_b":[{"label":"1.","content":"Overall survival[ Time Frame: Until death or loss to follow-up ]"}],"first_posted":"January 19, 2012","completion_date":"November 2013","primary_completion_date":"November 2009","start_date":"September 2007","last_update_posted":"June 14, 2017"},{"nctid":"NCT00548548","version_a":7,"version_b":8,"version_a_date":"2010-03-23","version_b_date":"2011-12-15","pom_a":[{"label":"1.","content":"Overall survival[ Time Frame: Until death or loss to follow-up ]"}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: From randomization until death, up to 26 months ]The primary efficacy endpoint for this study was overall survival (time to death), defined as the time between randomization and the date of death irrespective of the cause of death. Patients for whom no death was captured on the clinical database were censored at the most recent date they were known to be alive. Median survival was estimated by the Kaplan-Meier method."}],"first_posted":"January 19, 2012","completion_date":"November 2013","primary_completion_date":"November 2009","start_date":"September 2007","last_update_posted":"June 14, 2017"},{"nctid":"NCT02366143","version_a":28,"version_b":29,"version_a_date":"2016-11-01","version_b_date":"2017-04-17","pom_a":[{"label":"1.","content":"Progression Free Survival (PFS) as determined by the Investigator using Response Evaluation Criteria in Solid Tumors (RECIST v1.1)[ Time Frame: up to 2 years ]"}],"pom_b":[{"label":"1.","content":"Progression Free-Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) for Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 Population (Arm A vs Arm C, Arm B vs Arm C)[ Time Frame: Baseline until disease progression or death, whichever occurs first (up to approximately 44 months) ]"},{"label":"2.","content":"PFS as Determined by the Investigator Using RECIST v1.1 for TC1/2/3 or IC1/2/3 Population (Arm A vs Arm C, Arm B vs Arm C)[ Time Frame: Baseline until disease progression or death, whichever occurs first (up to approximately 44 months) ]"},{"label":"3.","content":"PFS as Determined by the Investigator Using RECIST v1.1 for Intent-to-Treat (ITT) Population (Arm A vs Arm C, Arm B vs Arm C)[ Time Frame: Baseline until disease progression or death, whichever occurs first (up to approximately 44 months) ]"},{"label":"4.","content":"Overall Survival (OS) for TC1/2/3 or IC1/2/3 Population (Arm A vs Arm C, Arm B vs Arm C)[ Time Frame: Baseline until death (up to approximately 44 months) ]"},{"label":"5.","content":"OS for ITT Population (Arm A vs Arm C, Arm B vs Arm C)[ Time Frame: Baseline until death (up to approximately 44 months) ]"}],"first_posted":"October 27, 2020","completion_date":"December 7, 2020","primary_completion_date":"September 13, 2019","start_date":"March 31, 2015","last_update_posted":"September 23, 2021"},{"nctid":"NCT02366143","version_a":30,"version_b":31,"version_a_date":"2017-06-09","version_b_date":"2017-10-09","pom_a":[{"label":"1.","content":"Progression Free-Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) for Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 Population (Arm A vs Arm C, Arm B vs Arm C)[ Time Frame: Baseline until disease progression or death, whichever occurs first (up to approximately 44 months) ]"},{"label":"2.","content":"PFS as Determined by the Investigator Using RECIST v1.1 for TC1/2/3 or IC1/2/3 Population (Arm A vs Arm C, Arm B vs Arm C)[ Time Frame: Baseline until disease progression or death, whichever occurs first (up to approximately 44 months) ]"},{"label":"3.","content":"PFS as Determined by the Investigator Using RECIST v1.1 for Intent-to-Treat (ITT) Population (Arm A vs Arm C, Arm B vs Arm C)[ Time Frame: Baseline until disease progression or death, whichever occurs first (up to approximately 44 months) ]"},{"label":"4.","content":"Overall Survival (OS) for TC1/2/3 or IC1/2/3 Population (Arm A vs Arm C, Arm B vs Arm C)[ Time Frame: Baseline until death (up to approximately 44 months) ]"},{"label":"5.","content":"OS for ITT Population (Arm A vs Arm C, Arm B vs Arm C)[ Time Frame: Baseline until death (up to approximately 44 months) ]"}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS), as Determined by the Investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)[ Time Frame: Baseline until disease progression or death, whichever occurs first (up to approximately 32 months) ]"},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Baseline until death (up to approximately 32 months) ]"}],"first_posted":"October 27, 2020","completion_date":"December 7, 2020","primary_completion_date":"September 13, 2019","start_date":"March 31, 2015","last_update_posted":"September 23, 2021"},{"nctid":"NCT02366143","version_a":44,"version_b":45,"version_a_date":"2020-07-06","version_b_date":"2020-10-05","pom_a":[{"label":"1.","content":"Progression Free Survival (PFS), as Determined by the Investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)[ Time Frame: Baseline until disease progression or death, whichever occurs first (up to approximately 32 months) ]"},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Baseline until death (up to approximately 32 months) ]"}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population[ Time Frame: Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months) ]Progression Free Survival (PFS), as Determined by the Investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Arm B versus Arm C in the T-effector (Teff)-high wild type (WT) population and the intent-to-treat (ITT)-WT population."},{"label":"2.","content":"Overall Survival (OS) in Arm B Versus Arm C in ITT-WT Population[ Time Frame: Baseline until death until data cut-off on 22 January 2018 (up to approximately 34 months) ]Overall Survival (OS) in Arm B Versus Arm C in ITT-WT Population"},{"label":"3.","content":"Overall Survival (OS) in Arm A Versus Arm C in ITT-WT Population[ Time Frame: Baseline until death (up approximately 53 months) ]Overall Survival (OS) in Arm A Versus Arm C in ITT-WT Population"}],"first_posted":"October 27, 2020","completion_date":"December 7, 2020","primary_completion_date":"September 13, 2019","start_date":"March 31, 2015","last_update_posted":"September 23, 2021"},{"nctid":"NCT02799069","version_a":1,"version_b":2,"version_a_date":"2016-06-09","version_b_date":"2017-02-02","pom_a":[{"label":"1.","content":"Overall subject complete response[ Time Frame: 12 weeks after the last photodynamic therapy (PDT) ]An overall complete responder was defined as a subject in whom all treated lesions were cleared 12 weeks after either the first PDT or re-treatment."}],"pom_b":[{"label":"1.","content":"Percentage of Participants With Complete Response 12 Weeks After the Last Photodynamic Therapy (PDT), ITT[ Time Frame: 12 weeks after the last PDT, up to 24 weeks after the first treatment ]An overall complete responder was defined as a subject in whom all treated lesions were cleared (all lesions showing complete remission) 12 weeks after the last PDT.The outcome measure considered complete responders who were completely cleared 12 weeks after the first PDT and responders who were completely cleared 12 weeks after the second PDT if a re-treatment was necessary (in case of partial- or non-responding lesions 12 weeks after the first PDT)"},{"label":"2.","content":"Percentage of Participants With Complete Response 12 Weeks After the Last Photodynamic Therapy (PDT), PP[ Time Frame: 12 weeks after the last PDT, up to 24 weeks after the first treatment ]An overall complete responder was defined as a subject in whom all treated lesions were cleared (all lesions showing complete remission) 12 weeks after the last PDT.The outcome measure considered complete responders who were completely cleared 12 weeks after the first PDT and responders who were completely cleared 12 weeks after the second PDT if a re-treatment was necessary (in case of partial- or non-responding lesions 12 weeks after the first PDT)"},{"label":"3.","content":"Percentage of Participants With Complete Response 12 Weeks After the Last Photodynamic Therapy (PDT) Illuminated With Narrow Spectrum Devices Only[ Time Frame: 12 weeks after the last PDT, up to 24 weeks after the first treatment ]Subgroup analysis of patients treated with a narrow spectrum device for PDT Illumination (~630 nm).An overall complete responder was defined as a subject in whom all treated lesions were cleared (all lesions showing complete remission) 12 weeks after the last PDT.The outcome measure considered complete responders who were completely cleared 12 weeks after the first PDT and responders who were completely cleared 12 weeks after the second PDT if a re-treatment was necessary (in case of partial- or non-responding lesions 12 weeks after the first PDT)"}],"first_posted":"March 23, 2017","completion_date":"August 2009","primary_completion_date":"August 2009","start_date":"April 2008","last_update_posted":"April 28, 2017"},{"nctid":"NCT00760877","version_a":14,"version_b":15,"version_a_date":"2012-03-07","version_b_date":"2012-04-19","pom_a":[{"label":"1.","content":"To determine rate of confirmed best cumulative CMR within the first year of study therapy with imatinib or nilotinib[ Time Frame: 12 months of treatment ]"}],"pom_b":[{"label":"1.","content":"Rate of confirmed best cumulative CMR within the first year of study therapy with imatinib or nilotinib[ Time Frame: 12 months of treatment ]"}],"first_posted":"August 16, 2016","completion_date":"July 2015","primary_completion_date":"July 2015","start_date":"June 2009","last_update_posted":"November 8, 2016"},{"nctid":"NCT00760877","version_a":31,"version_b":32,"version_a_date":"2016-03-10","version_b_date":"2016-07-01","pom_a":[{"label":"1.","content":"Rate of confirmed best cumulative CMR within the first year of study therapy with imatinib or nilotinib[ Time Frame: 12 months of treatment ]"}],"pom_b":[{"label":"1.","content":"Rate of Confirmed Best Cumulative Complete Molecular Response (CMR)[ Time Frame: 12 months ]The rate of confirmed best cumulative CMR was defined as the percentage of participants who had confirmed CMR during the first 12 months of treatment after the randomization date. Participants who achieved confirmed best cumulative CMR during the first 12 months were considered responders. Participants who dropped out early or who did not provide sufficient data for any reason were considered to be non-responders. The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) \u2264 0.00001 by real-time quantitative polymerase chain reaction (RQ-PCR) where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity >4.5 logs."}],"first_posted":"August 16, 2016","completion_date":"July 2015","primary_completion_date":"July 2015","start_date":"June 2009","last_update_posted":"November 8, 2016"},{"nctid":"NCT00760877","version_a":32,"version_b":33,"version_a_date":"2016-07-01","version_b_date":"2016-10-04","pom_a":[{"label":"1.","content":"Rate of Confirmed Best Cumulative Complete Molecular Response (CMR)[ Time Frame: 12 months ]The rate of confirmed best cumulative CMR was defined as the percentage of participants who had confirmed CMR during the first 12 months of treatment after the randomization date. Participants who achieved confirmed best cumulative CMR during the first 12 months were considered responders. Participants who dropped out early or who did not provide sufficient data for any reason were considered to be non-responders. The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) \u2264 0.00001 by real-time quantitative polymerase chain reaction (RQ-PCR) where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity >4.5 logs."}],"pom_b":[{"label":"1.","content":"Rate of Confirmed Best Cumulative Complete Molecular Response (CMR)[ Time Frame: 12 months ]The rate of confirmed best cumulative CMR was defined as the number of participants who had confirmed CMR during the first 12 months of treatment after the randomization date. Participants who achieved confirmed best cumulative CMR during the first 12 months were considered responders. Participants who dropped out early or who did not provide sufficient data for any reason were considered to be non-responders. The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) \u2264 0.00001 by real-time quantitative polymerase chain reaction (RQ-PCR) where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity >4.5 logs."}],"first_posted":"August 16, 2016","completion_date":"July 2015","primary_completion_date":"July 2015","start_date":"June 2009","last_update_posted":"November 8, 2016"},{"nctid":"NCT00947115","version_a":14,"version_b":15,"version_a_date":"2011-02-03","version_b_date":"2011-03-31","pom_a":[{"label":"1.","content":"Evaluation of immune response to components of the vaccine in serum of all subjects following first dose of GSK 580299 vaccine[ Time Frame: Years 5, 6, 7, 8, 9 and 10 ]"}],"pom_b":[{"label":"1.","content":"Anti-Human Papillomavirus (Anti-HPV) 16/18 Antibody Titers in Serum[ Time Frame: At year 5 ]Titers were expressed as Geometric Mean Titer (GMT) in Enzyme-Linked Immunosorbent Assay (ELISA) units per milliliter (EL.U/mL)."},{"label":"2.","content":"Anti-Human Papillomavirus (Anti-HPV) 16/18 Antibody Titers in Serum[ Time Frame: Years 6, 7, 8, 9, 10 ]"},{"label":"3.","content":"Number of Seroconverted Subjects[ Time Frame: At Year 5 ]Seroconversion was defined as the appearance of antibodies (i.e. anti-HPV-16 and anti-HPV-18 antibody titers respectively greater than or equal to 8 and 7 EL.U/mL) in the serum of subjects seronegative before vaccination in the primary study."},{"label":"4.","content":"Number of Seroconverted Subjects[ Time Frame: Years 6, 7, 8, 9, 10 ]"}],"first_posted":"May 2, 2011","completion_date":"February 3, 2015","primary_completion_date":"February 3, 2015","start_date":"September 22, 2009","last_update_posted":"October 30, 2020"},{"nctid":"NCT00947115","version_a":18,"version_b":19,"version_a_date":"2011-12-08","version_b_date":"2012-02-09","pom_a":[{"label":"1.","content":"Anti-Human Papillomavirus (Anti-HPV) 16/18 Antibody Titers in Serum[ Time Frame: At year 5 ]Titers were expressed as Geometric Mean Titer (GMT) in Enzyme-Linked Immunosorbent Assay (ELISA) units per milliliter (EL.U/mL)."},{"label":"2.","content":"Anti-Human Papillomavirus (Anti-HPV) 16/18 Antibody Titers in Serum[ Time Frame: Years 6, 7, 8, 9, 10 ]"},{"label":"3.","content":"Number of Seroconverted Subjects[ Time Frame: At Year 5 ]Seroconversion was defined as the appearance of antibodies (i.e. anti-HPV-16 and anti-HPV-18 antibody titers respectively greater than or equal to 8 and 7 EL.U/mL) in the serum of subjects seronegative before vaccination in the primary study."},{"label":"4.","content":"Number of Seroconverted Subjects[ Time Frame: Years 6, 7, 8, 9, 10 ]"}],"pom_b":[{"label":"1.","content":"Anti-Human Papillomavirus (Anti-HPV) 16/18 Antibody Titers in Serum[ Time Frame: At Year 5 and 6 ]Titers were expressed as Geometric Mean Titer (GMT) in Enzyme-Linked Immunosorbent Assay (ELISA) units per milliliter (EL.U/mL)."},{"label":"2.","content":"Anti-Human Papillomavirus (Anti-HPV) 16/18 Antibody Titers in Serum[ Time Frame: At Years 7, 8, 9, 10 ]"},{"label":"3.","content":"Number of Seroconverted Subjects.[ Time Frame: At Year 5 and Year 6 ]Seroconversion was defined as the appearance of antibodies (i.e. anti-HPV-16 and anti-HPV-18 antibody titers respectively greater than or equal to 8 and 7 EL.U/mL) in the serum of subjects seronegative before vaccination in the primary study."},{"label":"4.","content":"Number of Seroconverted Subjects.[ Time Frame: At Years 7, 8, 9, 10 ]"}],"first_posted":"May 2, 2011","completion_date":"February 3, 2015","primary_completion_date":"February 3, 2015","start_date":"September 22, 2009","last_update_posted":"October 30, 2020"},{"nctid":"NCT00947115","version_a":25,"version_b":26,"version_a_date":"2013-02-21","version_b_date":"2014-02-06","pom_a":[{"label":"1.","content":"Anti-Human Papillomavirus (Anti-HPV) 16/18 Antibody Titers in Serum[ Time Frame: At Year 5 and 6 ]Titers were expressed as Geometric Mean Titer (GMT) in Enzyme-Linked Immunosorbent Assay (ELISA) units per milliliter (EL.U/mL)."},{"label":"2.","content":"Anti-Human Papillomavirus (Anti-HPV) 16/18 Antibody Titers in Serum[ Time Frame: At Years 7, 8, 9, 10 ]"},{"label":"3.","content":"Number of Seroconverted Subjects.[ Time Frame: At Year 5 and Year 6 ]Seroconversion was defined as the appearance of antibodies (i.e. anti-HPV-16 and anti-HPV-18 antibody titers respectively greater than or equal to 8 and 7 EL.U/mL) in the serum of subjects seronegative before vaccination in the primary study."},{"label":"4.","content":"Number of Seroconverted Subjects.[ Time Frame: At Years 7, 8, 9, 10 ]"}],"pom_b":[{"label":"1.","content":"Anti-Human Papillomavirus (Anti-HPV) 16/18 Antibody Titers in Serum[ Time Frame: At Year 5, 6 and 7 ]Titers were expressed as Geometric Mean Titer (GMT) in Enzyme-Linked Immunosorbent Assay (ELISA) units per milliliter (EL.U/mL)."},{"label":"2.","content":"Anti-Human Papillomavirus (Anti-HPV) 16/18 Antibody Titers in Serum[ Time Frame: At Years 8, 9 and 10 ]"},{"label":"3.","content":"Number of Seroconverted Subjects.[ Time Frame: At Year 5, 6 and 7 ]Seroconversion was defined as the appearance of antibodies (i.e. anti-HPV-16 and anti-HPV-18 antibody titers respectively greater than or equal to 8 and 7 EL.U/mL) in the serum of subjects seronegative before vaccination in the primary study."},{"label":"4.","content":"Number of Seroconverted Subjects.[ Time Frame: At Years 8, 9 and 10 ]"}],"first_posted":"May 2, 2011","completion_date":"February 3, 2015","primary_completion_date":"February 3, 2015","start_date":"September 22, 2009","last_update_posted":"October 30, 2020"},{"nctid":"NCT00947115","version_a":32,"version_b":33,"version_a_date":"2015-09-10","version_b_date":"2016-04-14","pom_a":[{"label":"1.","content":"Anti-Human Papillomavirus (Anti-HPV) 16/18 Antibody Titers in Serum[ Time Frame: At Year 5, 6 and 7 ]Titers were expressed as Geometric Mean Titer (GMT) in Enzyme-Linked Immunosorbent Assay (ELISA) units per milliliter (EL.U/mL)."},{"label":"2.","content":"Anti-Human Papillomavirus (Anti-HPV) 16/18 Antibody Titers in Serum[ Time Frame: At Years 8, 9 and 10 ]"},{"label":"3.","content":"Number of Seroconverted Subjects.[ Time Frame: At Year 5, 6 and 7 ]Seroconversion was defined as the appearance of antibodies (i.e. anti-HPV-16 and anti-HPV-18 antibody titers respectively greater than or equal to 8 and 7 EL.U/mL) in the serum of subjects seronegative before vaccination in the primary study."},{"label":"4.","content":"Number of Seroconverted Subjects.[ Time Frame: At Years 8, 9 and 10 ]"}],"pom_b":[{"label":"1.","content":"Anti-Human Papillomavirus (Anti-HPV) 16/18 Antibody Titers in Serum[ Time Frame: At Year 5, 6 and 7 ]Titers were expressed as Geometric Mean Titer (GMT) in Enzyme-Linked Immunosorbent Assay (ELISA) units per milliliter (EL.U/mL)."},{"label":"2.","content":"Anti-Human Papillomavirus (Anti-HPV) 16/18 Antibody Titers in Serum[ Time Frame: At Years 8, 9 and 10 ]Seroconversion was defined as the appearance of antibodies (i.e. anti-HPV-16 and anti-HPV-18 antibody titers respectively greater than or equal to 19 and 18 EL.U/mL) in the serum of subjects seronegative before vaccination in the primary study."},{"label":"3.","content":"Number of Seroconverted Subjects.[ Time Frame: At Year 5, 6 and 7 ]Seroconversion was defined as the appearance of antibodies (i.e. anti-HPV-16 and anti-HPV-18 antibody titers respectively greater than or equal to 8 and 7 EL.U/mL) in the serum of subjects seronegative before vaccination in the primary study."},{"label":"4.","content":"Number of Seroconverted Subjects.[ Time Frame: At Years 8, 9 and 10 ]Seroconversion was defined as the appearance of antibodies (i.e. anti-HPV-16 and anti-HPV-18 antibody titers respectively greater than or equal to 19 and 18 EL.U/mL) in the serum of subjects seronegative before vaccination in the primary study."}],"first_posted":"May 2, 2011","completion_date":"February 3, 2015","primary_completion_date":"February 3, 2015","start_date":"September 22, 2009","last_update_posted":"October 30, 2020"},{"nctid":"NCT00947115","version_a":34,"version_b":35,"version_a_date":"2017-01-09","version_b_date":"2020-10-02","pom_a":[{"label":"1.","content":"Anti-Human Papillomavirus (Anti-HPV) 16/18 Antibody Titers in Serum[ Time Frame: At Year 5, 6 and 7 ]Titers were expressed as Geometric Mean Titer (GMT) in Enzyme-Linked Immunosorbent Assay (ELISA) units per milliliter (EL.U/mL)."},{"label":"2.","content":"Anti-Human Papillomavirus (Anti-HPV) 16/18 Antibody Titers in Serum[ Time Frame: At Years 8, 9 and 10 ]Seroconversion was defined as the appearance of antibodies (i.e. anti-HPV-16 and anti-HPV-18 antibody titers respectively greater than or equal to 19 and 18 EL.U/mL) in the serum of subjects seronegative before vaccination in the primary study."},{"label":"3.","content":"Number of Seroconverted Subjects.[ Time Frame: At Year 5, 6 and 7 ]Seroconversion was defined as the appearance of antibodies (i.e. anti-HPV-16 and anti-HPV-18 antibody titers respectively greater than or equal to 8 and 7 EL.U/mL) in the serum of subjects seronegative before vaccination in the primary study."},{"label":"4.","content":"Number of Seroconverted Subjects.[ Time Frame: At Years 8, 9 and 10 ]Seroconversion was defined as the appearance of antibodies (i.e. anti-HPV-16 and anti-HPV-18 antibody titers respectively greater than or equal to 19 and 18 EL.U/mL) in the serum of subjects seronegative before vaccination in the primary study."}],"pom_b":[{"label":"1.","content":"Anti-Human Papillomavirus (Anti-HPV)-16/18 Antibody Titers in Serum at Years 5, 6 and 7[ Time Frame: At Years 5, 6 and 7 ]Anti-HPV-16/18 antibody titers are presented as Geometric Mean Titers (GMTs) and expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).The immune response of the HPV-16/18 vaccine (as determined by anti-HPV-16/18 antibodies assessed by ELISA) in the HPV-060 study population was compared with the immune response obtained in study HPV-001 and its long-term follow-up studies HPV-007/HPV-023 at equivalent timepoints and with the immune response obtained after natural infection in subjects from study HPV-008.The immune response data for the efficacy studies HPV-001/HPV-007/HPV-023 can be found under the NCT record NCT00518336. The immune response data for the HPV-008 study can be found under the NCT record NCT00122681."},{"label":"2.","content":"Anti-HPV-16/18 Antibody Titers in Serum at Years 8, 9 and 10[ Time Frame: At Years 8, 9 and 10 ]Anti-HPV-16/18 antibody titers are presented as Geometric Mean Titers (GMTs) and expressed in EL.U/mL.The immune response of the HPV-16/18 vaccine (as determined by anti-HPV-16/18 antibodies assessed by ELISA) in the HPV-060 study population was compared with the immune response obtained in study HPV-001 and its long-term follow-up studies HPV-007/HPV-023 at equivalent timepoints and with the immune response obtained after natural infection in subjects from study HPV-008.The immune response data for the efficacy studies HPV-001/HPV-007/HPV-023 can be found under the NCT number NCT00518336. The immune response data for the HPV-008 study can be found under the NCT number NCT00122681."},{"label":"3.","content":"Number of Seroconverted Subjects for Anti-HPV-16 and Anti-HPV-18 Antibodies at Years 5, 6 and 7[ Time Frame: At Years 5, 6 and 7 ]Seroconversion was defined as the appearance of anti-HPV-16 and anti- HPV-18 antibodies [i.e. antibody titer greater than or equal to (\u2265) the cut-off value] in the serum of subjects seronegative before vaccination in the primary study HPV-014 (NCT00196937). Cut-off values were 8 EL.U/mL for anti-HPV-16 antibody titers and 7 EL.U/mL for anti-HPV-18 antibody titers."},{"label":"4.","content":"Number of Seroconverted Subjects for Anti-HPV-16 and Anti-HPV-18 Antibodies at Years 8, 9 and 10[ Time Frame: At Years 8, 9 and 10 ]Seroconversion was defined as the appearance of anti-HPV-16 and anti-HPV-18 antibodies (i.e. antibody titer \u2265 the cut-off value) in the serum of subjects seronegative before vaccination in the primary study HPV-014 (NCT00196937). Cut-off values were 19 EL.U/mL for anti-HPV-16 antibody titers and 18 EL.U/mL for anti-HPV-18 antibody titers."}],"first_posted":"May 2, 2011","completion_date":"February 3, 2015","primary_completion_date":"February 3, 2015","start_date":"September 22, 2009","last_update_posted":"October 30, 2020"},{"nctid":"NCT00262899","version_a":7,"version_b":8,"version_a_date":"2006-09-29","version_b_date":"2006-11-08","pom_a":[],"pom_b":[{"label":"1.","content":"Definitive surgery choice as measured by self-reported and medical record verification at 6 months after randomization"},{"label":"2.","content":"Quality of life as measured by functional assessment of cancer therapy for breast cancer (FACT-B) at 1, 6, and 12 months after randomization"},{"label":"3.","content":"Distress as measured by Impact of Events Scale Brief Symptom Inventory at 1, 6, and 12 months after randomization"},{"label":"4.","content":"Knowledge as assessed by Genetic Testing Knowledge Measure at 1 month after randomization"},{"label":"5.","content":"Decision outcomes as assessed by Decisional Conflict Scale Satisfaction with Decision Scale at 1 and 6 months after randomization"}],"first_posted":"No date provided","completion_date":"July 2011","primary_completion_date":"July 2010","start_date":"August 2005","last_update_posted":"January 7, 2013"},{"nctid":"NCT00262899","version_a":36,"version_b":37,"version_a_date":"2011-03-23","version_b_date":"2013-01-04","pom_a":[{"label":"1.","content":"Definitive surgery choice as measured by self-reported and medical record verification at 6 months after randomization"},{"label":"2.","content":"Quality of life as measured by functional assessment of cancer therapy for breast cancer (FACT-B) at 1, 6, and 12 months after randomization"},{"label":"3.","content":"Distress as measured by Impact of Events Scale Brief Symptom Inventory at 1, 6, and 12 months after randomization"},{"label":"4.","content":"Knowledge as assessed by Genetic Testing Knowledge Measure at 1 month after randomization"},{"label":"5.","content":"Decision outcomes as assessed by Decisional Conflict Scale Satisfaction with Decision Scale at 1 and 6 months after randomization"}],"pom_b":[{"label":"1.","content":"Definitive surgery choice as measured by self-reported and medical record verification at 6 months after randomization[ Time Frame: 1, 6, and 12 months ]"},{"label":"2.","content":"Quality of life as measured by functional assessment of cancer therapy for breast cancer (FACT-B) at 1, 6, and 12 months after randomization[ Time Frame: 1, 6, and 12 months ]"},{"label":"3.","content":"Distress as measured by Impact of Events Scale Brief Symptom Inventory at 1, 6, and 12 months after randomization[ Time Frame: 1, 6, and 12 months ]"},{"label":"4.","content":"Knowledge as assessed by Genetic Testing Knowledge Measure at 1 month after randomization[ Time Frame: 1 month ]"},{"label":"5.","content":"Decision outcomes as assessed by Decisional Conflict Scale Satisfaction with Decision Scale at 1 and 6 months after randomization[ Time Frame: 1 and 6 months ]"}],"first_posted":"No date provided","completion_date":"July 2011","primary_completion_date":"July 2010","start_date":"August 2005","last_update_posted":"January 7, 2013"},{"nctid":"NCT00130533","version_a":1,"version_b":2,"version_a_date":"2005-08-12","version_b_date":"2005-09-29","pom_a":[{"label":"1.","content":"5-year Disease Free Survival."}],"pom_b":[{"label":"1.","content":"5-year disease free survival"}],"first_posted":"October 25, 2019","completion_date":"February 17, 2017","primary_completion_date":"February 17, 2017","start_date":"January 2006","last_update_posted":"October 25, 2019"},{"nctid":"NCT00130533","version_a":9,"version_b":10,"version_a_date":"2010-02-11","version_b_date":"2010-08-09","pom_a":[{"label":"1.","content":"5-year disease free survival"}],"pom_b":[{"label":"1.","content":"Disease free survival"}],"first_posted":"October 25, 2019","completion_date":"February 17, 2017","primary_completion_date":"February 17, 2017","start_date":"January 2006","last_update_posted":"October 25, 2019"},{"nctid":"NCT00130533","version_a":18,"version_b":19,"version_a_date":"2017-09-08","version_b_date":"2018-02-14","pom_a":[{"label":"1.","content":"Disease free survival"}],"pom_b":[{"label":"1.","content":"Disease free survival[ Time Frame: At the end of Cycle 8 (each cycle is 28 days) ]"}],"first_posted":"October 25, 2019","completion_date":"February 17, 2017","primary_completion_date":"February 17, 2017","start_date":"January 2006","last_update_posted":"October 25, 2019"},{"nctid":"NCT00130533","version_a":19,"version_b":20,"version_a_date":"2018-02-14","version_b_date":"2019-10-03","pom_a":[{"label":"1.","content":"Disease free survival[ Time Frame: At the end of Cycle 8 (each cycle is 28 days) ]"}],"pom_b":[{"label":"1.","content":"Disease Free Survival (DFS) Events[ Time Frame: 5 years ]DFS was measured from the date of randomization assignment in the intent to treat (ITT) population to loco-regional or distant recurrence, second primary malignancy or death date, whichever occurred first."}],"first_posted":"October 25, 2019","completion_date":"February 17, 2017","primary_completion_date":"February 17, 2017","start_date":"January 2006","last_update_posted":"October 25, 2019"},{"nctid":"NCT03250377","version_a":15,"version_b":16,"version_a_date":"2019-03-18","version_b_date":"2019-04-09","pom_a":[{"label":"1.","content":"Number of subjects with Adverse Events (AEs) during the study[ Time Frame: From study entry until Final Visit (up to 70 months) ]An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment."},{"label":"2.","content":"Number of subjects who withdraw from the study due to Adverse Events (AEs)[ Time Frame: From study entry until Final Visit (up to 70 months) ]An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment."},{"label":"3.","content":"Number of subjects with Serious Adverse Events (SAEs) during the study[ Time Frame: From study entry until Final Visit (up to 70 months) ]A SAE must meet 1 or more of the following criteria:DeathLife-threateningSignificant or persistent disability/incapacityCongenital anomaly/birth defectInitial inpatient hospitalization or prolongation of hospitalizationImportant medical event that, based upon appropriate medical judgment, may jeopardize the patient or subject and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious"}],"pom_b":[{"label":"1.","content":"Adverse Events (AEs)[ Time Frame: From study entry until Final Visit (up to 70 months) ]An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment."}],"first_posted":"No date provided","completion_date":"March 3, 2025","primary_completion_date":"March 3, 2025","start_date":"August 5, 2017","last_update_posted":"August 12, 2022"},{"nctid":"NCT02303119","version_a":1,"version_b":2,"version_a_date":"2014-11-26","version_b_date":"2014-11-27","pom_a":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: 5.5 years ]The PFS is defined as the time from randomization into the study to the first observation of documented disease progression or death due to any cause. If a subject has not progressed or died, PFS will be censored at the time of last visit with adequate assessment"}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: 5.5 years ]Time from randomization into the study to the first observation of documented disease progression or death due to any cause. If a subject has not progressed or died, PFS will be censored at the time of last visit with adequate assessment"}],"first_posted":"No date provided","completion_date":"June 29, 2021","primary_completion_date":"June 29, 2021","start_date":"February 2, 2015","last_update_posted":"September 1, 2021"},{"nctid":"NCT01300351","version_a":12,"version_b":13,"version_a_date":"2013-05-09","version_b_date":"2013-08-22","pom_a":[{"label":"1.","content":"Progression-free survival (Response Evaluation Criteria in Solid Tumors) (RECIST 1.1)[ Time Frame: RECIST 1.1 tumour assessments carried out every 12 weeks (+/- 2 weeks) from randomisation until disease progression ]"}],"pom_b":[{"label":"1.","content":"Progression-free survival (PFS)[ Time Frame: RECIST 1.1 tumour assessments carried out every 12 weeks (+/- 2 weeks) from randomisation until disease progression ]To compare the efficacy of fulvestrant 500 mg treatment with fulvestrant 250 mg treatment in terms of progression-free survival."}],"first_posted":"April 24, 2015","completion_date":"March 2014","primary_completion_date":"March 2014","start_date":"March 2011","last_update_posted":"April 24, 2015"},{"nctid":"NCT01300351","version_a":16,"version_b":17,"version_a_date":"2014-04-23","version_b_date":"2015-04-23","pom_a":[{"label":"1.","content":"Progression-free survival (PFS)[ Time Frame: RECIST 1.1 tumour assessments carried out every 12 weeks (+/- 2 weeks) from randomisation until disease progression ]To compare the efficacy of fulvestrant 500 mg treatment with fulvestrant 250 mg treatment in terms of progression-free survival."}],"pom_b":[{"label":"1.","content":"Progression-free Survival[ Time Frame: 36 months ]Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, or unequivocal progression of existing non-target lesions, or the appearance of new lesions, or death (by any cause in the absence of progression). The primary analysis for PFS was the log rank test stratified by last endocrine therapy received prior to fulvestrant (AO vs. AI). The treatment effect was estimated using the HR of 500 mg fulvestrant to 250 mg fulvestrant together with the corresponding 95% CI and p value."}],"first_posted":"April 24, 2015","completion_date":"March 2014","primary_completion_date":"March 2014","start_date":"March 2011","last_update_posted":"April 24, 2015"},{"nctid":"NCT02813785","version_a":10,"version_b":11,"version_a_date":"2017-06-13","version_b_date":"2017-07-21","pom_a":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: From Screening until death, loss to follow-up, or study end (up to approximately 3 years overall) ]"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Baseline until death from any cause (up to approximately 3 years) ]"}],"first_posted":"No date provided","completion_date":"December 31, 2022","primary_completion_date":"August 1, 2019","start_date":"July 1, 2016","last_update_posted":"August 15, 2022"},{"nctid":"NCT05235165","version_a":4,"version_b":5,"version_a_date":"2022-05-06","version_b_date":"2022-05-18","pom_a":[{"label":"1.","content":"Thoracic event-free survival (tEFS)[ Time Frame: Number of days from randomization until the ascertainment of a tEFS-event, a competing event or last patient contact without an event, assessed up to 12 months after last patient is enrolled ]A 1-sided log rank test of size 0.05 will be used to test the null hypothesis H0: the cause-specific relative risk of a thoracic event associated with a thoracotomy is 1; with the alternative hypothesis H1: the cause-specific relative risk of a thoracic event associated with a thoracotomy is less than 1."}],"pom_b":[{"label":"1.","content":"Thoracic event-free survival (tEFS)[ Time Frame: Four years after enrollment ]Estimated four year thoracic event free survival (tEFS) where tEFS is calculated as the time from study enrollment. Any recurrence within the pulmonary parenchyma, involving the pleural surface or the drain/surgical site wound will be considered an event. A death that results from the procedure, as confirmed by the treating physician, will be considered an event. Patients with recurrences arising outside the thoracic region, the diagnosis of a malignancy that is not osteosarcoma (SMN) or death considered unrelated to the study surgical procedure, as confirmed by the treating physician will be considered competing events provided these occur prior to a thoracic cavity event as defined above. Patients without an event of any kind at last contact are considered censored."}],"first_posted":"No date provided","completion_date":"December 15, 2027","primary_completion_date":"December 15, 2027","start_date":"February 15, 2022","last_update_posted":"September 16, 2022"},{"nctid":"NCT03812510","version_a":7,"version_b":8,"version_a_date":"2020-01-06","version_b_date":"2020-09-23","pom_a":[{"label":"1.","content":"Proportion of subjects with Treatment Emergent AEs after application of A-101 45% for the treatment of common warts[ Time Frame: Day 182 ]Safety exposure will be measured by the proportion of subjects with treatment emergent adverse events."}],"pom_b":[{"label":"1.","content":"Proportion of Subjects With Treatment Emergent AEs After Application of A-101 45% for the Treatment of Common Warts[ Time Frame: Day 182 ]Safety exposure will be measured by the proportion of subjects exposed to A-101 45% who have emergent adverse events."}],"first_posted":"November 23, 2020","completion_date":"December 20, 2019","primary_completion_date":"November 27, 2019","start_date":"February 7, 2019","last_update_posted":"November 23, 2020"},{"nctid":"NCT03812510","version_a":8,"version_b":9,"version_a_date":"2020-09-23","version_b_date":"2020-10-20","pom_a":[{"label":"1.","content":"Proportion of Subjects With Treatment Emergent AEs After Application of A-101 45% for the Treatment of Common Warts[ Time Frame: Day 182 ]Safety exposure will be measured by the proportion of subjects exposed to A-101 45% who have emergent adverse events."}],"pom_b":[{"label":"1.","content":"Proportion of Subjects With Treatment Emergent AEs After Application of A-101 45% for the Treatment of Common Warts[ Time Frame: Day 137 to day 319 ]Safety exposure will be measured by the proportion of subjects exposed to A-101 45% who have emergent adverse events. In order to be eligible for A-101-WART-303, subjects must have completed protocol treatment on either the A-101-WART-301 or A-101-WART-302 study. The A-101-WART-303 study was an open-label with a single arm where all subjects received A-101 Topical Solution 45% twice a week. Since A-101-WART-303 is an extension study, statistical analyses were performed by stratifying patients by treatment arms in the A-101-WART-301 or A-101-WART-302 studies. In the A-101-WART-303 study, subjects will be followed every 6 weeks to assess for a recurrence or development of new common warts. If a recurrence occurs or a new wart develops these subjects may return to the site to receive A-101 Topical Solution 45% twice a week for an additional treatment cycle of 8 weeks."}],"first_posted":"November 23, 2020","completion_date":"December 20, 2019","primary_completion_date":"November 27, 2019","start_date":"February 7, 2019","last_update_posted":"November 23, 2020"},{"nctid":"NCT03812510","version_a":9,"version_b":10,"version_a_date":"2020-10-20","version_b_date":"2020-11-16","pom_a":[{"label":"1.","content":"Proportion of Subjects With Treatment Emergent AEs After Application of A-101 45% for the Treatment of Common Warts[ Time Frame: Day 137 to day 319 ]Safety exposure will be measured by the proportion of subjects exposed to A-101 45% who have emergent adverse events. In order to be eligible for A-101-WART-303, subjects must have completed protocol treatment on either the A-101-WART-301 or A-101-WART-302 study. The A-101-WART-303 study was an open-label with a single arm where all subjects received A-101 Topical Solution 45% twice a week. Since A-101-WART-303 is an extension study, statistical analyses were performed by stratifying patients by treatment arms in the A-101-WART-301 or A-101-WART-302 studies. In the A-101-WART-303 study, subjects will be followed every 6 weeks to assess for a recurrence or development of new common warts. If a recurrence occurs or a new wart develops these subjects may return to the site to receive A-101 Topical Solution 45% twice a week for an additional treatment cycle of 8 weeks."}],"pom_b":[{"label":"1.","content":"Proportion of Subjects With Treatment Emergent AEs After Application of A-101 45% for the Treatment of Common Warts[ Time Frame: Baseline to a maximum of 341 days ]Safety exposure will be measured by the proportion of subjects exposed to A-101 45% who have emergent adverse events. In order to be eligible for A-101-WART-303, subjects must have completed protocol treatment on either the A-101-WART-301 or A-101-WART-302 study. The A-101-WART-303 study was an open-label with a single arm where all subjects received A-101 Topical Solution 45% twice a week. Since A-101-WART-303 is an extension study, statistical analyses were performed by stratifying patients by treatment arms in the A-101-WART-301 or A-101-WART-302 studies. In the A-101-WART-303 study, subjects will be followed every 6 weeks to assess for a recurrence or development of new common warts. If a recurrence occurs or a new wart develops these subjects may return to the site to receive A-101 Topical Solution 45% twice a week for an additional treatment cycle of 8 weeks."}],"first_posted":"November 23, 2020","completion_date":"December 20, 2019","primary_completion_date":"November 27, 2019","start_date":"February 7, 2019","last_update_posted":"November 23, 2020"},{"nctid":"NCT00567190","version_a":1,"version_b":2,"version_a_date":"2007-12-03","version_b_date":"2007-12-31","pom_a":[{"label":"1.","content":"Progression-free survival"}],"pom_b":[{"label":"1.","content":"Progression-free survival based on independent review facility evaluation[ Time Frame: Length of study ]"}],"first_posted":"September 13, 2012","completion_date":"November 23, 2018","primary_completion_date":"May 13, 2011","start_date":"February 12, 2008","last_update_posted":"December 13, 2019"},{"nctid":"NCT00567190","version_a":11,"version_b":12,"version_a_date":"2009-04-03","version_b_date":"2009-08-19","pom_a":[{"label":"1.","content":"Progression-free survival based on independent review facility evaluation[ Time Frame: Length of study ]"}],"pom_b":[{"label":"1.","content":"Progression-free survival based on independent review facility (IRF) evaluation[ Time Frame: Time from randomization to progressive disease (PD) as determined by the IRF or death, whichever occurs first ]"}],"first_posted":"September 13, 2012","completion_date":"November 23, 2018","primary_completion_date":"May 13, 2011","start_date":"February 12, 2008","last_update_posted":"December 13, 2019"},{"nctid":"NCT00567190","version_a":26,"version_b":27,"version_a_date":"2011-12-08","version_b_date":"2012-08-14","pom_a":[{"label":"1.","content":"Progression-free survival based on independent review facility (IRF) evaluation[ Time Frame: Time from randomization to progressive disease (PD) as determined by the IRF or death, whichever occurs first ]"}],"pom_b":[{"label":"1.","content":"Progression-free Survival (PFS) Determined by the Independent Review Facility[ Time Frame: Baseline to data cut-off (up to 3 years, 3 months) ]PFS was defined as the time from randomization to first documented disease progression (PD) using Response Evaluation Criteria in Solid Tumors (RECIST) or death from any cause (within 18 weeks of last tumor assessment), whichever occurred first. For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions. Target lesions should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements by imaging techniques or clinically. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions."}],"first_posted":"September 13, 2012","completion_date":"November 23, 2018","primary_completion_date":"May 13, 2011","start_date":"February 12, 2008","last_update_posted":"December 13, 2019"},{"nctid":"NCT00567190","version_a":27,"version_b":28,"version_a_date":"2012-08-14","version_b_date":"2012-10-24","pom_a":[{"label":"1.","content":"Progression-free Survival (PFS) Determined by the Independent Review Facility[ Time Frame: Baseline to data cut-off (up to 3 years, 3 months) ]PFS was defined as the time from randomization to first documented disease progression (PD) using Response Evaluation Criteria in Solid Tumors (RECIST) or death from any cause (within 18 weeks of last tumor assessment), whichever occurred first. For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions. Target lesions should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements by imaging techniques or clinically. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions."}],"pom_b":[{"label":"1.","content":"Progression-free Survival (PFS) Determined by an Independent Review Facility[ Time Frame: Baseline to data cut-off (up to 3 years, 3 months) ]PFS was defined as the time from randomization to first documented disease progression (PD) using Response Evaluation Criteria in Solid Tumors (RECIST) or death from any cause (within 18 weeks of last tumor assessment), whichever occurred first. For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions. Target lesions were selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements by imaging techniques or clinically. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, were identified as target lesions."}],"first_posted":"September 13, 2012","completion_date":"November 23, 2018","primary_completion_date":"May 13, 2011","start_date":"February 12, 2008","last_update_posted":"December 13, 2019"},{"nctid":"NCT00567190","version_a":31,"version_b":32,"version_a_date":"2014-01-22","version_b_date":"2016-04-06","pom_a":[{"label":"1.","content":"Progression-free Survival (PFS) Determined by an Independent Review Facility[ Time Frame: Baseline to data cut-off (up to 3 years, 3 months) ]PFS was defined as the time from randomization to first documented disease progression (PD) using Response Evaluation Criteria in Solid Tumors (RECIST) or death from any cause (within 18 weeks of last tumor assessment), whichever occurred first. For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions. Target lesions were selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements by imaging techniques or clinically. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, were identified as target lesions."}],"pom_b":[{"label":"1.","content":"Progression-free Survival (PFS) Determined by an Independent Review Facility[ Time Frame: Baseline to primary data cut-off on 13 May 2011 (up to 3 years, 3 months) ]PFS was defined as the time from randomization to first documented disease progression (PD) using Response Evaluation Criteria in Solid Tumors (RECIST) or death from any cause (within 18 weeks of last tumor assessment), whichever occurred first. For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions. Target lesions were selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements by imaging techniques or clinically. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, were identified as target lesions."}],"first_posted":"September 13, 2012","completion_date":"November 23, 2018","primary_completion_date":"May 13, 2011","start_date":"February 12, 2008","last_update_posted":"December 13, 2019"},{"nctid":"NCT00567190","version_a":41,"version_b":42,"version_a_date":"2018-12-14","version_b_date":"2019-12-12","pom_a":[{"label":"1.","content":"Progression-free Survival (PFS) Determined by an Independent Review Facility[ Time Frame: Baseline to primary data cut-off on 13 May 2011 (up to 3 years, 3 months) ]PFS was defined as the time from randomization to first documented disease progression (PD) using Response Evaluation Criteria in Solid Tumors (RECIST) or death from any cause (within 18 weeks of last tumor assessment), whichever occurred first. For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions. Target lesions were selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements by imaging techniques or clinically. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, were identified as target lesions."}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS) Determined by an Independent Review Facility[ Time Frame: Tumor assessments every 9 weeks from randomization to IRF-determined PD or death from any cause, whichever occurred first, up to the primary completion date (up to 3 years, 3 months) ]PFS was defined as the time from randomization to first documented radiographical progressive disease (PD), as determined by an independent review facility (IRF) using RECIST version 1.0, or death from any cause (within 18 weeks of last tumor assessment), whichever occurred first (Kaplan-Meier method). For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum of the LD recorded since treatment started or the appearance of \u22651 new lesion. For non-target lesions, PD was defined as the appearance of \u22651 new lesion or unequivocal progression of existing lesions. Participants without IRF-determined PD or who had not died within 18 weeks of their last IRF-determined, progression-free tumor assessment were censored at the date of the last IRF-reviewed, evaluable tumor assessment; those with no post-baseline tumor assessment and who had not died within 18 weeks of baseline were censored at 1 day."}],"first_posted":"September 13, 2012","completion_date":"November 23, 2018","primary_completion_date":"May 13, 2011","start_date":"February 12, 2008","last_update_posted":"December 13, 2019"}]}'),Y=n(1184);var X=e.createContext(),ee=n(5878);function te(e){return(0,P.Z)("MuiGrid",e)}var ne=["auto",!0,1,2,3,4,5,6,7,8,9,10,11,12],re=(0,ee.Z)("MuiGrid",["root","container","item","zeroMinWidth"].concat((0,H.Z)([0,1,2,3,4,5,6,7,8,9,10].map((function(e){return"spacing-xs-".concat(e)}))),(0,H.Z)(["column-reverse","column","row-reverse","row"].map((function(e){return"direction-xs-".concat(e)}))),(0,H.Z)(["nowrap","wrap-reverse","wrap"].map((function(e){return"wrap-xs-".concat(e)}))),(0,H.Z)(ne.map((function(e){return"grid-xs-".concat(e)}))),(0,H.Z)(ne.map((function(e){return"grid-sm-".concat(e)}))),(0,H.Z)(ne.map((function(e){return"grid-md-".concat(e)}))),(0,H.Z)(ne.map((function(e){return"grid-lg-".concat(e)}))),(0,H.Z)(ne.map((function(e){return"grid-xl-".concat(e)}))))),oe=re,ae=["className","columns","columnSpacing","component","container","direction","item","rowSpacing","spacing","wrap","zeroMinWidth"];function ie(e){var t=parseFloat(e);return"".concat(t).concat(String(e).replace(String(t),"")||"px")}function se(e){var t=e.breakpoints,n=e.values,r="";Object.keys(n).forEach((function(e){""===r&&0!==n[e]&&(r=e)}));var o=Object.keys(t).sort((function(e,n){return t[e]-t[n]}));return o.slice(0,o.indexOf(r))}var le=(0,V.ZP)("div",{name:"MuiGrid",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState,r=n.container,o=n.direction,a=n.item,i=n.spacing,s=n.wrap,l=n.zeroMinWidth,c=n.breakpoints,u=[];r&&(u=function(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{};if(!e||e<=0)return[];if("string"===typeof e&&!Number.isNaN(Number(e))||"number"===typeof e)return[n["spacing-xs-".concat(String(e))]];var r=[];return t.forEach((function(t){var o=e[t];Number(o)>0&&r.push(n["spacing-".concat(t,"-").concat(String(o))])})),r}(i,c,t));var d=[];return c.forEach((function(e){var r=n[e];r&&d.push(t["grid-".concat(e,"-").concat(String(r))])})),[t.root,r&&t.container,a&&t.item,l&&t.zeroMinWidth].concat((0,H.Z)(u),["row"!==o&&t["direction-xs-".concat(String(o))],"wrap"!==s&&t["wrap-xs-".concat(String(s))]],d)}})((function(e){var t=e.ownerState;return(0,r.Z)({boxSizing:"border-box"},t.container&&{display:"flex",flexWrap:"wrap",width:"100%"},t.item&&{margin:0},t.zeroMinWidth&&{minWidth:0},"wrap"!==t.wrap&&{flexWrap:t.wrap})}),(function(e){var t=e.theme,n=e.ownerState,r=(0,Y.P$)({values:n.direction,breakpoints:t.breakpoints.values});return(0,Y.k9)({theme:t},r,(function(e){var t={flexDirection:e};return 0===e.indexOf("column")&&(t["& > .".concat(oe.item)]={maxWidth:"none"}),t}))}),(function(e){var t=e.theme,n=e.ownerState,r=n.container,o=n.rowSpacing,a={};if(r&&0!==o){var i,s=(0,Y.P$)({values:o,breakpoints:t.breakpoints.values});"object"===typeof s&&(i=se({breakpoints:t.breakpoints.values,values:s})),a=(0,Y.k9)({theme:t},s,(function(e,n){var r,o=t.spacing(e);return"0px"!==o?(0,_.Z)({marginTop:"-".concat(ie(o))},"& > .".concat(oe.item),{paddingTop:ie(o)}):null!=(r=i)&&r.includes(n)?{}:(0,_.Z)({marginTop:0},"& > .".concat(oe.item),{paddingTop:0})}))}return a}),(function(e){var t=e.theme,n=e.ownerState,r=n.container,o=n.columnSpacing,a={};if(r&&0!==o){var i,s=(0,Y.P$)({values:o,breakpoints:t.breakpoints.values});"object"===typeof s&&(i=se({breakpoints:t.breakpoints.values,values:s})),a=(0,Y.k9)({theme:t},s,(function(e,n){var r,o=t.spacing(e);return"0px"!==o?(0,_.Z)({width:"calc(100% + ".concat(ie(o),")"),marginLeft:"-".concat(ie(o))},"& > .".concat(oe.item),{paddingLeft:ie(o)}):null!=(r=i)&&r.includes(n)?{}:(0,_.Z)({width:"100%",marginLeft:0},"& > .".concat(oe.item),{paddingLeft:0})}))}return a}),(function(e){var t,n=e.theme,o=e.ownerState;return n.breakpoints.keys.reduce((function(e,a){var i={};if(o[a]&&(t=o[a]),!t)return e;if(!0===t)i={flexBasis:0,flexGrow:1,maxWidth:"100%"};else if("auto"===t)i={flexBasis:"auto",flexGrow:0,flexShrink:0,maxWidth:"none",width:"auto"};else{var s=(0,Y.P$)({values:o.columns,breakpoints:n.breakpoints.values}),l="object"===typeof s?s[a]:s;if(void 0===l||null===l)return e;var c="".concat(Math.round(t/l*1e8)/1e6,"%"),u={};if(o.container&&o.item&&0!==o.columnSpacing){var d=n.spacing(o.columnSpacing);if("0px"!==d){var f="calc(".concat(c," + ").concat(ie(d),")");u={flexBasis:f,maxWidth:f}}}i=(0,r.Z)({flexBasis:c,flexGrow:0,maxWidth:c},u)}return 0===n.breakpoints.values[a]?Object.assign(e,i):e[n.breakpoints.up(a)]=i,e}),{})}));var ce=function(e){var t=e.classes,n=e.container,r=e.direction,o=e.item,a=e.spacing,i=e.wrap,s=e.zeroMinWidth,l=e.breakpoints,c=[];n&&(c=function(e,t){if(!e||e<=0)return[];if("string"===typeof e&&!Number.isNaN(Number(e))||"number"===typeof e)return["spacing-xs-".concat(String(e))];var n=[];return t.forEach((function(t){var r=e[t];if(Number(r)>0){var o="spacing-".concat(t,"-").concat(String(r));n.push(o)}})),n}(a,l));var u=[];l.forEach((function(t){var n=e[t];n&&u.push("grid-".concat(t,"-").concat(String(n)))}));var d={root:["root",n&&"container",o&&"item",s&&"zeroMinWidth"].concat((0,H.Z)(c),["row"!==r&&"direction-xs-".concat(String(r)),"wrap"!==i&&"wrap-xs-".concat(String(i))],u)};return(0,k.Z)(d,te,t)},ue=e.forwardRef((function(t,n){var a=(0,o.Z)({props:t,name:"MuiGrid"}),i=(0,W.Z)(m.Z).breakpoints,s=G(a),l=s.className,c=s.columns,u=s.columnSpacing,d=s.component,p=void 0===d?"div":d,h=s.container,v=void 0!==h&&h,b=s.direction,y=void 0===b?"row":b,g=s.item,_=void 0!==g&&g,S=s.rowSpacing,P=s.spacing,k=void 0===P?0:P,x=s.wrap,C=void 0===x?"wrap":x,A=s.zeroMinWidth,M=void 0!==A&&A,F=(0,w.Z)(s,ae),E=S||k,R=u||k,N=e.useContext(X),O=v?c||12:N,V={},L=(0,r.Z)({},F);i.keys.forEach((function(e){null!=F[e]&&(V[e]=F[e],delete L[e])}));var D=(0,r.Z)({},s,{columns:O,container:v,direction:y,item:_,rowSpacing:E,columnSpacing:R,wrap:C,zeroMinWidth:M,spacing:k},V,{breakpoints:i.keys}),z=ce(D);return(0,f.jsx)(X.Provider,{value:O,children:(0,f.jsx)(le,(0,r.Z)({ownerState:D,className:(0,T.Z)(z.root,l),as:p,ref:n},L))})})),de=ue,fe=n(2065);function pe(e){return(0,P.Z)("MuiPaper",e)}(0,ee.Z)("MuiPaper",["root","rounded","outlined","elevation","elevation0","elevation1","elevation2","elevation3","elevation4","elevation5","elevation6","elevation7","elevation8","elevation9","elevation10","elevation11","elevation12","elevation13","elevation14","elevation15","elevation16","elevation17","elevation18","elevation19","elevation20","elevation21","elevation22","elevation23","elevation24"]);var me=["className","component","elevation","square","variant"],he=function(e){return((e<1?5.11916*Math.pow(e,2):4.5*Math.log(e+1)+2)/100).toFixed(2)},ve=(0,V.ZP)("div",{name:"MuiPaper",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t[n.variant],!n.square&&t.rounded,"elevation"===n.variant&&t["elevation".concat(n.elevation)]]}})((function(e){var t,n=e.theme,o=e.ownerState;return(0,r.Z)({backgroundColor:(n.vars||n).palette.background.paper,color:(n.vars||n).palette.text.primary,transition:n.transitions.create("box-shadow")},!o.square&&{borderRadius:n.shape.borderRadius},"outlined"===o.variant&&{border:"1px solid ".concat((n.vars||n).palette.divider)},"elevation"===o.variant&&(0,r.Z)({boxShadow:(n.vars||n).shadows[o.elevation]},!n.vars&&"dark"===n.palette.mode&&{backgroundImage:"linear-gradient(".concat((0,fe.Fq)("#fff",he(o.elevation)),", ").concat((0,fe.Fq)("#fff",he(o.elevation)),")")},n.vars&&{backgroundImage:null==(t=n.vars.overlays)?void 0:t[o.elevation]}))})),be=e.forwardRef((function(e,t){var n=(0,o.Z)({props:e,name:"MuiPaper"}),a=n.className,i=n.component,s=void 0===i?"div":i,l=n.elevation,c=void 0===l?1:l,u=n.square,d=void 0!==u&&u,p=n.variant,m=void 0===p?"elevation":p,h=(0,w.Z)(n,me),v=(0,r.Z)({},n,{component:s,elevation:c,square:d,variant:m}),b=function(e){var t=e.square,n=e.elevation,r=e.variant,o=e.classes,a={root:["root",r,!t&&"rounded","elevation"===r&&"elevation".concat(n)]};return(0,k.Z)(a,pe,o)}(v);return(0,f.jsx)(ve,(0,r.Z)({as:s,ownerState:v,className:(0,T.Z)(b.root,a),ref:t},h))}));function ye(e){return(0,P.Z)("MuiCard",e)}(0,ee.Z)("MuiCard",["root"]);var ge=["className","raised"],_e=(0,V.ZP)(be,{name:"MuiCard",slot:"Root",overridesResolver:function(e,t){return t.root}})((function(){return{overflow:"hidden"}})),we=e.forwardRef((function(e,t){var n=(0,o.Z)({props:e,name:"MuiCard"}),a=n.className,i=n.raised,s=void 0!==i&&i,l=(0,w.Z)(n,ge),c=(0,r.Z)({},n,{raised:s}),u=function(e){var t=e.classes;return(0,k.Z)({root:["root"]},ye,t)}(c);return(0,f.jsx)(_e,(0,r.Z)({className:(0,T.Z)(u.root,a),elevation:s?8:void 0,ref:t,ownerState:c},l))}));function Te(e){return(0,P.Z)("MuiCardContent",e)}(0,ee.Z)("MuiCardContent",["root"]);var Se=["className","component"],Pe=(0,V.ZP)("div",{name:"MuiCardContent",slot:"Root",overridesResolver:function(e,t){return t.root}})((function(){return{padding:16,"&:last-child":{paddingBottom:24}}})),ke=e.forwardRef((function(e,t){var n=(0,o.Z)({props:e,name:"MuiCardContent"}),a=n.className,i=n.component,s=void 0===i?"div":i,l=(0,w.Z)(n,Se),c=(0,r.Z)({},n,{component:s}),u=function(e){var t=e.classes;return(0,k.Z)({root:["root"]},Te,t)}(c);return(0,f.jsx)(Pe,(0,r.Z)({as:s,className:(0,T.Z)(u.root,a),ownerState:c,ref:t},l))}));function xe(e){return(0,P.Z)("MuiTypography",e)}(0,ee.Z)("MuiTypography",["root","h1","h2","h3","h4","h5","h6","subtitle1","subtitle2","body1","body2","inherit","button","caption","overline","alignLeft","alignRight","alignCenter","alignJustify","noWrap","gutterBottom","paragraph"]);var Ce=["align","className","component","gutterBottom","noWrap","paragraph","variant","variantMapping"],Ae=(0,V.ZP)("span",{name:"MuiTypography",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,n.variant&&t[n.variant],"inherit"!==n.align&&t["align".concat((0,O.Z)(n.align))],n.noWrap&&t.noWrap,n.gutterBottom&&t.gutterBottom,n.paragraph&&t.paragraph]}})((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({margin:0},n.variant&&t.typography[n.variant],"inherit"!==n.align&&{textAlign:n.align},n.noWrap&&{overflow:"hidden",textOverflow:"ellipsis",whiteSpace:"nowrap"},n.gutterBottom&&{marginBottom:"0.35em"},n.paragraph&&{marginBottom:16})})),Me={h1:"h1",h2:"h2",h3:"h3",h4:"h4",h5:"h5",h6:"h6",subtitle1:"h6",subtitle2:"h6",body1:"p",body2:"p",inherit:"p"},Fe={primary:"primary.main",textPrimary:"text.primary",secondary:"secondary.main",textSecondary:"text.secondary",error:"error.main"},Ee=e.forwardRef((function(e,t){var n=(0,o.Z)({props:e,name:"MuiTypography"}),a=function(e){return Fe[e]||e}(n.color),i=G((0,r.Z)({},n,{color:a})),s=i.align,l=void 0===s?"inherit":s,c=i.className,u=i.component,d=i.gutterBottom,p=void 0!==d&&d,m=i.noWrap,h=void 0!==m&&m,v=i.paragraph,b=void 0!==v&&v,y=i.variant,g=void 0===y?"body1":y,_=i.variantMapping,S=void 0===_?Me:_,P=(0,w.Z)(i,Ce),x=(0,r.Z)({},i,{align:l,color:a,className:c,component:u,gutterBottom:p,noWrap:h,paragraph:b,variant:g,variantMapping:S}),C=u||(b?"p":S[g]||Me[g])||"span",A=function(e){var t=e.align,n=e.gutterBottom,r=e.noWrap,o=e.paragraph,a=e.variant,i=e.classes,s={root:["root",a,"inherit"!==e.align&&"align".concat((0,O.Z)(t)),n&&"gutterBottom",r&&"noWrap",o&&"paragraph"]};return(0,k.Z)(s,xe,i)}(x);return(0,f.jsx)(Ae,(0,r.Z)({as:C,ref:t,ownerState:x,className:(0,T.Z)(A.root,c)},P))})),Re=n(5682),Ne=["component","direction","spacing","divider","children"];function Oe(t,n){var r=e.Children.toArray(t).filter(Boolean);return r.reduce((function(t,o,a){return t.push(o),a<r.length-1&&t.push(e.cloneElement(n,{key:"separator-".concat(a)})),t}),[])}var Ve=(0,V.ZP)("div",{name:"MuiStack",slot:"Root",overridesResolver:function(e,t){return[t.root]}})((function(e){var t=e.ownerState,n=e.theme,o=(0,r.Z)({display:"flex",flexDirection:"column"},(0,Y.k9)({theme:n},(0,Y.P$)({values:t.direction,breakpoints:n.breakpoints.values}),(function(e){return{flexDirection:e}})));if(t.spacing){var a=(0,Re.hB)(n),i=Object.keys(n.breakpoints.values).reduce((function(e,n){return("object"===typeof t.spacing&&null!=t.spacing[n]||"object"===typeof t.direction&&null!=t.direction[n])&&(e[n]=!0),e}),{}),s=(0,Y.P$)({values:t.direction,base:i}),l=(0,Y.P$)({values:t.spacing,base:i});"object"===typeof s&&Object.keys(s).forEach((function(e,t,n){if(!s[e]){var r=t>0?s[n[t-1]]:"column";s[e]=r}}));o=(0,j.Z)(o,(0,Y.k9)({theme:n},l,(function(e,n){return{"& > :not(style) + :not(style)":(0,_.Z)({margin:0},"margin".concat((r=n?s[n]:t.direction,{row:"Left","row-reverse":"Right",column:"Top","column-reverse":"Bottom"}[r])),(0,Re.NA)(a,e))};var r})))}return o=(0,Y.dt)(n.breakpoints,o)})),Le=e.forwardRef((function(e,t){var n=G((0,o.Z)({props:e,name:"MuiStack"})),a=n.component,i=void 0===a?"div":a,s=n.direction,l=void 0===s?"column":s,c=n.spacing,u=void 0===c?0:c,d=n.divider,p=n.children,m=(0,w.Z)(n,Ne),h={direction:l,spacing:u};return(0,f.jsx)(Ve,(0,r.Z)({as:i,ownerState:h,ref:t},m,{children:d?Oe(p,d):p}))})),De=Le,ze=n(1774),Ie=n.n(ze);var He=function(e){var t=e.datum,n=e.datumNumber,r=e.results,o=(e.setResults,t.pom_a),a=t.pom_b,i=t.version_a_date,s=t.version_b_date;console.log({datum:t});var l=function(e,t){return e.map((function(e){return(0,f.jsx)(we,{children:(0,f.jsx)(ke,{children:(0,f.jsxs)(Ee,{children:[(0,f.jsx)("b",{children:e.label})," ",e.content]})})},e.content)}))};return(0,f.jsxs)(de,{container:!0,spacing:2,children:[(0,f.jsx)(de,{item:!0,xs:12,children:(0,f.jsx)(we,{children:(0,f.jsx)(ke,{children:(0,f.jsxs)(de,{container:!0,children:[(0,f.jsxs)(de,{item:!0,xs:4,children:[(0,f.jsxs)(Ee,{variant:"h6",children:["Comparison Number ",n+1," of ",r.length]}),(0,f.jsxs)(Ee,{variant:"h4",children:["Trial ",t.nctid]})]}),(0,f.jsxs)(de,{item:!0,xs:4,children:[t.first_posted?(0,f.jsxs)(Ee,{children:["First Posted: ",t.first_posted]}):null,t.start_date?(0,f.jsxs)(Ee,{children:["Start Date: ",t.start_date]}):null]}),(0,f.jsxs)(de,{item:!0,xs:4,children:[t.primary_completion_date?(0,f.jsxs)(Ee,{children:["Primary Completion Date: ",t.primary_completion_date]}):null,t.last_update_posted?(0,f.jsxs)(Ee,{children:["Last Update Posted : ",t.last_update_posted]}):null]})]})})})}),(0,f.jsx)(de,{item:!0,xs:6,children:(0,f.jsx)(we,{children:(0,f.jsxs)(ke,{children:[(0,f.jsxs)(Ee,{variant:"h6",children:["Primary Outcomes for Version ",t.version_a,": ",i]}),(0,f.jsx)(Ee,{variant:"caption"}),(0,f.jsx)(De,{spacing:1,children:l(t.pom_a)})]})})}),(0,f.jsx)(de,{item:!0,xs:6,children:(0,f.jsx)(we,{children:(0,f.jsxs)(ke,{children:[(0,f.jsxs)(Ee,{variant:"h6",children:["Primary Outcomes for Version ",t.version_b,": ",s]}),(0,f.jsx)(De,{spacing:1,children:l(t.pom_b)})]})})}),(0,f.jsx)(de,{item:!0,xs:12,children:(0,f.jsx)(we,{children:(0,f.jsxs)(ke,{children:[(0,f.jsx)(Ee,{variant:"h6",children:"Compare the Raw Text"}),(0,f.jsx)(Ie(),{oldValue:JSON.stringify(o,void 0,4),newValue:JSON.stringify(a,void 0,4),splitView:!0,compareMethod:ze.DiffMethod.WORDS,styles:{variables:{light:{codeFoldGutterBackground:"#6F767E",codeFoldBackground:"#E2E4E5"}}},leftTitle:"Version ".concat(t.version_a),rightTitle:"Version ".concat(t.version_b)})]})})})]})};function je(e){return(0,P.Z)("MuiAppBar",e)}(0,ee.Z)("MuiAppBar",["root","positionFixed","positionAbsolute","positionSticky","positionStatic","positionRelative","colorDefault","colorPrimary","colorSecondary","colorInherit","colorTransparent"]);var Ze=["className","color","enableColorOnDark","position"],Be=function(e,t){return"".concat(null==e?void 0:e.replace(")",""),", ").concat(t,")")},Ge=(0,V.ZP)(be,{name:"MuiAppBar",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t["position".concat((0,O.Z)(n.position))],t["color".concat((0,O.Z)(n.color))]]}})((function(e){var t=e.theme,n=e.ownerState,o="light"===t.palette.mode?t.palette.grey[100]:t.palette.grey[900];return(0,r.Z)({display:"flex",flexDirection:"column",width:"100%",boxSizing:"border-box",flexShrink:0},"fixed"===n.position&&{position:"fixed",zIndex:(t.vars||t).zIndex.appBar,top:0,left:"auto",right:0,"@media print":{position:"absolute"}},"absolute"===n.position&&{position:"absolute",zIndex:(t.vars||t).zIndex.appBar,top:0,left:"auto",right:0},"sticky"===n.position&&{position:"sticky",zIndex:(t.vars||t).zIndex.appBar,top:0,left:"auto",right:0},"static"===n.position&&{position:"static"},"relative"===n.position&&{position:"relative"},!t.vars&&(0,r.Z)({},"default"===n.color&&{backgroundColor:o,color:t.palette.getContrastText(o)},n.color&&"default"!==n.color&&"inherit"!==n.color&&"transparent"!==n.color&&{backgroundColor:t.palette[n.color].main,color:t.palette[n.color].contrastText},"inherit"===n.color&&{color:"inherit"},"dark"===t.palette.mode&&!n.enableColorOnDark&&{backgroundColor:null,color:null},"transparent"===n.color&&(0,r.Z)({backgroundColor:"transparent",color:"inherit"},"dark"===t.palette.mode&&{backgroundImage:"none"})),t.vars&&(0,r.Z)({},"default"===n.color&&{"--AppBar-background":n.enableColorOnDark?t.vars.palette.AppBar.defaultBg:Be(t.vars.palette.AppBar.darkBg,t.vars.palette.AppBar.defaultBg),"--AppBar-color":n.enableColorOnDark?t.vars.palette.text.primary:Be(t.vars.palette.AppBar.darkColor,t.vars.palette.text.primary)},n.color&&!n.color.match(/^(default|inherit|transparent)$/)&&{"--AppBar-background":n.enableColorOnDark?t.vars.palette[n.color].main:Be(t.vars.palette.AppBar.darkBg,t.vars.palette[n.color].main),"--AppBar-color":n.enableColorOnDark?t.vars.palette[n.color].contrastText:Be(t.vars.palette.AppBar.darkColor,t.vars.palette[n.color].contrastText)},{backgroundColor:"var(--AppBar-background)",color:"inherit"===n.color?"inherit":"var(--AppBar-color)"},"transparent"===n.color&&{backgroundImage:"none",backgroundColor:"transparent",color:"inherit"}))})),We=e.forwardRef((function(e,t){var n=(0,o.Z)({props:e,name:"MuiAppBar"}),a=n.className,i=n.color,s=void 0===i?"primary":i,l=n.enableColorOnDark,c=void 0!==l&&l,u=n.position,d=void 0===u?"fixed":u,p=(0,w.Z)(n,Ze),m=(0,r.Z)({},n,{color:s,position:d,enableColorOnDark:c}),h=function(e){var t=e.color,n=e.position,r=e.classes,o={root:["root","color".concat((0,O.Z)(t)),"position".concat((0,O.Z)(n))]};return(0,k.Z)(o,je,r)}(m);return(0,f.jsx)(Ge,(0,r.Z)({square:!0,component:"header",ownerState:m,elevation:4,className:(0,T.Z)(h.root,a,"fixed"===d&&"mui-fixed"),ref:t},p))}));function Ue(e){return(0,P.Z)("MuiToolbar",e)}(0,ee.Z)("MuiToolbar",["root","gutters","regular","dense"]);var qe=["className","component","disableGutters","variant"],$e=(0,V.ZP)("div",{name:"MuiToolbar",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,!n.disableGutters&&t.gutters,t[n.variant]]}})((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({position:"relative",display:"flex",alignItems:"center"},!n.disableGutters&&(0,_.Z)({paddingLeft:t.spacing(2),paddingRight:t.spacing(2)},t.breakpoints.up("sm"),{paddingLeft:t.spacing(3),paddingRight:t.spacing(3)}),"dense"===n.variant&&{minHeight:48})}),(function(e){var t=e.theme;return"regular"===e.ownerState.variant&&t.mixins.toolbar})),Je=e.forwardRef((function(e,t){var n=(0,o.Z)({props:e,name:"MuiToolbar"}),a=n.className,i=n.component,s=void 0===i?"div":i,l=n.disableGutters,c=void 0!==l&&l,u=n.variant,d=void 0===u?"regular":u,p=(0,w.Z)(n,qe),m=(0,r.Z)({},n,{component:s,disableGutters:c,variant:d}),h=function(e){var t=e.classes,n={root:["root",!e.disableGutters&&"gutters",e.variant]};return(0,k.Z)(n,Ue,t)}(m);return(0,f.jsx)($e,(0,r.Z)({as:s,className:(0,T.Z)(h.root,a),ref:t,ownerState:m},p))})),Ke=n(792),Qe=n(6702),Ye=n(2763);function Xe(e,t){return t||(t=e.slice(0)),Object.freeze(Object.defineProperties(e,{raw:{value:Object.freeze(t)}}))}function et(e,t){return et=Object.setPrototypeOf?Object.setPrototypeOf.bind():function(e,t){return e.__proto__=t,e},et(e,t)}var tt=e.createContext(null);function nt(t,n){var r=Object.create(null);return t&&e.Children.map(t,(function(e){return e})).forEach((function(t){r[t.key]=function(t){return n&&(0,e.isValidElement)(t)?n(t):t}(t)})),r}function rt(e,t,n){return null!=n[t]?n[t]:e.props[t]}function ot(t,n,r){var o=nt(t.children),a=function(e,t){function n(n){return n in t?t[n]:e[n]}e=e||{},t=t||{};var r,o=Object.create(null),a=[];for(var i in e)i in t?a.length&&(o[i]=a,a=[]):a.push(i);var s={};for(var l in t){if(o[l])for(r=0;r<o[l].length;r++){var c=o[l][r];s[o[l][r]]=n(c)}s[l]=n(l)}for(r=0;r<a.length;r++)s[a[r]]=n(a[r]);return s}(n,o);return Object.keys(a).forEach((function(i){var s=a[i];if((0,e.isValidElement)(s)){var l=i in n,c=i in o,u=n[i],d=(0,e.isValidElement)(u)&&!u.props.in;!c||l&&!d?c||!l||d?c&&l&&(0,e.isValidElement)(u)&&(a[i]=(0,e.cloneElement)(s,{onExited:r.bind(null,s),in:u.props.in,exit:rt(s,"exit",t),enter:rt(s,"enter",t)})):a[i]=(0,e.cloneElement)(s,{in:!1}):a[i]=(0,e.cloneElement)(s,{onExited:r.bind(null,s),in:!0,exit:rt(s,"exit",t),enter:rt(s,"enter",t)})}})),a}var at=Object.values||function(e){return Object.keys(e).map((function(t){return e[t]}))},it=function(t){var n,o;function a(e,n){var r,o=(r=t.call(this,e,n)||this).handleExited.bind(function(e){if(void 0===e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return e}(r));return r.state={contextValue:{isMounting:!0},handleExited:o,firstRender:!0},r}o=t,(n=a).prototype=Object.create(o.prototype),n.prototype.constructor=n,et(n,o);var i=a.prototype;return i.componentDidMount=function(){this.mounted=!0,this.setState({contextValue:{isMounting:!1}})},i.componentWillUnmount=function(){this.mounted=!1},a.getDerivedStateFromProps=function(t,n){var r,o,a=n.children,i=n.handleExited;return{children:n.firstRender?(r=t,o=i,nt(r.children,(function(t){return(0,e.cloneElement)(t,{onExited:o.bind(null,t),in:!0,appear:rt(t,"appear",r),enter:rt(t,"enter",r),exit:rt(t,"exit",r)})}))):ot(t,a,i),firstRender:!1}},i.handleExited=function(e,t){var n=nt(this.props.children);e.key in n||(e.props.onExited&&e.props.onExited(t),this.mounted&&this.setState((function(t){var n=(0,r.Z)({},t.children);return delete n[e.key],{children:n}})))},i.render=function(){var t=this.props,n=t.component,r=t.childFactory,o=(0,w.Z)(t,["component","childFactory"]),a=this.state.contextValue,i=at(this.state.children).map(r);return delete o.appear,delete o.enter,delete o.exit,null===n?e.createElement(tt.Provider,{value:a},i):e.createElement(tt.Provider,{value:a},e.createElement(n,o,i))},a}(e.Component);it.propTypes={},it.defaultProps={component:"div",childFactory:function(e){return e}};var st=it;var lt=function(t){var n=t.className,r=t.classes,o=t.pulsate,a=void 0!==o&&o,i=t.rippleX,s=t.rippleY,l=t.rippleSize,c=t.in,u=t.onExited,d=t.timeout,p=e.useState(!1),m=(0,g.Z)(p,2),h=m[0],v=m[1],b=(0,T.Z)(n,r.ripple,r.rippleVisible,a&&r.ripplePulsate),y={width:l,height:l,top:-l/2+s,left:-l/2+i},_=(0,T.Z)(r.child,h&&r.childLeaving,a&&r.childPulsate);return c||h||v(!0),e.useEffect((function(){if(!c&&null!=u){var e=setTimeout(u,d);return function(){clearTimeout(e)}}}),[u,c,d]),(0,f.jsx)("span",{className:b,style:y,children:(0,f.jsx)("span",{className:_})})};var ct,ut,dt,ft,pt,mt,ht,vt,bt=(0,ee.Z)("MuiTouchRipple",["root","ripple","rippleVisible","ripplePulsate","child","childLeaving","childPulsate"]),yt=["center","classes","className"],gt=d(pt||(pt=ct||(ct=Xe(["\n  0% {\n    transform: scale(0);\n    opacity: 0.1;\n  }\n\n  100% {\n    transform: scale(1);\n    opacity: 0.3;\n  }\n"])))),_t=d(mt||(mt=ut||(ut=Xe(["\n  0% {\n    opacity: 1;\n  }\n\n  100% {\n    opacity: 0;\n  }\n"])))),wt=d(ht||(ht=dt||(dt=Xe(["\n  0% {\n    transform: scale(1);\n  }\n\n  50% {\n    transform: scale(0.92);\n  }\n\n  100% {\n    transform: scale(1);\n  }\n"])))),Tt=(0,V.ZP)("span",{name:"MuiTouchRipple",slot:"Root"})({overflow:"hidden",pointerEvents:"none",position:"absolute",zIndex:0,top:0,right:0,bottom:0,left:0,borderRadius:"inherit"}),St=(0,V.ZP)(lt,{name:"MuiTouchRipple",slot:"Ripple"})(vt||(vt=ft||(ft=Xe(["\n  opacity: 0;\n  position: absolute;\n\n  &."," {\n    opacity: 0.3;\n    transform: scale(1);\n    animation-name: ",";\n    animation-duration: ","ms;\n    animation-timing-function: ",";\n  }\n\n  &."," {\n    animation-duration: ","ms;\n  }\n\n  & ."," {\n    opacity: 1;\n    display: block;\n    width: 100%;\n    height: 100%;\n    border-radius: 50%;\n    background-color: currentColor;\n  }\n\n  & ."," {\n    opacity: 0;\n    animation-name: ",";\n    animation-duration: ","ms;\n    animation-timing-function: ",";\n  }\n\n  & ."," {\n    position: absolute;\n    /* @noflip */\n    left: 0px;\n    top: 0;\n    animation-name: ",";\n    animation-duration: 2500ms;\n    animation-timing-function: ",";\n    animation-iteration-count: infinite;\n    animation-delay: 200ms;\n  }\n"]))),bt.rippleVisible,gt,550,(function(e){return e.theme.transitions.easing.easeInOut}),bt.ripplePulsate,(function(e){return e.theme.transitions.duration.shorter}),bt.child,bt.childLeaving,_t,550,(function(e){return e.theme.transitions.easing.easeInOut}),bt.childPulsate,wt,(function(e){return e.theme.transitions.easing.easeInOut})),Pt=e.forwardRef((function(t,n){var a=(0,o.Z)({props:t,name:"MuiTouchRipple"}),i=a.center,s=void 0!==i&&i,l=a.classes,c=void 0===l?{}:l,u=a.className,d=(0,w.Z)(a,yt),p=e.useState([]),m=(0,g.Z)(p,2),h=m[0],v=m[1],b=e.useRef(0),y=e.useRef(null);e.useEffect((function(){y.current&&(y.current(),y.current=null)}),[h]);var _=e.useRef(!1),S=e.useRef(null),P=e.useRef(null),k=e.useRef(null);e.useEffect((function(){return function(){clearTimeout(S.current)}}),[]);var x=e.useCallback((function(e){var t=e.pulsate,n=e.rippleX,r=e.rippleY,o=e.rippleSize,a=e.cb;v((function(e){return[].concat((0,H.Z)(e),[(0,f.jsx)(St,{classes:{ripple:(0,T.Z)(c.ripple,bt.ripple),rippleVisible:(0,T.Z)(c.rippleVisible,bt.rippleVisible),ripplePulsate:(0,T.Z)(c.ripplePulsate,bt.ripplePulsate),child:(0,T.Z)(c.child,bt.child),childLeaving:(0,T.Z)(c.childLeaving,bt.childLeaving),childPulsate:(0,T.Z)(c.childPulsate,bt.childPulsate)},timeout:550,pulsate:t,rippleX:n,rippleY:r,rippleSize:o},b.current)])})),b.current+=1,y.current=a}),[c]),C=e.useCallback((function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},n=arguments.length>2?arguments[2]:void 0,r=t.pulsate,o=void 0!==r&&r,a=t.center,i=void 0===a?s||t.pulsate:a,l=t.fakeElement,c=void 0!==l&&l;if("mousedown"===(null==e?void 0:e.type)&&_.current)_.current=!1;else{"touchstart"===(null==e?void 0:e.type)&&(_.current=!0);var u,d,f,p=c?null:k.current,m=p?p.getBoundingClientRect():{width:0,height:0,left:0,top:0};if(i||void 0===e||0===e.clientX&&0===e.clientY||!e.clientX&&!e.touches)u=Math.round(m.width/2),d=Math.round(m.height/2);else{var h=e.touches&&e.touches.length>0?e.touches[0]:e,v=h.clientX,b=h.clientY;u=Math.round(v-m.left),d=Math.round(b-m.top)}if(i)(f=Math.sqrt((2*Math.pow(m.width,2)+Math.pow(m.height,2))/3))%2===0&&(f+=1);else{var y=2*Math.max(Math.abs((p?p.clientWidth:0)-u),u)+2,g=2*Math.max(Math.abs((p?p.clientHeight:0)-d),d)+2;f=Math.sqrt(Math.pow(y,2)+Math.pow(g,2))}null!=e&&e.touches?null===P.current&&(P.current=function(){x({pulsate:o,rippleX:u,rippleY:d,rippleSize:f,cb:n})},S.current=setTimeout((function(){P.current&&(P.current(),P.current=null)}),80)):x({pulsate:o,rippleX:u,rippleY:d,rippleSize:f,cb:n})}}),[s,x]),A=e.useCallback((function(){C({},{pulsate:!0})}),[C]),M=e.useCallback((function(e,t){if(clearTimeout(S.current),"touchend"===(null==e?void 0:e.type)&&P.current)return P.current(),P.current=null,void(S.current=setTimeout((function(){M(e,t)})));P.current=null,v((function(e){return e.length>0?e.slice(1):e})),y.current=t}),[]);return e.useImperativeHandle(n,(function(){return{pulsate:A,start:C,stop:M}}),[A,C,M]),(0,f.jsx)(Tt,(0,r.Z)({className:(0,T.Z)(bt.root,c.root,u),ref:k},d,{children:(0,f.jsx)(st,{component:null,exit:!0,children:h})}))})),kt=Pt;function xt(e){return(0,P.Z)("MuiButtonBase",e)}var Ct,At=(0,ee.Z)("MuiButtonBase",["root","disabled","focusVisible"]),Mt=["action","centerRipple","children","className","component","disabled","disableRipple","disableTouchRipple","focusRipple","focusVisibleClassName","LinkComponent","onBlur","onClick","onContextMenu","onDragLeave","onFocus","onFocusVisible","onKeyDown","onKeyUp","onMouseDown","onMouseLeave","onMouseUp","onTouchEnd","onTouchMove","onTouchStart","tabIndex","TouchRippleProps","touchRippleRef","type"],Ft=(0,V.ZP)("button",{name:"MuiButtonBase",slot:"Root",overridesResolver:function(e,t){return t.root}})((Ct={display:"inline-flex",alignItems:"center",justifyContent:"center",position:"relative",boxSizing:"border-box",WebkitTapHighlightColor:"transparent",backgroundColor:"transparent",outline:0,border:0,margin:0,borderRadius:0,padding:0,cursor:"pointer",userSelect:"none",verticalAlign:"middle",MozAppearance:"none",WebkitAppearance:"none",textDecoration:"none",color:"inherit","&::-moz-focus-inner":{borderStyle:"none"}},(0,_.Z)(Ct,"&.".concat(At.disabled),{pointerEvents:"none",cursor:"default"}),(0,_.Z)(Ct,"@media print",{colorAdjust:"exact"}),Ct)),Et=e.forwardRef((function(t,n){var a=(0,o.Z)({props:t,name:"MuiButtonBase"}),i=a.action,s=a.centerRipple,l=void 0!==s&&s,c=a.children,u=a.className,d=a.component,p=void 0===d?"button":d,m=a.disabled,h=void 0!==m&&m,v=a.disableRipple,b=void 0!==v&&v,y=a.disableTouchRipple,_=void 0!==y&&y,S=a.focusRipple,P=void 0!==S&&S,x=a.LinkComponent,C=void 0===x?"a":x,A=a.onBlur,M=a.onClick,F=a.onContextMenu,E=a.onDragLeave,R=a.onFocus,N=a.onFocusVisible,O=a.onKeyDown,V=a.onKeyUp,L=a.onMouseDown,D=a.onMouseLeave,z=a.onMouseUp,I=a.onTouchEnd,H=a.onTouchMove,j=a.onTouchStart,Z=a.tabIndex,B=void 0===Z?0:Z,G=a.TouchRippleProps,W=a.touchRippleRef,U=a.type,q=(0,w.Z)(a,Mt),$=e.useRef(null),J=e.useRef(null),K=(0,Ke.Z)(J,W),Q=(0,Ye.Z)(),Y=Q.isFocusVisibleRef,X=Q.onFocus,ee=Q.onBlur,te=Q.ref,ne=e.useState(!1),re=(0,g.Z)(ne,2),oe=re[0],ae=re[1];h&&oe&&ae(!1),e.useImperativeHandle(i,(function(){return{focusVisible:function(){ae(!0),$.current.focus()}}}),[]);var ie=e.useState(!1),se=(0,g.Z)(ie,2),le=se[0],ce=se[1];e.useEffect((function(){ce(!0)}),[]);var ue=le&&!b&&!h;function de(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:_;return(0,Qe.Z)((function(r){return t&&t(r),!n&&J.current&&J.current[e](r),!0}))}e.useEffect((function(){oe&&P&&!b&&le&&J.current.pulsate()}),[b,P,oe,le]);var fe=de("start",L),pe=de("stop",F),me=de("stop",E),he=de("stop",z),ve=de("stop",(function(e){oe&&e.preventDefault(),D&&D(e)})),be=de("start",j),ye=de("stop",I),ge=de("stop",H),_e=de("stop",(function(e){ee(e),!1===Y.current&&ae(!1),A&&A(e)}),!1),we=(0,Qe.Z)((function(e){$.current||($.current=e.currentTarget),X(e),!0===Y.current&&(ae(!0),N&&N(e)),R&&R(e)})),Te=function(){var e=$.current;return p&&"button"!==p&&!("A"===e.tagName&&e.href)},Se=e.useRef(!1),Pe=(0,Qe.Z)((function(e){P&&!Se.current&&oe&&J.current&&" "===e.key&&(Se.current=!0,J.current.stop(e,(function(){J.current.start(e)}))),e.target===e.currentTarget&&Te()&&" "===e.key&&e.preventDefault(),O&&O(e),e.target===e.currentTarget&&Te()&&"Enter"===e.key&&!h&&(e.preventDefault(),M&&M(e))})),ke=(0,Qe.Z)((function(e){P&&" "===e.key&&J.current&&oe&&!e.defaultPrevented&&(Se.current=!1,J.current.stop(e,(function(){J.current.pulsate(e)}))),V&&V(e),M&&e.target===e.currentTarget&&Te()&&" "===e.key&&!e.defaultPrevented&&M(e)})),xe=p;"button"===xe&&(q.href||q.to)&&(xe=C);var Ce={};"button"===xe?(Ce.type=void 0===U?"button":U,Ce.disabled=h):(q.href||q.to||(Ce.role="button"),h&&(Ce["aria-disabled"]=h));var Ae=(0,Ke.Z)(te,$),Me=(0,Ke.Z)(n,Ae);var Fe=(0,r.Z)({},a,{centerRipple:l,component:p,disabled:h,disableRipple:b,disableTouchRipple:_,focusRipple:P,tabIndex:B,focusVisible:oe}),Ee=function(e){var t=e.disabled,n=e.focusVisible,r=e.focusVisibleClassName,o=e.classes,a={root:["root",t&&"disabled",n&&"focusVisible"]},i=(0,k.Z)(a,xt,o);return n&&r&&(i.root+=" ".concat(r)),i}(Fe);return(0,f.jsxs)(Ft,(0,r.Z)({as:xe,className:(0,T.Z)(Ee.root,u),ownerState:Fe,onBlur:_e,onClick:M,onContextMenu:pe,onFocus:we,onKeyDown:Pe,onKeyUp:ke,onMouseDown:fe,onMouseLeave:ve,onMouseUp:he,onDragLeave:me,onTouchEnd:ye,onTouchMove:ge,onTouchStart:be,ref:Me,tabIndex:h?-1:B,type:U},Ce,q,{children:[c,ue?(0,f.jsx)(kt,(0,r.Z)({ref:K,center:l},G)):null]}))})),Rt=Et;function Nt(e){return(0,P.Z)("MuiIconButton",e)}var Ot=(0,ee.Z)("MuiIconButton",["root","disabled","colorInherit","colorPrimary","colorSecondary","edgeStart","edgeEnd","sizeSmall","sizeMedium","sizeLarge"]),Vt=["edge","children","className","color","disabled","disableFocusRipple","size"],Lt=(0,V.ZP)(Rt,{name:"MuiIconButton",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,"default"!==n.color&&t["color".concat((0,O.Z)(n.color))],n.edge&&t["edge".concat((0,O.Z)(n.edge))],t["size".concat((0,O.Z)(n.size))]]}})((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({textAlign:"center",flex:"0 0 auto",fontSize:t.typography.pxToRem(24),padding:8,borderRadius:"50%",overflow:"visible",color:(t.vars||t).palette.action.active,transition:t.transitions.create("background-color",{duration:t.transitions.duration.shortest})},!n.disableRipple&&{"&:hover":{backgroundColor:t.vars?"rgba(".concat(t.vars.palette.action.activeChannel," / ").concat(t.vars.palette.action.hoverOpacity,")"):(0,fe.Fq)(t.palette.action.active,t.palette.action.hoverOpacity),"@media (hover: none)":{backgroundColor:"transparent"}}},"start"===n.edge&&{marginLeft:"small"===n.size?-3:-12},"end"===n.edge&&{marginRight:"small"===n.size?-3:-12})}),(function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({},"inherit"===n.color&&{color:"inherit"},"inherit"!==n.color&&"default"!==n.color&&(0,r.Z)({color:(t.vars||t).palette[n.color].main},!n.disableRipple&&{"&:hover":{backgroundColor:t.vars?"rgba(".concat(t.vars.palette[n.color].mainChannel," / ").concat(t.vars.palette.action.hoverOpacity,")"):(0,fe.Fq)(t.palette[n.color].main,t.palette.action.hoverOpacity),"@media (hover: none)":{backgroundColor:"transparent"}}}),"small"===n.size&&{padding:5,fontSize:t.typography.pxToRem(18)},"large"===n.size&&{padding:12,fontSize:t.typography.pxToRem(28)},(0,_.Z)({},"&.".concat(Ot.disabled),{backgroundColor:"transparent",color:(t.vars||t).palette.action.disabled}))})),Dt=e.forwardRef((function(e,t){var n=(0,o.Z)({props:e,name:"MuiIconButton"}),a=n.edge,i=void 0!==a&&a,s=n.children,l=n.className,c=n.color,u=void 0===c?"default":c,d=n.disabled,p=void 0!==d&&d,m=n.disableFocusRipple,h=void 0!==m&&m,v=n.size,b=void 0===v?"medium":v,y=(0,w.Z)(n,Vt),g=(0,r.Z)({},n,{edge:i,color:u,disabled:p,disableFocusRipple:h,size:b}),_=function(e){var t=e.classes,n=e.disabled,r=e.color,o=e.edge,a=e.size,i={root:["root",n&&"disabled","default"!==r&&"color".concat((0,O.Z)(r)),o&&"edge".concat((0,O.Z)(o)),"size".concat((0,O.Z)(a))]};return(0,k.Z)(i,Nt,t)}(g);return(0,f.jsx)(Lt,(0,r.Z)({className:(0,T.Z)(_.root,l),centerRipple:!0,focusRipple:!h,disabled:p,ref:t,ownerState:g},y,{children:s}))})),zt=n(2156),It=n(5129);n(8472),(0,$.Z)({palette:{neutral:{main:"#fff",contrastText:"#000"}}});function Ht(e){var t=e.datumNumber,n=e.setDatumNumber,r=e.numComparisons,o=(e.outputData,e.batchNum),a=function(){n(t-1)},i=function(){n(t+1)};return(0,f.jsx)(K,{sx:{flexGrow:1},children:(0,f.jsx)(We,{position:"static",children:(0,f.jsxs)(Je,{children:[(0,f.jsxs)(Ee,{component:"div",variant:"h6",sx:{flexGrow:1},children:["Compare Trial Versions for Batch ",o]}),(0,f.jsxs)(Ee,{component:"div",children:[t>0?(0,f.jsx)(Dt,{color:"inherit",variant:"text",onClick:a,children:(0,f.jsx)(zt.Z,{})}):null,t<r-1?(0,f.jsx)(Dt,{color:"inherit",variant:"text",onClick:i,children:(0,f.jsx)(It.Z,{})}):null]})]})})})}for(var jt=JSON.parse('{"1":"Add endpoint to composite endpoint","2":"Add endpoint","3":"Change endpoint","4":"Change endpoint, add endpoint","5":"Change in endpoint in a composite endpoint","6":"Change method of analysis","7":"Change number of events","8":"Change population","9":"Change readers","10":"Change timepoint","11":"Error","12":"From nothing to something","13":"Refine definition","14":"Remove endpoint","15":"Shuffle Endpoints","16":"Syntax","":""}'),Zt=[],Bt=Q.e,Gt=Q.C,Wt=Gt.length,Ut=0;Ut<Wt;Ut++)Zt.push("");var qt=function(){var t=(0,e.useState)(0),n=(0,g.Z)(t,2),r=n[0],o=n[1],a=(0,e.useState)(Gt[r]),i=(0,g.Z)(a,2),s=i[0],l=i[1],c=(0,e.useState)(Zt),u=(0,g.Z)(c,2),d=u[0],p=u[1],m=(0,e.useState)([]),h=(0,g.Z)(m,2),v=h[0],b=h[1];return(0,e.useEffect)((function(){l(Gt[r])}),[r]),(0,e.useEffect)((function(){for(var e=[],t=0;t<Wt;t++){var n={};n.nctid=Gt[t].nctid,n.version_a=Gt[t].version_a,n.version_b=Gt[t].version_b,n.classification_number=d[t],n.classification_meaning=jt[d[t]],e.push(n)}b(e)}),[d]),(0,f.jsxs)(e.Fragment,{children:[(0,f.jsx)(Ht,{datumNumber:r,setDatumNumber:o,numComparisons:Wt,outputData:v,batchNum:Bt}),(0,f.jsx)(D,{children:(0,f.jsx)(K,{sx:{flexGrow:1,m:1},children:(0,f.jsx)(He,{datum:s,datumNumber:r,results:d,setResults:p})})})]})};t.createRoot(document.getElementById("root")).render((0,f.jsxs)(e.StrictMode,{children:[(0,f.jsx)(y,{}),(0,f.jsx)(qt,{})]}))}()}();
//# sourceMappingURL=main.11573d7d.js.map